

**General practice activity in Australia
1998–99 to 2007–08: 10 year data tables**

Australian GP Statistics and Classification Centre

The Australian Institute of Health and Welfare is Australia's national health and welfare statistics and information agency. The Institute's mission is *better information and statistics for better health and wellbeing*.

The Australian General Practice Statistics and Classification Centre (previously Unit) is a collaborating unit of the Australian Institute of Health and Welfare and the University of Sydney, situated within the Family Medicine Research Centre at Westmead Hospital. It fulfils the obligation of the Australian Institute of Health and Welfare to collect statistics regarding general practitioners, their patients and their patients' care.

Companion publication:

Britt H, Miller GC, Charles J, Henderson J, Bayram C, Harrison C, Valenti L, Fahridin S, Pan Y, O'Halloran J 2008. General practice activity in Australia 2007–08. General practice series no. 22. Cat. no. GEP 22. Canberra: AIHW.

Recent related publications:

Britt H, Miller GC, Charles J, Bayram C, Pan Y, Henderson J, Valenti L, O'Halloran J, Harrison C, Fahridin S 2008. General practice activity in Australia 2006–07. General practice series no. 21. Cat. no. GEP 21. Canberra: AIHW.

Britt H, Miller GC, Henderson J, Bayram C 2007. Patient-based substudies from BEACH: abstracts and research tools 1999–2006. General practice series no. 20. Cat. no. GEP 20. Canberra: AIHW.

Britt H, Miller GC, Charles J, Pan Y, Valenti L, Henderson J, Bayram C, O'Halloran J, Knox S 2007. General practice activity in Australia 2005–06. General practice series no. 19. Cat. no. GEP 19. Canberra: AIHW.

Britt H, Miller GC, Knox S, Charles J, Pan Y, Henderson J, Bayram C, Valenti L, Ng A, O'Halloran J 2005. General practice activity in Australia 2004–05. General practice series no. 18. Cat. no. GEP 18. Canberra: AIHW.

Knox S, Britt H, Pan Y, Miller GC, Bayram C, Valenti L, Charles J, Henderson J, Ng A, O'Halloran J 2005. Locality matters: the influence of geography on general practice activity in Australia 1998–2004. General practice series no. 17. Cat. no. GEP 17. Canberra: AIHW.

Britt H, Miller GC, Knox S, Charles J, Valenti L, Pan Y, Henderson J, Bayram C, O'Halloran J, Ng A 2004. General practice activity in Australia 2003–04. General practice series no. 16. Cat. no. GEP 16. Canberra: AIHW.

Australian General Practice Statistics and Classification Centre 2007. SAND abstracts from the BEACH program. Sydney: AIHW & University of Sydney. Viewed 25 October 2007, <www.fmrc.org.au/publications/SAND_abstracts.htm>.

Britt H, Miller GC, Knox S, Charles J, Valenti L, Bayram C, O'Halloran J, Henderson J, Pan Y, Harrison C 2004. General practice activity in the states and territories of Australia 1998–2003. General practice series no. 15. Cat. no. GEP 15. Canberra: AIHW.

Britt H, Miller GC, Knox S, Charles J, Valenti L, Henderson J, Pan Y, Bayram C, Harrison C 2003. General practice activity in Australia 2002–03. General practice series no. 14. Cat. no. GEP 14. Canberra: AIHW.

Britt H, Knox S, Miller GC 2003. Changes in pathology ordering by general practitioners in Australia, 1998–2001. General practice series no. 13. Cat. no. GEP 13. Canberra: AIHW.

O'Halloran J, Britt H, Valenti L, Harrison C, Pan Y, Knox S 2003. Older patients attending general practice 2000–02. General practice series no. 12. Cat. no. GEP 12. Canberra: AIHW.

GENERAL PRACTICE SERIES

Number 23

BEACH
*Bettering the Evaluation
And Care of Health*

**General practice activity in Australia
1998–99 to 2007–08: 10 year data tables**

**Helena Britt, Graeme C Miller, Janice Charles, Joan Henderson, Clare Bayram,
Christopher Harrison, Lisa Valenti, Salma Fahridin, Ying Pan, Julie O'Halloran**

October 2008

A joint report by the University of Sydney and the Australian Institute of Health and Welfare

Cat. no. GEP 23

© Australian Institute of Health and Welfare and the University of Sydney 2008

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced without prior written permission from the Australian Institute of Health and Welfare. Requests and enquiries concerning reproduction and rights should be directed to the Head, Media and Communications Unit, Australian Institute of Health and Welfare, GPO Box 570, Canberra ACT 2601.

This publication is part of the Australian Institute of Health and Welfare's General practice series, from the Australian General Practice Statistics and Classification Centre, a collaborating unit of the University of Sydney and the Australian Institute of Health and Welfare. A complete list of the Institute's publications is available from the Institute's website <www.aihw.gov.au>.

ISSN 1442-3022

ISBN 978 1 74024 829 7

Suggested citation

Britt H, Miller GC, Charles J, Henderson J, Bayram C, Harrison C, Valenti L, Fahridin S, Pan Y, O'Halloran J 2008. General practice activity in Australia 1998–99 to 2007–08: 10 year data tables. General practice series no. 23. Cat. no. GEP 23. Canberra: Australian Institute of Health and Welfare.

Keywords

Australia, Delivery of Health Care/statistics & numerical data, Family Practice/statistics & numerical data, Health Care Surveys/methods.

Australian Institute of Health and Welfare

Board Chair

Hon. Peter Collins, AM, QC

Director

Penny Allbon

Any enquiries about or comments on this publication should be directed to:

The Australian General Practice Statistics and Classification Centre

School of Public Health

University of Sydney

Acacia House

Westmead Hospital

Westmead NSW 2145

Phone: +61 2 9845 8151

Fax: +61 2 9845 8155

Email: gpstats@fmrc.org.au

Published by the Australian Institute of Health and Welfare

Acknowledgments

The Australian General Practice Statistics and Classification Centre (formerly the General Practice Statistics and Classification Unit) wishes to thank the general practitioners who participated in BEACH (Bettering the Evaluation And Care of Health) between April 1998 and March 2008. This report would not have been possible without their valued cooperation and effort in providing the data.

We also thank the following organisations for their financial support and their contribution to the ongoing development of the BEACH program since it began in April 1998:

- AstraZeneca Pty Ltd (Australia) (1998–2008)
- Janssen-Cilag Pty Ltd (2000–08)
- Merck, Sharp and Dohme (Australia) Pty Ltd (2002–08)
- Pfizer Australia (2003–08)
- National Prescribing Service Ltd (2005–08)
- Australian Government Department of Health and Ageing (1998–2004, 2007–08)
- Abbott Australasia (2006–08)
- Sanofi-Aventis Australia Pty Ltd (2006–08)
- Roche Products Pty Ltd (1998–2006)
- Aventis Pharma Pty Ltd (1998–2002)
- National Occupational Health and Safety Commission (1998–2000)
- Australian Government Department of Veterans' Affairs (1998–2000).

Some financial support for the program was also provided by:

- Australian Government Department of Veterans' Affairs (2004–08)
- The Office of the Australian Safety and Compensation Council, Department of Employment and Workplace Relations (2004–06).

We acknowledge the support of the Royal Australian College of General Practitioners, the Australian Medical Association, the Australian Divisions of General Practice, the Australian College of Rural and Remote Medicine, and the Consumers Health Forum, and the contribution of their representatives to the BEACH Advisory Board.

The research team is grateful to Clare Bayram for her coordination and editing of this report, for the IT support of Timothy Chambers and the administrative support of Gervaise Woods, and for the valuable contribution of the general practitioner recruitment staff (Errol Henderson and Jan Fitzgerald) and data entry staff. We recognise the contribution of past members of the BEACH team, particularly Stephanie Knox.

We appreciate the cooperation of the Primary Care Division of the Australian Government Department of Health and Ageing in regularly supplying general practitioner random samples and national Medicare data.

Ethics approval for this study was obtained from the Human Ethics Committee of the University of Sydney and the Ethics Committee of the Australian Institute of Health and Welfare.

Contents

Abbreviations	x
Symbols	xi
1 Introduction	1
1.1 Background – general practice in Australia	2
2 Methods	3
2.1 Data elements	3
2.2 Statistical methods	4
2.3 Changes over time	5
2.4 Extrapolated national estimates.....	5
2.5 Classification of data	7
2.6 Changes to data elements and reporting methods.....	9
3 The sample	11
4 The participating GPs	12
5 The encounters	19
5.1 Content of the encounters.....	19
6 The patients	25
6.1 Age-sex distribution of patients at encounter	25
6.2 Other patient characteristics.....	26
6.3 Patient reasons for encounter.....	26
7 Problems managed	36
7.1 Number of problems managed.....	36
7.2 Distribution of problems managed by ICPC-2 component	37
7.3 Problems managed by ICPC-2 chapter and individual problems managed.....	37
7.4 Most common new problems.....	38
7.5 Most frequently managed chronic problems	38
8 Overview of management	51
9 Medications	57
9.1 Prescribed medications	57
9.2 Medications supplied by GPs.....	67
9.3 Medications advised for over-the-counter purchase	67
10 Other treatments	70
10.1 Clinical treatments	70
10.2 Procedural treatments	71

11 Referrals and admissions.....	79
12 Investigations.....	83
12.1 Number of encounters where pathology or imaging was ordered	83
12.2 Pathology test orders by MBS groups.....	83
12.3 Imaging test orders by MBS group.....	84
13 Practice nurse activity.....	88
13.1 Practice nurse activity at GP-patient encounters	89
13.2 Distribution of practice nurse item numbers claimed at encounters.....	89
13.3 Treatments provided by practice nurses	90
13.4 Individual treatments most frequently involving practice nurses	91
13.5 Problems managed with practice nurse involvement	93
14 Patient risk factors.....	94
14.1 Body mass index	94
14.2 Smoking.....	97
14.3 Alcohol consumption	98
References.....	103
Glossary.....	105
Appendices.....	108
Appendix 1: BEACH methods	108
Appendix 2: Patient risk factor substudy methods.....	121
Appendix 3: Example of a 2007-08 recording form	124
Appendix 4: GP characteristics questionnaire, 2007-08	126
Appendix 5: Code groups from ICPC-2 and ICPC-2 PLUS	127
Appendix 6: Chronic code groups from ICPC-2 and ICPC-2 PLUS.....	153
Appendix 7: Dissemination of results from the BEACH program	154
List of tables	171
List of figures	173

Abbreviations

ABS	Australian Bureau of Statistics
AGPSCC	Australian General Practice Statistics and Classification Centre, University of Sydney, a collaborating unit of the Australian Institute of Health and Welfare
AIHW	Australian Institute of Health and Welfare
ASGC	Australian Standard Geographical Classification
ATC	Anatomical Therapeutic Chemical (classification)
AUDIT	Alcohol Use Disorders Identification Test
BEACH	Bettering the Evaluation And Care of Health
BMI	body mass index
CAPS	Coding Atlas for Pharmaceutical Substances
CI	confidence interval (in this report 95% CI is used)
CT	computerised tomography
DoHA	Australian Government Department of Health and Ageing
DVA	Australian Government Department of Veterans' Affairs
FMRC	Family Medicine Research Centre
FRACGP	Fellow of the Royal Australian College of General Practitioners
GP	general practitioner
HbA1c	haemoglobin, type A1c
ICPC	International Classification of Primary Care
ICPC-2	International Classification of Primary Care (Version 2)
ICPC-2 PLUS	a terminology classified according to ICPC-2
INR	International Normalised Ratio
MBS	Medicare Benefits Schedule
OTC	over-the-counter (that is, medications advised for over-the-counter purchase)
QA	quality assurance (in this case the Quality Assurance Program of the Royal Australian College of General Practitioners)
RACGP	Royal Australian College of General Practitioners
RFE(s)	reason(s) for encounter (see Glossary)
RRMA	Rural, Remote and Metropolitan Area
SAND	Supplementary Analysis of Nominated Data
SAS	Statistical Analysis System
WHO	World Health Organization
Wonca	World Organization of Family Doctors

Symbols

↑/↓	indicates a statistically significant linear change
↑/↓	indicates a marginally significant linear change
§	indicates a non-linear significant or marginal change
–	indicates no change
N/A	not applicable
NAv	not available
NEC	not elsewhere classified
NOS	not otherwise specified

1 Introduction

This publication is the 23rd book in the series from the BEACH (Bettering the Evaluation And Care of Health) program. This report includes summary results from 10 years of the program, from 1998–99 to 2007–08 inclusive.

BEACH is a continuous national study of general practice activity conducted by the Australian General Practice Statistics and Classification Centre (AGPSCC). The AGPSCC is a collaborating unit of the Family Medicine Research Centre at the University of Sydney and the Australian Institute of Health and Welfare (AIHW). BEACH is currently supported financially by government instrumentalities and private industry (see Acknowledgments).

BEACH began in April 1998, and at the end of its 10th year (March 2008) the BEACH database included records for almost 1 million encounters from 9,874 participants representing more than 7,400 individual general practitioners (almost half of the practising recognised GP population in Australia).

Annual results from the BEACH study are published each year. The most recent of these, released in parallel with this book, is *General practice activity in Australia 2007–08*, available from <www.aihw.gov.au/publications/index.cfm/subject/19> (AIHW catalogue number GEP 22).

This book brings the 10 years of data together to provide a reference document for those interested in changes that have occurred over the past decade in the GP workforce, the patients consulting them, the problems managed and the treatments provided by GPs.

For convenience, the methods for the BEACH study, drawn from the most recent BEACH report 2007–08 are attached as Appendix 1. A brief summary of these methods together with additional information about methods used specifically in this report, or essential to understanding the report are provided in Chapter 2.

The structure of this report follows the usual approach of the annual BEACH reports. Ten years of results are provided for the GPs, the patients and the problems managed, together with an overview of management, specific chapters for each management action and a chapter on practice nurse activity. Changes in the prevalence of some risk factors among patients at GP encounters are also presented.

Each chapter contains an overview of the section (including definitions where relevant), the results tables and a brief description of each table. In the tables, statistically significant changes in results between 1998–99 (or 2000–01 if relevant) and 2007–08 are marked. The national effect of significant change can be estimated by extrapolating the BEACH result to all GP Medicare claimed encounters. An example of an extrapolation of a measured change is provided for each table. The method adopted for extrapolation of the effect of a change is described in Section 2.4. The reader can apply this method to any significant change in the data presented, to gain an estimate of the size of the national change in frequency of an event, occurring as a result of changes in general practice.

In this report we do not investigate changes in (for example) the GP use of medications, referrals and investigations in the management of a specific problem, or changes in the problems presented by selected groups of patients. Such work is underway and will be published in mid-2009 for selected topics, including many of Australia's National Health Priority Areas.¹

1.1 Background—general practice in Australia

- In December 2007 the estimated population of Australia was 21.2 million people.²
- GPs are the first port of call in the Australian health care system.
- There were 98 full-time equivalent practising primary care practitioners per 100,000 people in Australia in 2005.³
- About 88% of the Australian population visited a GP at least once in 2005–06.⁴
- Payment is on a fee-for-service system, there being no patient lists or registration.
- People are free to visit multiple practitioners and multiple practices of their choice.
- There is a universal medical insurance scheme (managed by Medicare Australia), which covers all or most of an individual's costs for a GP visit.
- In 2007–08, 107 million general practitioner items of services were paid by Medicare Australia at an average rate of more than five visits per person per year.⁵ GPs provided an estimated additional 6.6 million services paid for by other funders (such as workers compensation, state government) or not charged for at all.⁶ In 2007, the primary cost to Medicare for GP items was over \$4 billion.⁵

BEACH gives us some understanding of the content of these encounters and of the services and treatments that GPs provide. The BEACH program aims to:

- provide a reliable and valid data collection process for general practice that is responsive to the ever-changing needs of information users
- establish an ongoing database of GP–patient encounter information
- assess patient risk factors and health states, and the relationship these factors have with health service activity.

Users of the BEACH data might wish to consolidate information from multiple national data sources. Integration of data from multiple sources can provide a more comprehensive picture of the health and health care of the Australian community. It is therefore important that readers are aware of how the BEACH data differ from those drawn from others. A summary of differences between those data collected in BEACH compared with those in the Medicare Benefits Schedule, the Pharmaceutical Benefits Scheme and the National Health survey is available in *General practice activity in Australia 2007–08* (Section 1.3).⁷

The BEACH program has generated many papers on a wide range of topics in journals and professional magazines. Appendix 7 lists all published material from BEACH. A complete list of publications is also available from the Family Medicine Research Centre's (FMRC) website <www.fmrc.org.au/publications/>.

2 Methods

The methods are fully described in Appendix 1. In summary, the program is a continuous national study of general practice activity in Australia. It uses details of about 100,000 encounters between GPs and patients (about a 0.1% sample of all general practice encounters) from an ever-changing random sample of approximately 1,000 recognised practising GPs per year.

A random sample of GPs who claimed at least 375 general practice Medicare items of service in the previous 3 months is regularly drawn from Medicare Australia data by the Primary and Ambulatory Care Division of the Australian Government Department of Health and Ageing (DoHA). GPs are approached by letter and followed up by telephone recruitment. Each participating GP completes details for 100 consecutive GP-patient encounters on structured paper encounter forms (Appendix 3). Each also provides information about themselves and their major practice (Appendix 4).

Post-stratification weighting of encounter data adjusts for any variance in the characteristics of the participating GPs from those of the sample frame from which they were drawn, and for the varying 'business' of each GP (measured by the number of claims each has made in the previous 12 months from Medicare Australia). The final sample of encounters shows excellent precision when the age-sex distribution of the patients is compared with the distribution in all Medicare-claimed services of this type.⁷

2.1 Data elements

BEACH includes three interrelated data collections: encounter data, GP characteristics and patient health status. An example of the form used to collect the encounter data and the data on patient health status is included in Appendix 3. The GP characteristics questionnaire is provided in Appendix 4. The data collected include the following:

- **Encounter data:** date of consultation, type of consultation (direct/indirect), up to three Medicare/Department of Veterans' Affairs (DVA) item numbers (where applicable) and other payment source (where applicable) (tick box).
- **Patient data:** date of birth, sex and postcode of residence. Tick boxes are provided for Commonwealth concession cardholder, holder of a Repatriation health card (from DVA), non-English-speaking background (patient self-report – a language other than English is the primary language at home), Aboriginal person (self-identification) and Torres Strait Islander person (self-identification). Space is provided for up to three patient reasons for encounter (RFEs).
- **The problems managed** at encounter (at least one and up to four). Tick boxes are provided to denote the status of each problem as new or continuing for the patient (if applicable).
- **Management of** each problem, including:
 - medications prescribed, supplied by the GP and advised for over-the-counter purchase including brand name, form (where required), strength, regimen, status (if new or continuing medication for this problem for this patient) and number of repeats

- other treatments provided for each problem including counselling, advice and education, and procedures undertaken; and if other treatment was provided by practice nurse (tick box)
- new referrals to medical specialists, allied health professionals and hospital
- investigations including pathology tests, imaging and other investigations ordered at the encounter.
- **GP characteristics:** age and sex, years in general practice, number of GP sessions worked per week, number of GPs working in the practice, postcode of major practice address, country of graduation, postgraduate general practice training and Fellow of the Royal Australian College of General Practitioners status, after-hours care arrangements, use of computers in the practice, whether the practice is accredited, whether it is a teaching practice, work undertaken in other clinical settings and hours worked in direct patient care.

2.2 Statistical methods

The analysis of all BEACH data was conducted with Statistical Analysis System (SAS) version 9.1.3.⁸ When originally published, data from 1999–00 to 2004–05 were analysed using SAS version 6.12⁹ (with additional programming to adjust for the cluster sample study design). In this report (and others published since 2007) these data have been re-analysed using SAS version 9.1.3 (which adjusts for the cluster design without the need for additional programming). This has resulted in slightly tighter confidence intervals and minor variations in point estimates (of up to 0.1) when compared with data published in earlier annual reports for the 1998–2004 data years.

BEACH is a single stage cluster sample study design, each 100 encounters forming a cluster around each GP participant. In cluster samples, variance needs to be adjusted to account for the correlation between observations within clusters. Procedures in SAS version 9.1.3 are used to calculate the intracluster correlation and adjust the confidence intervals accordingly.⁸

The encounter is the primary unit of inference. Proportions (%) are used when describing the distribution of an event that can arise only once at a consultation (for example, age, sex), or to describe the distribution of events within a class of events (for example, problem A as a percentage of total problems). Rates per 100 encounters are used when an event can occur more than once at the consultation (for example RFEs, problems managed or medications).

Rates per 100 problems are used when a management event can occur more than once per problem managed.

The statistical significance of changes in characteristics of the GPs is tested using the chi-square test statistic. However, in general, the results for events occurring at GP–patient encounters present the rate per 100 encounters and the 95% confidence interval.

- Changes over time, in the frequency of these events are judged significant (that is, a real change has occurred) if the two sets of confidence intervals do not overlap. For example, Result A: 11.5 per 100 encounters (95% CI: 11.3–11.7) is significantly less than Result B: 11.9 per 100 encounters (95% CI: 11.8–12.0).
- If the two sets of confidence intervals butt together the difference is regarded as marginal. For example, Result A: 11.5 per 100 encounters (95% CI: 11.3–11.7) is marginally lower than Result B: 11.9 (95% CI: 11.7–12.1).
- If they overlap, then no change has been measured.

2.3 Changes over time

While in this report SAS version 9.1.3⁸ was used for all analyses, changes in method or approach have occurred on occasion over the 10 years of the BEACH study. Data presented in this report are comparable for each result across all data years. Where methodological changes have occurred, the data have either:

- been recalculated using the new method (for example, body mass index was recalculated due to a change in the World Health Organization body mass index groupings)
- been regrouped for comparability (where this occurs, it has been noted in the footnotes of the table)
- been omitted from this report (if recalculation or grouping was not possible). Where data are omitted, this is noted in the tables as not applicable (N/A) or not available (NAv), as appropriate.

Readers should be aware that there may be discrepancies between data in this report and data published in earlier BEACH reports.

In measuring changes over time, the 2007–08 results are compared with those from 1998–99 wherever possible. However, as in any long-term research program, changes occur over the years. For example, in response to requests from DoHA (then the Department of Health and Aged Care), more detailed coding systems for pharmaceuticals, pathology and imaging test orders were developed, and these were applied from year 3 (2000–01) onwards. In these cases, change is measured from 2000–01 because earlier years are not comparable. Practice nurse activity data were not collected until 2005–06, so the changes are only considered between 2005–06 and 2007–08.

Each table includes the most frequent events occurring in 2007–08 and the comparative results for each of the earlier years have been provided. In addition, each table includes data for events that were more frequent in past year(s) that are no longer as frequent in 2007–08. All results are presented in decreasing order of frequency by the 2007–08 data.

The direction and type of change between 1998–99 (or 2000–01 where appropriate) and 2007–08 is indicated for each result in the far right column of the tables:

- ↑/↓ indicates a statistically significant linear change
- ⤴/⤵ indicates a marginally significant linear change
- § indicates a non-linear significant or marginal change
- – indicates there was no change.

2.4 Extrapolated national estimates

Where the results demonstrate a significant change over time, the estimated national change across total GP Medicare services from 1998–99 (or where appropriate 2000–01) to 2007–08 can be calculated using the method detailed below. An example of an extrapolated national change is given in the description of each table in the report from Chapter 5 onward.

- The national estimates are calculated by dividing the rate per 100 encounters of the selected event for 1998–99 (or 2000–01 where appropriate) by 100, and then multiplying by the total number of general practitioner services claimed through Medicare in that year (rounded to the nearest 100,000, see Table 1.1) to give the estimated annual number of events in 1998–99 (or 2000–01). The process is then repeated for 2007–08. The

difference between the two estimates (to the nearest 10,000) gives the estimated national change in the rate of encounters for that event over the period of interest.

- This is expressed as the estimated increase or decrease over the study period (between 1998–99 or 2000–01 and 2007–08), in the number of general practice contacts for that event. For example, an increase or decrease in the number of GP management contacts with problem X occurring in Australia in 2007–08 when compared with 1998–99 (or 2000–01).

Table 1.1 provides the total number of general practice professional service items claimed from Medicare in each financial year from 1998–99 to 2007–08. In this report extrapolations are calculated using the number of GP Medicare items claimed rounded to the nearest 100,000. The rounded number is also provided in Table 1.1. Readers can use the method described above to calculate the national effect of any significant change in a single result over any two time points.

Example of extrapolation

A significant increase in the number of problems managed at encounter (Chapter 7), from 145.3 per 100 encounters in 1998–99 to 151.3 in 2007–08:

- $(145.3/100) \times 102.6$ million = 149.1 million problems managed in general practice nationally in 1998–99, and $(151.3/100) \times 107.0$ million = 161.9 million problems managed in 2007–08.

This suggests there were 12.8 million (161.9 million minus 149.1 million) more problems managed at GP encounters in Australia in 2007–08 than in 1998–99.

Table 1.1: Number of general practice professional services claimed from Medicare Australia each financial year, 1998–99 to 2007–08 ('000)

	1998–99	1999–00	2000–01	2001–02	2002–03	2003–04	2004–05	2005–06	2006–07	2007–08 ^(a)
Number of GP MBS items	102,552	101,517	100,645	99,921	96,919	96,330	98,180	101,095	103,433	107,041
Rounded no. of GP MBS items	102,600	101,500	100,600	99,900	96,900	96,300	98,200	101,100	103,400	107,000

(a) Medicare data for the 2007–08 year included data from the March 2007 to April 2008 quarters because the 2007–08 financial year data were not available at the time of preparation of this report.

Source: Medicare statistics, Table B1 - Medicare: Number of services ('000) by quarter and financial year of processing by broad type of service. Available from <[www6.health.gov.au/internet/main/publishing.nsf/Content/41322B5BFABA25FFCA25744B000334C4/\\$File/tableb1.xls](http://www6.health.gov.au/internet/main/publishing.nsf/Content/41322B5BFABA25FFCA25744B000334C4/$File/tableb1.xls)>.

Limitations of extrapolations

The extrapolations to the total encounters occurring nationally in any one year is only an estimate. It is likely to provide:

- an underestimate of the true 'GP workload' of a condition/treatment because the extrapolations are made to GP Medicare items claimed, not to the total number of GP encounters per year (which include indirect encounters and those paid by sources other than Medicare, such as DVA, state governments, work cover, employers)
- an overestimate of the management rate of a group of conditions (for example cardiovascular disease) because there is a chance that more than one problem of this type will be managed at a single encounter. In the extrapolations, two cardiovascular problems managed at one encounter will be counted as two encounters.

Further, the base numbers used in the extrapolations are rounded to the nearest 100,000 and the extrapolations are rounded to the nearest 10,000. However, the rounding has been applied to all years, so the effect on measures of change will be very small. The extrapolation therefore still provides an indication of the size of the effect of measured change nationally.

2.5 Classification of data

Reasons for encounter, problems managed and the process of care

The following data elements are classified according to the International Classification of Primary Care – Version 2 (ICPC-2), a product of the World Organization of Family Doctors (Wonca)¹⁰, and the recommended Australian standard for classification of data from general practice or patient self-report¹¹:

- patient reasons for encounter (RFEs)
- problems managed
- clinical treatments (for example, counselling, advice)
- procedural treatments
- referrals
- investigations ordered (including pathology, imaging and other investigations).

Coding of data

The above data elements are coded in more detail using ICPC-2 PLUS¹², an interface terminology developed by the FMRC from all the terms used by GPs in studies such as the Australian Morbidity and Treatment Survey 1990–91¹³, the Morbidity and Therapeutic Index 1992–1998 (a clinical audit tool that was available to GPs) and BEACH 1998–2008, that together have included about 2 million encounter records. These terms are classified according to ICPC-2 to ensure international standards for reporting.

When the free-text data are received from the GPs, trained secondary coders (who are undergraduate students studying health information management or medical science) code the data in more specific terms using ICPC-2 PLUS. This ensures high coder reliability, and automatic classification of the concept, and gives the ability to ‘ungroup’ such ICPC-2 rubrics as ‘other diseases of the circulatory system’ and select a specific disease from the terms within it.

Presentation of data classified in ICPC-2

Statistical reporting is almost always at the level of the ICPC-2 classification (for example, acute otitis media/myringitis – ICPC-2 code H71). However, there are some exceptions where data are grouped either above the ICPC-2 level or across the ICPC-2 level. These grouped morbidity, pathology and imaging codes are defined in Appendix 5, and chronic morbidity groups are provided in Appendix 6.

Reporting morbidity with groups of ICPC-2 codes

When recording problems managed, the GP is not always very specific. For example, in recording the management of diabetes, they may simply record the problem as ‘diabetes’. In

ICPC-2, 'diabetes unspecified' is classified as non-insulin-dependent diabetes (code T90). There is another code for insulin-dependent diabetes (T89). In some cases the GP may simply have failed to specify that the patient had insulin-dependent diabetes. The research team therefore feels that for national data reporting, it is more reliable to group the two codes T90 and T89 and label this 'Diabetes – all*' – the asterisk indicating that multiple ICPC-2 codes (as in this example) or ICPC-2 PLUS codes (see below) are included. A list of codes included in these groups are provided in Appendix 5.

Reporting morbidity across ICPC-2 PLUS codes

In other cases a concept can be classified within (but be only part of) multiple ICPC-2 codes. For example, osteoarthritis is classified in ICPC-2 in multiple broader codes according to site, for example L92 – shoulder syndrome (includes bursitis, frozen shoulder, osteoarthritis of shoulder, rotator cuff syndrome). When reporting osteoarthritis in this publication, all the more specific osteoarthritis ICPC-2 PLUS terms are taken from all the appropriate ICPC-2 codes and grouped. This group is labelled 'Osteoarthritis*' – the asterisk again indicating multiple codes, but in this case they are PLUS codes rather than ICPC-2 codes. A list of codes included in these groups are provided in Appendix 5.

Reporting chronic morbidity

To identify chronic conditions, a chronic condition list¹⁴ classified according to ICPC-2 was applied to the BEACH data set. In general reporting, both chronic and non-chronic conditions (for example, diabetes and gestational diabetes) may have been grouped together when reporting (for example, diabetes – all*). When reporting chronic morbidity, only problems regarded as chronic have been included in the analysis. Where the group used for the chronic analysis differs from that used in other analyses in this report, they are marked with a double asterisk. Codes included in the chronic groups are provided in Appendix 6.

Reporting pathology and imaging test orders

All the pathology and imaging tests ordered by the GPs are coded very specifically in ICPC-2 PLUS, but the ICPC-2 classifies pathology and imaging tests very broadly (for example, a test of cardiac enzymes is classified in K34 – Blood test associated with the cardiovascular system; a CT scan of the lumbar spine is classified as L41 – Diagnostic radiology/imaging of the musculoskeletal system). In Australia, the Medicare Benefits Schedule (MBS) classifies pathology and imaging tests in groups that are relatively well recognised. The team therefore re-grouped all pathology and imaging ICPC-2 PLUS codes into MBS standard groups. This allows comparison of data between data sources. These groups are marked with an asterisk and included in Appendix 5.

Classification of pharmaceuticals

Pharmaceuticals that are prescribed, provided by the GP or advised for over-the-counter purchase are coded and classified according to an in-house classification, the Coding Atlas for Pharmaceutical Substances (CAPS).

This is a hierarchical structure that facilitates analysis of data at a variety of levels, such as medication class, medication group, generic composition and brand name.

Strength and regimen are independent fields that, when combined with the CAPS code, give an opportunity to derive the prescribed daily dose for any prescribed medication or group of medications.

CAPS is mapped to the Anatomical Therapeutic Chemical (ATC)¹⁵ classification, which is the Australian standard for classifying medications at the generic level.

The ATC has a hierarchical structure with five levels. For example:

- Level 1: C – Cardiovascular system
- Level 2: C10 – Serum lipid reducing agents
- Level 3: C10A – Cholesterol and triglyceride reducers
- Level 4: C10AA – HMG CoA reductase inhibitors
- Level 5: C10AA01 – Simvastatin (the generic drug).

Reporting pharmaceutical data

For pharmaceutical data, there is the choice of reporting in terms of the CAPS coding scheme or the ATC. They each have advantages in different circumstances.

In the CAPS system, a new drug enters at the product and generic level, and is immediately allocated a generic code. Therefore, the CAPS classification uses a bottom-up approach.

In the ATC, a new generic may initially enter the classification at any level (1 to 5), not necessarily always at the generic level. Reclassification to lower ATC levels may occur later. Therefore, the ATC uses a top-down approach.

When analysing medications across time, a generic medication that is initially classified to a higher ATC level will not be identifiable in that data period and may result in under-enumeration of that drug during earlier data collection periods.

In measuring changes in medications over time, the team chose to report at Level 2 of the ATC (which is more stable over time than Level 3), and in CAPS for the generic-level drugs.

2.6 Changes to data elements and reporting methods

Changes in data elements and reporting methods have occurred on occasion over the 10 years of the BEACH study:

- More detailed coding systems for pharmaceuticals, pathology and imaging test orders were developed, and these were applied from year 3 (2000–01) onwards. In these cases, change is measured from 2000–01 because earlier years are not comparable.
- Two changes were made to the BEACH form from 2005–06 onwards to capture practice nurse activity associated with the GP–patient consultations. From 2005–06 onwards:
 - GPs could record multiple (up to three) Medicare item numbers
 - in the ‘other treatments’ section, for each problem managed, the GP was asked to tick the practice nurse box if the treatment recorded was provided by the practice nurse rather than by the GP. If the box was not ticked, the research team assumed that the GP gave the treatment.

These two changes have implications for the reporting of Medicare/DVA-claimable encounters (Chapter 5), practice nurse activity (Chapter 13) and other treatments (Chapter 10).

Medicare/DVA-claimable encounters

For the first 7 years of the BEACH program (1998–99 to 2004–05), where a Medicare item number was claimable for the encounter, the GP was instructed to record only one item number. Where multiple item numbers (for example, an A1 item such as ‘standard surgery consultation’ and a procedural item number) were claimable for an encounter, the GP was instructed to record the lower of these (usually an A1 item number). For reporting purposes Medicare-claimable encounters were broken down according to the item number recorded by the GP as claimable (either through Medicare or through DVA) for the encounter.

In this report the Medicare/DVA claimable encounters count only one item number per Medicare/DVA-claimable encounter for comparability with previous years (see Chapter 5). Practice nurse Medicare-claimable encounters are not reported in Chapter 5.

The selection of one item number was undertaken on a priority basis: consultation item numbers override incentive item numbers, which override procedural item numbers, which override other Medicare item numbers.

Practice nurse activity

The research team began to capture practice nurse activity (in 2005–06) due to the introduction of four new MBS item numbers in November 2004 which covered some selected activities conducted by a practice nurse on behalf of a medical practitioner.¹⁶

The primary aim of BEACH is to describe general practice activity. Before 2005–06, ‘general practice activity’ has been described in terms of GP–patient encounters and this was considered close to equivalent to ‘general practitioner activity’. However, the introduction of the practice nurse item numbers meant that, if practice nurse activity associated with the GP–patient encounter was not included, the content of the consultation was not fully described.

Chapter 13 provides a breakdown of the practice nurse Medicare items claimed, the morbidity managed with the assistance of the practice nurse, and the other treatments given by the practice nurse as recorded by the GP participants from 2005–06 to 2007–08.

When viewing these results, it must be remembered that these practice nurse data do not include activities undertaken by the practice nurse during the GP’s BEACH recording period that were performed outside the recorded encounter. These could include Medicare-claimable activities (for example immunisations/vaccinations) provided under instruction from the GP but not provided at the time of the encounter recorded in BEACH, or provision of other activities not currently claimable from Medicare (for example dietary advice on a one-to-one basis, or in a group situation).

Other treatments

In the chapter on other treatments (Chapter 10), all recorded clinical and procedural treatments are included, irrespective of whether they were provided by the GP or by the practice nurse.

3 The sample

Table 3.1 shows the number of encounters contained in each year of the BEACH program since it began in April 1998, and the size of the total 10-year database for each variable (weighted), upon which all comparisons over time described in this report are based.

Table 3.1: Annual summary of data sets, 1998–99 to 2007–08 (final weighted data)

Variable	1998–99	1999–00	2000–01	2001–02	2002–03	2003–04	2004–05	2005–06	2006–07	2007–08	Total all years
General practitioners	984	1,047	999	983	1,008	1,000	953	1,017	930	953	9,874
Encounters	96,901	104,856	99,307	96,973	100,987	98,877	94,386	101,993	91,805	95,898	981,983
Reasons for encounter	141,766	155,690	149,962	144,654	152,352	144,674	141,215	153,309	138,434	146,696	1,468,752
Problems managed	140,824	153,857	143,528	139,092	146,336	148,521	137,330	149,088	136,333	145,078	1,439,987
Medications	106,320	115,432	107,400	101,350	104,813	103,210	95,816	106,493	93,193	98,439	1,032,466
Other treatments	41,839	48,194	49,072	51,130	53,676	52,315	53,630	47,847	44,035	49,130	490,838
Referrals	10,866	11,760	10,366	7,761	12,265	11,794	10,881	12,235	12,195	12,008	112,131
Imaging	6,844	7,841	8,227	7,642	8,678	8,121	7,840	9,003	8,229	9,143	81,568
Pathology	23,872	27,613	29,225	30,086	33,234	34,831	34,652	39,357	38,963	41,375	333,208

4 The participating GPs


Part of the BEACH method involves the completion of a GP profile questionnaire by each GP participant (see Appendix 4). This questionnaire provides information about the GP and the major practice at which they are employed. Over the 10 years, the questions have occasionally been altered to improve the quality and clarity of the data collected, or to investigate topics not previously surveyed as they become relevant. Therefore, some characteristics have data over the full 10-year period, and some for shorter periods.

Since BEACH began in 1998–99 some trends have emerged in the characteristics of GP participants (Table 4.1). The most noticeable changes over the 10 years of the study are listed below and some are presented in Figure 4.1.

- The feminisation of the general practice workforce is reflected in the growing proportion of GP participants who are female. The proportion of female participants increased from 30.0% in 1998–99 to 36.8% in 2007–08, and reflects the change in the sample frame of all recognised GPs claiming more than 375 A1 items in the previous quarter in Australia, as provided each year by DoHA from Medicare claims data. In 1998–99, the proportion of female GPs in the sample frame was 29.2% (Table 4.1 in *General practice activity in Australia 1998–99*)¹⁷, and in 2007–08, 35.9% (Table 3.2 in *General practice activity in Australia 2007–08*).⁷
- There has been a considerable decrease in the proportion of GPs aged 35–44 years (from 36.3% in 1998–99 to 22.2% in 2007–08), and an increase in the proportion aged 55 years and over (from 25.2% in 1998–99 to 33.5% in 2007–08). Again, these changes reflect the differences observed in the sample frame from Medicare data. Since 1998–99, the proportion of GPs aged less than 35 years and 35–44 years decreased from 14.8% and 33.4%, respectively, to 7.0% and 21.8%, respectively, in 2007–08. Over the same period, the proportion of GPs in the Medicare data sample frame aged 45–54 years increased from 29.5% to 34.8%, and those aged 55 years and over, from 22.4% to 36.4% (1998–99 data from Table 4.1 in *General practice activity in Australia 1998–99*⁷ and 2007–08 data from Table 3.2 *General practice activity in Australia 2007–08*).⁷ (For further information see Charles et al. *The independent effect of age of general practitioner on clinical practice*¹⁸ and *The evolution of the general practice workforce in Australia, 1991–2003*.¹⁹)
- Reflecting the change in age distribution, the proportion of GPs working in general practice for fewer than 2 years has decreased, from 0.8% in 1998–99 to 0.6% in 2007–08, and the proportion practising for 20 years and over has increased, from 42.2% to 55.9%. There has also been a decrease in the proportion working in general practice for 11–19 years, from 33.7% in 1998–99 to 20.6% in 2007–08.
- The proportion of GPs working fewer than six sessions per week has increased considerably, and the proportion working 11 or more sessions per week has decreased significantly. This was thought to partially reflect the larger proportion of female GPs working part-time in conjunction with motherhood. However, Charles et al. (2004) found that, while female GPs were much more likely than males to work fewer sessions, no significant change had occurred in the proportion of female GPs working part-time between 1999 and 2003. They found the proportion of males working fewer than six sessions per week rose from 6.1% in 1998–99 to 11.4% in 2002–03.¹⁹ There has also been a significant increase in the proportion of GPs working 6–10 sessions per week, from

68.5% in 1998–99 to 73.9% in 2007–08. The proportion of GPs working 11 or more sessions per week decreased by nearly half, from 19.0% to 10.9% over this period.

- The proportion of participants in solo practice has halved between 1998–99 and 2006–07, and the proportion in smaller practices of 2–4 GPs has also decreased considerably. There has been an associated significant increase in the proportion of GPs working in practices with five or more practitioners, from 38.9% in 1998–99 to 56.1% in 2006–07. From 2007–08, the question was altered to capture full-time equivalent GPs at the practice, so data are no longer comparable for the question in its original format.
- The results for consultations in a language other than English reflect a change in question design. Between 1998–99 and 2000–01 GPs were asked only one question: ‘Do you conduct more than 50% of consultations in a language other than English?’. The question was removed for the following 2 years, but was replaced as the issue again became of interest. A new question was designed to collect more specific data. The recent results suggest that about one-quarter of participants provide some consultations in a language other than English, but few are doing so at more than 50% of their consultations. It would appear that, in the survey’s original format, those GPs who did consult in another language were keen to let that be known, and the ‘> 50%’ category was the only avenue available to them.



(a) Data about after-hours services were only collected from 2000–01 onward. This figure compares the results from 2000–01 and 2007–08.

Note: Wk—week; FRACGP—Fellows of the Royal Australian College of General Practitioners; Own after-hours—the practice provides its own after-hours service for their patients; Co-op after-hours—the practice provides after-hours services in a cooperative arrangement with other practices.

- There was no significant change over the decade in the proportions of Australian trained GPs compared with those who had graduated outside Australia ($p = 0.121$). However, there was a significant change in the geographic distribution of country of graduation for those trained overseas ($p = 0.003$).
- The proportion of GP participants holding Fellowship of the RACGP significantly increased, from 27.3% in 1998–99 to 50.2% in 2007–08.
- Although the data period covers only 8 years, there has been a significant reduction ($p = <0.001$) in the proportion of GPs providing their own after-hours services, from 45.5% in 2000–01 to 33.2% in 2007–08, and those who provide after-hours services in cooperation with other practices, from 19.3% in 2000–01 to 11.3% in 2007–08.
- Over the same period there has been a significant increase in the proportion of GPs with a computer available at their major practice address, for either administrative or clinical use, or both, from 87.4% in 2000–01 to 96.7% in 2007–08.

Table 4.1: GP characteristics, summary of annual results, BEACH, 1998–99 to 2007–08

GP characteristic	Per cent of GPs ^(a)									
	1998–99 (n = 984)	1999–00 (n = 1,047)	2000–01 (n = 999)	2001–02 (n = 983)	2002–03 (n = 1,008)	2003–04 (n = 1,000)	2004–05 (n = 953)	2005–06 (n = 1,017)	2006–07 (n = 930)	2007–08 (n = 953)
Sex ($\chi^2 = 10.22$, $p = 0.001$) (missing n)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Male	70.0	69.6	68.4	64.2	64.8	67.3	67.9	62.8	65.9	63.2
Female	30.0	30.4	31.6	35.8	35.2	32.7	32.1	37.2	34.1	36.8
Age ($\chi^2 = 48.06$, $p < 0.001$) (missing n)	(4)	(4)	(9)	(1)	(0)	(1)	(1)	(18)	(11)	(8)
< 35 years	6.3	8.4	6.7	7.1	7.3	5.8	8.9	4.7	6.7	7.8
35–44 years	36.3	32.4	28.4	26.8	26.6	24.9	25.5	22.3	22.6	22.2
45–54 years	32.1	32.4	34.2	36.5	35.2	36.5	31.8	34.2	35.6	36.4
55+ years	25.2	26.7	29.7	29.5	30.9	32.7	33.6	38.7	35.0	33.5
Years in general practice ($\chi^2 = 63.86$, $p < 0.001$) (missing n)	(12)	(8)	(6)	(4)	(6)	(9)	(5)	(13)	(13)	(7)
< 2 years	0.8	0.7	0.5	0.3	0.6	1.3	0.4	0.6	0.5	0.6
2–5 years	6.1	8.0	6.4	7.2	7.5	5.3	10.3	4.9	7.9	9.9
6–10 years	17.2	15.9	13.7	13.4	13.5	10.7	12.6	12.1	11.1	12.9
11–19 years	33.7	31.9	29.9	28.4	28.0	28.1	25.4	24.0	23.4	20.6
20+ years	42.2	43.5	48.8	50.3	50.4	54.6	51.3	58.5	57.0	55.9
Currently in a general practice vocational training program ($\chi^2 = 1.008$, $p = 0.316$)	2.2	2.2	2.5	2.5	2.9	4.4	3.5	2.6	2.9	2.8
Fellow of RACGP ($\chi^2 = 112.73$, $p < 0.001$)	27.3	31.0	31.4	35.1	35.5	33.5	42.3	40.7	46.3	50.2

(continued)

Table 4.1 (continued): GP characteristics, summary of annual results, BEACH, 1998–99 to 2007–08

GP characteristic	Per cent of GPs ^(a)									
	1998–99 (n = 984)	1999–00 (n = 1,047)	2000–01 (n = 999)	2001–02 (n = 983)	2002–03 (n = 1,008)	2003–04 (n = 1,000)	2004–05 (n = 953)	2005–06 (n = 1,017)	2006–07 (n = 930)	2007–08 (n = 953)
Sessions per week ($\chi^2 = 32.45$, $p < 0.001$) (missing <i>n</i>)	(12)	(6)	(16)	(15)	(8)	(7)	(8)	(6)	(7)	(9)
< 6 per week	12.4	15.3	15.9	16.0	18.7	17.2	14.4	17.3	17.0	15.4
6–10 per week	68.5	66.0	66.3	67.8	67.9	68.2	71.2	70.7	73.3	73.9
11+ per week	19.0	18.3	16.2	14.8	13.4	13.6	11.4	12.0	9.6	10.9
Size of practice—Number of GPs ($\chi^2 = 38.33$, $p < 0.001$) (missing <i>n</i>)	(62)	(5)	(28)	(4)	(8)	(10)	(6)	(9)	(6)	
Solo	17.9	18.1	19.3	15.3	13.7	10.6	12.2	13.1	8.2	NAv
2–4 GPs	43.2	46.1	38.6	39.7	38.4	37.8	36.4	35.2	35.7	NAv
5+ GPs	38.9	35.8	42.1	44.7	47.9	51.6	51.3	51.7	56.1	NAv
Size of practice—Full-time equivalents (missing <i>n</i>)	(23)
< 2	NAv	NAv	NAv	NAv	NAv	NAv	NAv	NAv	NAv	17.6
2– < 5 GPs	NAv	NAv	NAv	NAv	NAv	NAv	NAv	NAv	NAv	41.2
5– < 10 GPs	NAv	NAv	NAv	NAv	NAv	NAv	NAv	NAv	NAv	31.9
10+ GPs	NAv	NAv	NAv	NAv	NAv	NAv	NAv	NAv	NAv	9.2
Consultations in languages other than English (missing <i>n</i>) ^(b)	(6)	(1)	(10)	(0)	(4)
< 25%	NAv	NAv	NAv	NAv	NAv	17.8	21.7	21.0	18.1	20.4
25–50%	NAv	NAv	NAv	NAv	NAv	2.9	2.4	3.6	2.7	3.0
> 50%	11.3	10.6	13.5	NAv	NAv	2.4	3.4	3.4	2.9	3.6

(continued)

Table 4.1 (continued): GP characteristics, summary of annual results, BEACH, 1998–99 to 2007–08

GP characteristic	Per cent of GPs ^(a)									
	1998–99 (n = 984)	1999–00 (n = 1,047)	2000–01 (n = 999)	2001–02 (n = 983)	2002–03 (n = 1,008)	2003–04 (n = 1,000)	2004–05 (n = 953)	2005–06 (n = 1,017)	2006–07 (n = 930)	2007–08 (n = 953)
Place of graduation ($\chi^2 = 19.7$, $p = 0.12$; 0.003) (missing n) ^(c)										
Australia	76.5	73.3	72.7	76.1	72.6	73.5	69.8	72.0	73.6	73.5
Overseas	23.5	26.7	27.3	23.9	27.4	26.5	30.2	28.0	26.4	26.8
United Kingdom	9.0	8.5	8.2	7.6	9.1	7.2	7.6	8.1	7.3	6.8
Asia	8.6	9.4	4.7	8.6	9.9	9.5	10.9	10.9	10.1	9.8
Europe	2.4	1.9	1.9	1.8	1.6	2.3	3.8	2.1	1.7	2.6
Africa	1.5	2.4	1.5	3.7	4.3	5.4	5.4	4.5	5.1	4.3
New Zealand	1.1	1.5	1.5	0.5	2.2	1.0	1.3	1.9	1.4	1.4
Other	0.9	2.8	9.5	1.6	0.9	1.0	1.3	0.6	0.8	0.5
Practice location by RRMA ($\chi^2 = 5.78$, $p = 0.447$) (missing n)										
Capital	68.2	65.2	68.1	69.3	64.7	62.4	64.9	69.1	63.9	67.8
Other metropolitan	7.5	7.4	6.9	8.1	8.5	6.4	6.7	6.8	7.3	7.0
Large rural	6.2	7.6	5.6	5.9	5.1	7.0	5.4	5.7	7.9	6.9
Small rural	6.1	6.2	5.6	4.9	7.7	7.0	6.9	6.0	5.4	4.7
Other rural	11.0	12.2	12.2	10.5	12.0	14.2	13.0	11.1	13.6	11.3
Remote central	0.5	0.4	1.0	0.5	0.6	0.9	1.3	0.5	1.0	0.7
Other remote, offshore	0.5	1.0	0.7	0.8	1.4	2.0	1.8	0.8	1.1	1.5

(continued)

Table 4.1 (continued): GP characteristics, summary of annual results, BEACH, 1998–99 to 2007–08

GP characteristic	Per cent of GPs ^(a)									
	1998–99 (n = 984)	1999–00 (n = 1,047)	2000–01 (n = 999)	2001–02 (n = 983)	2002–03 (n = 1,008)	2003–04 (n = 1,000)	2004–05 (n = 953)	2005–06 (n = 1,017)	2006–07 (n = 930)	2007–08 (n = 953)
Practice location by ASGC ($\chi^2 = 3.53$, $p = 0.472$) (missing n)	(0)	(0)	(1)	(0)	(0)	(2)	(2)	(0)	(0)	(1)
Major cities	70.9	68.6	70.9	71.4	69.4	65.4	67.6	72.1	66.3	72.2
Inner regional	18.2	20.3	18.9	17.3	19.1	21.8	20.1	18.8	22.7	17.4
Outer regional	9.6	9.7	8.4	10.1	9.3	10.1	10.1	7.8	9.4	8.6
Remote	1.2	1.2	1.4	0.9	1.6	1.6	1.5	0.8	1.3	1.3
Very remote	0.1	0.2	0.3	0.3	0.7	1.0	0.7	0.6	0.3	0.5
After-hours arrangements ($\chi^2 = 85.789$, $p < 0.001$) (missing n) ^(d)	NAv	NAv	(0)	(0)	(5)	(5)	(8)	(14)	(3)	(6)
Practice does its own	NAv	NAv	45.5	41.6	42.8	43.6	35.9	34.6	34.6	33.2
Cooperative with other practices	NAv	NAv	19.3	19.4	16.7	20.0	16.2	15.7	15.5	11.3
Computer use at practice ($\chi^2 = 57.07$, $p < 0.001$) ^(e)	NAv	NAv	87.4	89.7	91.3	95.0	93.7	96.4	96.6	96.7

(a) Missing data removed.

(b) Multiple responses were allowed.

(c) $p = 0.12^*$ - no significant difference when comparing Australia with all overseas countries of GP origin; $p = 0.003^*$ - significant difference within the distribution of overseas countries of GP origin.

(d) Data for all three groupings only available from 2003–04.

(e) Data refer to computer use at the major practice and may not reflect the use of computers by individual GPs.

Note: NAv—not available; RRMA—Rural, Remote and Metropolitan Areas classification; ASGC—Australian Standard Geographical Classification; RACGP—Royal Australian College of General Practitioners.

5 The encounters

This chapter includes details about the encounters in general practice from each of the 10 years of the BEACH study from 1998–99 to 2007–08. The direction and type of change from 1998–99 to 2007–08 is indicated for each result in the far right column of the tables: ↑/↓ indicates a statistically significant linear change, ↑/↓ indicates a marginally significant linear change, § indicates a non-linear significant or marginal change, and – indicates there was no change.

Significant linear changes can be extrapolated to estimate the national increase or decrease in the other treatments provided between 1998–99 and 2007–08. An example of an extrapolated change is given for each table. The method used to extrapolate to national change estimates is described in Chapter 2, Section 2.4.

5.1 Content of the encounters

Table 5.1 provides an overview of the changes over time for data collected in BEACH between 1998–99 and 2007–08. As the table shows, many changes have occurred over the 10-year period of the BEACH study, representing the changes occurring in Australian general practice over this time.

The number of reasons for encounter given by the patient and recorded by the GP has increased significantly between 1998–99 and 2007–08, from 146.3 RFEs per 100 encounters to 153.0 per 100 encounters. Changes in types of RFEs are investigated in Chapter 6.

Having remained steady for the first eight years of the BEACH study, the rate of problems managed increased in 2007–08 to a rate significantly higher than those reported in each of the first eight years. In 2007–08, problems were managed at a rate of 151.3 per 100 encounters, compared with 145.3 per 100 encounters in 1998–99. This represents an increase of 12.8 million problems managed over the 10-year period.

The increased rate of problems managed is reflected in the rate of chronic problems managed, which shows a linear increase between 1998–99 and 2007–08, from 46.1 chronic problems per 100 encounters to 52.3 per 100 encounters. This represents an estimated additional 8.7 million chronic problems managed in general practice nationally in 2007–08 compared with 1998–99.

In contrast to the increasing rate of chronic problems managed, the rate of work-related problems has declined over the 10-year period, from 4.0 per 100 encounters in 1998–99 to 2.8 per 100 in 2007–08.

The overall rate of medications prescribed, advised or supplied by the GP declined significantly between 1998–99 and 2007–08. This was reflected in the declining rate of prescriptions, with about 7.9 million fewer prescriptions written by GPs nationally in 2007–08 than in 1998–99. More detailed analysis of these results can be found in Chapter 9. In contrast, the rate at which medications were supplied by the GP over the same period increased significantly, from 7.3 per 100 encounters to 10.1 per 100. This equates to an additional 3.3 million medications supplied by the GP in 2007–08 compared with 1998–99.

Other areas that demonstrated an increase over time included procedures, overall referrals, pathology and imaging orders, and orders for other investigations (Table 5.1). These changes are reported in more detail in their respective chapters.

As a proportion of all Medicare/DVA-claimable encounters recorded in BEACH, long surgery consultations have increased, from 7.7% in 1998–99 to 9.9% in 2007–08 (Table 5.2). Home visits have decreased as a proportion of MBS-claimable encounters, from 1.9% in 1998–99 to 1.0% in 2007–08. This equates to approximately 880,000 fewer home visits in 2007–08 than 10 years earlier.

In the subsample study for length of consultation that included start and finish times for A1 Medicare/DVA-claimable encounters, there was no significant change in length of consultation between 2000–01 and 2007–08 at a mean length of 14.8 minutes, and median length of 13.0 minutes. There was also no significant change in consultation length when all encounters with a GP Medicare item number were considered over time, with the mean length equalling 14.9 minutes in 2000–01, and 15.1 minutes in 2007–08 (Table 5.3).

Table 5.1: Summary of morbidity and management, summary of annual results, BEACH, 1998–99 to 2007–08

Variable	Rate per 100 encounters (95% CI)										↑(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Reasons for encounter	146.3 (144.6–148.0)	148.5 (146.7–150.2)	151.0 (149.2–152.8)	149.2 (147.4–150.9)	150.9 (149.0–152.7)	150.2 (148.4–152.0)	149.6 (147.8–151.5)	150.3 (148.4–152.2)	150.8 (148.9–152.7)	153.0 (151.1–154.8)	↑
Problems managed	145.3 (143.5–147.2)	146.7 (144.9–148.6)	144.5 (142.8–146.3)	143.4 (141.7–145.2)	144.9 (143.0–146.8)	146.3 (144.4–148.2)	145.5 (143.6–147.4)	146.2 (144.2–148.2)	148.5 (146.4–150.6)	151.3 (149.2–153.4)	↑
New problems	54.5 (53.0–56.0)	45.3 (43.6–46.9)	47.4 (45.7–49.0)	55.1 (53.8–56.5)	57.0 (55.6–58.3)	55.9 (54.5–57.3)	55.2 (53.8–56.5)	56.9 (55.5–58.2)	56.5 (55.1–57.9)	57.7 (56.3–59.1)	↑
Chronic problems	46.1 (44.5–47.6)	47.2 (45.5–49.0)	47.0 (45.4–48.5)	48.0 (46.5–49.6)	47.8 (46.1–49.4)	50.4 (48.7–52.1)	50.4 (48.7–52.1)	50.6 (48.8–52.5)	51.8 (50.1–53.4)	52.3 (50.4–54.1)	↑
Work-related	4.0 (3.7–4.3)	3.2 (2.9–3.5)	3.3 (3.1–3.5)	3.0 (2.7–3.2)	NAv	NAv	3.1 (2.8–3.5)	2.8 (2.6–3.1)	2.9 (2.6–3.1)	2.8 (2.6–3.1)	↓
Medications	109.7 (107.4–112.0)	110.1 (107.8–112.4)	108.2 (105.7–110.6)	104.5 (102.2–106.9)	103.8 (101.4–106.2)	104.4 (102.1–106.7)	101.5 (99.3–103.8)	104.4 (101.8–107.0)	101.5 (99.2–103.9)	102.7 (100.3–105.0)	↓
Prescribed	93.6 (91.2–96.1)	93.8 (91.5–96.2)	92.3 (89.9–94.7)	88.0 (85.6–90.4)	84.3 (81.8–86.9)	86.0 (83.6–88.5)	83.4 (81.2–85.5)	85.8 (83.3–88.4)	83.3 (81.0–85.5)	82.4 (80.3–84.6)	↓
GP-supplied	7.3 (6.5–8.1)	6.9 (6.0–7.7)	6.9 (5.9–7.9)	7.6 (6.6–8.7)	9.3 (8.0–10.6)	8.6 (7.6–9.6)	8.1 (7.3–8.8)	8.8 (8.2–9.5)	8.9 (8.2–9.6)	10.1 (9.5–10.7)	↑
Advised OTC	8.8 (8.1–9.5)	9.4 (8.7–10.1)	9.0 (8.2–9.7)	8.9 (8.2–9.6)	10.2 (9.3–11.1)	9.8 (9.0–10.5)	10.1 (9.2–10.9)	9.8 (9.0–10.5)	9.4 (8.7–10.1)	10.1 (9.3–10.9)	—
Other treatments	43.2 (41.3–45.1)	46.0 (44.1–47.8)	49.4 (47.1–51.7)	51.9 (49.5–54.2)	51.8 (49.3–54.3)	51.4 (48.9–53.8)	54.7 (52.1–57.3)	43.6 (41.5–45.8)	44.7 (42.3–47.0)	51.2 (48.9–53.6)	↑
Clinical	31.4 (29.7–33.0)	33.5 (31.8–35.2)	37.2 (35.1–39.3)	38.1 (36.1–40.1)	37.2 (35.0–39.4)	36.6 (34.5–38.8)	39.2 (37.1–41.4)	29.2 (27.3–31.1)	29.5 (27.6–31.4)	34.5 (32.5–36.5)	§
Procedural	11.8 (11.2–12.5)	12.5 (11.9–13.0)	12.2 (11.6–12.8)	13.8 (13.1–14.5)	14.6 (13.9–15.3)	14.7 (14.0–15.5)	15.5 (14.6–16.4)	14.4 (13.7–15.1)	15.2 (14.4–16.0)	16.7 (15.9–17.5)	↑

(continued)

Table 5.1 (continued): Summary of morbidity and management, summary of annual results, BEACH, 1998–99 to 2007–08

Variable	Rate per 100 encounters (95% CI)										↑(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Referrals	11.1 (10.7–11.6)	11.1 (10.7–11.6)	10.4 (10.0–10.8)	10.5 (10.1–10.9)	11.1 (10.7–11.6)	11.6 (11.1–12.1)	11.5 (11.1–12.0)	12.0 (11.5–12.5)	12.2 (11.7–12.7)	12.5 (12.0–13.0)	↑
Specialist	7.4 (7.1–7.7)	7.3 (7.0–7.6)	7.4 (7.1–7.7)	7.3 (7.0–7.6)	7.7 (7.3–8.0)	7.9 (7.5–8.2)	7.7 (7.4–8.0)	8.2 (7.8–8.5)	8.0 (7.7–8.4)	8.0 (7.6–8.3)	§
Allied health services	3.0 (2.8–3.2)	3.1 (2.9–3.3)	2.3 (2.2–2.5)	2.3 (2.1–2.4)	2.5 (2.3–2.7)	2.6 (2.4–2.8)	2.7 (2.5–2.9)	2.9 (2.7–3.1)	3.1 (2.9–3.3)	3.4 (3.2–3.7)	§
Hospital	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.5 (0.4–0.6)	0.4 (0.4–0.5)	0.6 (0.5–0.6)	0.6 (0.5–0.6)	0.5 (0.4–0.5)	0.4 (0.3–0.4)	0.4 (0.3–0.5)	0.4 (0.3–0.5)	↓
Emergency department	0.1 (0.0–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.3)	↑
Other referrals/other medical services ^(b)	0.0 [†] (0.0–0.0)	0.0 [†] (0.0–0.0)	0.2 (0.1–0.2)	0.4 (0.3–0.4)	0.3 (0.2–0.3)	0.4 (0.4–0.5)	0.4 (0.4–0.5)	0.4 (0.3–0.4)	0.5 (0.5–0.6)	0.5 (0.4–0.6)	↑
Pathology ^(c)	NAv	NAv	29.7 (28.4–30.9)	31.0 (29.7–32.4)	32.9 (31.5–34.4)	35.2 (33.7–36.7)	36.7 (35.2–38.2)	38.6 (36.9–40.3)	42.4 (40.7–44.2)	43.2 (41.3–45.0)	↑
Imaging ^(d)	NAv	NAv	7.7 (7.3–8.0)	7.9 (7.6–8.2)	8.6 (8.2–9.0)	8.2 (7.8–8.6)	8.3 (8.0–8.6)	8.8 (8.4–9.2)	9.0 (8.6–9.3)	9.5 (9.2–9.9)	↑
Other investigations ^(d)	NAv	NAv	0.6 (0.5–0.7)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	1.0 (1.0–1.1)	1.1 (1.0–1.2)	1.0 (0.9–1.1)	1.1 (1.0–1.2)	1.0 (0.9–1.1)	↑

(a) The direction and type of change is indicated for each result: ↑/↓ indicates a statistically significant change, § indicates a non-linear significant or marginal change, and — indicates there was no change.

(b) Other referrals and other medical services have been reported together for comparability. The 'other medical services' group was introduced in 2003–04. Previously these were grouped with 'other referrals'.

(c) In the third year of BEACH, the data collection and data coding system for pathology changed. Changes over time are calculated using the 2000–01 data to ensure comparability.

(d) In the first 2 years 'imaging' and 'other investigations' were grouped and reported together.

† Rates are reported to one decimal place. This indicates that the rate is < 0.05 per 100 encounters.

Note: CI—confidence interval; NAv—not available; OTC—over-the-counter.

Table 5.2: Type of encounter, summary of annual results (most frequent events), BEACH, 1998–99 to 2007–08

MBS/DVA consultation category	Percentage distribution of Medicare/DVA-claimable encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 82,816)	1999–00 (n = 93,698)	2000–01 (n = 82,113)	2001–02 (n = 84,196)	2002–03 (n = 89,068)	2003–04 (n = 86,244)	2004–05 (n = 81,582)	2005–06 (n = 89,011)	2006–07 (n = 79,847)	2007–08 (n = 83,376)	
Short surgery consultations	1.5 (1.3–1.7)	1.4 (1.1–1.8)	1.6 (0.3–2.0)	1.1 (0.9–1.3)	1.2 (1.0–1.4)	1.2 (0.9–1.4)	1.0 (0.8–1.3)	1.0 (0.8–1.1)	1.1 (0.9–1.4)	1.2 (1.0–1.4)	—
Standard surgery consultations	84.6 (83.7–85.4)	84.1 (83.2–84.9)	83.9 (82.9–84.9)	84.1 (83.1–85.0)	82.8 (81.8–83.9)	82.4 (81.2–83.6)	82.3 (81.0–83.5)	83.7 (82.7–84.7)	83.4 (82.4–84.3)	82.1 (80.1–83.3)	↓
Long surgery consultations	7.7 (7.1–8.3)	8.7 (8.0–9.3)	8.8 (8.2–9.5)	8.7 (8.0–9.3)	9.6 (8.9–10.2)	9.7 (9.0–10.4)	10.5 (9.7–11.2)	9.8 (9.1–10.5)	10.0 (9.3–10.6)	9.9 (9.2–10.5)	↑
Prolonged surgery consultations	0.6 (0.4–0.8)	0.6 (0.5–0.7)	0.7 (0.5–0.8)	0.7 (0.5–0.8)	0.8 (0.6–0.9)	0.7 (0.6–0.9)	0.8 (0.6–0.9)	0.7 (0.5–0.8)	0.6 (0.5–0.7)	0.7 (0.5–0.8)	—
Home visits	1.9 (1.7–2.2)	1.5 (1.3–1.7)	1.5 (1.2–1.9)	1.6 (1.3–1.9)	1.3 (1.1–1.6)	1.4 (1.0–1.8)	1.0 (0.8–1.2)	1.2 (0.9–1.5)	0.9 (0.7–1.1)	1.0 (0.6–1.4)	↓
Hospital	0.4 (0.3–0.6)	0.5 (0.3–0.7)	0.2 (0.1–0.3)	0.2 (0.1–0.3)	0.4 (0.2–0.6)	0.4 (0.3–0.5)	0.2 (0.1–0.3)	0.2 (0.1–0.3)	0.2 (0.1–0.3)	0.2 (0.1–0.2)	↓
Residential aged care facility	0.9 (0.7–1.1)	1.0 (0.8–1.2)	0.7 (0.5–1.0)	1.0 (0.7–1.3)	1.2 (0.9–1.6)	1.2 (0.9–1.4)	1.2 (0.8–1.6)	1.3 (0.9–1.6)	1.3 (1.0–1.6)	1.2 (0.9–1.5)	—
Chronic disease management	N/A	N/A	0.0 [‡] (0.0–0.0)	0.1 (0.1–0.3)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.3 (0.2–0.4)	0.4 (0.3–0.5)	0.5 (0.4–0.6)	↑
Case conference	N/A	N/A	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	—
Health assessment	N/A	0.0 [‡] (0.0–0.0)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	↑
Incentive payments	N/A	N/A	N/A	N/A	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	—
GP mental health care	NAv	NAv	NAv	NAv	0.0 (0.0–0.0)	0.0 (0.0–0.0)	0.0 (0.0–0.0)	0.0 (0.0–0.0)	0.4 (0.3–0.5)	0.8 (0.7–0.9)	↑
Other items	2.4 (2.1–2.7)	2.3 (2.0–2.6)	2.5 (2.0–3.0)	2.5 (1.9–3.0)	2.4 (1.8–3.0)	2.7 (2.0–3.5)	2.6 (1.7–3.4)	1.6 (1.3–1.8)	1.4 (1.1–1.7)	2.0 (1.5–2.4)	§

(a) The direction and type of change is indicated for each result: ↑/↓ indicates a statistically significant change, § indicates a non-linear significant or marginal change, and — indicates there was no change.

‡ Rates are reported to one decimal place. This indicates that the rate is < 0.05 per 100 encounters.

Note: Includes encounters that were recorded as claimable through the Department of Veterans' Affairs (DVA). CI—confidence interval; MBS—Medicare Benefits Schedule; N/A—not applicable; NAv—not available.

Table 5.3: Consultation length (minutes), summary of annual results, BEACH, 2000–01 to 2007–08

Variable	Consultation length (minutes)							
	2000–01	2001–02	2002–03	2003–04	2004–05	2005–06	2006–07	2007–08
A1 Medicare/DVA items (A,B,C,D)	(n = 30,961)	(n = 35,104)	(n = 34,886)	(n = 31,844)	(n = 30,683)	(n = 32,830)	(n = 33,756)	(n = 29,956)
Mean	14.8 (14.5–15.1)	14.9 (14.7–15.2)	14.8 (14.5–15.1)	15.0 (14.7–15.3)	15.1 (14.8–15.4)	14.9 (14.6–15.1)	14.9 (14.7–15.2)	14.8 (14.6–15.1)
Median	13.0	13.0	13.0	13.0	13.0	13.0	13.0	13.0
Mode	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.0
Range	1–106	1–155	1–165	1–120	1–120	1–110	1–155	1–110
All Medicare/DVA-claimable encounters (GP items)	(n = 31,734)	(n = 36,142)	(n = 35,861)	(n = 32,839)	(n = 31,510)	(n = 34,111)	(n = 35,201)	(n = 31,722)
Mean	14.9 (14.6–15.2)	15.0 (14.8–15.3)	14.9 (14.6–15.2)	15.1 (14.9–15.4)	15.2 (14.9–15.5)	15.0 (14.7–15.2)	15.1 (14.8–15.3)	15.1 (14.8–15.3)
Median	13.0	13.0	13.0	14.0	13.0	13.0	13.0	13.0
Mode	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.0
Range	1–150	1–180	1–165	1–175	1–180	1–110	1–155	1–110

Note: A1 Medicare items—Group A includes: 3, 4, 13, 19, 20; Group B includes: 23, 24, 25, 33, 35; Group C includes: 36, 37, 38, 40, 43; Group D includes: 44, 47, 48, 50, 51.
DVA—Australian Government Department of Veterans' Affairs. Results for 1998–99 and 1999–00 are not presented, as data are not comparable for these years.


6 The patients

This chapter includes data about the patients who participated in the BEACH study, including the patient characteristics and reasons for the encounter (RFEs) from each of the 10 years of the BEACH study from 1998–99 to 2007–08. The direction and type of change from 1998–99 to 2007–08 is indicated for each result in the far right column of the tables: \uparrow/\downarrow indicates a statistically significant linear change, \uparrow/\downarrow indicates a marginally significant linear change, \S indicates a non-linear significant or marginal change, and – indicates that there was no change.

Significant linear changes can be extrapolated to estimate the national increase or decrease in patient characteristics or RFEs between 1998–99 and 2007–08. An example of an extrapolation is given for each table. The method used to extrapolate to national change estimates is described in Chapter 2, Section 2.4.

6.1 Age–sex distribution of patients at encounter

Figure 6.1 shows the age–sex distribution of patients at BEACH encounters in 1998–99 and 2007–08. Between 1998–99 and 2007–08, the proportion of encounters with patients aged less than 45 years decreased from 51.6% to 44.7%, which equates to approximately 5.1 million fewer encounters nationally. Over the same period, the proportion of encounters with patients aged 45 years and over increased from 48.4% to 55.4%, which equates to an additional 9.6 million encounters. The increasing proportion of the GP workload associated with patients in the 45–64 years and 75 years and older age groups is apparent.



Note: CI—confidence interval.

6.2 Other patient characteristics

Table 6.1 shows that the proportion of encounters with patients holding a Repatriation health card has decreased significantly from 3.4% in 1998–99 to 2.8% in 2007–08. The decrease equates to about half a million fewer encounters with repatriation cardholders.

6.3 Patient reasons for encounter

RFEs are those concerns and expectations that patients bring to the GP. International interest in reasons for encounter has been developing over the past three decades. RFEs reflect the patient's demand for care and can provide an indication of service use patterns, which may benefit from intervention on a population level.²⁰

Participating GPs were asked to record at least one and up to three patient RFEs in words as close as possible to those used by the patient, before the diagnostic or management process had begun. RFEs can be expressed in terms of one or more symptoms (for example 'itchy eyes', 'chest pain'), in diagnostic terms (for example 'about my diabetes', 'for my hypertension'), a request for a service ('I need more scripts', 'I want a referral'), an expressed fear of disease, or a need for a check-up.

Patient RFEs can have a one-to-one, one-to-many, many-to-one and many-to-many relationship to problems managed. That is, the patient may describe a single RFE that relates to a single problem managed at the encounter, one RFE that relates to multiple problems, multiple symptoms that relate to a single problem managed at the encounter, or multiple RFEs that relate to multiple problems managed at the encounter.

Number of reasons for encounter

Table 6.2 shows there has been a decrease in the proportion of patients giving a single RFE, from 63.4% in 1998–99 to 58.9% in 2007–08, equating to a national decrease of about 2 million encounters at which only one RFE was given. To balance this there has been an increase in the proportion of encounters at which two RFEs or three RFEs are recorded, from 26.8% in 1998–99 to 29.1% in 2007–08 for two RFEs, and from 9.7% in 1998–99 to 11.9% in 2007–08 for three RFEs. This suggests that there were 3.6 million more encounters nationally where two RFEs were reported and 2.8 million more encounters nationally where three RFEs were reported in 2007–08 than in 1998–99.

Reasons for encounter by ICPC-2 chapter

Table 6.3 shows that between 1998–99 and 2007–08, there has been:

- a significant increase in the overall rate of RFEs, from 146.3 per 100 encounters in 1998–99 to 153.0 per 100 encounters in 2007–08. This increase equates to about 13.5 million extra RFEs nationally in 2007–08 than in 1998–99
- a 50% increase in the rate of general and unspecified RFEs, equating to an approximate increase of 15.6 million general and unspecified RFEs from 1998–99 to 2007–08 nationally
- a significant decrease in RFEs relating to respiratory problems from 24.8 per 100 encounters in 1998–99 to 20.6 per 100 encounters in 2007–08.

Distribution of reasons for encounter by ICPC-2 component

Table 6.4 shows that between 1998–99 and 2007–08:

- RFEs expressed in terms of a symptom or complaint (for example, ‘tired’, ‘feeling anxious’) were the most frequent. The presentation rate of symptoms or complaints has fluctuated over the years. It increased between 1998–99 and 2000–01, and has been decreasing ever since
- the rate of patient attendance to request test results has more than doubled, equating to an increase of over 4.6 million encounters with an RFE of this type in 2007–08 than in 1998–99
- requests for an administrative procedure (such as a medical certificate) also doubled, equating to an increase of approximately 1.4 million requests for an administrative procedure nationally
- patient requests for medications, treatments and therapeutics (such as repeat prescriptions) increased by 50%, equating to an increase of approximately 5.6 million such requests in 2007–08 as compared with 1998–99.

Most frequent patient reasons for encounter

Table 6.5 shows that between 1998–99 and 2007–08:

- the rate at which patients cited a need to get their prescription(s) as an RFE has increased by 50%, equating to an increase of nearly 5 million encounters with this RFE
- the rate of requests for unspecified blood tests as a RFE increased by 70%, equating to over half a million additional encounters with this RFE
- the rate of requests for general advice and education about patient health has increased by over 60%
- the presentation rate of ear pain decreased by one-quarter, equating to 450,000 fewer encounters where ear pain was a reported RFE
- patient presentations about asthma decreased by more than 40%, and the rate of acute bronchitis/bronchiolitis as a RFE halved. And while the rate of upper respiratory tract infection fluctuated over the years it has decreased by about one-quarter since 1998–99. These three decreases combined suggests that there were approximately 1.7 million fewer encounters with any of these RFEs in 2007–08 than in 1998–99, which would partly explain the decrease in the rate of RFEs related to the respiratory system (Table 6.3).

Table 6.1: Characteristics of patients at encounters, summary of annual results, BEACH, 1998–99 to 2007–08

Patient characteristics	Rate per 100 encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Sex (missing n) ^(b)	(1,474)	(1,182)	(1,111)	(809)	(911)	(932)	(809)	(788)	(765)	(876)	—
Male	42.3 (41.6–43.0)	42.7 (42.0–43.5)	42.9 (42.2–43.6)	42.6 (41.9–43.3)	42.2 (41.4–42.9)	42.6 (41.8–43.3)	43.5 (42.7–44.3)	44.0 (43.2–44.7)	43.7 (42.9–44.5)	42.9 (42.1–43.7)	—
Female	57.7 (57.0–58.4)	57.3 (56.5–58.0)	57.1 (56.4–57.8)	57.4 (56.7–58.1)	57.8 (57.0–58.6)	57.4 (56.7–58.2)	56.5 (55.7–57.3)	56.0 (55.3–56.8)	56.3 (55.5–57.1)	57.1 (56.3–57.9)	—
Age group (missing n) ^(b)	(1,023)	(804)	(846)	(760)	(895)	(905)	(925)	(769)	(779)	(784)	—
< 1 year	2.4 (2.2–2.6)	2.4 (2.2–2.5)	2.1 (1.9–2.3)	2.0 (1.9–2.1)	1.9 (1.8–2.1)	1.8 (1.7–1.9)	1.9 (1.8–2.1)	2.1 (1.9–2.2)	1.8 (1.7–2.0)	2.0 (1.8–2.1)	↓
1–4 years	5.7 (5.3–6.0)	5.2 (4.9–5.5)	5.4 (5.1–5.7)	4.9 (4.6–5.2)	5.0 (4.7–5.3)	4.6 (4.3–4.8)	4.3 (4.0–4.7)	4.3 (4.0–4.5)	4.1 (3.9–4.4)	4.3 (4.1–4.6)	↓
5–14 years	7.7 (7.3–8.1)	7.2 (6.9–7.5)	6.8 (6.4–7.2)	6.4 (6.1–6.7)	6.6 (6.3–6.9)	5.9 (5.6–6.3)	5.8 (5.5–6.1)	6.0 (5.7–6.3)	5.6 (5.3–5.9)	5.5 (5.2–5.8)	↓
15–24 years	9.8 (9.4–10.2)	10.4 (9.9–10.8)	10.3 (9.8–10.7)	9.5 (9.1–10.0)	10.1 (9.7–10.4)	9.6 (9.2–10.1)	9.0 (8.6–9.4)	9.4 (9.0–9.8)	9.1 (8.6–9.5)	9.5 (9.0–9.9)	—
25–44 years	26.0 (25.3–26.7)	26.3 (25.5–27.0)	26.3 (25.6–27.0)	25.8 (25.1–26.5)	25.7 (24.9–26.4)	24.1 (23.4–24.8)	24.4 (23.7–25.1)	23.9 (23.2–24.7)	23.3 (22.6–24.0)	23.4 (22.7–24.1)	↓
45–64 years	24.4 (23.8–25.0)	24.5 (24.0–25.0)	26.1 (25.5–26.7)	26.3 (25.7–26.8)	26.5 (25.9–27.0)	27.2 (26.7–27.7)	28.0 (27.4–28.6)	27.6 (27.0–28.2)	28.2 (27.6–28.7)	28.1 (27.5–28.6)	↑
65–74 years	12.3 (11.7–12.8)	12.0 (11.5–12.5)	11.7 (11.2–12.2)	12.3 (11.8–12.8)	11.6 (11.1–12.0)	12.4 (11.9–12.9)	12.6 (12.1–13.2)	12.2 (11.7–12.6)	12.7 (12.2–13.2)	12.6 (12.1–13.1)	—
75+ years	11.7 (11.1–12.4)	12.1 (11.4–12.9)	11.3 (10.7–12.0)	12.8 (12.0–13.5)	12.7 (11.9–13.4)	14.4 (13.6–15.2)	13.9 (13.1–14.7)	14.6 (13.7–15.4)	15.2 (14.4–16.0)	14.7 (13.9–15.5)	↑

(continued)

Table 6.1 (continued): Characteristics of patients at encounters, summary of annual results, BEACH, 1998–99 to 2007–08

	Rate per 100 encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Patient characteristics											
Other characteristics ^(c)											
New patient to practice	9.1 (8.5–9.7)	7.3 (6.7–7.9)	8.0 (7.2–8.7)	8.9 (8.2–9.5)	9.7 (8.9–10.5)	9.1 (8.4–9.8)	8.9 (8.1–9.6)	8.9 (8.2–9.7)	8.4 (7.7–9.2)	8.6 (7.8–9.4)	—
Commonwealth concession card	43.1 (41.7–44.5)	38.6 (37.0–40.2)	36.7 (35.1–38.3)	41.9 (40.4–43.3)	40.4 (38.8–41.9)	42.5 (41.0–44.0)	43.2 (41.8–44.7)	42.1 (40.6–43.7)	41.5 (39.9–43.0)	41.8 (40.3–43.3)	§
Repatriation health card ^(d)	3.4 (3.1–3.6)	2.9 (2.6–3.1)	3.1 (2.9–3.4)	3.3 (3.0–3.5)	3.3 (3.0–3.6)	3.5 (3.2–3.8)	3.2 (2.9–3.4)	3.1 (2.8–3.3)	3.1 (2.8–3.3)	2.8 (2.5–3.0)	↓
Non-English-speaking background	14.5 (12.9–16.0)	8.0 (6.5–9.5)	8.0 (7.2–8.7)	9.3 (7.6–11.0)	10.6 (9.0–12.2)	9.7 (7.8–11.6)	10.8 (9.0–12.6)	9.8 (8.2–11.4)	7.1 (5.8–8.5)	9.9 (8.2–11.5)	§
Aboriginal person and/or Torres Strait Islander	1.2 (0.9–1.5)	0.7 (0.5–0.9)	0.8 (0.5–1.1)	1.0 (0.8–1.3)	1.0 (0.8–1.3)	1.6 (1.2–2.0)	1.3 (1.0–1.7)	0.9 (0.6–1.1)	0.9 (0.6–1.2)	0.9 (0.7–1.2)	§

(a) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, § indicates a non-linear significant or marginal change, and — indicates there was no change.

(b) Missing data removed.

(c) Missing data for each of the listed 'other' patient characteristics were counted as a 'no' response.

(d) The 1998–99 and 1999–00 results published here include patients who held either a gold or white Repatriation health card; some previously published figures only included patients who held the gold card.

Note: CI—confidence interval.

Table 6.2: Number of patient reasons for encounter, summary of annual results, BEACH, 1998–99 to 2007–08

Number of reasons for encounter	Rate per 100 encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
One RFE	63.4 (62.3–64.6)	62.0 (60.8–63.1)	60.4 (59.2–61.6)	61.8 (60.6–63.0)	60.7 (59.5–61.9)	61.0 (59.9–62.2)	61.4 (60.2–62.6)	60.9 (59.7–62.2)	60.6 (59.4–61.9)	58.9 (57.7–60.2)	↓
Two RFEs	26.8 (26.1–27.5)	27.5 (26.9–28.2)	28.2 (27.6–28.9)	27.2 (26.5–28.0)	27.8 (27.1–28.4)	27.7 (27.0–28.4)	27.6 (26.9–28.3)	27.8 (27.1–28.5)	27.9 (27.2–28.7)	29.1 (28.5–29.8)	↑
Three RFEs	9.7 (9.2–10.4)	10.5 (9.8–11.1)	11.4 (10.7–12.1)	11.0 (10.3–11.6)	11.6 (10.8–12.3)	11.3 (10.5–12.0)	11.0 (10.3–11.7)	11.2 (10.5–11.9)	11.4 (10.7–12.2)	11.9 (11.2–12.6)	↑

(a) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change.

Note: CI—confidence interval; RFEs—reasons for encounter.

Table 6.3: Rate of patient reasons for encounter by ICPC-2 chapter, summary of annual results, BEACH, 1998–99 to 2007–08

ICPC-2 Chapter	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
General & unspecified	26.6 (25.7–27.4)	29.0 (28.1–29.9)	28.3 (27.5–29.1)	30.9 (29.9–31.8)	34.6 (33.6–35.6)	36.2 (35.2–37.2)	36.5 (35.5–37.6)	36.3 (35.2–37.4)	37.7 (36.7–38.8)	40.1 (39.0–41.2)	↑
Respiratory	24.8 (24.0–25.6)	25.3 (24.3–26.2)	24.6 (23.7–25.4)	23.4 (22.6–24.2)	23.0 (22.0–24.0)	21.4 (20.6–22.2)	20.6 (19.8–21.4)	21.9 (21.1–22.7)	20.7 (19.9–21.6)	20.6 (19.7–21.5)	↓
Musculoskeletal	16.7 (16.1–17.4)	16.6 (16.1–17.1)	17.7 (17.1–18.2)	16.7 (16.1–17.3)	17.7 (17.2–18.3)	16.3 (15.7–16.9)	16.7 (16.0–17.3)	16.4 (15.8–16.9)	16.1 (15.6–16.6)	15.4 (14.9–15.9)	↓
Skin	15.1 (14.6–15.5)	15.1 (14.7–15.6)	15.5 (15.0–16.0)	14.4 (13.9–14.9)	14.7 (14.3–15.2)	15.1 (14.5–15.7)	15.6 (15.0–16.2)	15.0 (14.5–15.6)	15.7 (15.1–16.3)	15.4 (14.8–16.1)	—
Cardiovascular	11.4 (10.9–12.0)	11.2 (10.6–11.8)	11.7 (11.1–12.2)	11.4 (10.8–11.9)	10.6 (10.0–11.1)	10.7 (10.1–11.2)	10.5 (10.0–11.0)	10.8 (10.2–11.3)	11.2 (10.7–11.8)	11.2 (10.6–11.8)	—
Digestive	10.6 (10.3–10.9)	10.4 (10.0–10.7)	11.1 (10.7–11.5)	10.6 (10.2–11.0)	10.4 (10.0–10.8)	10.7 (10.3–11.2)	9.9 (9.5–10.3)	9.9 (9.5–10.3)	10.1 (9.7–10.5)	10.3 (10.0–10.7)	—

(continued)

Table 6.3 (continued): Rate of patient reasons for encounter by ICPC-2 chapter, summary of annual results, BEACH, 1998–99 to 2007–08

ICPC-2 Chapter	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Psychological	7.6 (7.2–8.0)	7.2 (6.8–7.6)	8.1 (7.7–8.6)	7.8 (7.3–8.3)	7.3 (6.9–7.8)	7.3 (6.9–7.7)	7.6 (7.2–8.0)	7.8 (7.3–8.3)	7.5 (7.1–7.8)	7.8 (7.5–8.2)	—
Endocrine & metabolic	5.6 (5.3–5.9)	5.4 (5.1–5.7)	6.2 (5.9–6.5)	6.4 (6.1–6.7)	6.0 (5.7–6.3)	6.2 (5.8–6.5)	6.2 (5.8–6.5)	6.2 (5.8–6.5)	6.4 (6.1–6.8)	6.5 (6.1–6.8)	↑
Female genital system	5.3 (5.0–5.7)	5.3 (4.9–5.7)	5.5 (5.1–5.9)	5.5 (5.1–5.9)	6.1 (5.7–6.6)	5.1 (4.8–5.5)	5.0 (4.6–5.4)	5.1 (4.8–5.5)	5.1 (4.7–5.4)	5.2 (4.8–5.6)	—
Neurological	5.3 (5.1–5.5)	5.6 (5.4–5.8)	5.8 (5.5–6.0)	5.4 (5.2–5.6)	5.7 (5.5–6.0)	5.3 (5.1–5.6)	5.1 (4.9–5.4)	4.9 (4.7–5.2)	4.9 (4.7–5.2)	4.8 (4.6–5.0)	↓
Ear	4.5 (4.3–4.7)	4.2 (4.0–4.4)	4.2 (4.0–4.3)	4.2 (4.0–4.4)	4.0 (3.8–4.1)	3.7 (3.6–3.9)	3.9 (3.7–4.1)	3.9 (3.7–4.1)	3.6 (3.4–3.7)	3.6 (3.4–3.8)	↓
Pregnancy & family planning	3.4 (3.4–4.0)	3.8 (3.5–4.2)	3.5 (3.2–3.8)	3.5 (3.2–3.8)	3.6 (3.3–3.9)	3.7 (3.4–4.0)	3.4 (3.1–3.7)	3.4 (3.1–3.6)	3.3 (3.0–3.6)	3.2 (3.0–3.5)	—
Urology	2.5 (2.3–2.6)	2.6 (2.5–2.8)	2.4 (2.3–2.6)	2.5 (2.4–2.7)	2.5 (2.3–2.6)	2.5 (2.4–2.7)	2.5 (2.4–2.7)	2.6 (2.5–2.8)	2.6 (2.4–2.7)	2.5 (2.4–2.7)	—
Eye	2.7 (2.7–3.0)	2.8 (2.7–3.0)	2.7 (2.5–2.8)	2.5 (2.4–2.7)	2.7 (2.6–2.9)	2.7 (2.6–2.9)	2.7 (2.6–2.9)	2.8 (2.6–2.9)	2.5 (2.4–2.7)	2.5 (2.4–2.6)	—
Blood	1.8 (1.6–2.0)	2.1 (1.9–2.3)	2.0 (1.8–2.2)	1.1 (0.9–1.2)	1.0 (0.8–1.2)	1.3 (1.1–1.4)	1.2 (1.0–1.5)	1.2 (1.0–1.3)	1.2 (1.1–1.4)	1.4 (1.2–1.5)	↓
Male genital system	1.1 (0.9–1.2)	1.0 (0.9–1.1)	1.1 (1.0–1.3)	1.0 (0.9–1.1)	1.0 (0.9–1.2)	1.1 (0.9–1.2)	1.2 (1.1–1.4)	1.3 (1.2–1.4)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	—
Social problems	0.9 (0.7–1.1)	1.0 (0.8–1.1)	0.9 (0.7–1.1)	1.0 (0.8–1.1)	1.0 (0.8–1.2)	0.9 (0.8–1.1)	1.0 (0.8–1.1)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	1.1 (1.0–1.2)	—
Total RFEs	146.3 (144.6–148.0)	148.5 (146.7–150.2)	151.0 (149.2–152.8)	149.2 (147.4–150.9)	150.9 (149.0–152.7)	150.2 (148.4–152.0)	149.6 (147.8–151.5)	150.3 (148.4–152.2)	150.8 (148.9–152.7)	153.0 (151.1–154.8)	↑

(a) Figures do not total 100, as more than one RFE can be recorded for each encounter.

(b) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, § indicates a non-linear significant or marginal change, and — indicates there was no change.

Note: CI—confidence interval; RFE—reason for encounter.

Table 6.4: Rate of patient reasons for encounter by ICPC-2 component, summary of annual results, BEACH, 1998–99 to 2007–08

ICPC component	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Symptoms & complaints	71.1 (69.4–72.9)	73.4 (71.5–75.3)	76.6 (74.6–78.6)	74.1 (72.3–75.9)	74.0 (72.0–76.1)	71.7 (69.8–73.5)	71.3 (69.4–73.2)	69.7 (67.9–71.5)	67.9 (66.1–69.8)	67.7 (65.8–69.6)	§
Diagnosis, diseases	33.6 (31.9–35.2)	27.7 (26.2–29.2)	29.0 (27.6–30.5)	27.3 (25.9–28.7)	26.0 (24.6–27.4)	25.1 (23.9–26.4)	24.5 (23.3–25.7)	26.8 (25.4–28.2)	27.9 (26.2–29.5)	27.8 (26.3–29.3)	§
Diagnostic & preventive procedures	22.4 (21.5–23.3)	22.9 (22.0–23.8)	22.3 (21.4–23.2)	22.7 (21.7–23.6)	23.8 (22.8–24.7)	24.0 (23.1–25.0)	23.4 (22.5–24.3)	24.4 (23.4–25.3)	24.8 (23.8–25.7)	25.6 (24.7–26.5)	↑
Medications, treatments & therapeutics	10.3 (9.8–10.9)	12.0 (11.4–12.6)	11.2 (10.6–11.8)	11.9 (11.3–12.4)	13.0 (12.4–13.6)	14.4 (13.7–15.1)	14.5 (13.8–15.3)	14.4 (13.7–15.1)	14.2 (13.5–14.8)	15.1 (14.3–15.8)	↑
Referral & other RFEs	4.4 (4.0–4.7)	7.2 (6.7–7.7)	6.5 (6.0–7.0)	7.2 (6.7–7.7)	7.0 (6.6–7.5)	7.2 (6.8–7.6)	7.4 (6.9–7.9)	6.9 (6.5–7.4)	7.3 (6.9–7.8)	6.8 (6.4–7.2)	↑
Results	3.4 (3.1–3.7)	4.0 (3.7–4.3)	4.2 (3.9–4.6)	4.7 (4.4–5.1)	5.4 (5.0–5.7)	6.0 (5.6–6.4)	6.8 (6.4–7.2)	6.5 (6.1–6.9)	6.9 (6.5–7.3)	7.6 (7.2–8.1)	↑
Administrative	1.1 (0.9–1.2)	1.3 (1.1–1.4)	1.1 (0.9–1.3)	1.3 (1.1–1.5)	1.6 (1.4–1.8)	1.8 (1.6–1.9)	1.7 (1.5–1.8)	1.7 (1.5–1.8)	1.9 (1.7–2.0)	2.4 (2.2–2.5)	↑
Total RFEs	146.3 (144.6–148.0)	148.5 (146.7–150.2)	151.0 (149.2–152.8)	149.2 (147.4–150.9)	150.9 (149.0–152.7)	150.2 (148.4–152.0)	149.6 (147.8–151.5)	150.3 (148.4–152.2)	150.8 (148.9–152.7)	153.0 (151.1–154.8)	↑

(a) Figures do not total 100, as more than one RFE can be recorded for each encounter.

(b) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, and § indicates a non-linear significant or marginal change.

Note: CI—confidence interval; RFE—reason for encounter.

Table 6.5: Most frequent patient reasons for encounter, summary of annual results, BEACH, 1998–99 to 2007–08

Patient reason for encounter	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Check-up—all*	13.6 (13.0–14.3)	14.2 (13.5–14.9)	13.2 (12.5–13.9)	13.4 (12.7–14.0)	13.6 (12.9–14.2)	14.1 (13.4–14.8)	13.4 (12.8–14.0)	14.1 (13.4–14.8)	14.6 (13.9–15.2)	14.5 (13.8–15.1)	—
Prescription—all*	8.2 (7.7–8.7)	9.6 (9.1–10.2)	9.2 (8.7–9.8)	9.8 (9.2–10.3)	10.8 (10.2–11.3)	12.1 (11.5–12.7)	12.2 (11.5–12.8)	12.1 (11.4–12.7)	11.8 (11.2–12.4)	12.5 (11.9–13.2)	↑
Test results*	3.4 (3.1–3.7)	4.0 (3.7–4.2)	4.3 (3.9–4.6)	4.7 (4.4–5.0)	5.4 (5.0–5.7)	6.0 (5.7–6.4)	6.8 (6.4–7.2)	6.5 (6.1–6.9)	6.9 (6.5–7.3)	7.6 (7.2–8.1)	↑
Cough	6.2 (5.8–6.6)	7.0 (6.5–7.4)	7.0 (6.5–7.4)	6.5 (6.1–6.9)	6.7 (6.3–7.2)	6.2 (5.8–6.6)	5.9 (5.5–6.2)	6.4 (6.0–6.8)	5.8 (5.4–6.2)	6.2 (5.8–6.7)	§
Immunisation/vaccination—all*	4.9 (4.5–5.3)	4.2 (3.9–4.6)	4.4 (4.0–4.8)	4.6 (4.2–5.0)	4.7 (4.3–5.1)	4.4 (4.0–4.9)	4.3 (3.9–4.8)	4.8 (4.4–5.2)	4.3 (3.9–4.7)	4.8 (4.4–5.1)	§
Throat complaint	3.8 (3.5–4.1)	4.2 (3.8–4.5)	4.0 (3.7–4.3)	3.8 (3.5–4.0)	3.8 (3.5–4.1)	3.4 (3.1–3.6)	3.5 (3.3–3.8)	3.3 (3.0–3.5)	3.3 (3.1–3.6)	3.3 (3.0–3.6)	§
Back complaint*	3.6 (3.3–3.8)	3.6 (3.4–3.8)	3.8 (3.5–4.0)	3.8 (3.6–4.1)	3.5 (3.3–3.8)	3.5 (3.2–3.7)	3.4 (3.2–3.6)	3.5 (3.2–3.7)	3.2 (3.0–3.4)	3.2 (3.0–3.4)	§
Rash*	2.6 (2.4–2.8)	2.7 (2.6–2.9)	2.9 (2.8–3.1)	2.8 (2.6–3.0)	2.8 (2.7–3.0)	2.8 (2.6–2.9)	2.9 (2.7–3.1)	2.6 (2.5–2.8)	2.8 (2.6–3.0)	2.5 (2.3–2.6)	—
Upper respiratory tract infection	2.9 (2.6–3.2)	2.7 (2.4–3.0)	2.6 (2.3–2.9)	2.3 (2.1–2.6)	2.2 (1.9–2.4)	1.9 (1.7–2.1)	1.8 (1.5–2.0)	2.4 (2.0–2.7)	2.4 (2.1–2.7)	2.2 (2.0–2.5)	§
Fever	1.8 (1.6–2.0)	2.2 (1.9–2.5)	2.3 (2.0–2.5)	2.0 (1.8–2.2)	2.2 (1.9–2.5)	1.9 (1.7–2.1)	1.8 (1.6–2.0)	2.2 (1.9–2.5)	1.8 (1.6–2.0)	2.1 (1.8–2.5)	—
Hypertension/high blood pressure*	2.5 (2.2–2.8)	1.7 (1.4–1.9)	2.2 (1.9–2.4)	2.1 (1.8–2.3)	1.8 (1.6–2.0)	1.9 (1.6–2.1)	1.7 (1.5–1.9)	1.9 (1.6–2.1)	2.1 (1.8–2.5)	2.1 (1.8–2.3)	—
Depression*	2.1 (2.0–2.3)	1.7 (1.6–1.8)	2.1 (2.0–2.3)	1.9 (1.8–2.0)	1.9 (1.7–2.0)	1.8 (1.7–1.9)	1.9 (1.7–2.0)	1.9 (1.7–2.0)	1.9 (1.8–2.1)	2.0 (1.9–2.2)	—
Administrative procedure NOS	0.8 (0.8–0.9)	1.1 (1.0–1.2)	1.0 (0.9–1.1)	1.2 (1.0–1.3)	1.4 (1.3–1.6)	1.5 (1.4–1.7)	1.4 (1.3–1.5)	1.4 (1.3–1.6)	1.6 (1.5–1.8)	2.0 (1.8–2.1)	↑
Abdominal pain*	2.2 (2.1–2.4)	2.1 (1.9–2.2)	2.3 (2.1–2.4)	2.1 (2.0–2.2)	1.9 (1.8–2.1)	2.0 (1.9–2.2)	1.9 (1.8–2.0)	1.8 (1.7–1.9)	1.8 (1.7–1.9)	1.8 (1.6–1.9)	↓

(continued)

Table 6.5 (continued): Most frequent patient reasons for encounter, summary of annual results, BEACH, 1998–99 to 2007–08

Patient reason for encounter	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Headache	1.9 (1.8–2.1)	2.2 (2.0–2.3)	2.2 (2.0–2.3)	2.0 (1.9–2.2)	2.1 (1.9–2.3)	1.8 (1.6–1.9)	1.7 (1.6–1.8)	1.7 (1.6–1.8)	1.6 (1.4–1.7)	1.6 (1.5–1.8)	↓
Diarrhoea	1.4 (1.3–1.5)	1.3 (1.2–1.4)	1.5 (1.4–1.6)	1.4 (1.3–1.5)	1.6 (1.4–1.7)	1.5 (1.3–1.6)	1.4 (1.3–1.5)	1.3 (1.2–1.4)	1.3 (1.2–1.5)	1.4 (1.3–1.6)	—
Skin complaint	1.2 (1.1–1.3)	1.2 (1.1–1.4)	1.5 (1.4–1.6)	1.3 (1.1–1.5)	1.3 (1.2–1.5)	1.4 (1.2–1.5)	1.5 (1.3–1.6)	1.4 (1.3–1.5)	1.4 (1.3–1.5)	1.4 (1.3–1.5)	↑
Nasal congestion/sneezing	1.4 (1.2–1.5)	1.7 (1.4–1.9)	1.6 (1.4–1.8)	1.5 (1.3–1.7)	1.7 (1.4–2.0)	1.3 (1.1–1.5)	1.4 (1.2–1.6)	1.3 (1.1–1.6)	1.1 (0.9–1.2)	1.4 (1.2–1.6)	§
Ear pain	1.9 (1.8–2.1)	1.9 (1.7–2.0)	1.8 (1.7–1.9)	1.7 (1.6–1.9)	1.7 (1.5–1.8)	1.6 (1.4–1.7)	1.6 (1.5–1.7)	1.6 (1.5–1.7)	1.4 (1.3–1.5)	1.4 (1.3–1.5)	↓
Weakness/tiredness	1.6 (1.4–1.7)	1.5 (1.4–1.6)	1.7 (1.5–1.8)	1.5 (1.4–1.6)	1.5 (1.3–1.6)	1.5 (1.4–1.6)	1.7 (1.5–1.8)	1.3 (1.2–1.4)	1.4 (1.2–1.5)	1.4 (1.2–1.5)	—
Knee complaint	1.2 (1.1–1.3)	1.3 (1.2–1.4)	1.4 (1.3–1.5)	1.4 (1.3–1.5)	1.3 (1.2–1.4)	1.4 (1.3–1.5)	1.4 (1.3–1.5)	1.4 (1.3–1.5)	1.3 (1.2–1.4)	1.3 (1.2–1.4)	—
Diabetes—all*	1.1 (1.0–1.2)	0.8 (0.7–0.9)	1.0 (0.8–1.1)	1.0 (0.9–1.1)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	1.0 (0.9–1.1)	1.1 (1.0–1.2)	1.3 (1.1–1.4)	§
Blood test NOS	0.7 (0.6–0.9)	0.8 (0.7–0.9)	0.8 (0.7–1.0)	0.8 (0.7–1.0)	1.0 (0.9–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.3)	1.2 (1.0–1.3)	1.2 (1.1–1.4)	1.2 (1.0–1.3)	↑
Vertigo/dizziness	1.1 (1.0–1.2)	1.2 (1.1–1.3)	1.3 (1.2–1.4)	1.2 (1.1–1.3)	1.1 (1.0–1.2)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	1.1 (1.1–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	—
Foot/toe complaint	1.2 (1.1–1.3)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	1.1 (1.0–1.2)	1.2 (1.1–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	—
Anxiety*	1.1 (1.0–1.2)	1.0 (0.9–1.1)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	1.2 (1.0–1.3)	1.0 (0.9–1.1)	1.1 (1.0–1.2)	—
Vomiting	1.1 (1.0–1.2)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.3)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	1.1 (1.0–1.2)	—
Swelling*	1.1 (1.0–1.2)	1.1 (1.0–1.1)	1.1 (0.9–1.1)	1.1 (1.0–1.2)	1.1 (1.0–1.1)	1.2 (1.0–1.3)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	—

(continued)

Table 6.5 (continued): Most frequent patient reasons for encounter, summary of annual results, BEACH, 1998–99 to 2007–08

Patient reason for encounter	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Chest pain NOS	1.3 (1.2–1.4)	1.3 (1.2–1.4)	1.3 (1.2–1.4)	1.2 (1.1–1.3)	1.1 (1.0–1.2)	1.3 (1.2–1.4)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.2 (1.1–1.3)	1.1 (1.0–1.1)	↓
Shoulder complaint	1.1 (1.0–1.2)	1.0 (1.0–1.1)	1.1 (1.0–1.2)	1.2 (1.1–1.3)	1.1 (1.0–1.2)	1.0 (0.9–1.1)	1.3 (1.1–1.4)	1.1 (1.0–1.2)	1.2 (1.1–1.3)	1.0 (0.9–1.1)	—
Advice/education	0.6 (0.5–0.7)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.6 (0.6–0.7)	0.6 (0.6–0.7)	0.7 (0.7–0.8)	0.8 (0.7–1.0)	0.7 (0.7–0.8)	0.8 (0.8–0.9)	1.0 (0.9–1.1)	↑
Sleep disturbance	1.2 (1.1–1.3)	1.2 (1.1–1.3)	1.3 (1.2–1.4)	1.3 (1.2–1.4)	1.2 (1.0–1.3)	1.2 (1.0–1.3)	1.2 (1.1–1.4)	1.2 (1.1–1.3)	1.1 (1.0–1.2)	1.0 (0.9–1.1)	—
Neck complaint	1.2 (1.1–1.3)	1.1 (1.0–1.2)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	1.1 (1.0–1.2)	0.9 (0.9–1.0)	1.0 (0.9–1.2)	0.9 (0.8–1.1)	0.9 (0.8–0.9)	0.9 (0.8–1.0)	↓
Leg/thigh complaint	1.0 (1.0–1.1)	1.0 (0.9–1.0)	1.2 (1.1–1.3)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.0 (0.9–1.1)	1.0 (1.0–1.1)	0.9 (0.8–1.0)	—
Asthma	1.4 (1.3–1.5)	1.2 (1.0–1.3)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (0.9–1.2)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.8)	↓
Oral contraception*	0.9 (0.8–0.9)	1.0 (0.9–1.1)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	↓
Acute bronchitis/bronchiolitis	1.0 (0.9–1.1)	0.7 (0.6–0.8)	0.6 (0.5–0.7)	0.6 (0.5–0.7)	0.5 (0.4–0.6)	0.5 (0.4–0.6)	0.5 (0.4–0.6)	0.6 (0.5–0.7)	0.5 (0.4–0.5)	0.5 (0.5–0.6)	↓
Total RFEs	146.3 (144.6–148.0)	148.5 (146.7–150.2)	151.0 (149.2–152.8)	149.2 (147.4–150.9)	150.9 (149.0–152.7)	150.2 (148.4–152.0)	149.6 (147.8–151.5)	150.3 (148.4–152.2)	150.8 (148.9–152.7)	153.0 (151.1–154.8)	↑

(a) Figures do not total 100, as more than one RFE can be recorded for each encounter.

(b) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, § indicates a non-linear significant change, and — indicates there was no change.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5).

Note: CI—confidence interval; RFE—reason for encounter; NOS—not otherwise specified.

7 Problems managed

A 'problem managed' is a formal statement of the provider's understanding of a health problem presented by the patient, family or community, and can be described in terms of a disease, symptom or complaint, social problem, or ill-defined condition managed at the encounter. As GPs were instructed to record each problem at the most specific level possible from the information available, the problem managed may at times be limited to the level of a presenting symptom.

At each patient encounter, up to four problems could be recorded by the GP. A minimum of one problem was compulsory. The status of each problem to the patient – new (first presentation to a medical practitioner) or old (follow-up of previously managed problem) – was also indicated. The concept of a principal diagnosis, which is often used in hospital statistics, is not adopted in studies of general practice where multiple problem management is the norm rather than the exception. Further, the range of problems managed at the encounter often crosses multiple body systems and may include undiagnosed symptoms, psychosocial problems or chronic disease, which makes the designation of a principal diagnosis difficult. Thus the order in which the problems were recorded by the GP is not significant.

This chapter includes data about the problems managed in general practice from each of the 10 years of the BEACH study from 1998–99 to 2007–08. The direction and type of change from 1998–99 to 2007–08 is indicated for each result in the far right column of the tables: \uparrow/\downarrow indicates a statistically significant linear change, \uparrow/\downarrow indicates a marginally significant linear change, § indicates a non-linear significant or marginal change, and – indicates there was no change.

Significant linear changes can be extrapolated to estimate the national increase or decrease in the management rate of a problem between 1998–99 and 2007–08. An example of an extrapolated change is given for each table. The method used to extrapolate to national change estimates is described in Chapter 2, Section 2.4.

There are two ways to describe the relative frequency of problems managed: as a percentage of all problems managed in the study, or as a rate of problems managed per 100 encounters. Where groups of problems are reported (for example cardiovascular problems), it must be remembered that more than one of that type of problem (such as hypertension and heart failure) may have been managed at a single encounter. In considering these results, the reader must be mindful that although a rate per 100 encounters for a single ungrouped problem (for example asthma, 2.2 per 100 encounters) can be regarded as equivalent to 'asthma is managed at 2.2% of encounters', such a statement cannot be made for grouped concepts (ICPC-2 chapters and those marked with asterisks in the tables).

7.1 Number of problems managed

GPs are asked to record information about the management of up to four problems at each encounter. Table 7.1 shows the number of problems managed at each encounter over time.

There has been an increase in the number of encounters where three and four problems were managed, and a decrease in encounters where only one problem was managed. When extrapolated to all GP encounters in Australia this indicates there were about 1.5 million

more occasions where three problems were managed, 840,000 more occasions where four problems were managed and 610,000 fewer occasions where one problem was managed by GPs in Australia in 2007–08 than in 1998–99.

There has been a significant increase in the number of problems managed at encounter, from 145.3 per 100 encounters in 1998–99 to 151.3 in 2007–08 (Table 7.2). This suggests there were an additional 12.8 million problems managed at GP encounters in Australia in 2007–08 than in 1998–99. This was reflected in significant increases in the management rate of new problems (Table 7.5), and the management rate of chronic conditions (Table 7.6).

7.2 Distribution of problems managed by ICPC-2 component

As shown in Table 7.2, there has been no significant change in the management rate of problems described in terms of a diagnosis or disease or in terms of symptoms and complaints between 1998–99 and 2007–08. However, there was an increase in the management rate of problems described and classified as ‘results’ and ‘administrative procedures’. The increase in the management of test results represents an extrapolated national increase of 1.1 million contacts for this problem and the increase in administrative procedures represents an extrapolated increase of 550,000 contacts in Australia in 2007–08 when compared with 1998–99. There was also a marginal increase in the management rate of problems described and classified as ‘diagnostic and preventive procedures’.

7.3 Problems managed by ICPC-2 chapter and individual problems managed

Problems managed at general practice encounters by ICPC chapter are described in Table 7.3 for all years from 1998–99 to 2007–08. Problems related to the respiratory system have remained the most common type of problem managed since 1998–99. However, the management rate of respiratory problems has decreased significantly from 24.3 per 100 encounters in 1998–99 to 19.4 per 100 in 2007–08. This represents a national decrease of approximately 4.2 million occasions where a respiratory problem was managed in 2007–08 when compared with 1998–99.

The most common individual problems managed are described in Table 7.4 for all years from 1998–99 to 2007–08. Hypertension was the most common individual problem managed in general practice in Australia. Its management rate increased significantly between 1998–99 and 2007–08, from 8.3 to 9.9 per 100 encounters. This represents an extrapolated increase of more than 2 million occasions where hypertension was managed in Australia in 2007–08 than in 1998–99.

Changes in the management rate of selected chronic and acute conditions from 1998–99 to 2007–08 are presented graphically in figures 7.1 and 7.2.

7.4 Most common new problems


Table 7.5 shows the most frequently managed new problems between 1998–99 and 2007–08. There was a significant increase in the management rate of new problems over the 10 years of the study from 54.5 per 100 encounters in 1998–99 to 57.7 in 2007–08, suggesting approximately 5.8 million more GP contacts with management of new problems than in 1998–99.

The most common new problems managed in general practice over the decade were upper respiratory tract infection, immunisation/vaccination and acute bronchitis/bronchiolitis. The management of general check-ups as a new problem increased significantly from 0.7 per 100 encounters in 1998–99 to 1.2 per 100 encounters in 2007–08, representing an additional 570,000 occasions where general check-ups were managed in 2007–08 compared with 1998–99 (Table 7.5).

7.5 Most frequently managed chronic problems

Table 7.6 shows the most frequently managed chronic problems between 1998–99 and 2007–08. The management rate of chronic conditions significantly increased from 46.1 per 100 encounters in 1998–99 to 52.3 per 100 in 2007–08, suggesting approximately 8.6 million more GP contacts in Australia in 2007–08 with chronic problems than in 1998–99.

The most common chronic problems managed were non-gestational hypertension, depressive disorder, non-gestational diabetes and lipid disorders. These problems all increased significantly over the decade. For example, lipid disorders increased from 2.5 to 3.7 per 100 encounters, representing an increase in management of 1.4 million lipid problems from 1998–99 to 2007–08 (Table 7.6). In parallel to these increases, the management rate of many acute problems decreased significantly over the study period (Figure 7.2).



* Indicates a statistically significant change from 1998–99 to 2007–08 (for management rates see Table 7.4).

Note: CI—confidence interval.




Figure 7.2: Changes in management rate of selected acute problems, 1998-99 to 2007-08 (95% CI)

* Indicates a statistically significant change from 1998-99 to 2007-08 (for management rates see Table 7.4).

Note: CI—confidence interval.

Table 7.1: Number of problems managed at an encounter, summary of annual results, BEACH, 1998–99 to 2007–08

Number of problems managed at encounter	Per cent of encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
One problem	66.3 (65.1–67.4)	65.4 (64.3–66.5)	66.5 (65.4–67.5)	67.7 (66.6–68.8)	66.9 (65.8–68.1)	66.2 (65.0–67.3)	66.5 (65.3–67.7)	66.4 (65.1–67.6)	65.0 (63.7–66.2)	63.0 (61.7–64.3)	↓
Two problems	24.1 (23.4–24.8)	24.7 (24.0–25.3)	24.4 (23.8–25.1)	23.1 (22.4–23.7)	23.4 (22.6–24.1)	23.8 (23.1–24.5)	23.6 (22.9–24.3)	23.4 (22.7–24.1)	24.0 (23.3–24.8)	25.4 (24.7–26.2)	—
Three problems	7.7 (7.3–8.1)	7.7 (7.3–8.1)	7.3 (6.9–7.7)	7.3 (6.9–7.7)	7.6 (7.2–8.0)	7.7 (7.2–8.1)	7.7 (7.3–8.2)	7.9 (7.4–8.4)	8.5 (8.1–9.0)	8.8 (8.3–9.3)	↑
Four problems	2.0 (1.6–2.3)	2.2 (1.9–2.5)	1.9 (1.5–2.2)	1.9 (1.6–2.2)	2.1 (1.7–2.5)	2.4 (2.0–2.8)	2.2 (1.8–2.5)	2.3 (2.1–2.6)	2.5 (2.2–2.7)	2.7 (2.4–3.0)	↑

(a) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, and — indicates there was no change.

Note: CI—confidence interval.

Table 7.2: Distribution of problems managed, by ICPC-2 component, summary of annual results, BEACH, 1998–99 to 2007–08

ICPC-2 component	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Diagnosis, diseases	94.7 (93.1–96.3)	96.1 (94.4–97.8)	95.2 (93.6–96.7)	93.7 (92.1–95.2)	93.1 (91.5–94.8)	94.8 (93.0–96.5)	94.2 (94.2–96.0)	95.5 (93.6–97.3)	96.6 (94.8–98.3)	98.1 (96.2–99.9)	—
Symptoms & complaints	33.1 (32.3–33.9)	32.0 (31.2–32.8)	31.7 (30.9–32.5)	31.4 (30.6–32.2)	31.4 (30.6–32.2)	30.8 (30.0–31.6)	31.1 (30.2–31.9)	30.4 (29.6–31.2)	31.4 (30.6–32.2)	32.3 (31.5–33.1)	—
Diagnostic & preventive procedures	12.8 (12.2–13.5)	13.1 (12.4–13.7)	12.6 (11.9–13.2)	12.4 (11.8–13.0)	13.5 (12.8–14.2)	13.6 (12.9–14.4)	13.3 (12.5–14.0)	13.7 (13.1–14.4)	13.8 (13.0–14.5)	14.2 (13.5–14.8)	↑
Medications, treatments & therapeutics	2.6 (2.4–2.8)	3.1 (2.9–3.3)	2.9 (2.7–3.1)	3.3 (3.0–3.6)	3.6 (3.3–3.8)	4.0 (3.6–4.3)	3.7 (3.4–3.9)	3.2 (3.0–3.5)	3.2 (2.9–3.5)	2.9 (2.7–3.2)	§
Results	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	1.1 (0.9–1.2)	1.1 (0.9–1.2)	1.2 (1.1–1.4)	1.4 (1.3–1.5)	1.4 (1.3–1.6)	1.6 (1.4–1.7)	1.8 (1.6–1.9)	↑
Referral & other RFE	1.0 (0.8–1.1)	1.3 (1.2–1.4)	1.1 (1.0–1.2)	1.1 (1.0–1.3)	1.7 (1.5–1.9)	1.3 (1.1–1.4)	1.4 (1.2–1.5)	1.2 (1.1–1.4)	1.3 (1.2–1.5)	1.2 (1.1–1.3)	§
Administrative	0.4 (0.3–0.5)	0.4 (0.4–0.5)	0.4 (0.3–0.4)	0.5 (0.4–0.5)	0.5 (0.5–0.6)	0.6 (0.6–0.7)	0.6 (0.5–0.6)	0.7 (0.6–0.8)	0.8 (0.7–0.8)	0.9 (0.8–1.0)	↑
Total problems	145.3 (143.5–147.2)	146.7 (144.9–148.6)	144.5 (142.8–146.3)	143.4 (141.7–145.2)	144.9 (143.0–146.8)	146.3 (144.4–148.2)	145.5 (143.6–147.4)	146.2 (144.2–148.2)	148.5 (146.4–150.6)	151.3 (149.2–153.4)	↑

(a) Figures do not total 100, as more than one problem can be recorded for each encounter.

(b) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, § indicates a non-linear significant or marginal change, and — indicates there was no change.

Note: CI—confidence interval; RFE—reason for encounter.

Table 7.3: Distribution of problems managed, by ICPC-2 chapter, summary of annual results, BEACH, 1998–99 to 2007–08

ICPC-2 Chapter	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Respiratory	24.3 (23.6–25.0)	24.2 (23.5–24.9)	22.5 (21.9–23.2)	21.4 (20.7–22.0)	20.6 (20.0–21.3)	20.1 (19.5–20.7)	19.2 (18.6–19.9)	20.6 (19.9–21.3)	19.6 (18.9–20.3)	19.4 (18.8–20.1)	↓
General & unspecified	13.2 (12.7–13.7)	13.9 (13.4–14.5)	14.2 (13.7–14.7)	14.7 (14.0–15.5)	15.8 (15.2–16.3)	15.0 (14.5–15.5)	15.1 (14.5–15.7)	15.1 (14.5–15.7)	16.2 (15.6–16.8)	17.8 (17.1–18.5)	↑
Cardiovascular	16.1 (15.4–16.8)	16.3 (15.5–17.0)	16.0 (15.3–16.7)	16.1 (15.5–16.8)	16.0 (15.3–16.7)	16.8 (16.1–17.5)	16.2 (15.5–16.9)	16.6 (16.1–17.7)	17.4 (16.7–18.1)	17.6 (16.8–18.3)	↑
Musculoskeletal	16.9 (16.3–17.5)	16.9 (16.4–17.4)	17.4 (16.9–18.0)	17.5 (17.0–18.0)	17.1 (16.5–17.6)	17.1 (16.6–17.6)	17.7 (17.1–18.3)	17.2 (16.7–17.7)	17.1 (16.6–17.6)	17.3 (16.7–17.8)	—
Skin	16.5 (16.0–17.0)	17.0 (16.6–17.5)	16.7 (16.2–17.3)	16.1 (15.6–16.6)	16.5 (16.0–17.0)	16.9 (16.2–17.6)	17.2 (16.6–17.9)	16.6 (16.1–17.2)	17.5 (16.9–18.2)	17.2 (16.5–17.9)	—
Endocrine & metabolic	8.8 (8.4–9.2)	9.1 (8.7–9.6)	9.8 (9.3–10.2)	10.4 (10.0–10.9)	10.6 (10.2–11.0)	11.3 (10.8–11.8)	11.8 (11.2–12.3)	11.6 (11.0–12.1)	12.1 (11.6–12.6)	12.9 (12.3–13.5)	↑
Psychological	10.5 (10.0–11.0)	10.5 (10.0–11.1)	10.8 (10.2–11.3)	10.6 (10.1–11.2)	10.3 (9.8–10.8)	10.8 (10.3–11.4)	11.4 (10.8–12.0)	11.1 (10.5–11.7)	11.0 (10.5–11.4)	11.5 (10.9–12.0)	—
Digestive	10.2 (9.9–10.5)	10.1 (9.7–10.3)	9.9 (9.6–10.2)	9.9 (9.6–10.2)	10.1 (9.8–10.4)	10.5 (10.2–10.8)	9.9 (9.6–10.2)	10.1 (9.8–10.4)	10.4 (10.1–10.7)	10.7 (10.4–11.1)	—
Female genital system	6.3 (5.9–6.6)	6.2 (5.8–6.5)	6.1 (5.7–6.4)	6.1 (5.8–6.5)	6.7 (6.2–7.1)	5.9 (5.5–6.3)	5.7 (5.3–6.1)	5.8 (5.4–6.2)	5.7 (5.3–6.1)	5.8 (5.4–6.2)	—
Pregnancy & family planning	4.1 (3.8–4.3)	4.3 (4.0–4.6)	3.9 (3.6–4.2)	4.0 (3.7–4.2)	4.2 (3.9–4.5)	4.2 (3.9–4.5)	3.8 (3.6–4.1)	3.8 (3.6–4.1)	3.9 (3.6–4.2)	3.9 (3.6–4.2)	—
Ear	4.9 (4.7–5.1)	4.5 (4.3–4.7)	4.4 (4.2–4.6)	4.2 (4.0–4.4)	4.0 (3.8–4.2)	4.0 (3.8–4.1)	4.1 (3.9–4.2)	4.0 (3.8–4.1)	3.8 (3.6–3.9)	3.8 (3.6–3.9)	↓
Neurological	4.0 (3.8–4.2)	3.9 (3.7–4.1)	3.8 (3.6–3.9)	3.7 (3.5–3.9)	4.2 (4.0–4.4)	3.9 (3.8–4.1)	3.6 (3.5–3.8)	3.6 (3.4–3.8)	3.8 (3.6–3.9)	3.6 (3.4–3.7)	↓
Urology	2.8 (2.7–3.0)	3.0 (2.9–3.2)	2.7 (2.5–2.8)	2.8 (2.7–3.0)	2.8 (2.7–3.0)	3.0 (2.9–3.2)	3.0 (2.9–3.2)	3.1 (2.9–3.2)	3.2 (3.0–3.3)	3.1 (3.0–3.3)	↑

(continued)

Table 7.3 (continued): Distribution of problems managed, by ICPC-2 chapter, summary of annual results, BEACH, 1998–99 to 2007–08

ICPC-2 Chapter	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Eye	2.8 (2.7–3.0)	2.7 (2.6–2.9)	2.6 (2.5–2.7)	2.5 (2.4–2.6)	2.6 (2.5–2.7)	2.7 (2.6–2.9)	2.7 (2.5–2.8)	2.8 (2.6–2.9)	2.7 (2.5–2.8)	2.6 (2.4–2.7)	§
Male genital system	1.4 (1.3–1.5)	1.4 (1.3–1.5)	1.5 (1.3–1.6)	1.3 (1.2–1.4)	1.4 (1.3–1.6)	1.6 (1.5–1.7)	1.8 (1.6–1.9)	1.9 (1.7–2.0)	1.9 (1.7–2.0)	1.8 (1.7–1.9)	↑
Blood	1.7 (1.5–1.9)	1.7 (1.6–1.8)	1.7 (1.5–1.8)	1.3 (1.2–1.4)	1.4 (1.3–1.5)	1.7 (1.5–1.8)	1.6 (1.4–1.8)	1.5 (1.4–1.6)	1.7 (1.5–1.8)	1.6 (1.5–1.8)	—
Social problems	0.8 (0.7–0.8)	0.9 (0.8–1.0)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.6 (0.5–0.7)	0.7 (0.6–0.7)	0.7 (0.6–0.8)	—
Total problems	145.3 (143.5–147.2)	146.7 (144.9–148.6)	144.5 (142.8–146.3)	143.4 (141.7–145.2)	144.9 (143.0–146.8)	146.3 (144.4–148.2)	145.5 (143.6–147.4)	146.2 (144.2–148.2)	148.5 (146.4–150.6)	151.3 (149.2–153.4)	↑

(a) Figures do not total 100, as more than one problem can be managed at each encounter.

(b) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, § indicates a non-linear significant or marginal change, and — indicates there was no change.

Note: CI—confidence interval.

Table 7.4: Most frequently managed problems, summary of annual results, BEACH, 1998–99 to 2007–08

Problem managed	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Hypertension*	8.3 (7.8–8.7)	8.4 (7.9–8.9)	8.6 (8.2–9.1)	9.0 (8.5–9.5)	8.8 (8.4–9.3)	9.2 (8.7–9.7)	8.9 (8.4–9.4)	9.4 (8.9–10.0)	9.6 (9.1–10.0)	9.9 (9.4–10.5)	↑
Check-up—all*	5.9 (5.5–6.3)	6.4 (6.0–6.8)	5.9 (5.5–6.2)	5.8 (5.4–6.1)	6.4 (6.0–6.8)	6.4 (5.9–6.9)	6.3 (5.9–6.7)	6.4 (6.0–6.8)	6.6 (6.2–7.0)	6.3 (6.0–6.7)	—
General check-up*	1.6 (1.4–1.7)	1.8 (1.6–1.9)	1.6 (1.5–1.8)	1.8 (1.6–1.9)	1.9 (1.8–2.1)	1.8 (1.7–2.0)	2.1 (1.9–2.2)	2.1 (1.9–2.2)	2.4 (2.2–2.6)	2.5 (2.3–2.7)	↑
Female genital check-up*	1.6 (1.5–1.8)	1.6 (1.4–1.7)	1.5 (1.3–1.6)	1.6 (1.4–1.7)	1.8 (1.6–2.0)	1.8 (1.6–2.0)	1.8 (1.6–2.0)	1.8 (1.6–2.0)	1.7 (1.5–1.9)	1.8 (1.6–2.0)	—
Cardiac check-up*	1.2 (1.1–1.4)	1.3 (1.2–1.5)	1.3 (1.2–1.4)	1.1 (1.0–1.3)	1.1 (0.9–1.2)	1.2 (1.0–1.3)	1.0 (0.9–1.1)	1.2 (1.0–1.3)	1.3 (1.1–1.5)	1.2 (1.0–1.4)	—
Upper respiratory tract infection	6.8 (6.4–7.3)	7.2 (6.7–7.7)	6.9 (6.5–7.3)	6.2 (5.8–6.6)	6.4 (6.0–6.8)	5.5 (5.1–5.8)	5.6 (5.2–5.9)	6.2 (5.8–6.6)	5.8 (5.3–6.2)	6.2 (5.7–6.7)	§
Immunisation/vaccination—all*	5.2 (4.7–5.6)	4.6 (4.2–5.0)	4.6 (4.2–4.9)	4.7 (4.3–5.1)	4.6 (4.3–5.0)	4.7 (4.3–5.2)	4.6 (4.2–5.1)	5.0 (4.6–5.4)	4.7 (4.3–5.2)	5.2 (4.8–5.6)	—
Depression*	3.5 (3.3–3.7)	3.4 (3.2–3.6)	3.7 (3.4–3.9)	3.4 (3.2–3.6)	3.5 (3.3–3.7)	3.6 (3.4–3.9)	3.7 (3.5–3.9)	3.6 (3.4–3.8)	3.7 (3.5–3.9)	4.0 (3.8–4.2)	↑
Diabetes—all*	2.6 (2.4–2.7)	2.7 (2.5–2.9)	2.8 (2.6–3.0)	3.1 (2.9–3.3)	2.9 (2.7–3.1)	3.3 (3.1–3.5)	3.2 (3.0–3.4)	3.5 (3.3–3.8)	3.7 (3.5–3.9)	3.9 (3.6–4.1)	↑
Lipid disorders*	2.5 (2.3–2.7)	2.6 (2.4–2.8)	2.9 (2.7–3.1)	2.9 (2.7–3.1)	3.0 (2.8–3.2)	3.1 (2.9–3.4)	3.3 (3.1–3.6)	3.4 (3.1–3.7)	3.5 (3.2–3.7)	3.7 (3.4–4.0)	↑
Arthritis—all*	3.5 (3.2–3.7)	3.6 (3.3–3.8)	3.9 (3.7–4.1)	3.8 (3.5–4.0)	3.7 (3.5–3.9)	4.0 (3.8–4.2)	3.9 (3.7–4.2)	3.8 (3.5–4.0)	3.7 (3.5–3.9)	3.6 (3.4–3.8)	§
Osteoarthritis*	2.2 (2.0–2.4)	2.2 (2.1–2.4)	2.5 (2.3–2.7)	2.6 (2.4–2.8)	2.6 (2.4–2.7)	2.8 (2.6–3.0)	2.8 (2.6–3.0)	2.7 (2.5–2.9)	2.6 (2.4–2.8)	2.6 (2.4–2.8)	↑
Back complaint*	2.7 (2.4–2.9)	2.8 (2.6–2.9)	2.6 (2.4–2.8)	2.6 (2.4–2.8)	2.6 (2.4–2.8)	2.7 (2.5–2.8)	2.8 (2.6–3.0)	2.6 (2.5–2.8)	2.6 (2.5–2.8)	2.7 (2.6–2.9)	—

(continued)

Table 7.4 (continued): Most frequently managed problems, summary of annual results, BEACH, 1998–99 to 2007–08

Problem managed	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Acute bronchitis/ bronchiolitis	3.3 (3.0–3.5)	3.2 (3.0–3.4)	2.7 (2.5–2.9)	2.7 (2.5–2.9)	2.6 (2.4–2.8)	2.4 (2.2–2.6)	2.4 (2.2–2.6)	2.5 (2.3–2.7)	2.2 (2.1–2.4)	2.4 (2.2–2.6)	↓
Oesophageal disease	1.5 (1.4–1.6)	1.6 (1.5–1.8)	1.5 (1.4–1.6)	1.8 (1.7–2.0)	1.9 (1.8–2.1)	2.2 (2.0–2.4)	2.1 (1.9–2.2)	2.4 (2.2–2.5)	2.3 (2.1–2.5)	2.3 (2.2–2.5)	↑
Asthma	3.2 (3.0–3.4)	3.2 (3.0–3.4)	2.8 (2.7–3.0)	2.8 (2.7–3.0)	2.7 (2.6–2.9)	2.6 (2.4–2.7)	2.3 (2.2–2.5)	2.3 (2.1–2.4)	2.3 (2.1–2.4)	2.2 (2.0–2.3)	↓
Prescription—all*	1.4 (1.2–1.6)	1.8 (1.6–2.0)	1.7 (1.5–1.8)	1.9 (1.6–2.1)	2.0 (1.8–2.2)	2.3 (2.0–2.6)	2.1 (1.8–2.3)	2.0 (1.7–2.2)	2.2 (1.9–2.4)	2.0 (1.7–2.2)	↑
Contact dermatitis	1.8 (1.7–2.0)	1.9 (1.8–2.0)	2.1 (1.9–2.2)	1.9 (1.8–2.0)	1.9 (1.8–2.0)	1.8 (1.6–1.9)	1.9 (1.8–2.0)	1.8 (1.7–1.9)	1.9 (1.8–2.0)	1.8 (1.7–1.9)	—
Anxiety*	1.7 (1.6–1.8)	1.7 (1.6–1.9)	1.7 (1.5–1.8)	1.6 (1.5–1.8)	1.6 (1.4–1.7)	1.7 (1.6–1.9)	1.7 (1.6–1.9)	1.8 (1.6–2.0)	1.7 (1.6–1.9)	1.8 (1.6–1.9)	—
Test results*	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	1.1 (0.9–1.2)	1.1 (0.9–1.2)	1.2 (1.1–1.4)	1.4 (1.3–1.5)	1.4 (1.3–1.6)	1.6 (1.4–1.7)	1.8 (1.6–1.9)	↑
Gastroenteritis*	1.7 (1.6–1.8)	1.6 (1.4–1.7)	1.6 (1.5–1.8)	1.6 (1.5–1.7)	1.7 (1.6–1.9)	1.7 (1.5–1.8)	1.5 (1.4–1.7)	1.5 (1.4–1.7)	1.7 (1.5–1.8)	1.7 (1.5–1.8)	—
Sleep disturbance	1.6 (1.5–1.8)	1.5 (1.4–1.7)	1.6 (1.4–1.7)	1.6 (1.5–1.8)	1.6 (1.4–1.7)	1.6 (1.5–1.7)	1.7 (1.5–1.9)	1.6 (1.5–1.7)	1.6 (1.4–1.7)	1.6 (1.5–1.7)	—
Urinary tract infection*	1.6 (1.5–1.7)	1.8 (1.7–1.9)	1.5 (1.4–1.6)	1.6 (1.5–1.7)	1.7 (1.6–1.8)	1.7 (1.6–1.8)	1.7 (1.6–1.8)	1.8 (1.6–1.9)	1.6 (1.5–1.8)	1.6 (1.5–1.7)	—
Sprain/strain*	1.9 (1.7–2.1)	1.8 (1.7–2.0)	2.0 (1.9–2.2)	1.8 (1.7–1.9)	1.7 (1.5–1.8)	1.6 (1.5–1.7)	1.7 (1.5–1.9)	1.8 (1.6–1.9)	1.5 (1.4–1.7)	1.6 (1.4–1.7)	§
Solar keratosis/sunburn	1.0 (0.9–1.1)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.0 (0.9–1.2)	1.2 (1.0–1.3)	1.3 (1.1–1.5)	1.3 (1.1–1.6)	1.2 (1.1–1.3)	1.3 (1.2–1.4)	1.4 (1.1–1.6)	↑
Pregnancy*	0.7 (0.6–0.8)	0.7 (0.6–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.8 (0.7–1.0)	0.8 (0.7–0.9)	0.8 (0.7–0.8)	0.9 (0.8–1.0)	1.3 (1.1–1.4)	1.3 (1.2–1.5)	↑

(continued)

Table 7.4 (continued): Most frequently managed problems, summary of annual results, BEACH, 1998–99 to 2007–08

Problem managed	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Viral disease, other/NOS	1.3 (1.2–1.5)	1.5 (1.3–1.7)	1.6 (1.4–1.8)	1.5 (1.3–1.7)	1.4 (1.2–1.6)	1.3 (1.2–1.5)	1.2 (1.1–1.4)	1.2 (1.0–1.4)	1.1 (0.9–1.2)	1.3 (1.2–1.4)	—
Malignant neoplasm, skin	0.8 (0.8–0.9)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.9 (0.7–1.0)	0.8 (0.7–0.9)	1.1 (0.9–1.3)	1.2 (1.0–1.4)	1.0 (0.9–1.1)	1.1 (1.0–1.3)	1.3 (1.2–1.4)	↑
Ischaemic heart disease*	1.5 (1.4–1.7)	1.6 (1.4–1.7)	1.3 (1.2–1.4)	1.3 (1.1–1.4)	1.2 (1.1–1.3)	1.4 (1.2–1.5)	1.2 (1.1–1.3)	1.3 (1.2–1.4)	1.3 (1.2–1.4)	1.2 (1.0–1.4)	↓
Sinusitis acute/chronic	1.6 (1.4–1.7)	1.6 (1.4–1.7)	1.5 (1.4–1.6)	1.4 (1.3–1.5)	1.3 (1.2–1.4)	1.3 (1.2–1.4)	1.2 (1.1–1.3)	1.3 (1.2–1.4)	1.4 (1.3–1.5)	1.2 (1.0–1.4)	↑
Acute otitis media/ myringitis	1.8 (1.6–2.0)	1.6 (1.5–1.7)	1.5 (1.4–1.6)	1.3 (1.2–1.4)	1.3 (1.2–1.4)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	1.2 (1.0–1.3)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	↓
Atrial fibrillation/flutter	0.6 (0.5–0.6)	0.6 (0.5–0.7)	0.6 (0.5–0.6)	0.7 (0.6–0.8)	0.6 (0.6–0.7)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	1.1 (1.0–1.2)	↑
Abnormal test results*	0.5 (0.5–0.6)	0.5 (0.5–0.6)	0.6 (0.5–0.7)	0.7 (0.6–0.8)	0.8 (0.7–0.8)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.8)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	↑
Oral contraception*	1.0 (0.9–1.1)	1.0 (0.9–1.1)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	1.4 (1.2–1.5)	1.3 (1.2–1.4)	1.2 (1.1–1.3)	1.3 (1.2–1.4)	1.3 (1.2–1.4)	↑
Fracture*	1.1 (1.0–1.2)	1.0 (0.9–1.1)	1.1 (1.0–1.2)	1.0 (1.0–1.1)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	1.0 (1.0–1.1)	1.0 (0.9–1.1)	—
Tonsillitis*	1.5 (1.3–1.6)	1.3 (1.2–1.4)	1.2 (1.1–1.3)	1.1 (1.0–1.3)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (0.9–1.2)	1.1 (1.0–1.2)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	↓
Menopausal complaint	1.5 (1.4–1.6)	1.4 (1.2–1.5)	1.4 (1.3–1.5)	1.4 (1.3–1.5)	1.5 (1.3–1.6)	1.0 (0.9–1.1)	0.9 (0.8–1.0)	0.9 (0.8–0.9)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	↓
Osteoporosis	0.5 (0.4–0.6)	0.5 (0.5–0.6)	0.6 (0.5–0.6)	0.7 (0.6–0.8)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	↑

(continued)

Table 7.4 (continued): Most frequently managed problems, summary of annual results, BEACH, 1998–99 to 2007–08

Problem managed	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Allergic rhinitis	1.0 (0.9–1.1)	1.1 (0.9–1.2)	1.0 (0.9–1.1)	0.8 (0.7–0.9)	0.6 (0.5–0.7)	0.7 (0.6–0.8)	0.7 (0.6–0.9)	0.6 (0.5–0.7)	0.5 (0.5–0.6)	0.6 (0.5–0.7)	↓
Pre-postnatal check-up*	1.0 (0.9–1.2)	1.1 (1.0–1.3)	0.7 (0.6–0.9)	0.7 (0.6–0.9)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	0.6 (0.5–0.7)	0.6 (0.5–0.7)	0.4 (0.3–0.5)	0.1 (0.1–0.2)	↓
Total problems	145.3 (143.5–147.2)	146.7 (144.9–148.6)	144.5 (142.8–146.3)	143.4 (141.7–145.2)	144.9 (143.0–146.8)	146.3 (144.4–148.2)	145.5 (143.6–147.4)	146.2 (144.2–148.2)	148.5 (146.4–150.6)	151.3 (149.2–153.4)	↑

(a) Figures do not total 100, as more than one problem can be managed at each encounter. Also only the most frequent problems are included.

(b) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, § indicates a non-linear significant or marginal change, and — indicates there was no change.

* Includes multiple ICPC–2 or ICPC–2 PLUS codes (see Appendix 5).

Note: CI—confidence interval; NOS—not otherwise specified. This table includes individual problems which were managed at >= 1.0 per 100 encounters in any year, and any other statistically significant differences of interest.

Table 7.5: Most frequently managed new problems, summary of annual results, BEACH, 1998–99 to 2007–08

New problem managed	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Upper respiratory tract infection	5.0 (4.7–5.4)	4.5 (4.1–4.9)	4.4 (4.1–4.8)	4.7 (4.4–5.1)	5.1 (4.7–5.5)	4.2 (3.8–4.5)	4.3 (4.0–4.6)	4.8 (4.4–5.2)	4.4 (4.1–4.8)	4.8 (4.4–5.2)	—
Immunisation/ vaccination—all*	2.9 (2.6–3.3)	1.3 (1.1–1.5)	1.5 (1.3–1.8)	2.7 (2.4–3.0)	2.9 (2.6–3.2)	2.9 (2.6–3.3)	2.7 (2.4–3.1)	2.7 (2.5–3.0)	2.8 (2.5–3.1)	2.8 (2.5–3.0)	§
Acute bronchitis/ bronchiolitis	2.1 (1.9–2.3)	1.7 (1.6–1.9)	1.6 (1.5–1.7)	1.9 (1.7–2.0)	1.9 (1.7–2.1)	1.8 (1.6–1.9)	1.7 (1.5–1.9)	1.9 (1.7–2.1)	1.6 (1.5–1.7)	1.7 (1.6–1.9)	↓
Gastroenteritis*	1.3 (1.1–1.4)	1.0 (0.9–1.2)	1.1 (1.0–1.2)	1.2 (1.1–1.4)	1.3 (1.2–1.5)	1.3 (1.2–1.5)	1.2 (1.1–1.3)	1.3 (1.2–1.4)	1.3 (1.2–1.4)	1.3 (1.2–1.5)	—
General check-up*	0.7 (0.6–0.7)	0.5 (0.4–0.5)	0.4 (0.3–0.5)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	1.0 (0.9–1.1)	1.0 (0.8–1.1)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	↑

(continued)

Table 7.5 (continued): Most frequently managed new problems, summary of annual results, BEACH, 1998–99 to 2007–08

	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Urinary tract infection*	0.9 (0.9–1.0)	0.8 (0.8–0.9)	0.8 (0.7–0.9)	1.0 (0.9–1.1)	1.1 (1.0–1.2)	1.1 (1.0–1.1)	1.1 (1.0–1.1)	1.2 (1.1–1.3)	1.1 (1.0–1.2)	1.0 (0.9–1.1)	—
Sprain/strain*	1.1 (0.9–1.2)	0.9 (0.8–1.0)	1.1 (0.9–1.2)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	1.0 (0.9–1.0)	1.0 (0.9–1.1)	1.1 (1.0–1.2)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	—
Viral disease, other/NOS	0.9 (0.8–1.0)	1.0 (0.8–1.1)	1.1 (0.9–1.2)	1.0 (0.9–1.2)	1.1 (0.9–1.2)	1.0 (0.9–1.1)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.9 (0.8–1.1)	—
Sinusitis acute/chronic	1.0 (0.8–1.1)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.7 (0.7–0.8)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	—
Acute otitis media/ myringitis	1.2 (1.1–1.3)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	1.0 (0.9–1.0)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.8 (0.8–0.9)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.8 (0.7–0.8)	↓
Tonsillitis*	1.0 (0.9–1.1)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–0.9)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.8 (0.7–1.0)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	↓
Test results*	0.1 (0.1–0.2)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.4 (0.3–0.4)	0.4 (0.3–0.5)	0.4 (0.4–0.5)	0.5 (0.4–0.6)	↑
Skin disease, other	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.3–0.3)	0.4 (0.3–0.4)	0.4 (0.3–0.4)	0.4 (0.3–0.4)	0.5 (0.4–0.6)	0.4 (0.4–0.5)	0.4 (0.4–0.5)	0.4 (0.4–0.5)	↑
Otitis externa	0.5 (0.5–0.6)	0.4 (0.3–0.5)	0.4 (0.4–0.5)	0.5 (0.4–0.6)	0.4 (0.4–0.5)	0.5 (0.4–0.5)	0.4 (0.4–0.5)	0.5 (0.4–0.5)	0.4 (0.3–0.4)	0.4 (0.3–0.4)	↓
Total new problems	54.5 (53.0–56.0)	45.3 (43.6–46.9)	47.4 (45.7–49.0)	55.1 (53.8–56.5)	57.0 (55.6–58.3)	55.9 (54.5–57.3)	55.2 (53.8–56.5)	56.9 (55.5–58.2)	56.5 (55.1–57.9)	57.7 (56.3–59.1)	↑

(a) Figures do not total 100, as more than one problem can be managed at each encounter. Also only the most frequent problems are included.

(b) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↗/↘ indicates a marginal change, § indicates a non-linear significant or marginal change, and — indicates there was no change.

* Includes multiple ICPC–2 or ICPC–2 PLUS codes (see Appendix 5).

Note: CI—confidence interval; NOS—not otherwise specified. This table includes individual new problems which were managed at ≥ 1.0 per 100 encounters in any year, and any other statistically significant differences of interest.

Table 7.6: Most frequently managed chronic problems, summary of annual results, BEACH, 1998–99 to 2007–08

Chronic problem managed	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Hypertension (non-gestational)**	8.2 (7.8–8.7)	8.4 (7.9–8.9)	8.6 (8.1–9.1)	9.0 (8.5–9.5)	8.8 (8.3–9.3)	9.2 (8.7–9.7)	8.9 (8.4–9.4)	9.4 (8.9–10.0)	9.5 (9.0–10.0)	9.9 (9.3–10.4)	↑
Depressive disorder	3.5 (3.3–3.7)	3.4 (3.2–3.6)	3.6 (3.4–3.9)	3.4 (3.2–3.6)	3.5 (3.3–3.7)	3.6 (3.4–3.8)	3.7 (3.5–3.9)	3.6 (3.4–3.8)	3.7 (3.5–3.9)	4.0 (3.7–4.2)	↑
Diabetes (non-gestational)**	2.6 (2.4–2.7)	2.7 (2.5–2.9)	2.8 (2.6–3.0)	3.1 (2.9–3.3)	2.9 (2.7–3.1)	3.3 (3.1–3.5)	3.2 (3.0–3.4)	3.5 (3.3–3.8)	3.7 (3.5–3.9)	3.9 (3.6–4.1)	↑
Lipid disorders*	2.5 (2.3–2.7)	2.6 (2.4–2.8)	2.9 (2.7–3.1)	2.9 (2.7–3.1)	3.0 (2.8–3.2)	3.1 (2.9–3.4)	3.3 (3.1–3.6)	3.4 (3.1–3.7)	3.5 (3.2–3.7)	3.7 (3.4–4.0)	↑
Osteoarthritis*	2.2 (2.0–2.4)	2.2 (2.1–2.4)	2.5 (2.3–2.7)	2.6 (2.4–2.8)	2.6 (2.4–2.7)	2.8 (2.6–3.0)	2.8 (2.6–3.0)	2.7 (2.5–2.9)	2.6 (2.4–2.8)	2.6 (2.4–2.8)	↑
Oesophageal disease	1.5 (1.4–1.6)	1.6 (1.5–1.8)	1.5 (1.4–1.6)	1.8 (1.7–2.0)	1.9 (1.8–2.1)	2.2 (2.0–2.4)	2.1 (2.0–2.3)	2.4 (2.2–2.5)	2.3 (2.1–2.5)	2.3 (2.2–2.5)	↑
Asthma	3.2 (3.0–3.4)	3.2 (3.0–3.4)	2.8 (2.7–3.0)	2.8 (2.7–3.0)	2.7 (2.6–2.9)	2.6 (2.4–2.7)	2.3 (2.2–2.5)	2.3 (2.1–2.4)	2.3 (2.1–2.4)	2.2 (2.0–2.3)	↓
Malignant neoplasm skin	0.8 (0.8–0.9)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.9 (0.7–1.0)	0.8 (0.7–0.9)	1.1 (0.9–1.3)	1.2 (1.0–1.4)	1.0 (0.9–1.1)	1.1 (1.0–1.3)	1.2 (1.0–1.4)	↑
Ischaemic heart disease*	1.5 (1.4–1.7)	1.6 (1.4–1.7)	1.3 (1.2–1.4)	1.3 (1.1–1.4)	1.2 (1.1–1.3)	1.4 (1.2–1.5)	1.2 (1.1–1.3)	1.3 (1.2–1.4)	1.3 (1.2–1.4)	1.1 (1.0–1.2)	↓
Atrial fibrillation/flutter	0.6 (0.5–0.6)	0.6 (0.5–0.7)	0.6 (0.5–0.6)	0.7 (0.6–0.8)	0.6 (0.6–0.7)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	↑
Osteoporosis	0.5 (0.4–0.6)	0.5 (0.5–0.6)	0.6 (0.5–0.6)	0.7 (0.6–0.8)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	↑
Back syndrome with radiating pain	0.8 (0.7–0.9)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.9 (0.8–1.1)	0.9 (0.8–1.0)	0.9 (0.8–0.9)	0.9 (0.8–1.0)	—

(continued)

Table 7.6 (continued): Most frequently managed chronic problems, summary of annual results, BEACH, 1998–99 to 2007–08

Chronic problem managed	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Chronic obstructive pulmonary disease	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.7–0.8)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	0.8 (0.8–0.9)	0.8 (0.7–0.9)	—
Obesity (BMI > 30)	0.5 (0.4–0.6)	0.5 (0.4–0.6)	0.6 (0.6–0.7)	0.8 (0.6–0.9)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.8 (0.7–0.9)	0.6 (0.5–0.6)	0.8 (0.6–0.9)	0.7 (0.6–0.8)	↑
Hypothyroidism/myxoedema	0.5 (0.4–0.5)	0.5 (0.4–0.5)	0.4 (0.4–0.5)	0.5 (0.5–0.6)	0.5 (0.5–0.6)	0.6 (0.5–0.6)	0.6 (0.6–0.7)	0.7 (0.6–0.7)	0.6 (0.6–0.7)	0.7 (0.6–0.8)	↑
Migraine	0.9 (0.9–1.0)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.8 (0.8–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.7)	0.7 (0.6–0.7)	↓
Heart failure	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.7 (0.6–0.7)	0.7 (0.6–0.8)	0.7 (0.7–0.8)	0.7 (0.7–0.8)	0.7 (0.6–0.8)	0.6 (0.6–0.7)	0.7 (0.6–0.8)	0.6 (0.6–0.7)	↓
Gout	0.6 (0.6–0.7)	0.6 (0.5–0.7)	0.5 (0.5–0.6)	0.6 (0.5–0.6)	0.6 (0.5–0.6)	0.6 (0.5–0.6)	0.6 (0.5–0.7)	0.6 (0.5–0.6)	0.6 (0.5–0.6)	0.6 (0.5–0.7)	—
Arthritis (excl osteoarthritis and rheumatoid arthritis)**	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.7 (0.7–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.6 (0.5–0.6)	0.6 (0.5–0.6)	0.5 (0.5–0.6)	↓
Malignant neoplasm prostate	0.2 (0.2–0.3)	0.2 (0.2–0.2)	0.8 (0.7–0.9)	0.2 (0.1–0.2)	0.8 (0.7–0.9)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.3–0.3)	§
Total chronic problems	46.1 (44.5–47.6)	47.2 (45.5–49.0)	47.0 (45.4–48.5)	48.0 (46.5–49.6)	47.8 (46.1–49.4)	50.4 (48.7–52.1)	50.4 (48.7–52.1)	50.6 (48.8–52.5)	51.8 (50.1–53.4)	52.3 (50.4–54.1)	↑

(a) Figures do not total 100, as more than one problem can be managed at each encounter. Also only the most frequent problems are included.

(b) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, § indicates a non-linear significant or marginal change, and — indicates there was no change.

* Includes multiple ICPC–2 or ICPC–2 PLUS codes (see Appendix 5).

** Indicates that this group differs from that used for analysis in other sections of this chapter, as only chronic conditions have been included in this analysis (see Appendix 6 for codes included in analysis of chronic conditions).

Note: CI—confidence interval; excl—excluding. This table includes individual chronic problems which were managed at > 0.5 per 100 encounters in any year, and any other statistically significant differences of interest.

8 Overview of management

This chapter includes an overview of management in general practice from each of the 10 years of the BEACH study from 1998–99 to 2007–08. The direction and type of change from 1998–99 to 2007–08 is indicated for each result in the far right column of the tables: ↑/↓ indicates a statistically significant linear change, ↑/↓ indicates a marginally significant linear change, § indicates a non-linear significant or marginal change, and – indicates that there was no change.

Since BEACH began in 1998–99, some trends have emerged in the management of patients' problems (Table 8.1). Most noticeably, over the 10 years of the study:

- the rate of medications prescribed, supplied or advised for over-the-counter purchase has significantly decreased, from 109.7 per 100 encounters in 1998–99 to 102.7 per 100 encounters in 2007–08
 - The above reduction is a direct result of a significant decrease in the rate of prescribed medications, from 93.6 per 100 encounters in 1998–99 to 82.4 per 100 in 2007–08.
- the rate of other treatments (including clinical treatments and therapeutic procedures) increased significantly from 43.2 per 100 encounters in 1998–99 to 54.7 in 2004–05, decreased to 43.6 in 2005–06 with the introduction of the practice nurse provider numbers, but then increased again to 51.2 per 100 in 2007–08
 - The above change was reflecting changes in the rate of clinical treatments. These rose repeatedly over 6 years, from 31.4 per 100 encounters in 1998–99 to 39.2 per 100 in 2004–05, decreased sharply to 29.2 per 100 in 2005–06, and increased again to 34.5 per 100 in 2007–08.
- there has been an increase in the rate of procedural treatments undertaken in general practice, from 11.8 per 100 encounters in 1998–99 to 16.7 per 100 encounters in 2007–08
- the rate of referrals to other health providers has significantly increased, from 11.1 to 12.5 per 100 encounters between 1998–99 and 2007–08
- since 2000–01, the rate of pathology tests ordered has significantly increased by 45%, from 29.7 orders per 100 encounters to 43.2 per 100 encounters in 2007–08
- there has been a significant increase in the rate of imaging tests ordered, from 7.7 per 100 encounters in 2000–01 to 9.5 per 100 in 2007–08, and in the rate of other investigations, from 0.6 per 100 in 2000–01 to 1.0 per 100 encounters in 2007–08.

Similar changes can be observed in each of these areas, for the percentages of encounters where at least one management type was provided (Table 8.2). This reflects a change in the likelihood of each action eventuating at an encounter.

- There was a significant reduction in the likelihood of patients being provided with at least one medication (from 68.7% in 1998–99 to 64.4% in 2007–08), particularly prescribed medications, which decreased from 60.1% to 53.6% over this time. The latter reflects the reduction in the rate of prescribed medications reported above and shown in Table 8.1.
- There was an increase in the likelihood of patients receiving at least one GP-supplied medication, from 5.6% in 1998–99 to 7.9% in 2007–08.
- The likelihood of patients receiving at least one other (non-pharmacological) treatment increased from 34.5% of encounters in 1998–99 to 39.9% in 2007–08.

- The likelihood of patients receiving at least one procedural treatment at the encounter continually and significantly increased from 10.8% in 1998–99 to 15.0% in 2007–08.
- The likelihood of patients being referred increased significantly (from 10.6% in 1998–99 to 11.8% in 2007–08), particularly referrals to specialists (from 7.1% in 1998–99 to 7.7% in 2007–08) and referrals to emergency departments.
- Contributing to the increase in the rates of pathology and imaging tests ordered per 100 encounters shown in Table 8.1, there was an increase in the likelihood of the GP ordering at least one investigation, from 18.1% in 1998–99 to 23.8% in 2007–08. In 1998–99 the likelihood of at least one pathology test being ordered was 13.2%, and that of at least one imaging test being ordered was 6.3%. By 2007–08 these proportions had significantly increased to 17.4% and 8.3%, respectively (Table 8.2).

Table 8.1: Summary of management, summary of annual results, BEACH, 1998–99 to 2007–08

Management type	Rate per 100 encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Medications	109.7 (107.4–112.0)	110.1 (107.8–112.4)	108.2 (105.7–110.6)	104.5 (102.2–106.9)	103.8 (101.4–106.2)	104.4 (102.1–106.7)	101.5 (99.3–103.8)	104.4 (101.8–107.0)	101.5 (99.2–103.9)	102.7 (100.3–105.0)	↓
Prescribed	93.6 (91.2–96.1)	93.8 (91.5–96.2)	92.3 (89.9–94.7)	88.0 (85.6–90.4)	84.3 (81.8–86.9)	86.0 (83.6–88.5)	83.4 (81.2–85.5)	85.8 (83.3–88.4)	83.3 (81.0–85.5)	82.4 (80.3–84.6)	↓
GP-supplied	7.3 (6.5–8.1)	6.9 (5.8–7.9)	6.9 (5.7–8.1)	7.6 (6.3–9.0)	9.3 (7.6–11.0)	8.6 (7.4–9.8)	8.1 (7.3–8.9)	8.8 (8.2–9.5)	8.9 (8.2–9.6)	10.1 (9.5–10.7)	↑
Advised OTC	8.8 (8.1–9.5)	9.4 (8.6–10.2)	9.0 (8.1–9.8)	8.9 (8.1–9.6)	10.2 (9.2–11.1)	9.8 (9.0–10.6)	10.1 (9.1–11.0)	9.8 (9.0–10.5)	9.4 (8.7–10.1)	10.0 (9.3–10.9)	—
Other treatments	43.2 (41.3–45.1)	46.0 (44.1–47.8)	49.4 (47.1–51.7)	51.9 (49.6–54.2)	51.8 (49.3–54.3)	51.4 (48.9–53.8)	54.7 (52.1–57.3)	43.6 (41.5–45.8)	44.7 (42.3–47.0)	51.2 (48.9–53.6)	↑
Clinical	31.4 (29.7–33.0)	33.5 (31.8–35.2)	37.2 (35.1–39.3)	38.1 (36.1–40.1)	37.2 (35.0–39.4)	36.6 (34.5–38.8)	39.2 (37.1–41.4)	29.2 (27.3–31.1)	29.5 (27.6–31.4)	34.5 (32.5–36.5)	§
Procedural	11.8 (11.2–12.5)	12.5 (11.9–13.0)	12.2 (11.6–12.8)	13.8 (13.1–14.5)	14.6 (13.9–15.3)	14.7 (14.0–15.5)	15.5 (14.6–16.4)	14.4 (13.7–15.1)	15.2 (14.4–16.0)	16.7 (15.9–17.5)	↑
Referrals	11.1 (10.7–11.6)	11.1 (10.7–11.6)	10.4 (10.0–10.8)	10.5 (10.1–10.9)	11.1 (10.7–11.6)	11.6 (11.1–12.1)	11.5 (11.1–12.0)	12.0 (11.5–12.5)	12.2 (11.7–12.7)	12.5 (12.0–13.0)	↑
Specialist	7.4 (7.1–7.7)	7.2 (6.9–7.5)	7.4 (7.0–7.7)	7.3 (7.0–7.6)	7.7 (7.3–8.0)	7.9 (7.5–8.2)	7.7 (7.4–8.0)	8.2 (7.8–8.5)	8.0 (7.7–8.4)	8.0 (7.6–8.3)	§
Allied health service	3.0 (2.8–3.2)	3.1 (2.9–3.3)	2.3 (2.2–2.5)	2.3 (2.1–2.4)	2.5 (2.3–2.7)	2.6 (2.4–2.8)	2.7 (2.5–2.9)	2.9 (2.7–3.1)	3.1 (2.9–3.3)	3.5 (3.2–3.7)	§
Hospital	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.5 (0.4–0.6)	0.4 (0.4–0.5)	0.6 (0.5–0.6)	0.6 (0.5–0.6)	0.5 (0.4–0.5)	0.4 (0.3–0.4)	0.4 (0.3–0.5)	0.4 (0.3–0.5)	↓
Emergency department	0.1 (0.0–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.3)	↑
Other referrals/other medical services ^(b)	0.0 [†] (0.0–0.0)	0.0 [†] (0.0–0.0)	0.2 (0.1–0.2)	0.4 (0.3–0.4)	0.3 (0.2–0.3)	0.4 (0.4–0.5)	0.4 (0.4–0.5)	0.4 (0.3–0.4)	0.5 (0.5–0.6)	0.5 (0.4–0.6)	↑

(continued)

Table 8.1 (continued): Summary of management, summary of annual results, BEACH, 1998–99 to 2007–08

Management type	Rate per 100 encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Pathology ^(c)	NAv	NAv	29.7 (28.4–30.9)	31.0 (29.7–32.4)	32.9 (31.5–34.4)	35.2 (33.7–36.7)	36.7 (35.2–38.2)	38.6 (36.9–40.3)	42.4 (40.7–44.2)	43.2 (41.3–45.0)	↑
Imaging ^(c)	NAv	NAv	7.7 (7.3–8.0)	7.9 (7.6–8.2)	8.6 (8.2–9.0)	8.2 (7.8–8.6)	8.3 (8.0–8.6)	8.8 (8.4–9.2)	9.0 (8.6–9.3)	9.5 (9.2–9.9)	↑
Other investigations ^(c)	NAv	NAv	0.6 (0.5–0.7)	0.9 (0.8–1.0)	1.0 (0.8–1.2)	1.0 (0.9–1.2)	1.1 (0.9–1.3)	1.0 (0.9–1.1)	1.1 (1.0–1.2)	1.0 (0.9–1.1)	↑

(a) The direction and type of change is indicated for each result: ↑/↓ indicates a statistically significant change, § indicates a non-linear significant or marginal change, and — indicates there was no change.

(b) Other referrals and other medical services have been grouped for comparability. In the first 2 years 'other medical services' and 'other referrals' were grouped and reported together.

(c) In the third year of BEACH, the data collection and data coding system for pathology, imaging and other investigations changed. Data from 1998–99 and 1999–00 are not comparable to those from 2000–01 onward.

† Rates are reported to one decimal place. This indicates that the rate is < 0.05 per 100 encounters.

Note: CI—confidence interval; NAv—not available; OTC—over-the-counter.

Table 8.2: Encounters and problems for which at least one management was recorded, BEACH, 1998–99 to 2007–08

At least one...	Per cent of encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Management type	91.9 (91.5–92.4)	92.2 (91.7–92.7)	91.6 (91.0–92.2)	91.8 (91.3–92.3)	91.3 (90.6–92.0)	91.5 (90.9–92.0)	91.9 (91.3–92.5)	91.2 (90.6–91.8)	90.4 (89.8–91.0)	91.9 (91.3–92.4)	—
Medication or other treatment	83.7 (83.1–84.3)	83.8 (83.1–84.5)	83.5 (82.7–84.2)	83.2 (82.5–84.0)	82.5 (81.6–83.3)	82.3 (81.5–83.1)	82.4 (81.6–83.2)	81.4 (80.6–82.1)	79.9 (79.1–80.8)	82.2 (81.4–82.9)	↓
Medication	68.7 (67.9–69.5)	68.5 (67.6–69.3)	68.0 (67.1–68.9)	66.6 (65.7–67.5)	65.8 (64.9–66.8)	65.6 (64.7–66.5)	64.3 (63.4–65.2)	65.2 (64.3–66.2)	63.9 (63.0–64.9)	64.4 (63.4–65.3)	↓
Prescription	60.1 (59.1–61.1)	60.1 (59.1–61.1)	59.8 (58.7–60.8)	57.4 (56.4–58.5)	54.9 (53.7–56.1)	55.7 (54.6–56.9)	54.8 (53.8–55.8)	55.6 (54.5–56.6)	54.1 (53.2–55.1)	53.6 (52.6–54.5)	↓
GP-supplied	5.6 (5.0–6.2)	5.1 (4.5–5.6)	5.1 (4.5–5.7)	5.8 (5.1–6.5)	6.8 (6.0–7.7)	6.5 (5.8–7.3)	6.2 (5.7–6.7)	6.4 (6.0–6.9)	6.8 (6.3–7.3)	7.9 (7.4–8.4)	↑
Advised OTC	7.9 (7.3–8.5)	8.3 (7.7–8.9)	8.0 (7.3–8.6)	8.0 (7.4–8.6)	9.0 (8.3–9.8)	8.7 (8.0–9.3)	8.7 (8.1–9.4)	8.6 (8.0–9.2)	8.4 (7.8–8.9)	8.9 (8.3–9.6)	—
Other treatment	34.5 (33.2–35.7)	36.2 (35.0–37.4)	37.6 (36.2–39.1)	39.5 (38.1–41.0)	39.4 (37.8–40.9)	39.3 (37.8–40.8)	41.2 (39.7–42.8)	35.1 (33.7–36.6)	35.3 (33.8–36.9)	39.9 (38.3–41.4)	↑
Clinical treatment	25.5 (24.4–26.7)	27.0 (25.8–28.2)	29.0 (27.6–30.3)	29.7 (28.4–31.1)	29.2 (27.7–30.6)	28.9 (27.4–30.3)	30.5 (29.1–32.0)	24.0 (22.7–25.4)	23.8 (22.5–25.2)	27.5 (26.1–28.9)	§
Procedural treatment	10.8 (10.3–11.3)	11.4 (11.0–11.9)	11.1 (10.6–11.7)	12.7 (12.0–13.3)	13.2 (12.6–13.8)	13.3 (12.7–13.9)	13.8 (13.1–14.6)	13.2 (12.6–13.8)	13.8 (13.2–14.5)	15.0 (14.3–15.7)	↑
Referral	10.6 (10.2–11.0)	10.4 (10.0–10.8)	9.9 (9.6–10.3)	10.0 (9.6–10.4)	10.6 (10.2–11.0)	11.0 (10.5–11.5)	10.9 (10.5–11.3)	11.3 (10.9–11.8)	11.5 (11.0–11.9)	11.8 (11.3–12.2)	↑
Specialist	7.1 (6.8–7.4)	6.9 (6.6–7.2)	7.1 (6.8–7.4)	7.0 (6.7–7.3)	7.4 (7.0–7.7)	7.6 (7.3–8.0)	7.5 (7.2–7.8)	7.9 (7.5–8.2)	7.7 (7.4–8.0)	7.7 (7.4–8.0)	↑
Allied health	2.9 (2.8–3.1)	3.0 (2.8–3.2)	2.3 (2.1–2.4)	2.2 (2.1–2.4)	2.4 (2.2–2.6)	2.5 (2.3–2.7)	2.6 (2.5–2.8)	2.8 (2.6–3.0)	3.0 (2.8–3.1)	3.3 (3.1–3.5)	§
Hospital	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.5 (0.4–0.6)	0.4 (0.4–0.5)	0.6 (0.5–0.6)	0.6 (0.5–0.6)	0.5 (0.4–0.5)	0.4 (0.3–0.4)	0.4 (0.3–0.5)	0.4 (0.3–0.5)	↓

(continued)

Table 8.2 (continued): Encounters and problems for which at least one management was recorded, BEACH, 1998–99 to 2007–08

At least one...	Per cent of encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Emergency department	0.1 (0.0–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.3)	↑
Other referral/other medical service ^(c)	0.0 [†] (0.0–0.0)	0.0 [†] (0.0–0.0)	0.2 (0.1–0.2)	0.4 (0.3–0.4)	0.3 (0.2–0.3)	0.4 (0.4–0.5)	0.4 (0.4–0.5)	0.4 (0.3–0.4)	0.5 (0.5–0.6)	0.5 (0.4–0.6)	↑
Investigation	18.1 (17.5–18.7)	18.9 (18.3–19.5)	19.3 (18.7–19.9)	19.7 (19.1–20.3)	20.8 (20.2–21.5)	21.3 (20.7–22.0)	21.8 (21.1–22.4)	22.6 (21.9–23.3)	23.5 (22.8–24.2)	23.8 (23.1–24.5)	↑
Pathology order ^(d)	13.2 (12.8–13.7)	13.8 (13.3–14.3)	13.8 (13.3–14.3)	14.0 (13.5–14.5)	14.7 (14.2–15.3)	15.5 (14.9–16.1)	15.7 (15.2–16.3)	16.4 (15.8–16.9)	17.4 (16.8–18.0)	17.4 (16.7–18.0)	↑
Imaging order ^(d)	6.3 (6.0–6.6)	6.7 (6.4–7.0)	7.2 (6.9–7.5)	6.9 (6.6–7.2)	7.5 (7.1–7.8)	7.2 (6.9–7.5)	7.3 (7.0–7.6)	7.8 (7.4–8.1)	7.9 (7.6–8.2)	8.3 (8.0–8.6)	↑
Other investigation ^(d)	NAv	NAv	0.6 (0.5–0.7)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	0.9 (0.8–1.0)	↑

(a) Figures will not total 100, as multiple events may occur in one encounter or in the management of one problem at encounter.

(b) The direction and type of change is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, § indicates a non-linear significant or marginal change, and — indicates there was no change.

(c) Other referrals and other medical services have been grouped for comparability. In the first 2 years 'other medical services' and 'other referrals' were grouped and reported together.

(d) While the coding system for pathology and imaging changed in the third year of BEACH, the presence or absence of a test at the encounter was still recorded. These figures are therefore comparable with data from subsequent years.

† Rates are reported to one decimal place. This indicates that the rate is < 0.05 per 100 encounters.

Note: OTC—over-the-counter; NAv—not available.


9 Medications

This chapter includes data about the medications prescribed, advised or supplied by general practitioners from each of the 10 years of the BEACH study from 1998–99 to 2007–08. The direction and type of change from 1998–99 to 2007–08 is indicated for each result in the far right column of the tables: ↑/↓ indicates a statistically significant linear change, ↑/↓ indicates a marginally significant linear change, § indicates a non-linear significant or marginal change, and – indicates there was no change.

Significant linear changes can be extrapolated to estimate the national increase or decrease in the prescribed, supplied, or advised medication rate between 1998–99 and 2007–08. An example of an extrapolated change is given for each table. The method used to extrapolate to national change estimates is described in Chapter 2, Section 2.4.

GPs could record up to four medications for each of four problems – a maximum of 16 medications per encounter. Each medication could be recorded as prescribed (the default), supplied by the GP or recommended for over-the-counter (OTC) purchase.


Changes in medication rates demonstrate a significant decrease from 109.7 per 100 encounters in 1998–99 to 102.7 per 100 in 2007–08 (Figure 9.1).




9.1 Prescribed medications

The rate of prescribed medications fell from 93.6 per 100 encounters in 1998–99 to 82.4 per 100 in 2007–08. This significant decrease in prescription rate means that 11 fewer prescriptions were being written on average for every 100 GP–patient encounters in 2007–08 than 10 years earlier (Table 9.1). The extrapolated national effect of this change is 7.9 million fewer prescriptions given by GPs in 2007–08 than in 1998–99. Figure 9.2 shows the change graphically, with the 95% confidence intervals around the estimates.

GPs recorded 86.1% of prescribed medications by brand (proprietary) name and 13.9% by their generic (non-proprietary) name in 2007-08, a similar finding to that of 1998-99 (Figure 9.3).



Note: Meds—medications; CI—confidence interval.



Number of repeats ordered

The pattern of the number of repeat prescriptions recorded by GPs changed between 1998–99 and 2007–08. Table 9.2 shows there has been a significant increase in the proportion of prescribed medications for which no repeats were ordered (from 29.6% of prescriptions to 34.5%), and a significant move away from ordering one repeat (from 21.3% to 16.8%) or two repeats (from 18.4% to 10.2%). There was a significant increase in the proportion of prescriptions for which five repeats were recorded. In 1998–99, 25.9% of prescriptions were given five repeats whereas, in 2007–08, 33.8 of prescribed medications had five repeats. The extrapolated national effect of this change is 9.6 million more prescriptions with five repeats given by GPs in 2007–08 than in 1998–99. This trend was apparent for all prescriptions, not just those for chronic conditions (which make up about one-third of all problems and account for 40% of all prescriptions). The change in frequency of recording five repeats is presented graphically in Figure 9.4, for all medications prescribed, and for those prescribed in the management of chronic problems.




Table 9.3 shows prescribing rates of common drug groups at ATC drug group Level 2 over the 10-year period. There were approximately 2.5 million fewer antibacterials for systemic use and 2.6 million fewer drugs for obstructive airways disease prescribed in 2007–08 than in 1998–99. Conversely, there were close to 3 million more agents acting on the rennin-angiotensin system and 2 million more serum lipid reducing agents prescribed in 2007–08 than in 1998–99.

Table 9.4 shows prescribed medication rates at the generic level. Atorvastatin was prescribed 1.2 million times more often, and salbutamol was prescribed 1 million times less often in 2007–08 than in 1998–99.

Table 9.1: Rates of medications prescribed, advised for over-the-counter purchase, supplied, summary of annual results, BEACH, 1998–99 to 2007–08

Medications	Rate per 100 encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Prescribed	93.6 (91.2–96.1)	93.8 (91.5–96.2)	92.3 (89.9–94.7)	88.0 (85.6–90.4)	84.3 (81.8–86.9)	86.0 (83.6–88.5)	83.4 (81.2–85.5)	85.8 (83.3–88.4)	83.3 (81.0–85.5)	82.4 (80.3–84.6)	↓
GP-supplied	7.3 (6.5–8.1)	6.9 (6.0–7.7)	6.9 (5.9–7.9)	7.6 (6.6–8.7)	9.3 (8.0–10.6)	8.6 (7.6–9.6)	8.1 (7.3–8.8)	8.8 (8.2–9.5)	8.9 (8.2–9.6)	10.1 (9.5–10.7)	↑
Advised OTC	8.8 (8.1–9.5)	9.4 (8.7–10.1)	9.0 (8.2–9.7)	8.9 (8.2–9.6)	10.2 (9.3–11.1)	9.8 (9.0–10.5)	10.1 (9.2–10.9)	9.8 (9.0–10.5)	9.4 (8.7–10.1)	10.1 (9.3–10.9)	—
Total medications	109.7 (107.4–112.0)	110.1 (107.8–112.4)	108.2 (105.7–110.6)	104.5 (102.2–106.9)	103.8 (101.4–106.2)	104.4 (102.1–106.7)	101.5 (99.3–103.8)	104.4 (101.8–107.0)	101.5 (99.2–103.9)	102.7 (100.3–105.0)	↓

Table 9.2: Number of repeats for prescribed medications, summary of annual results, BEACH, 1998–99 to 2007–08

Number of repeats	Rate per 100 prescriptions (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
No repeats	29.6 (27.4–31.9)	31.9 (30.2–33.7)	33.0 (31.2–34.8)	38.3 (36.7–39.4)	38.0 (36.4–39.6)	37.8 (36.2–39.3)	38.5 (36.8–40.2)	35.9 (34.4–37.5)	35.2 (33.7–36.7)	34.5 (33.1–35.9)	↑
One repeat	21.3 (20.2–22.3)	20.4 (19.5–21.3)	20.3 (19.3–21.4)	17.6 (16.8–18.3)	17.7 (16.8–18.6)	16.6 (15.8–17.3)	17.6 (16.7–18.4)	17.6 (16.8–18.4)	16.4 (15.6–17.1)	16.8 (16.0–17.6)	↓
Two repeats	18.4 (17.1–19.7)	16.3 (15.2–17.4)	15.2 (14.1–16.3)	13.1 (12.3–14.0)	12.0 (11.0–13.0)	11.4 (10.6–12.1)	10.6 (10.0–11.3)	10.1 (9.4–10.9)	10.5 (9.6–11.4)	10.2 (9.3–11.1)	↓
Three or four repeats	4.5 (4.0–4.9)	4.3 (3.7–4.8)	4.4 (4.0–4.8)	4.5 (4.1–4.9)	4.8 (4.4–5.1)	5.0 (4.7–5.4)	4.8 (4.4–5.2)	4.5 (3.8–5.2)	4.8 (4.3–5.3)	4.6 (4.0–5.2)	—
Five repeats	25.9 (24.5–27.3)	26.8 (25.3–28.3)	26.9 (25.6–28.2)	26.4 (25.2–27.7)	27.4 (26.0–28.7)	29.2 (27.9–30.4)	28.3 (27.0–29.6)	31.7 (30.3–33.1)	33.0 (31.7–34.4)	33.8 (32.5–35.1)	↑
Six or more repeats	0.3 (0.2–0.4)	0.3 (0.0–0.6)	0.1 (0.1–0.2)	0.0 (0.0–0.0)	0.2 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.3)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	↓

(a) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, and — indicates there was no change.

Note: Missing data removed. Rates are reported to one decimal place, a rate of 0.0 indicates that the rate is < 0.05 per 100 prescriptions. CI—confidence interval; OTC—over-the-counter medication.

Table 9.3: Distribution of prescribed medications, by ATC Level 2, summary of annual results, BEACH, 1998–99 to 2007–08

ATC Level 2	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Antibacterials for systemic use	16.8 (16.2–17.4)	15.7 (15.2–16.3)	15.4 (14.8–16.0)	13.9 (13.4–14.4)	13.3 (12.8–13.9)	13.6 (13.1–14.2)	14.0 (13.5–14.6)	14.6 (14.0–15.2)	14.0 (13.4–14.5)	13.8 (13.2–14.3)	↓
Analgesics	9.5 (9.0–10.1)	9.6 (9.1–10.2)	8.9 (8.4–9.4)	8.5 (8.1–9.0)	8.5 (8.0–9.1)	8.5 (8.0–9.0)	8.3 (7.8–8.7)	9.0 (8.4–9.5)	8.6 (8.1–9.0)	8.5 (8.0–8.9)	§
Agents acting on the renin-angiotensin system	4.0 (3.8–4.3)	4.1 (3.8–4.3)	4.6 (4.3–4.8)	5.0 (4.7–5.3)	4.9 (4.6–5.2)	5.5 (5.1–5.8)	5.5 (5.2–5.8)	6.1 (5.7–6.5)	6.5 (6.1–6.9)	6.6 (6.2–7.0)	↑
Psycholeptics	5.4 (5.1–5.7)	5.4 (5.0–5.7)	5.2 (4.9–5.5)	5.1 (4.8–5.5)	4.7 (4.4–5.0)	5.0 (4.7–5.4)	4.9 (4.6–5.2)	5.0 (4.6–5.3)	4.8 (4.5–5.2)	4.7 (4.4–5.0)	—
Serum lipid reducing agents	1.9 (1.8–2.1)	2.2 (2.0–2.4)	2.4 (2.2–2.5)	2.4 (2.3–2.6)	2.4 (2.2–2.6)	2.8 (2.6–3.0)	3.0 (2.8–3.2)	3.3 (3.0–3.6)	3.4 (3.2–3.7)	3.7 (3.5–4.0)	↑
Drugs for obstructive airway diseases	6.3 (5.9–6.6)	6.6 (6.1–7.0)	5.6 (5.2–5.9)	5.1 (4.8–5.5)	4.6 (4.3–4.9)	4.1 (3.9–4.4)	3.8 (3.6–4.1)	3.9 (3.6–4.1)	3.8 (3.5–4.0)	3.6 (3.3–3.8)	↓
Anti-inflammatory and antirheumatic products	4.5 (4.3–4.8)	4.6 (4.4–4.9)	5.8 (5.5–6.0)	5.3 (5.1–5.6)	4.8 (4.6–5.1)	4.8 (4.5–5.0)	4.5 (4.2–4.7)	3.9 (3.7–4.2)	3.6 (3.3–3.7)	3.5 (3.2–3.7)	↓
Psychoanaleptics	2.9 (2.7–3.1)	3.0 (2.8–3.1)	3.1 (2.9–3.3)	3.0 (2.8–3.2)	3.0 (2.8–3.2)	3.3 (3.1–3.5)	3.1 (3.0–3.3)	3.3 (3.1–3.5)	3.5 (3.3–3.7)	3.5 (3.3–3.6)	↑
Drugs for acid-related disorders	2.6 (2.5–2.8)	2.6 (2.4–2.8)	2.4 (2.2–2.5)	2.5 (2.4–2.7)	2.5 (2.4–2.7)	2.9 (2.7–3.0)	2.7 (2.5–2.9)	3.1 (2.9–3.2)	3.0 (2.8–3.2)	3.1 (2.9–3.2)	↑
Sex hormones and modulators of the genital system	3.9 (3.7–4.2)	3.9 (3.7–4.1)	3.9 (3.7–4.1)	3.8 (3.6–4.0)	3.7 (3.5–3.9)	3.5 (3.3–3.7)	3.1 (2.9–3.3)	3.0 (2.8–3.2)	3.0 (2.7–3.3)	2.9 (2.7–3.0)	↓
Corticosteroids, dermatological preparations	2.8 (2.7–3.0)	2.8 (2.7–3.0)	3.1 (2.8–3.3)	2.8 (2.7–3.0)	2.6 (2.5–2.8)	2.6 (2.4–2.7)	2.8 (2.6–2.9)	2.5 (2.4–2.7)	2.6 (2.4–2.8)	2.6 (2.4–2.7)	—
Drugs used in diabetes	1.8 (1.6–2.0)	1.8 (1.6–2.0)	2.0 (1.8–2.2)	2.2 (2.0–2.4)	1.9 (1.7–2.1)	2.2 (2.0–2.4)	2.1 (1.9–2.2)	2.5 (2.2–2.7)	2.4 (2.2–2.6)	2.5 (2.3–2.7)	↑
Calcium channel blockers	2.7 (2.5–2.9)	2.5 (2.3–2.7)	2.3 (2.1–2.5)	2.2 (2.0–2.4)	2.0 (1.8–2.1)	2.2 (2.0–2.3)	2.0 (1.8–2.1)	2.2 (2.0–2.4)	2.1 (2.0–2.3)	2.1 (1.9–2.3)	↓

(continued)

Table 9.3 (continued): Distribution of prescribed medications, by ATC Level 2, summary of annual results, BEACH, 1998–99 to 2007–08

ATC Level 2	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Beta-blocking agents	1.8 (1.7–2.0)	1.9 (1.7–2.1)	1.7 (1.5–1.8)	1.8 (1.6–1.9)	1.6 (1.5–1.7)	1.8 (1.7–2.0)	1.7 (1.5–1.8)	1.9 (1.8–2.1)	1.8 (1.7–2.0)	1.7 (1.6–1.9)	—
Ophthalmologicals	1.7 (1.6–1.8)	1.7 (1.6–1.8)	1.6 (1.5–1.7)	1.5 (1.4–1.6)	1.6 (1.5–1.7)	1.7 (1.5–1.8)	1.7 (1.6–1.8)	1.9 (1.7–2.0)	1.7 (1.6–1.8)	1.7 (1.5–1.8)	—
Vaccines	3.8 (3.3–4.2)	4.2 (3.8–4.6)	3.8 (3.5–4.2)	3.9 (3.5–4.2)	4.2 (3.8–4.5)	3.3 (3.0–3.6)	2.9 (2.6–3.3)	2.5 (2.2–2.8)	1.7 (1.5–1.9)	1.6 (1.4–1.8)	↓
Anti-thrombotic agents	0.7 (0.6–0.8)	0.8 (0.7–0.9)	1.0 (0.9–1.1)	1.1 (1.0–1.3)	1.1 (1.0–1.2)	1.3 (1.2–1.4)	1.3 (1.2–1.4)	1.3 (1.2–1.4)	1.5 (1.3–1.6)	1.5 (1.4–1.7)	↑
Diuretics	2.3 (2.1–2.4)	2.1 (1.9–2.3)	1.9 (1.7–2.0)	1.7 (1.5–1.9)	1.6 (1.4–1.7)	1.5 (1.4–1.7)	1.4 (1.2–1.5)	1.4 (1.3–1.5)	1.4 (1.3–1.5)	1.3 (1.1–1.4)	↓
Corticosteroids for systemic use	1.2 (1.1–1.3)	1.4 (1.3–1.5)	1.2 (1.1–1.3)	1.3 (1.2–1.5)	1.1 (1.0–1.2)	1.3 (1.1–1.4)	1.2 (1.1–1.4)	1.3 (1.2–1.4)	1.3 (1.2–1.5)	1.2 (1.1–1.3)	—
Nasal preparations	1.4 (1.3–1.5)	1.6 (1.5–1.7)	1.5 (1.3–1.6)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.8 (0.7–0.9)	↓
Otologicals	1.0 (0.9–1.1)	0.9 (0.8–1.0)	1.0 (0.9–1.0)	0.9 (0.8–1.0)	0.8 (0.8–0.9)	0.8 (0.8–1.0)	0.9 (0.8–1.0)	0.8 (0.7–0.8)	0.7 (0.6–0.8)	0.8 (0.7–0.8)	§
Drugs used for functional gastrointestinal disorders	1.0 (0.9–1.1)	1.2 (1.1–1.3)	1.0 (0.9–1.1)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	1.0 (0.9–1.0)	0.7 (0.6–0.8)	0.8 (0.7–0.9)	0.8 (0.7–0.8)	0.8 (0.7–0.9)	↓
Thyroid therapy	0.5 (0.5–0.6)	0.5 (0.4–0.5)	0.5 (0.5–0.6)	0.6 (0.5–0.6)	0.6 (0.5–0.6)	0.7 (0.6–0.7)	0.7 (0.6–0.7)	0.7 (0.6–0.8)	0.7 (0.7–0.8)	0.7 (0.6–0.8)	↑
Cardiac therapy	1.7 (1.6–1.9)	1.7 (1.5–1.8)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	1.0 (0.8–1.1)	1.0 (0.9–1.2)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	↓
Total prescribed medications	93.6 (91.2–96.1)	93.8 (91.5–96.2)	92.3 (89.9–94.7)	88.0 (85.6–90.4)	84.3 (81.8–86.9)	86.0 (83.6–88.5)	83.4 (81.2–85.5)	85.8 (83.3–88.4)	83.3 (81.0–85.5)	82.4 (80.3–84.6)	↓

(a) Column will not add to 100, as multiple prescriptions could be written at each encounter. Also, only the most frequent medications are included.

(b) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, § indicates a non-linear significant change, and — indicates there was no change.

Note: CI—confidence interval.

Table 9.4: Most frequently prescribed medications (CAPS generic), summary of annual results, BEACH, 1998–99 to 2007–08

Generic drug	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Amoxicillin	3.2 (3.0–3.5)	3.1 (2.9–3.4)	3.2 (3.0–3.5)	2.9 (2.7–3.1)	3.1 (2.8–3.4)	3.3 (3.0–3.5)	3.5 (3.2–3.8)	3.6 (3.3–3.8)	3.3 (3.0–3.6)	3.5 (3.2–3.7)	—
Paracetamol	3.9 (3.6–4.2)	4.1 (3.7–4.4)	3.9 (3.6–4.3)	3.1 (2.8–3.4)	3.1 (2.8–3.5)	2.9 (2.5–3.2)	2.7 (2.4–2.9)	3.0 (2.7–3.3)	2.6 (2.3–2.9)	2.5 (2.2–2.7)	↓
Cephalexin	2.1 (1.9–2.3)	2.1 (1.9–2.2)	2.2 (2.0–2.4)	2.0 (1.9–2.2)	1.9 (1.8–2.0)	2.0 (1.9–2.2)	2.4 (2.2–2.6)	2.5 (2.3–2.7)	2.3 (2.2–2.5)	2.4 (2.3–2.6)	§
Paracetamol–codeine	2.7 (2.4–2.9)	2.4 (2.2–2.6)	2.2 (2.0–2.4)	2.2 (2.1–2.4)	2.0 (1.8–2.2)	2.1 (1.9–2.3)	2.0 (1.8–2.2)	2.0 (1.8–2.2)	2.0 (1.8–2.1)	1.9 (1.7–2.1)	↓
Atorvastatin	0.6 (0.5–0.6)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	1.0 (1.0–1.2)	1.2 (1.1–1.3)	1.4 (1.3–1.5)	1.6 (1.4–1.8)	1.7 (1.5–1.8)	1.7 (1.6–1.9)	↑
Amoxicillin–potassium clavulanate	1.8 (1.6–2.0)	1.6 (1.5–1.8)	1.7 (1.5–1.9)	1.6 (1.4–1.7)	1.6 (1.4–1.7)	1.7 (1.5–1.8)	1.7 (1.5–1.8)	1.7 (1.5–1.8)	1.7 (1.5–1.9)	1.7 (1.6–1.9)	—
Salbutamol	2.4 (2.2–2.6)	2.4 (2.2–2.6)	2.1 (1.9–2.2)	2.0 (1.8–2.1)	1.7 (1.6–1.9)	1.5 (1.4–1.6)	1.4 (1.3–1.5)	1.5 (1.4–1.6)	1.4 (1.3–1.5)	1.3 (1.2–1.5)	↓
Roxithromycin	1.8 (1.6–2.0)	1.8 (1.7–2.0)	1.6 (1.4–1.8)	1.4 (1.3–1.5)	1.3 (1.2–1.5)	1.1 (1.0–1.2)	1.1 (1.0–1.3)	1.5 (1.3–1.7)	1.4 (1.2–1.5)	1.2 (1.1–1.4)	§
Metformin	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.8 (0.8–0.9)	1.0 (0.9–1.1)	1.0 (0.9–1.0)	1.2 (1.0–1.3)	1.1 (1.0–1.3)	1.2 (1.1–1.3)	↑
Perindopril	0.6 (0.5–0.6)	0.7 (0.6–0.8)	0.6 (0.6–0.7)	0.7 (0.7–0.8)	0.7 (0.6–0.8)	0.7 (0.7–0.8)	0.8 (0.7–0.9)	1.0 (0.9–1.1)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	↑
Esomeprazole	N/A	N/A	N/A	N/A	0.3 (0.2–0.3)	0.6 (0.5–0.7)	0.7 (0.6–0.8)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	1.2 (1.1–1.3)	↑
Diazepam	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.0 (0.9–1.2)	1.0 (0.9–1.2)	1.0 (0.9–1.1)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	—
Temazepam	1.4 (1.3–1.6)	1.4 (1.3–1.6)	1.4 (1.3–1.6)	1.3 (1.2–1.5)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	↓

(continued)

Table 9.4 (continued): Most frequently prescribed medications (CAPS generic), summary of annual results, BEACH, 1998–99 to 2007–08

Generic drug	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Warfarin sodium	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.9 (0.8–1.1)	0.9 (0.8–1.0)	1.0 (0.9–1.2)	1.1 (0.9–1.2)	↑
Oxycodone	0.2 (0.2–0.2)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.4 (0.4–0.5)	0.5 (0.5–0.6)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	1.0 (0.9–1.2)	↑
Levonorgestrel– ethinyloestradiol	1.2 (1.1–1.4)	1.3 (1.2–1.4)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	1.1 (1.0–1.2)	1.2 (1.1–1.3)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	↓
Irbesartan	0.5 (0.5–0.6)	0.7 (0.6–0.8)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	1.1 (1.0–1.2)	1.0 0.9–1.1)	1.0 (0.9–1.1)	↑
Meloxicam	N/A	N/A	N/A	0.0 ^F (0.0–0.1)	0.3 (0.3–0.4)	0.4 (0.3–0.5)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.7 (0.7–0.8)	0.9 (0.8–1.1)	↑
Chloramphenicol eye	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.9 (0.8–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.9 (0.9–1.0)	1.1 (1.0–1.1)	1.0 (0.9–1.1)	0.9 (0.9–1.0)	—
Simvastatin	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	1.0 (1.0–1.1)	1.1 (1.0–1.2)	1.2 (1.0–1.3)	1.1 (1.0–1.2)	0.9 (0.8–1.0)	↑
Atenolol	1.0 (0.9–1.1)	1.0 (0.9–1.2)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	0.8 (0.7–0.9)	1.0 (0.9–1.1)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	0.9 (0.8–1.0)	—
Tramadol	0.0 ^F (0.0–0.0)	0.1 (0.0–1.1)	0.2 (0.1–0.2)	0.7 (0.6–0.8)	1.0 (0.9–1.1)	0.9 (0.9–1.1)	1.0 (0.9–1.1)	1.0 (0.9–1.0)	0.9 (0.8–1.1)	0.9 (0.8–0.9)	↑
Fluticasone–salmeterol	N/A	N/A	0.2 (0.2–0.3)	0.6 (0.5–0.7)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.9 (0.8–0.9)	0.8 (0.7–0.9)	
Ramipril	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.4 (0.4–0.5)	0.6 (0.5–0.7)	0.7 (0.6–0.7)	0.7 (0.7–0.8)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	↑
Mometasone	0.6 (0.5–0.7)	0.6 (0.6–0.7)	0.7 (0.6–0.7)	0.8 (0.7–0.9)	0.6 (0.6–0.7)	0.5 (0.5–0.6)	0.8 (0.7–0.9)	0.7 (0.6–0.7)	0.7 (0.6–0.7)	0.8 (0.7–0.8)	—
Irbesartan– hydrochlorothiazide	N/A	N/A	0.3 (0.2–0.4)	0.6 (0.5–0.6)	0.6 (0.5–0.7)	0.7 (0.7–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.8 (0.7–0.8)	0.8 (0.7–0.9)	↑

(continued)

Table 9.4 (continued): Most frequently prescribed medications (CAPS generic), summary of annual results, BEACH, 1998–99 to 2007–08

Generic drug	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Doxycycline hydrochloride	1.2 (1.1–1.3)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.7–0.8)	0.8 (0.7–0.9)	0.7 (0.7–0.9)	0.7 (0.7–0.8)	↓
Amlodipine	0.8 (0.7–0.8)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.7)	0.7 (0.6–0.7)	0.6 (0.6–0.7)	0.7 (0.6–0.8)	0.8 (0.7–0.8)	0.7 (0.6–0.8)	—
Betamethasone topical	0.9 (0.9–1.0)	0.9 (0.8–0.9)	1.0 (0.9–1.2)	0.9 (0.8–1.0)	0.7 (0.6–0.8)	0.8 (0.8–0.9)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	—
Diclofenac sodium systemic	1.3 (1.2–1.4)	1.3 (1.1–1.4)	1.2 (1.0–1.3)	0.9 (0.8–1.0)	0.7 (0.6–0.8)	0.8 (0.7–0.9)	1.0 (0.8–1.1)	1.0 (0.9–1.1)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	§
Thyroxine	0.5 (0.4–0.5)	0.5 (0.4–0.5)	0.5 (0.4–0.6)	0.5 (0.5–0.6)	0.6 (0.5–0.6)	0.6 (0.5–0.7)	0.6 (0.5–0.7)	0.6 (0.6–0.7)	0.7 (0.6–0.8)	0.7 (0.6–0.7)	↑
Aspirin	0.7 (0.7–0.8)	0.8 (0.8–1.0)	0.8 (0.7–0.9)	0.7 (0.6–0.7)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.7)	0.7 (0.7–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.7)	—
Candesartan cilexetil	0.0 [†] (0.0–0.0)	0.1 (0.1–0.1)	0.2 (0.2–0.2)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.4 (0.4–0.5)	0.6 (0.5–0.7)	0.6 (0.5–0.7)	↑
Sertraline	0.6 (0.5–0.7)	0.8 (0.7–0.9)	0.8 (0.7–0.8)	0.6 (0.6–0.7)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.7)	0.7 (0.6–0.8)	0.7 (0.6–0.7)	0.6 (0.5–0.7)	—
Frusemide	1.0 (0.9–1.1)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.6 (0.5–0.7)	0.6 (0.6–0.7)	0.6 (0.6–0.7)	0.6 (0.5–0.7)	↓
Cefaclor monohydrate	2.2 (1.9–2.4)	1.6 (1.3–2.0)	1.6 (1.4–1.8)	1.1 (1.0–1.2)	1.0 (0.9–1.2)	0.8 (0.7–0.9)	0.8 (0.7–1.0)	0.8 (0.6–1.0)	0.8 (0.6–0.9)	0.6 (0.5–0.7)	↓
Generic medication frequently prescribed in previous years											
Erythromycin	1.1 (0.9–1.2)	0.7 (0.7–0.8)	0.8 (0.7–0.9)	0.6 (0.5–0.6)	0.5 (0.4–0.6)	0.6 (0.5–0.6)	0.5 (0.4–0.6)	0.5 (0.4–0.6)	0.5 (0.4–0.6)	0.5 (0.4–0.5)	↓
Influenza virus vaccine	1.7 (1.4–2.1)	1.5 (1.3–1.7)	1.5 (1.3–1.8)	1.5 (1.2–1.7)	1.4 (1.2–1.7)	1.2 (1.0–1.4)	0.9 (0.7–1.1)	1.1 (0.9–1.3)	0.6 (0.5–0.8)	0.4 (0.3–0.5)	↓
Naproxen systemic	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.6 (0.5–0.6)	0.4 (0.4–0.5)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.2–0.4)	0.4 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.2–0.4)	↓

(continued)

Table 9.4 (continued): Most frequently prescribed medications (CAPS generic), summary of annual results, BEACH, 1998–99 to 2007–08

Generic drug	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Budesonide topical nasal	0.7 (0.6–0.8)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.5 (0.4–0.5)	0.3 (0.3–0.4)	0.4 (0.3–0.4)	0.3 (0.2–0.4)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	↓
Ranitidine	1.0 (0.9–1.1)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	0.6 (0.6–0.7)	0.5 (0.4–0.5)	0.4 (0.3–0.4)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.1–0.2)	↓
Enalapril maleate	0.7 (0.7–0.8)	0.7 (0.6–0.8)	0.5 (0.5–0.6)	0.4 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.2)	0.2 (0.1–0.2)	0.1 (0.1–0.2)	↓
Budesonide	0.7 (0.6–0.8)	0.7 (0.7–0.8)	0.6 (0.5–0.6)	0.5 (0.4–0.5)	0.3 (0.3–0.4)	0.3 (0.2–0.3)	0.2 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.1)	↓
Beclomethasone inhaled	0.7 (0.6–0.8)	0.6 (0.5–0.7)	0.4 (0.3–0.5)	0.3 (0.3–0.4)	0.2 (0.1–0.2)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.0–0.1)	0.0 [†] (0.0–0.0)	↓
Rofecoxib	N/A	N/A	0.1 (0.1–0.2)	1.2 (1.0–1.4)	1.2 (1.0–1.3)	1.0 (0.9–1.1)	0.3 (0.2–0.3)	N/A	N/A	N/A	§
Total prescribed medications	93.6 (91.2–96.1)	93.8 (91.5–96.2)	92.3 (89.9–94.7)	88.0 (85.6–90.4)	84.3 (81.8–86.9)	86.0 (83.6–88.5)	83.4 (81.2–85.5)	85.8 (83.3–88.4)	83.3 (81.0–85.5)	82.4 (80.3–84.6)	↓

(a) Column will not add to 100, as multiple prescriptions could be written at each encounter.

(b) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, § indicates a non-linear significant change, and — indicates there was no change.

† Rates are reported to one decimal place. This indicates that the rate is < 0.05 per 100 encounters.


Note: CI—confidence interval; N/A—not applicable (that is, drug was not available at that time).

9.2 Medications supplied by GPs

The rate of medications supplied by GPs rose significantly, from 7.3 per 100 encounters in 1998–99 to 10.1 in 2007–08. The extrapolated national effect of this change is 3.3 million more medications supplied directly to the patient by GPs in 2007–08 than in 1998–99 (Table 9.5).

Table 9.5 shows rates of generic medications most frequently supplied by GPs between 1998–99 and 2007–08. The supply of vitamin B12 rose significantly from 0.1 per 100 encounters in 1998–99 to 0.4 in 2007–08. The extrapolated national effect of this change is that vitamin B12 was supplied 330,000 more times in 2007–08 than in 1998–99.

The move away from prescribing towards GP supply of the influenza vaccine was evident in the significant increase in its supply by GPs that coincided with the significant decrease in its prescribing rates (Figure 9.5). The extrapolated national effect of this change is 780,000 more influenza vaccines supplied by GPs in 2007–08 than in 1998–99 and 1.3 million fewer prescriptions for influenza vaccine over the same period. It is interesting also to note the marginal decrease in overall influenza vaccine prescription/supply rates between 2006–07 (2.6 per 100 encounters) and 2007–08 (1.9 per 100).



9.3 Medications advised for over-the-counter purchase

The overall rate of advised OTC medications showed no significant change over the period (Table 9.1). Table 9.6 shows the most commonly advised OTC medications at the generic level. The rate of advised ibuprofen rose significantly from 0.2 per 100 encounters in 1998–99 to 0.6 in 2007–08. The extrapolated national effect of this change is that ibuprofen was advised by GPs 440,000 more times in 2007–08 than in 1998–99.

Table 9.5: Medications most frequently supplied by GPs, summary of annual results, BEACH, 1998–99 to 2007–08

Generic medication	Rate per 100 encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Influenza virus vaccine	0.8 (0.6–1.1)	0.7 (0.5–0.9)	0.6 (0.4–0.7)	0.9 (0.7–1.1)	0.7 (0.5–0.9)	1.2 (0.9–1.4)	1.2 (0.9–1.6)	1.6 (1.3–1.8)	2.0 (1.6–2.3)	1.5 (1.2–1.7)	↑
Papillomavirus vaccine	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.0 [‡]	1.0 (0.9–1.1)	↑
Pneumococcal vaccine	0.1 (0.1–0.2)	0.1 (0.0–0.1)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.1–0.1)	0.4 (0.3–0.5)	0.9 (0.8–1.0)	0.6 (0.6–0.7)	0.6 (0.5–0.7)	§
Vitamin B12 (cobalamin)	0.1 (0.1–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.0 [‡] (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.1–0.2)	0.2 (0.2–0.2)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.4 (0.3–0.4)	↑
Mumps–measles–rubella vaccine	0.2 (0.2–0.3)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	↑
<i>Haemophilus</i> B vaccine	0.3 (0.2–0.4)	0.3 (0.3–0.4)	0.2 (0.2–0.3)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.2)	0.3 (0.2–0.4)	0.2 (0.2–0.2)	0.3 (0.2–0.3)	—
Polio vaccine oral sabin/injection	0.4 (0.3–0.5)	0.4 (0.3–0.5)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.3 (0.2–0.4)	0.3 (0.3–0.4)	0.4 (0.4–0.5)	0.5 (0.4–0.5)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	↓
ADT–CDT vaccine (diphtheria–tetanus)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.2–0.2)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	—
Diphtheria–pertussis–tetanus–polio vaccine	N/A	N/A	N/A	N/A	N/A	N/A	0.0 [‡] (0.0–0.0)	0.1 (0.0–0.1)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	↑
Chicken pox (varicella zoster) vaccine	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.1 (0.0–0.7)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	↑
Meningitis vaccine	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.2 (0.1–0.2)	0.3 (0.2–0.3)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	↑
Total GP-supplied medications	7.3 (6.5–8.1)	6.9 (6.0–7.7)	6.9 (5.9–7.9)	7.6 (6.6–8.7)	9.3 (8.0–10.6)	8.6 (7.6–9.6)	8.1 (7.3–8.8)	8.8 (8.2–9.5)	8.9 (8.2–8.6)	10.1 (9.5–10.7)	↑

(a) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, § indicates a non-linear significant change, and — indicates there was no change.

‡ Rates are reported to one decimal place. This indicates that the rate is < 0.05 per 100 encounters.

Note: CI—confidence interval. N/A—not applicable (that is, drug was not available at that time).

Table 9.6: Most frequently advised over-the-counter medications, summary of annual results, BEACH, 1998–99 to 2007–08

Generic medication	Rate per 100 encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Paracetamol	2.4 (2.1–2.7)	2.5 (2.2–2.8)	2.4 (2.0–2.7)	2.1 (1.9–2.4)	2.6 (2.3–2.9)	2.5 (2.1–2.8)	2.3 (2.0–2.6)	2.5 (2.2–2.8)	2.4 (2.1–2.7)	2.6 (2.2–2.9)	—
Ibuprofen	0.2 (0.2–0.3)	0.3 (0.2–0.4)	0.5 (0.4–0.6)	0.5 (0.4–0.6)	0.7 (0.5–0.8)	0.6 (0.5–0.7)	0.5 (0.4–0.6)	0.6 (0.5–0.7)	0.5 (0.5–0.6)	0.6 (0.5–0.7)	↑
Loratadine	0.2 (0.2–0.2)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.3)	—
Diclofenac diethyl topical	0.2 (0.1–0.2)	0.2 (0.2–0.3)	0.2 (0.1–0.2)	0.2 (0.2–0.2)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	—
Sodium chloride topical nasal	0.0 [†] (0.0–0.0)	0.0 [†] (0.0–0.0)	0.1 (0.0–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	↑
Sodium/potassium/citric/ glucose	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	—
Fexofenadine	0.1 (0.0–0.5)	0.1 (0.0–0.9)	0.1 (0.0–0.5)	0.1 (0.0–0.5)	0.1 (0.0–0.4)	0.1 (0.0–0.5)	0.2 (0.0–0.5)	0.1 (0.1–0.2)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	—
Aspirin	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.1 (0.1–0.2)	—
Cetirizine	0.0 [†] (0.0–0.0)	0.0 [†] (0.0–0.0)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	↑
Paracetamol–codeine	0.2 (0.2–0.3)	0.3 (0.2–0.4)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	↓
Total advised medications	8.8 (8.1–9.5)	9.4 (8.7–10.1)	9.0 (8.2–9.7)	8.9 (8.2–9.6)	10.2 (9.3–11.1)	9.8 (9.0–10.5)	10.1 (9.2–10.9)	9.8 (9.0–10.5)	9.4 (8.7–10.1)	10.1 (9.3–10.9)	—

(a) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, and — indicates there was no change.

† Rates are reported to one decimal place. This indicates that the rate is < 0.05 per 100 encounters.

Note: CI—confidence interval.

10 Other treatments

This chapter includes data about the other treatments provided in general practice from each of the 10 years of the BEACH study from 1998–99 to 2007–08. The survey form allowed GPs to record up to two other treatments for each problem managed at the encounter. Other treatments included all clinical and procedural treatments provided. These groups are defined in Appendix 5. Between 2005–06 and 2007–08 the GPs were asked to indicate whether the treatment was provided by a practice nurse (tick box). In this chapter all ‘other treatments’ are reported, irrespective of whether they were done by the GP or by the practice nurse. That is, the non-pharmacological management provided in general practice patient encounters is described, rather than management provided specifically by the general practitioner. Treatments provided by the practice nurse are reported separately in Chapter 13.

Patient observations that were regarded as routine clinical measurements or observations, such as measurements of blood pressure and physical examinations, were not included between 1998–99 and 2004–05. With the inclusion of practice nurse activities in BEACH since 2005–06, patient observations have been recorded since this time only when undertaken by the practice nurse.

The direction and type of change from 1998–99 to 2007–08 is indicated for each result in the far right column of the tables: \uparrow/\downarrow indicates a statistically significant linear change, \uparrow/\downarrow indicates a marginally significant linear change, \S indicates a non-linear significant or marginal change, and – indicates there was no change.

Significant linear changes can be extrapolated to estimate the national increase or decrease in the other treatments provided between 1998–99 and 2007–08. An example of an extrapolated change is given for each table. The method used to extrapolate to national change estimates is described in Chapter 2, Section 2.4.

10.1 Clinical treatments

Overall, there has been no change in the rate of clinical treatments provided at general practice encounters when comparing 1998–99 and 2007–08 data. However, a comparison of the clinical treatment rates for each year demonstrates a number of changes over the 10-year period. As shown in Table 10.1, there was a steady significant rise between 1998–99 and 2004–05 in the rate of clinical treatments recorded. A 25% decline in clinical treatments followed in 2005–06 (from 39.2 per 100 encounters in 2004–05 to 29.2 per 100 in 2005–06). The rate then increased in 2007–08 to 34.5 per 100 encounters.

Some interesting changes over time are evident in the rate of specific types of clinical treatments provided. The decline in clinical treatments overall in 2005–06 was reflected in some of the specific types of clinical treatments given. For example, the rate of general advice and education steadily increased between 1998–99 and 2004–05, peaking at a rate of 7.0 per 100 encounters in 2004–05. The rate then decreased in 2005–06 to 4.8 per 100 encounters, a decrease of more than 30%. It again increased to the peak seen in 2004–05, with general advice and education provided in 2007–08 at a rate of 7.2 per 100 encounters (Table 10.1).

A significant linear increase was seen in the rate of sickness certificates provided over the 10-year period, given at a rate of 0.7 per 100 encounters in 1998–99 and increasing to 1.7 per

100 encounters in 2007–08. This represents an estimated 1.1 million more sickness certificates provided nationally in 2007–08 than in 1998–99.

Table 10.2 shows that some changes have occurred in the rates at which clinical treatments were used in the management of specific problems. The rate at which clinical treatments were used in the management of upper respiratory tract infection fluctuated over the years, but there was a significant rise overall in the rate of clinical treatments provided for this problem, from 1.2 per 100 upper respiratory tract infection encounters in 1998–99 to 1.8 per 100 in 2007–08. Clinical treatments were provided in the management of asthma less often in 2007–08 than in 1998–99. A significant linear decrease over the 10-year period is shown, equating to 290,000 fewer occasions at which a clinical treatment was given in the management of asthma in 2007–08 than in 1998–99.

10.2 Procedural treatments

Overall, the rate at which procedural treatments were provided by GPs increased significantly over time, from 11.8 per 100 encounters in 1998–99 to 16.7 per 100 encounters in 2007–08. This equates to an estimated additional 5.8 million occasions at which a procedure was performed in 2007–08 compared with 1998–99 (Table 10.3).

This significant rise in the rate of procedural treatments is reflected in the rates of individual types of procedural treatments. For example, there has been an increase in the group of procedures that includes excisions, biopsies and cauterisation, from 2.8 per 100 encounters in 1998–99 to 3.4 per 100 encounters in 2007–08. This equates to a national estimated 770,000 additional procedures undertaken by GPs in 2007–08 compared with 1998–99. Other procedural treatments that demonstrate a significant increase over this time included local injections and pap smears (Table 10.3).

A number of changes were apparent in the most common problems managed with a procedural treatment between 1998–99 and 2007–08 (Table 10.4). For solar keratosis (the problem most often managed with a procedure) the rate at which a procedure was performed rose marginally, from 0.7 per 100 contacts in 1998–99 to 0.9 per 100 in 2007–08.

Significantly more procedures were performed in the management of vitamin/nutritional deficiency over time, with an additional 320,000 procedures performed nationally for this problem in 2007–08 than in 1998–99 (Table 10.4).

Table 10.1: The most frequent clinical treatments, summary of annual results, BEACH, 1998–99 to 2007–08

Treatment	Rate per 100 encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Advice/education*	3.5 (3.0–4.0)	4.2 (3.7–4.7)	5.8 (5.2–6.4)	6.3 (5.6–7.0)	6.9 (6.1–7.7)	6.8 (6.1–7.6)	7.0 (6.2–7.8)	4.8 (4.1–5.4)	5.7 (5.0–6.5)	7.2 (6.3–8.1)	§
Counselling—problem*	2.9 (2.6–3.3)	3.4 (3.0–3.9)	3.4 (3.0–3.8)	4.7 (4.0–5.3)	5.5 (4.8–6.1)	4.7 (4.1–5.3)	4.2 (3.3–5.0)	4.8 (4.1–5.4)	4.4 (3.7–5.0)	4.3 (3.8–4.9)	§
Counselling/advice— nutrition/weight*	3.8 (3.4–4.1)	4.2 (3.8–4.6)	5.6 (5.0–6.1)	5.5 (5.0–5.9)	5.2 (4.7–5.8)	4.6 (4.2–5.1)	5.3 (4.7–5.9)	3.6 (3.2–4.0)	3.4 (3.0–3.7)	4.2 (3.8–4.6)	—
Advice/education— treatment*	6.2 (5.6–6.8)	6.2 (5.6–6.8)	5.9 (5.3–6.5)	5.1 (4.6–5.6)	4.2 (3.8–4.7)	4.4 (3.8–4.9)	4.6 (4.0–5.1)	3.1 (2.6–3.5)	2.8 (2.5–3.1)	3.5 (3.1–3.8)	↓
Counselling— psychological*	2.5 (2.3–2.7)	2.6 (2.4–2.8)	2.8 (2.6–3.1)	3.2 (2.8–3.5)	2.9 (2.6–3.1)	2.9 (2.6–3.1)	3.2 (2.9–3.5)	3.1 (2.8–3.3)	2.9 (2.6–3.1)	3.2 (2.9–3.4)	§
Advice/education— medication*	2.4 (2.2–2.6)	2.9 (2.6–3.2)	2.6 (2.3–2.9)	2.8 (2.6–3.1)	2.5 (2.2–2.7)	3.4 (3.1–3.7)	3.4 (2.9–3.8)	1.6 (1.4–1.7)	1.8 (1.6–2.0)	2.0 (1.8–2.2)	§
Sickness certificate*	0.7 (0.6–0.9)	0.6 (0.5–0.7)	1.1 (0.9–1.3)	1.1 (0.9–1.3)	1.3 (1.1–1.5)	1.0 (0.9–1.2)	1.7 (1.3–2.1)	1.6 (1.4–1.9)	1.6 (1.3–1.8)	1.7 (1.4–2.0)	↑
Other admin/document*	0.9 (0.8–1.0)	1.0 (0.9–1.2)	1.5 (1.3–1.6)	1.5 (1.4–1.7)	1.6 (1.4–1.7)	1.8 (1.6–2.0)	1.3 (1.1–1.5)	1.0 (0.9–1.1)	1.2 (1.1–1.4)	1.5 (1.4–1.7)	§
Reassurance, support	1.6 (1.4–1.8)	1.6 (1.4–1.8)	1.5 (1.3–1.8)	1.5 (1.3–1.7)	1.4 (1.2–1.5)	1.5 (1.3–1.7)	1.6 (1.2–1.9)	1.0 (0.8–1.2)	1.1 (0.9–1.3)	1.4 (1.2–1.6)	§
Counselling/advice— exercise*	1.4 (1.1–1.6)	1.6 (1.4–1.8)	2.2 (1.9–2.4)	2.1 (1.8–2.3)	1.6 (1.4–1.8)	1.5 (1.3–1.7)	1.9 (1.4–2.3)	1.1 (0.9–1.2)	1.1 (1.0–1.3)	1.3 (1.1–1.5)	§
Counselling/advice— smoking*	0.6 (0.5–0.7)	0.7 (0.6–0.8)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	0.6 (0.6–0.7)	0.8 (0.6–1.0)	0.5 (0.4–0.6)	0.6 (0.5–0.6)	0.6 (0.5–0.7)	§
Counselling/advice— prevention*	0.4 (0.3–0.5)	0.3 (0.3–0.4)	0.3 (0.2–0.4)	0.3 (0.2–0.4)	0.3 (0.2–0.4)	0.4 (0.3–0.5)	0.4 (0.1–0.8)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.5 (0.4–0.6)	—
Counselling/advice— lifestyle*	0.3 (0.2–0.4)	0.3 (0.2–0.4)	0.3 (0.2–0.4)	0.4 (0.3–0.5)	0.5 (0.3–0.7)	0.3 (0.2–0.4)	0.4 (0.0–1.0)	0.5 (0.3–0.6)	0.4 (0.3–0.5)	0.4 (0.3–0.5)	—

(continued)

Table 10.1 (continued): The most frequent clinical treatments, summary of annual results, BEACH, 1998–99 to 2007–08

Treatment	Rate per 100 encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Counselling/advice—alcohol*	0.4 (0.3–0.4)	0.4 (0.3–0.4)	0.4 (0.4–0.5)	0.4 (0.3–0.4)	0.4 (0.3–0.4)	0.4 (0.3–0.4)	0.5 (0.2–0.7)	0.3 (0.3–0.3)	0.3 (0.3–0.4)	0.4 (0.3–0.4)	—
Family planning*	0.3 (0.2–0.4)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.4 (0.3–0.4)	0.4 (0.3–0.4)	0.4 (0.2–0.6)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.4 (0.3–0.4)	—
Observe/wait*	1.0 (0.8–1.2)	0.6 (0.5–0.7)	0.7 (0.4–1.0)	0.3 (0.2–0.4)	0.3 (0.2–0.3)	0.3 (0.2–0.4)	0.4 (0.0–0.7)	0.3 (0.2–0.4)	0.3 (0.2–0.4)	0.3 (0.2–0.4)	↓
Counselling/advice—health/body*	0.8 (0.7–1.0)	0.6 (0.4–0.7)	0.4 (0.3–0.5)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.2–0.3)	0.4 (0.1–0.6)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.3 (0.2–0.4)	§
Counselling/advice—pregnancy*	0.1 (0.1–0.2)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.4)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	↑
Counselling/advice—relaxation*	0.4 (0.3–0.4)	0.3 (0.3–0.4)	0.4 (0.3–0.4)	0.4 (0.3–0.4)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.3 (0.2–0.4)	0.2 (0.2–0.3)	§
Counselling/advice—STDs*	0.1 (0.1–0.2)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	—
Counselling/advice—drug abuse*	0.2 (0.1–0.2)	0.4 (0.1–0.6)	0.3 (0.2–0.5)	0.2 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.3)	0.2 (0.1–0.3)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	↓
Counselling/advice—relationship*	0.4 (0.3–0.5)	0.4 (0.3–0.4)	0.3 (0.2–0.3)	0.2 (0.1–0.2)	0.2 (0.2–0.2)	0.2 (0.2–0.2)	0.2 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	↓
Total clinical treatments	31.4 (29.7–33.0)	33.5 (31.8–35.2)	37.2 (35.1–39.3)	38.1 (36.1–40.1)	37.2 (35.0–39.4)	36.6 (34.5–38.8)	39.2 (37.1–41.4)	29.2 (27.3–31.1)	29.5 (27.6–31.4)	34.5 (32.5–36.5)	§

(a) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, § indicates a non-linear significant or marginal change, and — indicates there was no change.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5).

Note: CI—confidence interval; admin—administration; STD—sexually transmitted disease.

Table 10.2: The most common problems managed with a clinical treatment, summary of annual results, BEACH, 1998–99 to 2007–08

Problem managed	Rate at which a clinical treatment was given, per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Depression*	1.6 (1.5–1.8)	1.6 (1.5–1.8)	1.8 (1.6–2.0)	1.7 (1.6–1.9)	1.7 (1.6–1.9)	1.7 (1.6–1.9)	1.8 (1.7–2.0)	1.7 (1.5–1.8)	1.5 (1.4–1.6)	1.8 (1.6–1.9)	—
Upper respiratory tract infection	1.2 (1.1–1.4)	1.4 (1.2–1.6)	1.7 (1.5–1.9)	2.0 (1.7–2.2)	1.8 (1.6–2.0)	1.6 (1.4–1.8)	1.8 (1.5–2.0)	1.6 (1.3–1.8)	1.5 (1.3–1.6)	1.8 (1.6–2.0)	↑
Hypertension*	0.9 (0.8–1.1)	1.1 (0.9–1.2)	1.4 (1.2–1.6)	1.4 (1.2–1.5)	1.5 (1.3–1.7)	1.3 (1.1–1.4)	1.3 (1.2–1.5)	1.0 (0.9–1.2)	0.9 (0.8–1.0)	1.2 (1.1–1.4)	§
Lipid disorders*	0.7 (0.6–0.8)	0.8 (0.7–0.9)	1.0 (0.9–1.2)	1.0 (0.9–1.1)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	1.0 (0.9–1.1)	0.8 (0.7–0.9)	0.8 (0.7–0.8)	1.0 (0.9–1.1)	§
Diabetes—all*	0.7 (0.6–0.8)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	§
Anxiety*	0.8 (0.7–0.8)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.7 (0.6–0.8)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.7 (0.7–0.8)	0.8 (0.7–0.9)	—
Gastroenteritis*	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.7 (0.6–0.7)	0.7 (0.6–0.7)	0.8 (0.7–0.9)	§
Test results*	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.4 (0.3–0.4)	0.3 (0.2–0.4)	0.4 (0.3–0.5)	0.5 (0.4–0.6)	0.5 (0.3–0.6)	0.4 (0.3–0.4)	0.6 (0.5–0.7)	↑
Back complaint*	0.5 (0.4–0.6)	0.6 (0.5–0.7)	0.6 (0.5–0.7)	0.6 (0.5–0.7)	0.6 (0.5–0.6)	0.6 (0.5–0.6)	0.6 (0.5–0.7)	0.5 (0.4–0.6)	0.5 (0.4–0.5)	0.5 (0.5–0.6)	—
Sprain/strain*	0.5 (0.5–0.6)	0.5 (0.5–0.6)	0.6 (0.5–0.7)	0.6 (0.5–0.6)	0.4 (0.4–0.5)	0.5 (0.4–0.5)	0.5 (0.4–0.6)	0.5 (0.4–0.5)	0.4 (0.3–0.4)	0.4 (0.3–0.5)	↓
Obesity	0.4 (0.3–0.4)	0.4 (0.3–0.5)	0.5 (0.4–0.5)	0.5 (0.4–0.6)	0.5 (0.4–0.6)	0.5 (0.4–0.5)	0.5 (0.4–0.6)	0.4 (0.3–0.4)	0.5 (0.4–0.5)	0.4 (0.4–0.5)	§
Acute stress reaction	0.5 (0.4–0.5)	0.4 (0.3–0.5)	0.4 (0.3–0.4)	0.4 (0.4–0.5)	0.4 (0.3–0.5)	0.4 (0.3–0.5)	0.5 (0.4–0.5)	0.4 (0.3–0.4)	0.4 (0.4–0.5)	0.4 (0.4–0.5)	—
Osteoarthritis*	0.3 (0.3–0.4)	0.4 (0.3–0.4)	0.4 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.4 (0.3–0.4)	0.5 (0.4–0.5)	0.3 (0.3–0.4)	0.3 (0.2–0.4)	0.4 (0.3–0.4)	—

(continued)

Table 10.2 (continued): The most common problems managed with a clinical treatment, summary of annual results, BEACH, 1998–99 to 2007–08

Problem managed	Rate at which a clinical treatment was given, per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓ — ↑ § — ↑ § § § § —
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
General check-up*	0.2 (0.2–0.2)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.3–0.3)	0.3 (0.2–0.4)	0.4 (0.3–0.4)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.4 (0.3–0.4)	↑
Asthma	0.6 (0.5–0.6)	0.6 (0.5–0.7)	0.6 (0.5–0.7)	0.7 (0.6–0.8)	0.6 (0.5–0.6)	0.5 (0.5–0.6)	0.5 (0.4–0.6)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	↓
Acute bronchitis/ bronchiolitis	0.3 (0.3–0.4)	0.4 (0.3–0.5)	0.4 (0.3–0.4)	0.5 (0.4–0.5)	0.4 (0.3–0.5)	0.4 (0.3–0.5)	0.4 (0.3–0.5)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	—
Tobacco abuse	0.2 (0.2–0.2)	0.1 (0.1–0.2)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.2–0.2)	0.2 (0.2–0.2)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	↑
Oesophageal disease	0.2 (0.2–0.2)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.4 (0.3–0.4)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	§
Pregnancy*	0.2 (0.1–0.2)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	↑
Adverse effect medical agent	0.2 (0.2–0.2)	0.3 (0.2–0.3)	0.2 (0.2–0.2)	0.2 (0.2–0.2)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.3 (0.2–0.3)	0.2 (0.1–0.2)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	§
Urinary tract infection*	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.3)	§
Menopausal complaint	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.4 (0.3–0.5)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	§
Total problems with clinical treatments	28.7 (27.3–30.2)	30.4 (28.9–31.9)	32.8 (31.1–34.5)	33.6 (31.9–35.2)	32.8 (31.0–34.7)	32.4 (30.7–34.2)	34.4 (32.6–36.2)	26.7 (25.1–28.3)	26.8 (25.1–28.4)	31.2 (29.5–33.0)	—

(a) Rate of provision of clinical treatment for selected problem per 100 total encounters.

(b) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, § indicates a non-linear significant change, and — indicates there was no change.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5).

Note: CI—confidence interval. This table includes individual problems which had clinical treatments given at a rate of ≥ 0.5 per 100 encounters in any year, and any other statistically significant differences of interest.

Table 10.3: The most frequent procedural treatments, summary of annual results, BEACH, 1998–99 to 2007–08

Treatment	Rate per 100 encounters (95% CI)										↑ ^(e) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Excision/removal tissue/ biopsy/destruction/ debridement/cauterisation*	2.8 (2.6–3.0)	3.0 (2.8–3.2)	2.6 (2.4–2.9)	2.7 (2.5–3.0)	2.9 (2.6–3.1)	3.1 (2.7–3.6)	3.3 (3.0–3.6)	3.0 (2.7–3.2)	3.4 (3.0–3.7)	3.4 (3.1–3.8)	↑
Local injection/ infiltration* ^(b)	0.3 (0.1–0.5)	0.2 (0.2–0.3)	0.2 (0.1–0.2)	1.2 (0.9–1.4)	1.5 (1.3–1.7)	1.6 (1.4–1.8)	2.0 (1.7–2.2)	2.0 (1.8–2.2)	1.9 (1.7–2.1)	2.3 (2.1–2.5)	↑
Dressing/pressure/ compression/tamponade*	2.0 (1.8–2.2)	2.2 (2.0–2.3)	1.8 (1.6–1.9)	1.8 (1.7–1.9)	2.0 (1.8–2.1)	1.8 (1.7–2.0)	2.0 (1.8–2.1)	2.1 (1.9–2.3)	2.3 (2.1–2.4)	2.2 (2.1–2.4)	—
Physical medicine/ rehabilitation*	1.8 (1.5–2.1)	1.7 (1.5–1.8)	2.0 (1.8–2.3)	2.2 (1.9–2.4)	2.1 (1.8–2.4)	1.7 (1.5–1.9)	2.0 (1.7–2.3)	1.4 (1.1–1.6)	1.1 (0.9–1.3)	1.3 (1.1–1.5)	§
Incision/drainage/flushing/ aspiration/removal body fluid*	1.0 (0.9–1.1)	1.1 (1.0–1.2)	1.1 (1.0–1.1)	1.2 (1.0–1.2)	1.1 (1.0–1.2)	1.2 (1.1–1.3)	1.0 (1.0–1.1)	1.3 (1.2–1.4)	1.3 (1.1–1.4)	1.2 (1.1–1.3)	§
Pap smear*	0.6 (0.5–0.7)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	1.1 (0.9–1.2)	1.1 (0.9–1.3)	1.0 (0.8–1.1)	1.0 (0.8–1.1)	0.9 (0.8–1.0)	1.1 (0.9–1.2)	↑
Repair/fixation—suture/ cast/prosthetic device (apply/remove)*	1.0 (0.9–1.1)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	0.9 (0.8–1.0)	—
Other therapeutic procedures/surgery NEC*	0.9 (0.7–1.1)	1.1 (0.8–1.3)	1.1 (0.9–1.4)	1.4 (1.2–1.7)	1.2 (1.0–1.4)	1.1 (0.9–1.3)	1.2 (0.9–1.5)	0.8 (0.6–0.9)	0.7 (0.6–0.9)	0.8 (0.6–0.9)	§
Electrical tracings*	0.4 (0.3–0.5)	0.4 (0.3–0.5)	0.4 (0.3–0.4)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.4 (0.3–0.5)	0.5 (0.4–0.5)	0.6 (0.5–0.6)	↑
Physical function test*	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.5 (0.3–0.6)	0.4 (0.3–0.5)	0.5 (0.4–0.7)	0.4 (0.3–0.5)	0.4 (0.3–0.5)	0.4 (0.3–0.5)	0.6 (0.4–0.7)	0.5 (0.4–0.6)	↑
Urine test*	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.3 (0.2–0.4)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.4 (0.4–0.5)	↑
Glucose test*	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.1–0.2)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	↓

(continued)

Table 10.3 (continued): The most frequent procedural treatments, summary of annual results, BEACH, 1998–99 to 2007–08

Treatment	Rate per 100 encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Other diagnostic procedures*	0.0 [‡] (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.2 (0.1–0.3)	0.2 (0.2–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.3)	0.2 (0.1–0.3)	↑
Total procedural treatments	11.8 (11.2–12.5)	12.5 (11.9–13.0)	12.2 (11.6–12.8)	13.8 (13.1–14.5)	14.6 (13.9–15.3)	14.7 (14.0–15.5)	15.5 (14.6–16.4)	14.4 (13.7–15.1)	15.2 (14.4–16.0)	16.7 (15.9–17.5)	↑

(a) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, § indicates a non-linear significant change, and — indicates there was no change.

(b) Excludes all local injection/infiltrations performed for immunisations.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5).

‡ Rates are reported to one decimal place. This indicates that the rate is < 0.05 per 100 encounters.

Note: CI—confidence interval; NEC—not elsewhere classified.

Table 10.4: The most common problems managed with a procedural treatment, summary of annual results, BEACH, 1998–99 to 2007–08

Problem managed	Rate at which a procedural treatment was given, per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Solar keratosis/sunburn	0.7 (0.6–0.8)	0.8 (0.7–0.8)	0.7 (0.6–0.8)	0.8 (0.6–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.1)	0.9 (0.7–1.1)	0.9 (0.8–1.0)	0.9 (0.8–1.0)	0.9 (0.8–1.1)	↑
Female genital check-up*	0.3 (0.3–0.4)	0.5 (0.4–0.6)	0.5 (0.5–0.6)	0.6 (0.5–0.7)	0.8 (0.7–0.9)	0.8 (0.7–1.0)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)	↑
Laceration/cut	0.7 (0.6–0.7)	0.7 (0.6–0.7)	0.5 (0.5–0.6)	0.5 (0.4–0.5)	0.6 (0.5–0.7)	0.5 (0.4–0.6)	0.5 (0.5–0.6)	0.5 (0.5–0.6)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	—
Excessive ear wax	0.5 (0.4–0.5)	0.5 (0.4–0.6)	0.5 (0.4–0.6)	0.6 (0.5–0.6)	0.5 (0.5–0.6)	0.5 (0.4–0.6)	0.6 (0.5–0.6)	0.7 (0.6–0.8)	0.6 (0.5–0.6)	0.6 (0.5–0.6)	§
Malignant neoplasm skin	0.4 (0.2–0.6)	0.4 (0.3–0.5)	0.4 (0.3–0.4)	0.4 (0.3–0.4)	0.4 (0.3–0.4)	0.5 (0.4–0.6)	0.6 (0.4–0.7)	0.6 (0.5–0.6)	0.6 (0.5–0.7)	0.5 (0.4–0.6)	—

(continued)

Table 10.4 (continued): The most common problems managed with a procedural treatment, summary of annual results, BEACH, 1998–99 to 2007–08

Problem managed	Rate at which a procedural treatment was given, per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Warts	0.5 (0.4–0.5)	0.5 (0.5–0.6)	0.5 (0.4–0.5)	0.5 (0.4–0.6)	0.5 (0.4–0.5)	0.5 (0.4–0.5)	0.5 (0.4–0.5)	0.4 (0.4–0.5)	0.6 (0.5–0.6)	0.5 (0.4–0.6)	—
Chronic ulcer skin (including varicose ulcer)	0.5 (0.4–0.5)	0.5 (0.4–0.5)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.4 (0.3–0.4)	0.4 (0.3–0.4)	0.3 (0.2–0.4)	0.4 (0.4–0.5)	0.4 (0.3–0.5)	—
Sprain/strain*	0.5 (0.4–0.7)	0.5 (0.4–0.6)	0.5 (0.4–0.6)	0.5 (0.5–0.6)	0.5 (0.4–0.6)	0.4 (0.3–0.4)	0.5 (0.4–0.6)	0.4 (0.3–0.4)	0.3 (0.2–0.3)	0.4 (0.3–0.5)	§
General check-up*	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.3)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.3 (0.2–0.3)	0.4 (0.3–0.5)	↑
Back complaint*	0.4 (0.3–0.6)	0.4 (0.3–0.5)	0.4 (0.3–0.5)	0.5 (0.4–0.5)	0.4 (0.3–0.6)	0.4 (0.3–0.5)	0.5 (0.4–0.6)	0.4 (0.4–0.5)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	§
Skin complaint	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.3 (0.2–0.3)	0.3 (0.2–0.4)	↑
Vitamin/nutritional deficiency	0.0 [†] (0.0–0.0)	0.0 [†] (0.0–0.0)	0.0 [†] (0.0–0.0)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.3 (0.2–0.3)	↑
Hypertension*	0.0 [†] (0.0–0.1)	0.1 (0.0–0.1)	0.2 (0.1–0.2)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	↑
Asthma	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.3 (0.3–0.4)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.2)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	↑
Total problems with procedural treatments	11.2 (10.6–11.7)	11.8 (11.3–12.3)	11.5 (10.9–12.1)	13.1 (12.4–13.7)	13.6 (13.0–14.2)	13.7 (13.1–14.4)	14.3 (13.5–15.0)	13.6 (12.9–14.2)	14.3 (13.6–15.0)	15.6 (14.9–16.4)	↑

(a) Rate of provision of clinical treatment for selected problem per 100 total encounters.

(b) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, § indicates a non-linear significant change, and — indicates there was no change.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5).

† Rates are reported to one decimal place. This indicates that the rate is < 0.05 per 100 encounters.

Note: CI—confidence interval. This table includes individual problems which had procedural treatments done at a rate of ≥ 0.5 per 100 encounters in any year, and any other statistically significant differences of interest.

11 Referrals and admissions

A referral is defined as the process by which the responsibility for part or all of the care of a patient is temporarily transferred to another health care provider. Only new referrals arising at the encounter were included (that is, continuations were not recorded). For each encounter, GPs could record up to two referrals. These included referrals to specialists, allied health professionals, hospitals for admission, emergency departments or other medical services. Referrals to hospital outpatient clinics and other GPs were classified as referrals to other medical services.

This chapter includes data about the referrals and admissions from each of the 10 years of the BEACH study from 1998–99 to 2007–08. The direction and type of change from 1998–99 to 2007–08 is indicated for each result in the far right column of the tables: \uparrow/\downarrow indicates a statistically significant linear change, \uparrow/\downarrow indicates a marginally significant linear change, \S indicates a non-linear significant change, and – indicates there was no change.

Significant linear changes can be extrapolated to estimate the national increase or decrease in referrals and admissions between 1998–99 and 2007–08. An example of an extrapolated change is given for each table. The method used to extrapolate to national change estimates is described in Chapter 2, Section 2.4.

Table 11.1 shows there was an increasing likelihood that the patient would be referred at the encounters (at 11.8% of encounters in 2007–08 compared with 10.6% in 1998–99), suggesting that the patient was referred to at least one other provider on about 1.75 million more occasions in 2007–08 than in 1998–99. There was a significant increase in the overall number of referrals per 100 encounters, from 11.1 in 1998–99 to 12.5 in 2007–08, reflecting both the increased likelihood of referral and a slight increase in the likelihood of multiple referrals at the encounter once the decision to refer has been made.

There was no overall increase in specialist referrals, but referral rates to cardiologists increased significantly and rates to dermatologists increased marginally.

The rate of referral to an allied health service has changed significantly since 1998–99, but not in a linear manner. It decreased from a referral rate of 3.0 per 100 encounters in 1998–99 to a low of 2.3 per 100 in 2001–02, and then steadily increased to 3.5 per 100 in 2007–08. The rate of referrals to physiotherapists, psychologists, podiatrist or chiropodists, and dietitians or nutritionists all significantly increased between 1998–99 and 2007–08.

In 2007–08 there were significantly fewer referrals/admissions to hospitals compared with 1998–99 but the numbers were very small in all years.

Table 11.1: The most frequent referrals, summary of annual results, BEACH, 1998–99 to 2007–08

Referral	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
At least one referral	10.6 (10.2–11.0)	10.4 (10.0–10.8)	9.9 (9.6–10.3)	10.0 (9.6–10.4)	10.6 (10.2–11.0)	11.0 (10.5–11.5)	10.9 (10.5–11.3)	11.3 (10.9–11.8)	11.5 (11.0–11.9)	11.8 (11.3–12.2)	↑
Medical specialist	7.4 (7.1–7.7)	7.3 (7.0–7.6)	7.4 (7.1–7.7)	7.3 (7.0–7.6)	7.7 (7.3–8.0)	7.9 (7.5–8.2)	7.7 (7.4–8.0)	8.2 (7.8–8.5)	8.0 (7.7–8.4)	8.0 (7.6–8.3)	§
Surgeon	0.8 (0.7–0.9)	0.8 (0.7–0.8)	0.7 (0.7–0.8)	0.8 (0.7–0.8)	0.7 (0.7–0.8)	0.8 (0.8–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.8)	0.8 (0.8–0.9)	0.8 (0.8–0.9)	—
Orthopaedic surgeon	0.6 (0.5–0.7)	0.7 (0.6–0.7)	0.7 (0.6–0.7)	0.7 (0.7–0.8)	0.8 (0.7–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.8 (0.7–0.8)	0.7 (0.6–0.7)	—
Dermatologist	0.5 (0.5–0.6)	0.6 (0.5–0.6)	0.6 (0.5–0.7)	0.6 (0.5–0.7)	0.6 (0.5–0.6)	0.6 (0.6–0.7)	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.6 (0.5–0.7)	0.7 (0.6–0.7)	↑
Ophthalmologist	0.7 (0.7–0.8)	0.7 (0.6–0.7)	0.7 (0.6–0.7)	0.8 (0.7–0.8)	0.7 (0.7–0.8)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.7 (0.6–0.7)	—
Cardiologist	0.4 (0.3–0.4)	0.4 (0.3–0.4)	0.4 (0.3–0.4)	0.4 (0.4–0.5)	0.4 (0.4–0.5)	0.5 (0.4–0.6)	0.5 (0.5–0.6)	0.6 (0.5–0.7)	0.6 (0.5–0.7)	0.5 (0.5–0.6)	↑
Ear, nose and throat	0.5 (0.5–0.6)	0.5 (0.4–0.5)	0.5 (0.5–0.6)	0.5 (0.5–0.6)	0.5 (0.5–0.6)	0.5 (0.5–0.6)	0.5 (0.5–0.6)	0.5 (0.4–0.5)	0.5 (0.4–0.6)	0.5 (0.5–0.6)	—
Gastroenterologist	0.4 (0.4–0.5)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.4 (0.3–0.5)	0.4 (0.4–0.5)	0.4 (0.4–0.5)	0.4 (0.3–0.4)	0.5 (0.5–0.6)	0.4 (0.4–0.5)	0.5 (0.4–0.6)	—
Gynaecologist	0.6 (0.5–0.6)	0.5 (0.5–0.6)	0.6 (0.5–0.6)	0.5 (0.5–0.6)	0.6 (0.6–0.7)	0.6 (0.5–0.6)	0.5 (0.5–0.6)	0.5 (0.5–0.6)	0.5 (0.5–0.6)	0.4 (0.4–0.5)	↓
Urologist	0.3 (0.3–0.4)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.3 (0.3–0.3)	0.3 (0.3–0.4)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.3–0.3)	↓
Neurologist	0.2 (0.2–0.2)	0.2 (0.2–0.2)	0.2 (0.2–0.2)	0.2 (0.2–0.2)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	↑
Psychiatrist	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	—

(continued)

Table 11.1 (continued): The most frequent referrals, summary of annual results, BEACH, 1998–99 to 2007–08

Referral	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Allied health service	3.0 (2.8–3.2)	3.1 (2.9–3.3)	2.3 (2.2–2.5)	2.3 (2.1–2.4)	2.5 (2.3–2.7)	2.6 (2.4–2.8)	2.7 (2.5–2.9)	2.9 (2.7–3.1)	3.1 (2.9–3.3)	3.5 (3.2–3.7)	§
Physiotherapy	0.9 (0.8–1.0)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	0.9 (0.8–1.0)	1.1 (0.9–1.2)	1.0 (0.9–1.1)	1.1 (0.9–1.1)	1.1 (1.0–1.3)	1.1 (1.0–1.2)	1.2 (1.1–1.3)	↑
Psychologist	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.4 (0.4–0.5)	0.7 (0.6–0.7)	↑
Podiatrist/chiropracist	0.2 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	↑
Dietitian/nutritionist	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.1)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.2)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	↑
Dentist	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	—
Audiologist/acoustic testing	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.0 [‡] (0.0–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.0 [‡] (0.0–0.0)	0.1 (0.1–0.1)	—
Optometrist	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.1–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	—
Breast clinic	NA ^v	0.0 [‡] (0.0–0.1)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.1)	0.1 (0.0–0.1)	0.0 [‡] (0.0–0.1)	0.0 [‡] (0.0–0.1)	0.0 [‡] (0.0–0.1)	0.1 (0.1–0.1)	—
Diabetes education	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.1 (0.0–0.1)	0.0 [‡] (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	—
Counsellor	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.1–0.1)	0.1 (0.0–0.1)	0.1 (0.1–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	—
Mental health team	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.0 [‡] (0.0–0.1)	—
Drug and alcohol	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.0 [‡] (0.0–0.0)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.1 (0.0–0.1)	0.0 [‡] (0.0–0.1)	0.0 [‡] (0.0–0.1)	0.1 (0.0–0.1)	—

(continued)

Table 11.1 (continued): The most frequent referrals, summary of annual results, BEACH, 1998–99 to 2007–08

Referral	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Hospital	0.7 (0.6–0.8)	0.7 (0.6–0.8)	0.5 (0.4–0.6)	0.4 (0.4–0.5)	0.6 (0.5–0.6)	0.6 (0.5–0.6)	0.5 (0.4–0.5)	0.4 (0.3–0.4)	0.4 (0.3–0.5)	0.4 (0.3–0.5)	↓
Emergency department	0.1 (0.0–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.3)	↑
Other referrals/other medical services ^(c)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.2 (0.1–0.2)	0.4 (0.3–0.4)	0.3 (0.2–0.3)	0.4 (0.4–0.5)	0.4 (0.4–0.5)	0.4 (0.3–0.4)	0.5 (0.5–0.6)	0.5 (0.4–0.6)	↑
Total referrals	11.1 (10.7–11.6)	11.1 (10.7–11.6)	10.4 (10.0–10.8)	10.5 (10.1–10.9)	11.1 (10.7–11.6)	11.6 (11.1–12.1)	11.5 (11.1–12.0)	12.0 (11.5–12.5)	12.2 (11.7–12.7)	12.5 (12.0–13.0)	↑

(a) Column will not add to 100, as multiple referrals could be written at each encounter.

(b) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, § indicates a non-linear significant or marginal change, and — indicates there was no change.

(c) Other referrals and other medical services have been reported together for comparability. The 'other medical services' group was introduced in 2003–04, previously these were grouped with 'other referrals'.

‡ Rates are reported to one decimal place. This indicates that the rate is < 0.05 per 100 encounters.

Note: CI—confidence interval; NAV—not available.

12 Investigations

The GPs participating in the study were asked to record (in free text) any pathology, imaging or other tests ordered or undertaken at the encounter, and to nominate the patient problem(s) associated with each test order placed. This allows the linkage of test orders to a single problem or multiple problems. Up to five orders for pathology and two for imaging and other tests could be recorded at each encounter. A single test may have been ordered for the management of multiple problems, and multiple tests may have been used in the management of a single problem.

A pathology test order may be for a single test (for example Pap smear, HbA1c) or for a battery of tests (for example lipids, full blood count). Where a battery of tests was ordered, the battery name was recorded rather than each individual test. GPs also recorded the body site for any imaging ordered (for example X-ray chest, CT head).

This chapter includes data about the investigations ordered or performed in general practice from each of the 10 years of the BEACH study from 1998–99 to 2007–08. The direction and type of change from 1998–99 to 2007–08 is indicated for each result in the far right column of the tables: \uparrow/\downarrow indicates a statistically significant linear change, \uparrow/\downarrow indicates a marginally significant linear change, \S indicates a non-linear significant or marginal change, and — indicates there was no change.

Significant linear changes can be extrapolated to estimate the national increase or decrease in investigations ordered or performed between 1998–99 and 2007–08 or between 2000–01 for pathology and imaging groups. An example of an extrapolated change is given for each table. The method used to extrapolate to national change estimates is described in Chapter 2, Section 2.4.

12.1 Number of encounters where pathology or imaging was ordered

Table 12.1 shows there has been a significant increase in the proportion of encounters at which pathology and/or imaging was ordered, from 18.1% in 1998–99 to 23.4% in 2007–08, equating to an increase of almost 6.5 million encounters at which tests were ordered in 2007–08. The likelihood of ordering at least one pathology test increased from 13.2% of encounters in 1998–99 to 17.4% in 2007–08, which is just over 5 million additional encounters at which pathology was ordered in 2007–08. The proportion of encounters generating imaging orders increased from 6.3% in 1998–99 to 8.3% in 2007–08, resulting in an estimated 2.4 million more encounters nationally at which imaging was ordered in 2007–08.

12.2 Pathology test orders by MBS groups

Table 12.2 shows the changes in the total number of pathology test orders, and in the distribution of these by MBS pathology groups. These can only be compared from 2000–01 onwards because of the change in coding method introduced in 2000–01 (see Chapter 2). The number of tests ordered increased from 29.7 tests (or battery of tests) per 100 encounters in

2000–01 to 43.2 in 2007–08, which extrapolates to approximately 16.3 million more test orders in 2007–08 than in 2000–01 nationally.

The largest increase was in orders for chemical pathology, which increased from 15.6 per 100 encounters in 2000–01 to 24.9 in 2007–08. This extrapolates to an estimated 10.9 million additional chemistry test orders in 2007–08 than 8 years earlier. Haematology increased at a slower rate, rising from 5.8 tests per 100 encounters in 2000–01 to 7.9 in 2007–08, a national increase of approximately 2.6 million tests. Microbiology test orders increased from 4.6 per 100 encounters in 2000–01 to 5.7 in 2007–08, extrapolating to an increase of about 1.5 million additional test orders in 2007–08. There were far smaller increases in order rates for tissue pathology, immunology and simple tests, and no increases in the other test groups.

As shown in Figure 12.1, both the likelihood of ordering pathology and the total number of tests ordered have significantly increased over the 8 years to 2007–08. However, the growth in the number of tests/batteries ordered has been larger than the growth in likelihood of ordering, because the number of tests ordered, once a decision to order has been made, has increased from an average of 2.15 tests/batteries per tested encounter to 2.49.




Figure 12.1: Encounters where pathology was ordered, and pathology test order rates per 100 encounters, 1998–99 to 2007–08 (95% CI)

Note: CI—confidence interval. Data collection method and coding system changed in 2000–01. Data from 1998–99 and 1999–00 are not comparable with data from 2000–01 to 2007–08 in regard to pathology test orders.

12.3 Imaging test orders by MBS group

Table 12.3 shows the changes in imaging orders by imaging group from 2000–01 to 2007–08. The first 2 years of imaging data cannot be compared with subsequent years because of coding changes introduced in 2000.

Total test orders increased significantly from 7.7 per 100 encounters in 2000–01 to 9.5 in 2007–08, suggesting a national increase of just over 2.4 million encounters generating an order for imaging. Ultrasound imaging increased from 2.1 tests per 100 encounters in 2000–01 to 3.4 per 100 in 2007–08, a national increase of over 1.5 million encounters with ultrasound orders. Computerised tomography increased from 0.7 per 100 encounters in 2000–01 to 1.2 in 2007–08, equating to 580,000 encounters. Magnetic resonance imaging increased from less than 0.05 per 100 encounters in 2000–01 to 0.1 in 2007–08. Diagnostic radiology and nuclear medicine imaging order rates did not change significantly during this period.

Table 12.1: Number of encounters for which pathology or imaging was ordered, summary of annual results, BEACH, 1998–99 to 2007–08

Test ordered	Per cent of encounters (95% CI)										↑ ^(a) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
At least one test ordered	18.1 (17.5–18.7)	18.9 (18.3–19.5)	19.3 (18.7–19.9)	19.2 (18.6–19.8)	20.3 (19.7–21.0)	20.8 (20.1–21.5)	21.2 (20.6–21.8)	22.1 (21.4–22.7)	23.0 (22.3–23.7)	23.4 (22.7–24.1)	↑
At least one pathology test ordered	13.2 (12.8–13.7)	13.8 (13.3–14.3)	13.8 (13.3–14.3)	14.0 (13.5–14.5)	14.7 (14.2–15.3)	15.5 (14.9–16.1)	15.7 (15.2–16.3)	16.4 (15.8–16.9)	17.4 (16.8–18.0)	17.4 (16.7–18.0)	↑
At least one imaging test ordered	6.3 (6.0–6.6)	6.7 (6.4–7.0)	6.8 (6.5–7.1)	6.9 (6.6–7.2)	7.5 (7.1–7.8)	7.2 (6.9–7.5)	7.3 (7.0–7.6)	7.8 (7.4–8.1)	7.9 (7.6–8.2)	8.3 (8.0–8.6)	↑

(a) The direction and type of change from 1998–99 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change.

Note: CI—confidence interval.

Table 12.2: Distribution of pathology orders across pathology groups, summary of annual results, BEACH, 2000–01 to 2007–08

Pathology test ordered	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,804)	2007–08 (n = 95,898)	
Chemistry*	NAv	NAv	15.6 (14.8–16.5)	16.5 (15.6–17.3)	17.7 (16.8–18.6)	19.1 (18.1–20.1)	20.4 (19.5–21.4)	21.8 (20.6–22.9)	24.5 (23.3–25.7)	24.9 (23.6–26.2)	↑
Haematology*	NAv	NAv	5.8 (5.5–6.1)	6.2 (5.8–6.5)	6.3 (5.9–6.6)	6.8 (6.4–7.2)	7.0 (6.6–7.3)	7.3 (6.9–7.7)	7.9 (7.5–8.3)	7.9 (7.5–8.3)	↑
Microbiology*	NAv	NAv	4.6 (4.3–4.9)	4.9 (4.5–5.2)	5.1 (4.8–5.5)	5.3 (4.9–5.7)	5.2 (4.9–5.6)	5.6 (5.2–5.9)	5.9 (5.4–6.3)	5.7 (5.3–6.0)	↑
Cytology*	NAv	NAv	1.5 (1.3–1.7)	1.6 (1.4–1.7)	1.7 (1.5–1.8)	1.8 (1.5–2.0)	1.6 (1.5–1.8)	1.7 (1.6–1.9)	1.7 (1.5–1.9)	1.9 (1.7–2.1)	↑
Other NEC*	NAv	NAv	0.8 (0.7–0.9)	0.7 (0.6–0.8)	0.8 (0.6–0.9)	0.8 (0.7–0.9)	0.8 (0.7–1.0)	0.7 (0.6–0.8)	0.8 (0.7–1.0)	1.0 (0.8–1.2)	—
Tissue pathology*	NAv	NAv	0.5 (0.4–0.5)	0.5 (0.4–0.6)	0.5 (0.4–0.6)	0.7 (0.5–0.8)	0.8 (0.6–0.9)	0.6 (0.5–0.7)	0.7 (0.6–0.8)	0.8 (0.6–0.9)	↑
Immunology*	NAv	NAv	0.5 (0.4–0.6)	0.5 (0.4–0.5)	0.5 (0.4–0.5)	0.5 (0.4–0.5)	0.5 (0.4–0.6)	0.6 (0.5–0.7)	0.6 (0.5–0.7)	0.7 (0.6–0.7)	↑
Infertility/pregnancy*	NAv	NAv	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.3 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.2–0.3)	0.2 (0.1–0.2)	—
Simple test; other*	NAv	NAv	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.2 (0.1–0.2)	0.2 (0.1–0.2)	↑
Total pathology tests	NAv	NAv	29.7 (28.4–30.9)	31.0 (29.7–32.4)	32.9 (31.5–34.4)	35.2 (33.7–36.7)	36.7 (35.2–38.2)	38.6 (36.9–40.3)	42.4 (40.7–44.2)	43.2 (41.3–45.0)	↑

(a) Data collection method and coding system changed at the end of the second year of BEACH. Years 1 and 2 are not comparable with years 3 to 10 in regard to pathology groups.

(b) The direction and type of change from 2000–01 to 2007–08 is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginal change, and — indicates there was no change.

* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 5).

Note: CI—confidence interval; NAv—not available; NEC—not elsewhere classified.

Table 12.3: Most frequent imaging tests ordered, summary of annual results, BEACH, 1998–99 to 2007–08

Imaging test ordered	Rate per 100 encounters ^(a) (95% CI)										↑ ^(b) ↓
	1998–99 (n = 96,901)	1999–00 (n = 104,856)	2000–01 (n = 99,307)	2001–02 (n = 96,973)	2002–03 (n = 100,987)	2003–04 (n = 98,877)	2004–05 (n = 94,386)	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)	
Diagnostic radiology*	NAv	NAv	4.7 (4.5–5.0)	4.5 (4.3–4.7)	5.0 (4.8–5.3)	4.6 (4.3–4.8)	4.5 (4.3–4.7)	4.8 (4.5–5.0)	4.6 (4.4–4.8)	4.8 (4.6–5.0)	—
Ultrasound*	NAv	NAv	2.1 (2.0–2.3)	2.5 (2.3–2.6)	2.6 (2.5–2.8)	2.7 (2.5–2.8)	2.7 (2.5–2.8)	2.9 (2.7–3.1)	3.2 (3.0–3.3)	3.4 (3.2–3.5)	↑
Computerised tomography*	NAv	NAv	0.7 (0.6–0.7)	0.8 (0.7–0.8)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	1.0 (0.9–1.1)	1.0 (0.9–1.1)	1.1 (1.0–1.2)	1.2 (1.1–1.3)	↑
Nuclear medicine imaging*	NAv	NAv	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	—
Magnetic resonance imaging*	NAv	NAv	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.0)	0.0 [‡] (0.0–0.1)	0.0 [‡] (0.0–0.0)	0.1 (0.0–0.1)	0.0 [‡] (0.0–0.1)	0.1 (0.1–0.1)	↑
Total imaging tests	NAv	NAv	7.7 (7.3–8.0)	7.9 (7.6–8.2)	8.6 (8.2–9.0)	8.2 (7.8–8.6)	8.3 (8.0–8.6)	8.8 (8.4–9.2)	9.0 (8.6–9.3)	9.5 (9.2–9.9)	↑

(a) Data collection method and coding system changed at the end of the second year of BEACH. Years 1 and 2 are not comparable with years 3 to 10 in regard to imaging groups.

(b) The direction and type of change from 2000–01 to 2007–08 for imaging is indicated for each result: ↑/↓ indicates a statistically significant change and — indicates there was no change.

‡ Rates are reported to one decimal place. This indicates that the rate is < 0.05 per 100 encounters.

* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 5).

Note: CI—confidence interval; NAv—not available.

13 Practice nurse activity

This section investigates changes in the activities of practice nurses in association with the GP-patient encounters, for the years 2005–06, 2006–07 and 2007–08.

In November 2004, four Medicare item numbers were introduced into the MBS that allowed GPs to claim for specified tasks undertaken by a practice nurse under the direction of the GP. The recording form for the 2005–06 BEACH year was amended to allow the capture of this information.

- GPs were allowed to record multiple (up to three) Medicare item numbers where appropriate, rather than be limited to one item number.
- In the 'other treatments' section, for each problem managed, GPs were asked to tick the 'practice nurse' box if the treatment recorded was provided by the practice nurse rather than by the GP. If the box was not ticked it was assumed that the GP gave the 'other treatment'.

The survey form allowed GPs to record up to two other treatments for each problem managed at the encounter. Other treatments include all clinical and procedural treatments provided at the encounters. These groups are defined in Appendix 5.

In November 2007, a new Medicare item number was added for practice nurse services. This item, 10997, was only available to BEACH 2007–08 participants between November 2007 and March 2008 inclusive. The seven practice nurse Medicare items available during the 2007–08 BEACH data period are listed with a short description in Table 13.1.²¹

This section investigates changes in:

- the distribution of the Medicare items claimed for practice nurses
- treatments provided by practice nurses in association with the GP-recorded encounter
- problems for which the practice nurse provided the treatment in direct association with the GP-recorded encounters.

In Chapter 10, all treatments (other than medications) recorded by the GPs were reported, irrespective of whether they were provided by the GP or by a practice nurse. As in previous years, injections recorded in the provision of immunisations and vaccinations were not included, as these are already counted as pharmacological management. In contrast, this section, being a description of practice nurse activity, reports only the activities indicated as being conducted by a practice nurse and includes the injections for immunisation/vaccination that were not counted in Chapter 10. GPs are also instructed not to record their taking of routine clinical measurements, such as blood pressure. However, where the practice nurse undertook these activities at the consultation, and it was recorded as a practice nurse activity, they have been included in the analysis in this chapter.

When viewing these results, it must be remembered that these practice nurse data will not include activities undertaken by the practice nurse during the GP's BEACH recording period that were outside (not associated with) the recorded encounter. Such activities could include Medicare-claimable activities (for example, immunisations/vaccinations) provided under instruction from the GP but not at the time of the encounter, or provision of other services not currently claimable from Medicare (for example, dietary advice to an individual or in a group situation).

13.1 Practice nurse activity at GP–patient encounters

Encounters involving the practice nurse as a proportion of all recorded encounters increased significantly from 3.9% in 2005–06 to 6.0% in 2007–08. The number of problems for which the practice nurse was involved in the care provided at the encounter also increased significantly between 2005–06 (2.8%) and 2007–08 (4.1%). However, of those encounters at which the practice nurse activity was specified, the proportion said to be claimable from Medicare, remained constant over the 3 years, at about 35% (Table 13.1).

Extrapolation of these results to national Medicare claims for these years suggests that in 2007–08, practice nurses were actively involved in provision of care at 6.4 million encounters, 2.2 million more than in 2005–06. However, Medicare data suggest there were about 1.35 million more practice nurse items claimed in 2007–08 than in the 2005–06 financial year.⁵ These results suggest that at GP–patient encounters practice nurses are providing a considerable amount of care that cannot be claimed from Medicare.

Table 13.1: Summary of practice nurse involvement at encounter, and claims made, BEACH, 2005–06 to 2007–08

Variable	2005–06	2006–07	2007–08
Total encounters (<i>n</i>)	101,993	91,805	95,898
Number of encounters involving practice nurse (<i>n</i>)	4,013	4,710	5,712
Encounters involving the practice nurse as a proportion of total encounters (95% CI)	3.9% (3.5–4.4)	5.1% (4.5–5.7)	6.0% (5.4–6.5)
Extrapolated national estimated number of GP–patient encounters involving practice nurse (<i>n</i>)	3.9 million	5.3 million	6.4 million
Total problems managed (<i>n</i>)	149,088	136,333	145,078
Problems managed with practice nurse involvement	4,110	4,922	5,909
Problems involving the practice nurse as a proportion of total problems (95% CI)	2.8% (2.4–3.1)	3.6% (3.2–4.1)	4.1% (3.7–4.5)
Number of practice nurse items recorded (<i>n</i>)	1,696	1,835	2,073
Number of encounters at which 1 or more practice nurse item numbers were claimable (<i>n</i>)	1,696	1,823	2,047
Practice nurse claimable encounters as a proportion of total encounters	1.7%	2.0%	2.1%
Proportion of encounters involving practice nurse that were claimable from Medicare (95% CI)	34.9% (30.6–38.9)	37.5% (33.2–41.7)	35.8% (31.5–37.8)

Note: CI—confidence interval.

13.2 Distribution of practice nurse item numbers claimed at encounters

The number of practice nurse item numbers claimed per 100 GP–patient encounters increased from 1.7 per 100 in 2005–06 to 2.1 (Table 13.1) per 100 in 2007–08, but this did not constitute a statistically significant change. Extrapolation of these results suggests that the BEACH sample represent about 1.7 million claimed practice nurse items in 2005–06 and about 2.2 million in 2007–08. Medicare data show there were 3.2 million such claims in 2005–06 and 4.6 million in 2007–08. In turn, this suggests that the BEACH samples represent about 50% of the practice nurse activity claimed from Medicare in these years⁵, and that the

other 50% of services claimed for the practice nurse were conducted independently of the recorded consultation.

The distribution of practice nurse item numbers claimed for work associated with the BEACH encounters changed little; about two-thirds accounted for by immunisation/vaccination and about one-third by wound treatment, in each of the 3 data years. The combined uptake of all cervical smear items numbers did increase, from 0.5 in 2004–05 to 0.9 in 2007–08 (Table 13.2).

Table 13.2: Distribution of practice nurse item numbers recorded at encounter

Medicare item number	Short descriptor	Per cent of total (95% CI)		
		2005–06 (n = 1,696)	2006–07 (n = 1,835)	2007–08 (n = 2,073)
10993	Immunisation	69.5 (63.8–75.3)	66.8 (61.5–72.2)	64.1 (59.6–68.6)
10994 ^(a)	Cervical smear and preventive checks	N/A	0.2 (0.0–0.5)	0.2 (0.0–0.4)
10995 ^(a)	Cervical smear and preventive checks—women 20–69 years, no smear in past 4 years	N/A	0.1 (0.0–0.2)	0.1 (0.0–0.2)
10996	Wound treatment (other than normal aftercare)	30.0 (24.3–35.7)	32.6 (27.2–40.0)	34.4 (30.0–38.8)
10997 ^(b)	Service provided to a person with a chronic disease by a practice nurse or registered Aboriginal Health Worker	N/A	N/A	0.7 (0.2–1.2)
10998 ^(c)	Cervical smear	0	0.1 (0.0–0.3)	0.3 (0.2–0.5)
10999 ^(c)	Cervical smear—women 20–69 years, no smear in past 4 years	0.5 (0.0–0.9)	0.2 (0.0–0.4)	0.3 (0.0–0.8)
Total practice nurse item numbers—rate per 100 total encounters		1.5 (1.2–1.8)	1.9 (1.6–2.2)	2.0 (1.7–2.2)

(a) Item number introduced in November 2006.

(b) Item number introduced in November 2007.

(c) Item numbers introduced in November 2004, but broadened in 2006, so they are not limited to services in rural areas.

Note: N/A—Not applicable.

13.3 Treatments provided by practice nurses

The number of procedures involving practice nurses at encounters rose significantly, from 3.6 per 100 encounters in 2005–06 to 5.5 per 100 in 2007–08. Extrapolation to national estimates suggest that practice nurses were involved in procedural work on about 5.9 million occasions nationally in 2007–08. However, their activities in the areas of other investigations and provision of clinical treatments (such as advice and health education) at the GP–patient encounters remained infrequent (Table 13.3).

Table 13.3: Summary of treatments provided by practice nurse

Treatment	Per cent of each activity that was performed/assisted by the practice nurse (95% CI)			Rate per 100 encounters (95% CI)		
	2005–06	2006–07	2007–08	2005–06 (n = 101,993)	2006–07 (n = 91,805)	2007–08 (n = 95,898)
Procedural treatments ^(a)	21.7 (19.2–24.1)	27.1 (24.5–29.8)	28.9 (26.7–31.2)	3.6 (3.1–4.1)	4.7 (4.1–5.3)	5.5 (5.1–6.1)
Clinical treatments	0.7 (0.5–0.9)	1.5 (0.9–2.2)	1.3 (1.0–1.6)	0.2 (0.1–0.3)	0.5 (0.3–0.6)	0.5 (0.4–0.6)
Other investigations	39.7 (33.8–45.7)	42.1 (35.9–48.4)	41.5 (35.6–47.4)	0.4 (0.3–0.5)	0.5 (0.4–0.6)	0.5 (0.1–0.7)
All other treatments	9.0 (7.9–10.1)	11.8 (10.4–13.2)	11.9 (10.8–13.0)	4.2 (3.7–4.8)	5.7 (4.9–6.4)	6.5 5.9–7.2)

(a) Procedural treatments here include all injections for immunisations/vaccinations. These are not included in the summary of the content of encounter in Table 5.1, summary of management in Table 8.1 or in the analyses of other treatments in Chapter 10, because the immunisation/vaccination is already counted as a prescription or GP-supplied medication.

13.4 Individual treatments most frequently involving practice nurses

In terms of procedural treatments, increases were apparent in two specific areas: check-ups and INR blood tests. In 2005–06, these two actions could not be coded by the data entry staff as specific procedures. In 2006–07 such codes were introduced as possible practice nurse activities in response to the data recorded by the GPs in 2005–06. In 2007–08, practice nurses-conducted check-ups were recorded at a rate of 6.1 per 100 practice nurse encounters (or 0.36 per 100 total GP-patient encounters) suggesting an extrapolated figure of about 360,000 check-ups conducted by practice nurses nationally.

In the area of clinical treatments only one treatment demonstrated significant change in its rate between 2005–06 and 2007–08. Administrative procedures/documentation events by practice nurses at GP-patient encounters more than doubled between 2005–06 and 2007–08.

Table 13.4: Most frequent treatments provided by practice nurses

Treatment	Rate per 100 encounters involving practice nurse ^(a) (95% CI)		
	2005–06 (n = 4,013)	2006–07 (n = 4,710)	2007–08 (n = 5,712)
Procedural treatments	92.0 (89.5–94.4)	91.3 (88.5–94.1)	93.2 (91.5–94.8)
Local injection/infiltration*	41.0 (36.6–45.4)	37.3 (33.0–41.6)	37.7 (34.7–40.7)
Dressing/pressure/compression/tamponade*	23.7 (21.3–26.2)	22.4 (19.8–24.9)	20.7 (18.7–22.8)
Incision/drainage/flushing/aspiration/removal body fluid*	8.1 (6.2–10.0)	8.8 (6.7–11.0)	6.8 (5.6–7.9)
Check-up—practice nurse*	NAv	4.0 (2.3–5.6)	6.1 (4.8–7.4)
Repair/fixation-suture/cast/prosthetic device (apply/remove)*	6.4 (5.0–7.8)	6.0 (5.0–7.0)	5.0 (4.2–5.7)
INR test	NAv	1.8 (1.0–2.6)	4.9 (3.6–6.2)
Excision/removal tissue/biopsy/destruction/debride/cauterise*	7.4 (5.6–9.2)	5.7 (4.2–7.2)	4.9 (3.8–5.9)
Urine test*	1.4 (0.8–2.0)	1.4 (0.8–2.0)	2.1 (1.3–3.0)
Other procedures/minor surgery NEC*	0.9 (0.5–1.3)	1.0 (0.7–1.4)	1.5 (1.0–2.0)
Glucose test	0.7 (0.3–1.1)	1.0 (0.4–1.5)	1.0 (0.7–1.3)
Physical medicine/rehabilitation*	0.9 (0.4–1.5)	0.6 (3–0.9)	0.6 (0.2–1.1)
Pregnancy test*	0.3 (0.1–0.6)	0.3 (0.1–0.5)	0.5 (0.3–0.8)
Pap smear	0.3 (0.0–0.6)	0.6 (0.2–0.9)	0.5 (0.3–0.8)
Clinical treatments	5.2 (3.7–6.7)	8.9 (5.6–12.1)	7.7 (6.2–9.2)
Other admin/document*	0.7 (0.4–1.0)	1.1 (0.7–1.6)	2.0 (1.4–2.6)
Advice/education*	0.9 (0.4–1.3)	1.5 (0.6–2.4)	1.4 (0.8–2.1)
Advice/education—treatment*	0.2 (0.1–0.4)	0.9 (0.5–1.3)	0.6 (0.4–0.8)
Counselling—problem*	0.9 (0.2–1.5)	0.8 (0.3–1.3)	0.6 (0.3–0.8)
Counselling/advice—nutrition/weight*	0.6 (0.2–0.9)	1.2 (0.2–2.1)	0.5 (0.1–0.9)
Other investigations	10.3 (8.3–12.2)	10.0 (7.8–12.2)	9.1 (7.5–10.8)
Electrical tracings*	5.4 (4.1–6.7)	4.5 (3.7–5.2)	5.2 (4.3–6.1)
Physical function tests*	3.9 (2.6–5.3)	4.3 (2.8–5.7)	3.5 (2.3–4.7)
All practice nurse activities at the encounter	107.4 (105.0–108.9)	110.2 (107.7–112.8)	110.0 (108.4–111.6)

(a) Figures do not total 100, as more than one treatment can be performed by a practice nurse at each encounter, and only those individual treatments accounting for $\geq 0.5\%$ of total treatments by practice nurse are included.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5).

Note: CI—confidence interval; NEC—not elsewhere classified; NAv—data not available; INR—International Normalised Ratio blood test.

13.5 Problems managed with practice nurse involvement

The problems managed most often with the assistance of a practice nurse in association with the consultation were immunisation/vaccination, followed by laceration/cut, chronic skin ulcer, diabetes, and general check-up. There was little change in the rate of nurse involvement in most problems managed. The exception was their work associated with atrial fibrillation/flutter. Nurses were involved in the management of this problem at more than twice the rate in 2007–08 than in 2005–06. This increase in activity is clearly related to the increase in the number of INR tests (noted above) over the same period, as these tests are used for patients taking warfarin, usually those with atrial fibrillation (Table 13.5).

Table 13.5: The most common problems managed with the involvement of practice nurse

Problem managed	Rate per 100 encounters involving practice nurse (95% CI) ^(a)		
	2005–06 (n = 4,013)	2006–07 (n = 4,710)	2007–08 (n = 5,712)
Immunisation/vaccination—all*	30.9 (26.9–34.9)	30.8 (26.5–35.0)	29.5 (26.7–32.2)
Laceration/cut	6.4 (5.0–7.8)	6.2 (5.2–7.2)	6.0 (5.0–7.0)
Chronic ulcer skin (including varicose ulcer)	6.8 (5.6–8.0)	6.0 (4.9–7.1)	4.7 (3.7–5.6)
General check-up*	2.5 (1.7–3.3)	3.1 (2.2–3.9)	4.3 (3.1–5.4)
Diabetes—all*	1.7 (1.0–2.4)	2.5 (1.8–3.1)	3.0 (2.4–3.7)
Atrial fibrillation/flutter	1.2 (0.6–1.7)	1.4 (0.8–2.0)	2.8 (2.0–3.6)
Excessive ear wax	2.2 (1.6–2.9)	3.0 (2.4–3.6)	2.8 (2.2–3.4)
Malignant neoplasm skin	3.2 (2.3–4.2)	2.9 (2.1–3.8)	2.6 (1.8–3.3)
Hypertension*	1.1 (0.6–1.5)	1.6 (1.0–2.2)	1.8 (1.2–2.3)
Skin infection, post-traumatic	1.8 (1.3–2.3)	1.7 (1.2–2.2)	1.6 (1.0–2.1)
Asthma	1.5 (1.0–2.0)	2.3 (1.6–3.0)	1.2 (0.9–1.6)
Abrasion/scratch/blister	1.2 (0.7–1.6)	0.7 (0.4–1.0)	1.2 (0.6–1.7)
Repair/fixate-suture/cast/prosthetic device (apply/remove)	1.2 (0.7–1.8)	1.2 (0.7–1.6)	1.1 (0.8–1.5)
Burns/scalds	0.9 (0.5–1.3)	1.2 (0.8–1.7)	1.1 (0.8–1.4)
Skin complaint	1.2 (0.7–1.7)	1.2 (0.8–1.7)	1.0 (0.7–1.3)
Contraception, other than oral	1.1 (0.6–1.5)	0.5 (0.3–0.8)	0.9 (0.6–1.2)
Fracture	1.1 (0.7–1.5)	1.0 (0.6–1.5)	0.8 (0.5–1.0)
Injury skin NEC	1.0 (0.6–1.4)	0.6 (0.3–0.9)	0.4 (0.2–0.6)
Total problems	102.4 (101.7–103.2)	104.5 (103.3–105.8)	103.4 (102.7–104.2)

(a) Rate of nurse provision of treatment for selected problem per 100 encounters.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5).

Note: CI—confidence interval; incl—including; NEC—not elsewhere classified.

14 Patient risk factors

General practice is a useful intervention point for health promotion because about 88% of Australians visit a GP at least once each year.⁴ GPs, through ongoing professional education, have substantial knowledge of population health, screening programs and other interventions. They are also in an ideal position to advise patients about the benefits of health screening, and to counsel patients about their lifestyle choices on an individual basis.

Since April 1998, a section on the bottom of each encounter form has been used to investigate aspects of patient health or health care delivery not covered by general practice consultation-based information. These additional substudies are referred to as SAND (Supplementary Analysis of Nominated Data). The SAND methods are described in Appendix 1.

The patient risk factors measured include self-reported height and weight (for calculation of body mass index, BMI), alcohol consumption and smoking status. Patient risk factors are investigated for a subsample of 40 of the 100 patient encounters recorded by each GP. An example of the encounter form with the patient risk factor SAND questions is included in Appendix 3. The methods used for investigating patient risk factors are described in Appendix 2.

Summaries of results from all SAND substudies from April 1999 to July 2006 inclusive have been published in *Patient-based substudies from BEACH: abstracts and research tools 1999–2006*.²² Abstracts of results and the research tools used in SAND substudies conducted from August 2006 to March 2007 were published in *General practice activity in Australia 2006–07*³ and those conducted from April 2007 to January 2008 are included in *General practice activity in Australia 2007–08*.⁷

This chapter includes data about the risk behaviours of general practice patients from each of the 10 years of the BEACH study from 1998–99 to 2007–08. The direction and type of change from 1998–99 to 2007–08 is indicated for each result in the far right column of the tables:

↑/↓ indicates a statistically significant linear change, ↑/↓ indicates a marginally significant linear change, § indicates a non-linear significant or marginal change, and – indicates there was no change.

The results of the patient risk factors body mass index (BMI), alcohol consumption and smoking status are presented in tables 14.1 to 14.3 for each year from 1998–99 to 2007–08. These are also graphically summarised in figures 14.1 to 14.5.



14.1 Body mass index

Adults

There has been a significant increase in the prevalence of overweight and obesity in adults attending general practice, from 32.8% and 18.3%, respectively, in 1998–98 to 35.4% and 23.9% in 2007–08 (Table 14.1; Figure 14.1). The significant increase of overweight and obesity are apparent in both male and female patients. The increase is largely due to an increase in prevalence of obesity; rates of overweight increased but by a much smaller amount (tables 14.2 and 14.3; figures 14.2 and 14.3).

Children

In contrast, the rates of overweight and obesity in children aged 2–17 years have remained static over from 1998–99 to 2007–08, with about 11% of children being obese and about 17% overweight (Table 14.1).







Figure 14.3: Rates of overweight and obesity among female adults (aged 18 years and over), 1998-99 to 2007-08

14.2 Smoking

There has been a significant decrease in the rates of current daily and occasional smoking in all adults aged 18 years and over, from 19.2% and 5.6%, respectively, in 1998–99 to 16.5% and 2.9% in 2007–08 (Table 14.1). This decrease was apparent in both male and female patients (tables 14.2 and 14.3; Figure 14.4).



14.3 Alcohol consumption

The rates of at-risk levels of alcohol consumption among adults attending general practice have remained static at 26–27% of adult patients from 2001–02 to 2007–08 (Table 14.1; Figure 14.5).




Table 14.1: Comparative results for all patient risk factors, summary of annual results, BEACH, 1998–99 to 2007–08

Risk factor	Per cent (95% CI)										↑ ^(a) ↓
	1998–99	1999–00	2000–01	2001–02	2002–03	2003–04	2004–05	2005–06	2006–07	2007–08	
Adults (aged 18 years and over)											
BMI class^(b) (n)	(30,485)	(33,069)	(31,957)	(31,789)	(32,367)	(31,890)	(30,476)	(33,101)	(32,334)	(31,062)	
Obese	18.3 (17.7–18.9)	19.4 (18.8–20.0)	20.2 (19.5–20.8)	21.5 (20.8–22.2)	20.9 (20.2–21.5)	22.1 (21.4–22.7)	22.4 (21.7–23.2)	22.2 (21.5–22.9)	23.5 (22.7–24.2)	23.9 (23.1–24.6)	↑
Overweight	32.8 (32.1–33.4)	33.1 (32.5–33.8)	34.1 (33.4–34.7)	33.5 (32.9–34.1)	33.8 (33.2–34.5)	34.5 (33.8–35.1)	34.6 (33.9–35.2)	34.6 (33.9–35.2)	35.0 (34.3–35.6)	35.4 (34.7–36.0)	↑
Normal	45.5 (44.7–46.4)	44.3 (43.5–45.1)	42.8 (42.0–43.7)	42.1 (41.3–42.9)	42.4 (41.6–43.3)	40.7 (39.9–41.6)	40.3 (39.5–41.2)	40.5 (39.7–41.4)	39.0 (38.1–39.8)	38.3 (37.4–39.2)	↓
Underweight	3.4 (3.1–3.6)	3.2 (3.0–3.5)	2.9 (2.7–3.1)	3.0 (2.8–3.2)	2.9 (2.7–3.1)	2.8 (2.6–3.0)	2.7 (2.5–2.9)	2.8 (2.5–3.0)	2.6 (2.4–2.8)	2.5 (2.3–2.7)	↓
Smoking status (n)	(30,265)	(32,483)	(32,124)	(31,966)	(32,651)	(32,718)	(31,295)	(33,558)	(31,176)	(31,652)	
Daily	19.2 (18.4–20.0)	18.9 (18.1–19.6)	19.3 (18.5–20.1)	18.4 (17.7–19.2)	17.2 (16.5–17.9)	17.6 (16.8–18.3)	18.0 (17.2–18.7)	17.1 (16.3–17.8)	16.1 (15.4–16.9)	16.5 (15.8–17.3)	↓
Occasional	5.6 (5.2–6.0)	5.2 (4.9–5.6)	4.4 (4.0–4.7)	4.1 (3.8–4.4)	4.1 (3.8–4.4)	4.3 (4.0–4.7)	3.7 (3.4–4.0)	3.6 (3.4–3.9)	3.2 (2.9–3.4)	2.9 (2.7–3.2)	↓
Previous	27.0 (26.2–27.8)	27.1 (26.3–27.8)	27.3 (26.5–28.1)	27.8 (27.0–28.6)	27.2 (26.5–28.0)	28.0 (27.3–28.8)	28.0 (27.2–28.8)	27.1 (26.3–27.8)	28.8 (28.0–29.6)	27.9 (27.1–28.6)	—
Never	48.2 (47.2–49.2)	48.8 (47.9–49.7)	49.1 (48.1–50.1)	49.7 (48.7–50.7)	51.4 (50.4–52.4)	50.1 (49.1–51.0)	50.3 (49.4–51.3)	52.3 (51.3–53.2)	51.9 (50.9–52.9)	52.7 (51.7–53.6)	↑
Alcohol consumption^(c) (n)	(31,559)	(32,140)	(31,721)	(30,414)	(32,753)	(30,347)	(30,796)	
At-risk alcohol level	NAv	NAv	NAv	26.0 (25.1–26.8)	26.2 (25.3–27.1)	26.7 (25.8–27.6)	26.4 (25.5–27.3)	25.9 (25.0–26.8)	27.0 (26.1–28.0)	26.2 (25.3–27.1)	—
Responsible drinker	NAv	NAv	NAv	44.1 (43.3–45.0)	44.2 (43.4–45.1)	44.9 (44.1–45.8)	44.9 (44.0–45.7)	44.8 (44.0–45.7)	44.6 (43.7–45.5)	44.6 (43.7–45.5)	—
Non-drinker	NAv	NAv	NAv	29.9 (28.9–30.9)	29.5 (28.5–30.6)	28.4 (27.3–29.4)	28.7 (27.7–29.8)	29.3 (28.2–30.4)	28.3 (27.3–29.4)	29.3 (28.2–30.3)	—

(continued)

Table 14.1 (continued): Comparative results for all patient risk factors, summary of annual results, BEACH, 1998–99 to 2007–08

Risk factor	Per cent (95% CI)										↑ ^(a) ↓
	1998–99	1999–00	2000–01	2001–02	2002–03	2003–04	2004–05	2005–06	2006–07	2007–08	
Children (aged 2–17 years)^(d) (n)	(4,019)	(4,053)	(3,610)	(3,518)	(3,380)	(3,189)	(3,018)	(3,338)	(3,087)	(3,046)	—
Obese	11.0 (9.8–12.1)	10.4 (9.3–11.5)	11.4 (10.1–12.6)	10.9 (9.7–12.1)	11.9 (10.5–13.2)	11.8 (10.5–13.2)	10.8 (9.5–12.2)	10.9 (9.7–12.1)	10.6 (9.3–11.9)	11.2 (10.0–12.5)	—
Overweight	17.1 (15.9–18.4)	17.4 (16.3–18.6)	17.8 (16.5–19.2)	17.9 (16.5–19.3)	18.3 (16.9–19.6)	19.2 (17.7–20.7)	17.7 (16.3–19.1)	17.9 (16.5–19.2)	18.6 (17.2–20.0)	17.1 (15.7–18.5)	—

(a) The direction and type of change is indicated for each result: ↑/↓ indicates a statistically significant change, and — indicates there was no change.

(b) Adult patients aged 18+ with a recorded height outside the ABS height range based on age and sex were excluded. WHO BMI criteria for normal (BMI 18.5 to < 25) and underweight (BMI < 18.5) have been applied.

(c) From 2001–02 onwards, the wording of the responses to the first and third alcohol questions was amended to exactly reflect the AUDIT instrument from which they are derived. Therefore 1998–99 to 2000–01 are not directly comparable with data from 2001–02 onwards, and as such are not listed.

(d) Children with height outside the ABS height range based on age and sex were excluded. Child BMI has been re-calculated for 1998–99 to 2005–06 and will differ from data previously published to incorporate this exclusion and to apply a more precise method for calculating child BMI.

Note: CI—confidence interval; BMI—body mass index; NAv —not available.

Table 14.2: Comparative results for male patient risk factors, summary of annual results, BEACH, 1998–99 to 2007–08

Risk factor	Per cent (95% CI)										↑ ^(a) ↓
	1998–99	1999–00	2000–01	2001–02	2002–03	2003–04	2004–05	2005–06	2006–07	2007–08	
BMI class^(b) (n)	(12,030)	(13,062)	(12,800)	(12,512)	(12,450)	(12,434)	(12,288)	(12,882)	(12,715)	(12,126)	
Obese	17.0 (16.2–17.8)	18.1 (17.3–19.0)	19.2 (18.4–20.1)	20.0 (19.1–20.9)	19.9 (19.1–20.8)	20.7 (19.8–21.5)	21.3 (20.4–22.3)	21.6 (20.7–22.5)	22.4 (21.6–23.3)	23.1 (22.1–24.1)	↑
Overweight	40.2 (39.2–41.2)	40.9 (39.9–41.8)	41.0 (39.9–41.8)	41.0 (40.0–42.0)	41.5 (40.5–42.4)	42.3 (41.3–43.2)	42.0 (41.0–43.0)	42.6 (41.6–43.6)	42.3 (41.4–43.3)	43.0 (42.0–44.0)	↑
Normal	41.0 (39.9–42.2)	39.4 (38.3–40.4)	38.2 (37.0–39.3)	37.4 (36.3–38.6)	37.2 (36.2–38.3)	35.6 (34.5–36.7)	35.3 (34.2–36.5)	34.3 (33.3–35.4)	34.0 (32.9–35.1)	32.7 (31.6–33.8)	↓
Underweight	1.8 (1.5–2.0)	1.6 (1.4–1.9)	1.6 (1.4–1.9)	1.5 (1.3–1.8)	1.4 (1.1–1.6)	1.5 (1.3–1.7)	1.4 (1.1–1.6)	1.5 (1.3–1.7)	1.2 (1.0–1.4)	1.2 (1.0–1.4)	↓
Smoking status (n)	(11,797)	(12,230)	(12,869)	(12,547)	(12,521)	(12,692)	(12,613)	(13,016)	(12,257)	(12,335)	
Daily	22.6 (21.5–23.7)	23.4 (22.3–24.5)	22.6 (21.5–23.7)	21.6 (20.5–22.6)	20.4 (19.4–21.4)	21.0 (20.0–22.0)	21.2 (20.2–22.3)	20.7 (19.7–21.8)	19.4 (18.3–20.5)	19.8 (18.8–20.8)	↓
Occasional	6.2 (5.6–6.8)	5.4 (4.9–5.9)	4.4 (4.0–4.9)	4.6 (4.1–5.1)	4.5 (4.0–5.0)	4.5 (4.0–4.9)	4.3 (3.9–4.7)	4.1 (3.7–4.6)	3.8 (3.4–4.2)	3.3 (2.9–3.7)	↓
Previous	36.8 (35.5–38.0)	36.3 (35.1–37.4)	36.5 (35.2–37.8)	36.6 (35.4–37.9)	36.4 (35.2–37.6)	37.3 (36.2–38.5)	36.5 (35.3–37.6)	35.7 (34.5–36.9)	37.1 (35.8–38.4)	36.5 (35.3–37.7)	—
Never	34.5 (33.3–35.7)	35.0 (33.9–36.1)	36.5 (35.3–37.7)	37.2 (36.0–38.4)	38.7 (37.5–40.0)	37.2 (36.0–38.4)	38.0 (36.8–39.2)	39.5 (38.2–40.7)	39.7 (38.5–41.0)	40.4 (39.2–41.6)	↑
Alcohol consumption^(c) (n)	(12,464)	(12,391)	(12,334)	(12,294)	(12,792)	(12,005)	(12,071)	
At-risk alcohol level	NAv	NAv	NAv	32.0 (30.8–33.2)	32.8 (31.6–34.1)	33.1 (31.9–34.3)	32.6 (31.3–33.8)	31.6 (30.3–32.8)	32.5 (31.2–33.8)	31.7 (30.5–32.9)	—
Responsible drinker	NAv	NAv	NAv	46.8 (45.7–48.0)	46.6 (45.5–47.8)	47.3 (46.1–48.5)	47.7 (46.4–48.9)	47.9 (46.7–49.1)	48.0 (46.7–49.2)	47.6 (46.4–48.8)	—
Non-drinker	NAv	NAv	NAv	21.2 (20.1–22.2)	20.5 (19.5–21.5)	19.6 (18.5–20.7)	19.8 (18.7–20.9)	20.5 (19.4–21.6)	19.5 (18.5–20.6)	20.7 (19.6–21.8)	—

(a) The direction and type of change is indicated for each result: ↑/↓ indicates a statistically significant change, and — indicates there was no change.

(b) Adult patients aged 18+ with a recorded height outside the ABS height range based on age and sex were excluded. WHO BMI criteria for normal (BMI 18.5 to < 25) and underweight (BMI < 18.5) have been applied.

(c) From 2001–02 onwards, the wording of the responses to the first and third alcohol questions was amended to exactly reflect the AUDIT instrument from which they are derived. Therefore 1998–99 to 2000–01 are not directly comparable with data from 2001–02 onwards and as such are not listed. Note: CI—confidence interval; BMI—body mass index; NAv—not available.

Table 14.3: Comparative results for female patient risk factors, summary of annual results, BEACH, 1998–99 to 2007–08

Risk factor	Per cent (95% CI)										↑ ^(a) ↓
	1998–99	1999–00	2000–01	2001–02	2002–03	2003–04	2004–05	2005–06	2006–07	2007–08	
BMI class^(b) (n)	(18,092)	(19,655)	(18,820)	(19,039)	(19,670)	(19,214)	(17,976)	(19,976)	(19,410)	(18,703)	
Obese	19.2 (18.4–19.9)	20.2 (19.5–21.0)	20.8 (20.0–21.6)	22.4 (21.6–23.2)	21.5 (20.7–22.3)	23.0 (22.1–23.8)	23.2 (22.4–24.1)	22.6 (21.7–23.4)	24.2 (23.3–25.1)	24.3 (23.5–25.2)	↑
Overweight	27.8 (27.1–28.6)	27.9 (27.2–28.7)	29.4 (28.6–30.1)	28.5 (27.8–29.3)	29.0 (28.2–29.8)	29.4 (28.6–30.1)	29.3 (28.6–30.1)	29.3 (28.6–30.0)	30.1 (29.4–30.9)	30.4 (29.7–31.2)	↑
Normal	48.6 (47.6–49.5)	47.6 (46.6–48.5)	46.0 (45.0–47.0)	45.2 (44.2–46.1)	45.7 (44.7–46.8)	44.1 (43.1–45.1)	43.8 (42.7–44.8)	44.6 (43.6–45.6)	42.2 (41.2–43.2)	41.9 (40.9–43.0)	↓
Underweight	4.5 (4.1–4.8)	4.3 (4.0–4.6)	3.8 (3.5–4.1)	3.9 (3.6–4.2)	3.8 (3.5–4.2)	3.6 (3.3–3.9)	3.6 (3.3–4.0)	3.5 (3.2–3.8)	3.5 (3.2–3.8)	3.3 (3.0–3.6)	↓
Smoking status (n)	(18,073)	(19,930)	(18,920)	(19,182)	(19,875)	(19,780)	(18,468)	(20,288)	(18,718)	(19,081)	
Daily	17.0 (16.2–17.7)	16.2 (15.4–16.9)	17.1 (16.3–17.9)	16.4 (15.6–17.2)	15.2 (14.4–15.9)	15.4 (14.6–16.1)	15.7 (15.0–16.5)	14.7 (14.0–15.4)	14.0 (13.3–14.8)	14.4 (13.7–15.2)	↓
Occasional	5.2 (4.8–5.7)	5.1 (4.7–5.4)	4.3 (4.0–4.7)	3.8 (3.4–4.1)	3.9 (3.5–4.3)	4.2 (3.9–4.6)	3.3 (3.0–3.7)	3.3 (3.0–3.6)	2.7 (2.5–3.0)	2.6 (2.4–2.9)	↓
Previous	20.6 (19.8–21.4)	21.4 (20.7–22.2)	20.9 (20.0–21.7)	22.0 (21.2–22.9)	21.5 (20.7–22.3)	22.0 (21.2–22.8)	22.2 (21.3–23.0)	21.5 (20.7–22.3)	23.3 (22.5–24.2)	22.3 (21.4–23.1)	↑
Never	57.2 (56.1–58.4)	57.4 (56.3–58.4)	57.7 (56.6–58.8)	57.8 (56.7–58.9)	59.4 (58.3–60.5)	58.4 (57.3–59.5)	58.8 (57.7–59.9)	60.5 (59.5–61.6)	59.9 (58.8–61.0)	60.7 (59.6–61.7)	↑
Alcohol consumption^(c) (n)	(19,095)	(19,749)	(19,387)	(18,120)	(19,961)	(18,342)	(18,715)	
At-risk alcohol level	NAv	NAv	NAv	22.0 (21.1–22.9)	22.1 (21.2–23.0)	22.6 (21.7–23.6)	22.2 (21.3–23.2)	22.2 (21.3–23.2)	23.5 (22.5–24.5)	22.6 (21.6–23.6)	—
Responsible drinker	NAv	NAv	NAv	42.4 (41.3–43.4)	42.7 (41.7–43.8)	43.5 (42.4–44.5)	43.0 (41.9–44.0)	42.8 (41.8–43.9)	42.4 (41.3–43.5)	42.6 (41.6–43.7)	—
Non-drinker	NAv	NAv	NAv	35.6 (34.4–36.9)	35.2 (33.9–36.5)	33.9 (32.7–35.2)	34.8 (33.4–36.2)	35.0 (33.6–36.3)	34.1 (32.8–35.4)	34.8 (33.5–36.1)	—

(a) The direction and type of change is indicated for each result: ↑/↓ indicates a statistically significant change, ↑/↓ indicates a marginally significant change, and — indicates there was no change.

(b) Adult patients aged 18+ with a recorded height outside the ABS height range based on age and sex were excluded. WHO BMI criteria for normal (BMI 18.5 to < 25) and underweight (BMI < 18.5) have been applied.

(c) From 2001–02 onwards, the wording of the responses to the first and third alcohol questions was amended to exactly reflect the AUDIT instrument from which they are derived. Therefore 1998–99 to 2000–01 are not directly comparable with data from 2001–02 onwards and as such are not listed. Note: CI—confidence interval; BMI—body mass index; NAv—not available.

References

1. Australian Institute of Health and Welfare 2005. National health priority areas. Viewed 4 September 2008, <www.aihw.gov.au/nhpa/index.cfm>
2. Australian Bureau of Statistics 2008. Australian Demographic Statistics, Dec 2007. ABS cat. no. 3101.0, Viewed 4 September 2008, <www.abs.gov.au/ausstats/abs@.nsf/mf/3101.0/>
3. Australian Institute of Health and Welfare 2008. Medical labour force 2005. Cat. no. HWL 41. Canberra: AIHW.
4. Knox SA, Harrison CM, Britt HC, Henderson JV 2008. Estimating prevalence of common chronic morbidities in Australia. *Med J Aust* 189(2):66-70.
5. Australian Government Department of Health and Ageing 2008. Medicare statistics, March quarter 2008, Group B tables. Viewed 4 September 2008, <www.health.gov.au/internet/main/publishing.nsf/Content/medstat-mar08-tables-b>
6. Britt H, Miller GC, Charles J, Pan Y, Valenti L, Bayram C et al. 2007. General practice activity in Australia 2005-06. AIHW General practice series no. 19. Cat. no. GEP 19. Canberra: AIHW.
7. Britt H, Miller GC, Charles J, Henderson J, Bayram C, Harrison C et al. 2008. General practice activity in Australia 2007-08. AIHW General practice series no. 22. Cat. no. GEP 22. Canberra: AIHW.
8. SAS Proprietary Software Release 9.1, 2003. Cary: SAS Institute Inc.
9. SAS Proprietary Software Release 6.12, 1996. Cary: SAS Institute Inc.
10. Classification Committee of the World Organization of Family Doctors (WICC) 1998. ICPC-2: International Classification of Primary Care. 2nd ed. Oxford: Oxford University Press.
11. Australian Institute of Health and Welfare 2005. Australian family of health and related classifications matrix. Viewed 14 August 2008, <www.aihw.gov.au/datadevelopment/matrix/index.cfm>
12. Britt H 1997. A new coding tool for computerised clinical systems in primary care-ICPC plus. *Aust Fam Physician* 26(Suppl 2):S79-S82.
13. Bridges-Webb C, Britt H, Miles DA, Neary S, Charles J, Traynor V 1992. Morbidity and treatment in general practice in Australia 1990-1991. *Med J Aust* 157(19 Oct Spec Sup):S1-S56.

14. O'Halloran J, Miller GC, Britt H 2004. Defining chronic conditions for primary care with ICPC-2. *Fam Pract* 21(4):381-386.
15. World Health Organization Collaborating Centre for Drug Statistics Methodology (WHO) 1997. Anatomical Therapeutic Chemical (ATC) classification index with Defined Daily Doses (DDDs). January 1998 edn. Oslo: WHO.
16. Australian Government Department of Health and Ageing 2004. Medicare benefits schedule book. Canberra: DoHA.
17. Britt H, Sayer GP, Miller GC, Charles J, Scahill S, Horn F et al. 1999. General practice activity in Australia 1998-99. AIHW General practice series no. 2. Cat. no. GEP 2. Canberra: AIHW.
18. Charles J, Britt H, Valenti L 2006. The independent effect of age of general practitioner on clinical practice. *Med J Aust* 185(2):105-109.
19. Charles J, Britt H, Valenti L 2004. The evolution of the general practice workforce in Australia, 1991-2003. *Med J Aust* 181(2):85-90.
20. McWhinney IR 1986. Are we on the brink of a major transformation of clinical method? *Can Med Assoc J* 135:873-878.
21. Australian Government Department of Health and Ageing 2007. Medicare benefits schedule book. Canberra: DoHA.
22. Britt H, Miller GC, Henderson J, Bayram C 2007. Patient-based substudies from BEACH: abstracts and research tools 1999-2006. AIHW General practice series no. 20. Cat. no. GEP 20. Canberra: AIHW.
23. Britt H, Miller G, Charles J, Bayram C, Pan Y, Henderson J et al. 2008. General practice activity in Australia 2006-07. AIHW General practice series no. 21. Cat. no. GEP 21. Canberra: AIHW.

Glossary

A1 Medicare items: Medicare item numbers 1, 2, 3, 4, 13, 19, 20, 23, 24, 25, 33, 35, 36, 37, 38, 40, 43, 44, 47, 48, 50, 51, 601, 602.

Aboriginal: The patient identifies himself or herself as an Aboriginal person.

Activity level: The number of general practice A1 Medicare items claimed during the previous 3 months by a participating GP.

Allied and other health professionals: Those who provide clinical and other specialised services in the management of patients, including physiotherapists, occupational therapists, dietitians, dentists and pharmacists.

Chapters (ICPC-2): The main divisions within ICPC-2. There are 17 chapters primarily representing the body systems.

Chronic problem: see *Diagnosis/problem, Chronic problem.*

Commonwealth concession card: An entitlement card provided by the Australian Government that entitles the holder to reduced cost medicines under the Pharmaceutical Benefits Scheme and a limited number of other concessions from state and local government authorities.

Complaint: A symptom or disorder expressed by the patient when seeking care.

Component (ICPC-2): In ICPC-2 there are seven components which act as a second axis across all chapters.

Consultation: See *Encounter.*

Diagnosis/problem: A statement of the provider's understanding of a health problem presented by a patient, family or community. GPs are instructed to record at the most specific level possible from the information available at the time. It may be limited to the level of symptoms.

- *New problem:* The first presentation of a problem, including the first presentation of a recurrence of a previously resolved problem, but excluding the presentation of a problem first assessed by another provider.
- *Old problem:* A previously assessed problem that requires ongoing care, including follow-up for a problem or an initial presentation of a problem previously assessed by another provider.
- *Chronic problem:* A medical condition characterised by a combination of the following characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of recurrence or deterioration, a poor prognosis, and consequences or sequelae that impact on an individual's quality of life. (*Source:* O'Halloran J, Miller GC, Britt H 2004. Defining chronic conditions for primary care with ICPC-2. *Fam Pract* 21(4):381-6)
- *Work-related problem:* Irrespective of the source of payment for the encounter, it is likely in the GP's view that the problem has resulted from work-related activity or workplace exposures or that a pre-existing condition has been significantly exacerbated by work activity or workplace exposure.

Encounter (enc): Any professional interchange between a patient and a GP.

- *Indirect:* Encounter where there is no face-to-face meeting between the patient and the GP but a service is provided (for example prescription, referral).

- *Direct*: Encounter where there is a face-to-face meeting of the patient and the GP.

Direct encounters can be further divided into:

- Medicare-claimable
 - *Surgery consultations*: Encounters identified by any one of MBS item numbers 3, 23, 36, 44, 52, 53, 54, 57, 5000, 5020, 5040, 5060, 5200, 5203, 5207, 5208.
 - *Home visits*: Encounters identified by any one of MBS item numbers 4, 24, 37, 47, 58, 59, 60, 65, 5003, 5023, 5043, 5063, 5220, 5223, 5227, 5228.
 - *Hospital encounters*: Encounters identified by any one of MBS item numbers 19, 33, 40, 50, 87, 89, 90, 91.
 - *Residential aged care facility*: Encounters identified by any one of MBS item numbers 20, 35, 43, 51, 92, 93, 95, 96, 5010, 5028, 5049, 5067, 5260, 5263, 5265, 5267.
 - *Health assessments*: Encounters identified by any one of MBS item numbers 700, 702, 704, 706, 708, 710, 712.
 - *Chronic disease management items*: Encounters identified by any one of MBS item numbers 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731.
 - *Case conferences*: Encounters identified by any one of MBS item numbers 734, 736, 738, 740, 742, 744, 746, 749, 757, 759, 762, 765, 768, 771, 773, 775, 778, 779.
 - *Incentive payments*: Encounters identified by any one of MBS item numbers 2497, 2501, 2503, 2504, 2506, 2507, 2509, 2517, 2518, 2521, 2522, 2525, 2526, 2546, 2547, 2552, 2553, 2558, 2559, 2574, 2575, 2577, 2578, 2598, 2600, 2603, 2606, 2610, 2613, 2616, 2620, 2622, 2624, 2631, 2633, 2635, 2664, 2666, 2668, 2673, 2675, 2677, 2704, 2705, 2707, 2708.
 - *Other MBS encounters*: Encounters identified by an MBS item number that does not identify place of encounter (see *A1 Medicare items*).
- *Workers compensation*: Encounters paid by workers compensation insurance.
- *Other paid*: Encounters paid from another source (for example state).

General practitioner (GP): A medical practitioner who provides primary comprehensive and continuing care to patients and their families within the community (Royal Australian College of General Practitioners).

Medication: Medication that is prescribed, provided by the GP at the encounter or advised for over-the-counter purchase.

Medication rates: The rate of use of all medications, including medications that were prescribed, supplied by the GP and advised for over-the-counter purchase.

Medication status:

- *New*: The medication prescribed/provided at the encounter/advised is being used for the management of the problem for the first time.
- *Continuation*: The medication prescribed/provided at the encounter/advised is a continuation or repeat of previous therapy for this problem.
- *Old*: See *Continuation*.

Morbidity: Any departure, subjective or objective, from a state of physiological wellbeing. In this sense, sickness, illness and morbid conditions are synonymous.

Patient status: The status of the patient to the practice.

- *New patient:* The patient has not been seen before in the practice.
- *Old patient:* The patient has attended the practice before.

Prescribed rates: The rate of use of prescribed medications (that is, does not include medications that were GP-supplied or advised for over-the-counter purchase).

Problem managed: See *Diagnosis/problem*.

Provider: A person to whom a patient has access when contacting the health care system.

Reasons for encounter (RFEs): The subjective reasons given by the patient for seeing or contacting the general practitioner. These can be expressed in terms of symptoms, diagnoses or the need for a service.

Recognised GP: A medical practitioner who is:

- vocationally recognised under Section 3F of the Health Insurance Act, **or**
- a holder of the Fellowship of the Royal Australian College of General Practitioners who participates in, and meets the requirements for, quality assurance and continuing medical education as defined in the RACGP Quality Assurance and Continuing Medical Education Program, **or**
- undertaking an approved placement in general practice as part of a training program for general practice leading to the award of the Fellowship of the Royal Australian College of General Practitioners, or undertaking an approved placement in general practice as part of some other training program recognised by the RACGP as being of equivalent standard. (*Source:* Commonwealth Department of Health and Aged Care (DHAC) 2001. Medicare Benefits Schedule Book. Canberra: DHAC.)

Referral: The process by which the responsibility for part or all of the care of a patient is temporarily transferred to another health care provider. Only new referrals to specialists and allied health professionals, and for hospital and residential aged care facility admissions arising at a recorded encounter are included. Continuation referrals are not included. Multiple referrals can be recorded at any one encounter.

Repatriation health card: An entitlement card provided by the Department of Veterans' Affairs that entitles the holder to access a range of Repatriation health care benefits, including access to prescription and other medications under the Pharmaceutical Benefits Scheme.

Rubric: The title of an individual code in ICPC-2.

Significant: This term is used to refer to a statistically significant results. Statistical significance is measured at the 95% confidence level in this report.

Torres Strait Islander: The patient identifies himself or herself as a Torres Strait Islander person.

Work-related problem: See *Diagnosis/problem*.

Appendices

Appendix 1: BEACH methods

Published as Chapter 2 in *General practice activity in Australia 2007–08* available from <www.aihw.gov.au/publications/index.cfm/subject/19> (AIHW catalogue number GEP 22).

In summary:

- each year BEACH involves a random sample of approximately 1,000 GPs
- each GP records details about 100 doctor–patient encounters of all types
- the GP sample is a rolling (ever-changing) sample, with approximately 20 GPs participating in any one week, 50 weeks a year
- each GP can be selected only once per quality assurance (QA) triennium (that is, once every three years)
- the encounter information is recorded by the GPs on structured paper encounter forms (Appendix 3)
- each GP participant also completes a questionnaire about themselves and their practice (Appendix 4).

Sampling methods

The source population includes all vocationally registered GPs and all general practice registrars who claimed a minimum of 375 general practice A1 Medicare items in the most recently available 3-month Medicare data period (which equates to 1,500 A1 Medicare claims a year). This ensures inclusion of the majority of part-time GPs while excluding those who are not in private practice but claim for a few consultations a year.

On a quarterly basis the Primary and Ambulatory Care Division of DoHA updates the sample frame from the Medicare records, leaving out of the sample frame any GPs already randomly sampled in the current triennium, and draws a new sample from those currently in the sample frame. This ensures the timely addition of new entries to the profession, and timely exclusion of those GPs who have stopped practising.

Recruitment methods

The randomly selected GPs are approached by letter posted to the address provided by DoHA.

- Over the following 10 days the telephone numbers generated from the Medicare data are checked using the electronic white and yellow pages. This is necessary because many of the telephone numbers provided from the Medicare data are incorrect.
- The GPs are then telephoned in the order they were approached and, referring to the approach letter, asked whether they will participate.

- This initial telephone contact with the practice often indicates that the selected GP has moved elsewhere, but is still in practice. Where forward address and/or telephone number can be obtained, these GPs are followed up at their new address.
- GPs who agree to participate are set an agreed recording date several weeks ahead.
- A research pack is sent to each participant about 10 days before the planned start date.
- Each GP receives a telephone reminder in the first days of the agreed recording period – this also provides the GP with an opportunity to ask questions about the recording process.
- GPs can use a ‘freecall’ (1800) number to ring the research team with any questions during their recording period.
- Non-returns are followed up by regular telephone calls for up to 3 months after the set recording time.
- Participating GPs earn Clinical Audit points towards their QA requirements through the Royal Australian College of General Practitioners (RACGP). As part of this QA process, each receives an analysis of his or her results compared with those of nine other de-identified GPs who recorded at approximately the same time. Comparisons with the national average and with targets relating to the National Health Priority Areas are also provided. In addition, GPs receive some educational material related to the identification and management of patients who smoke or consume alcohol at hazardous levels. Additional points can be earned if the participant chooses to do a follow-up audit of smoking and alcohol consumption among a sample of patients about 6 months later.

Data elements

BEACH includes three interrelated data collections: encounter data, GP characteristics and patient health status. An example of the form used to collect the encounter data and the data on patient health status is included in Appendix 3. The GP characteristics questionnaire is provided in Appendix 4. The data collected include the following:

- **Encounter data:** date of consultation, type of consultation (direct/indirect), up to three Medicare/Department of Veterans’ Affairs (DVA) item numbers (where applicable) and other payment source (where applicable) (tick boxes).
- **Patient data:** date of birth, sex and postcode of residence. Tick boxes are provided for Commonwealth concession cardholder, holder of a Repatriation health card (from DVA), non-English-speaking background (patient self-report – a language other than English is the primary language at home), Aboriginal person (self-identification) and Torres Strait Islander person (self-identification). Space is provided for up to three patient reasons for encounter (RFEs).
- **The problems managed** at encounter (at least one and up to four). Tick boxes are provided to denote the status of each problem as new or continuing for the patient (if applicable).
- **Management of** each problem, including:
 - medications prescribed, supplied by the GP and advised for over-the-counter purchase including brand name, form (where required), strength, regimen, status (if new or continuing medication for this problem for this patient) and number of repeats

- other treatments provided for each problem including counselling, advice and education, and procedures undertaken; and if other treatment was provided by practice nurse (tick box)
- new referrals to medical specialists, allied health professionals and hospital
- investigations including pathology tests, imaging and other investigations ordered at the encounter.
- **GP characteristics:** age and sex, years in general practice, number of GP sessions worked per week, number of full-time equivalent GPs working in the practice, postcode of major practice address, country of graduation, postgraduate general practice training and Fellow of the RACGP status, after-hours care arrangements, use of computers in the practice, whether the practice is accredited, whether it is a teaching practice, work undertaken in other clinical settings and hours worked in direct patient care.

Supplementary Analysis of Nominated Data

A section at the bottom of each recording form investigates aspects of patient health or health care delivery in general practice not covered by the consultation-based data. These additional substudies are referred to as SAND, Supplementary Analysis of Nominated Data.

- The year-long data period is divided into 10 blocks, each of 5 weeks with three substudies per block. The research team aims to include data from about 100 GPs in each block.
- Each GP's pack of 100 forms is made up of 40 forms that ask for the start and finish times of the encounter, and include questions about patient risk factors: patient height and weight (used to calculate body mass index, BMI), alcohol intake and smoking status (patient self-report). The methods used in the SAND substudies for alcohol consumption, smoking status and BMI are reported in Appendix 2. The start and finish times collected on these encounters is used to calculate the length of consultation. The length of consultation for Medicare-claimable encounters is reported in Table 5.3.
- The remaining 60 forms in each pack are divided into two blocks of 30. Different questions are asked of the patient in each block and these vary throughout the year.
- The order of SAND sections is rotated in the GP recording pack, so that 40 patient risk factor forms may appear first, second or third in the pad. Rotation of ordering ensures there was no order effect on the quality of the information collected.

Abstracts for all SAND substudies from April 1999 to July 2006 inclusive were published in *Patient-based substudies from BEACH: abstracts and research tools 1999–2006*.¹ Abstracts of results and the research tools used in SAND substudies conducted between August 2006 and March 2007 were published in *General practice activity in Australia 2006–07*² and those conducted from April 2007 to January 2008 are in *General practice activity in Australia 2007–08*.³

Abstracts of results for all SAND substudies are also available on the Family Medicine Research Centre's (FMRC) website <www.fmrc.org.au/publications/SAND_abstracts.htm>.

The BEACH relational database

The BEACH relational database is described diagrammatically in Figure A1.1. Note that:

- all variables can be directly related to GP and patient characteristics, and to the encounter
- RFEs have only an indirect relationship with problems managed, as a patient may describe one RFE (such as 'repeat prescriptions') that is related to multiple problems managed, or several RFEs (such as 'runny nose' and 'cough') that relate to a single problem (such as upper respiratory tract infection) managed at the encounter.
- all types of management are directly related to the problem being treated.




Figure A1.1: The BEACH relational database

Note: FTE—full time equivalent; NESB—non-English-speaking background; SAND—Supplementary Analysis of Nominated Data.

Statistical methods

The analysis of the 2007–08 BEACH data was conducted with Statistical Analysis System (SAS) version 9.1.3⁴ and the encounter is the primary unit of inference. Proportions are used only when describing the distribution of an event that can arise only once at a consultation (for example, age, sex), or to describe the distribution of events within a class of events (for example, problem *A* as a percentage of total problems). Rates per 100 encounters are used when an event can occur more than once at the consultation (for example, RFEs, problems managed or medications).

Rates per 100 problems are also used when a management event can occur more than once per problem managed. In general, the results present the number of observations (*n*), the rate per 100 encounters and the 95% confidence interval.

BEACH is a single stage cluster sample study design, each 100 encounters forming a cluster around each GP participant. In cluster samples, variance needs to be adjusted to account for the correlation between observations within clusters. We use procedures in SAS version 9.1.3 to calculate the intraclass correlation and adjust the confidence intervals accordingly.⁴

Classification of data

The following data elements are classified according to the International Classification of Primary Care – Version 2 (ICPC-2), a product of the World Organization of Family Doctors (Wonca)⁵:

- patient reasons for encounter (RFEs)
- problems managed
- clinical treatments (for example, counselling, advice)
- procedural treatments
- referrals
- investigations ordered (including pathology, imaging and other investigations).

The ICPC-2 is used in more than 45 countries as the standard for data classification in primary care. It is accepted by the World Health Organization (WHO) in the WHO Family of International Classifications⁶, and is the declared national standard in Australia for reporting of health data from general practice and patient self-reported health information.⁷

The ICPC-2 has a biaxial structure, with 17 chapters on one axis (each with an alphabetic code) and seven components on the other (numeric codes) (Figure A1.2). Chapters are based on body systems, with additional chapters for psychological and social problems.

Component 1 includes symptoms and complaints. Component 7 covers diagnoses. These are independent in each chapter and both can be used for patient RFEs or problems managed.

Components 2 to 6 cover the process of care, and are common throughout all chapters. The processes of care, including referrals, other (non-pharmacological) treatments and orders for pathology and imaging, are classified in these process components of ICPC-2. Component 2 (diagnostic, screening and prevention) is also often applied in describing the problem managed (for example, check-up, immunisation).

The ICPC-2 is an excellent epidemiological tool. The diagnostic and symptomatic rubrics have been selected for inclusion on the basis of their relative frequency in primary care settings, or because of their relative importance in describing the health of the community.

It has approximately 1,370 rubrics and these are sufficient for meaningful analyses. However, reliability of data entry, using ICPC-2 alone, requires a thorough knowledge of the classification for correct classification of a concept to be ensured.

In 1995, recognising a need for a coding and classification system for general practice electronic health records, the FMRC (then the Family Medicine Research Unit) developed an extended vocabulary of terms classified according to the ICPC, now called ICPC-2 PLUS.⁸ This is an interface terminology, developed by the FMRC from all the terms used by GPs in studies such as the Australian Morbidity and Treatment Survey 1990–91⁹, the Morbidity and Therapeutic Index 1992–1998 (a clinical audit tool that was available to GPs) and BEACH 1998–2008 that together have included close to 1.5 million encounter records. These terms are classified according to ICPC-2 to ensure international standards for reporting. Readers interested in seeing how coding works can download the ICPC-2 PLUS Demonstrator at <www.fmrc.org.au/icpc2plus/demonstrator.htm>.

When the free-text data are received from the GPs, trained secondary coders (who are undergraduate students studying health information management or medical science) code the data in more specific terms using ICPC-2 PLUS. This ensures high coder reliability and automatic classification of the concept, and provides the ability to ‘ungroup’ such ICPC-2 rubrics as ‘other diseases of the circulatory system’, and select a specific disease from the terms within it.

Components	Chapters																
	A	B	D	F	H	K	L	N	P	R	S	T	U	W	X	Y	Z
1. Symptoms, complaints																	
2. Diagnostic, screening, prevention																	
3. Treatment, procedures, medication																	
4. Test results																	
5. Administrative																	
6. Other																	
7. Diagnoses, disease																	

A	General	L	Musculoskeletal	U	Urinary
B	Blood, blood-forming	N	Neurological	W	Pregnancy, family planning
D	Digestive	P	Psychological	X	Female genital
F	Eye	R	Respiratory	Y	Male genital
H	Ear	S	Skin	Z	Social
K	Circulatory	T	Metabolic, endocrine, nutritional		

Figure A1.2: The structure of the International Classification of Primary Care—Version 2 (ICPC-2)

Presentation of data classified in ICPC-2

Statistical reporting is almost always at the level of the ICPC-2 classification (for example, acute otitis media/myringitis – ICPC-2 code H71). However, there are some exceptions where data are grouped either above the ICPC-2 level or across the ICPC-2 level. These grouped morbidity, pathology and imaging codes are defined in Appendix 5, and chronic morbidity groups are provided in Appendix 6.

Reporting morbidity with groups of ICPC-2 codes

When recording problems managed, the GP may not always be very specific. For example, in recording the management of hypertension, they may simply record the problem as 'hypertension'. In ICPC-2, 'hypertension, unspecified' is classified as 'uncomplicated hypertension' (code K86). There is another code for 'complicated hypertension' (K87). In some cases the GP may simply have failed to specify that the patient had hypertension with complications. The research team therefore feels that for national data reporting, it is more reliable to group the codes K86 and K87 and label this 'Hypertension*' – the asterisk indicating that multiple ICPC-2 codes (as in this example) or ICPC-2 PLUS codes (see below) are included. A list of codes included in these groups are provided in Appendix 5.

Reporting morbidity with groups of ICPC-2 PLUS codes

In other cases a concept can be classified within (but be only part of) multiple ICPC-2 codes. For example, osteoarthritis is classified in ICPC-2 in multiple broader codes according to site, for example, L92 – shoulder syndrome (includes bursitis, frozen shoulder, osteoarthritis of shoulder, rotator cuff syndrome). When reporting osteoarthritis in this publication, all the more specific osteoarthritis ICPC-2 PLUS terms are grouped within all the appropriate ICPC-2 codes. This group is labelled 'Osteoarthritis*' – the asterisk again indicating multiple codes, but in this case they are PLUS codes rather than ICPC-2 codes. A list of codes included in these groups are provided in Appendix 5.

Reporting chronic morbidity

Chronic conditions are medical conditions characterised by a combination of the following characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of recurrence or deterioration, a poor prognosis, and consequences or sequelae that affect an individual's quality of life.

To identify chronic conditions, a chronic condition list¹⁰ classified according to ICPC-2 was applied to the BEACH data set. In general reporting, both chronic and non-chronic conditions (for example, diabetes and gestational diabetes) may have been grouped together when reporting (for example, diabetes – all*). When reporting chronic morbidity, only problems regarded as chronic have been included in the analysis. Where the group used for the chronic analysis differs from that used in other analyses in this report, they are marked with a double asterisk. Codes included in the chronic groups are provided in Appendix 6.

Reporting pathology and imaging test orders

All the pathology and imaging tests are coded very specifically in ICPC-2 PLUS, but the ICPC-2 classifies pathology and imaging tests very broadly (for example, a test of cardiac enzymes is classified in K34 – Blood test associated with the cardiovascular system; a CT scan of the lumbar spine is classified as L41 – Diagnostic radiology/imaging of the musculoskeletal system). In Australia, the MBS classifies pathology and imaging tests in groups that are relatively well recognised. The team therefore re-grouped all pathology and imaging ICPC-2 PLUS codes into MBS standard groups. This allows comparison of data between data sources. These groups are marked with an asterisk, and inclusions are provided in Appendix 5.

Classification of pharmaceuticals

Pharmaceuticals that are prescribed, provided by the GP or advised for over-the-counter purchase are coded and classified according to an in-house classification, the Coding Atlas for Pharmaceutical Substances (CAPS).

This is a hierarchical structure that facilitates analysis of data at a variety of levels, such as medication class, medication group, generic composition and brand name.

Strength and regimen are independent fields that, when combined with the CAPS code, give an opportunity to derive the prescribed daily dose for any prescribed medication or group of medications.

CAPS is mapped to the Anatomical Therapeutic Chemical (ATC)¹¹ classification, which is the Australian standard for classifying medications at the generic level.

The ATC has a hierarchical structure with five levels. For example:

- Level 1: C – Cardiovascular system
- Level 2: C10 – Serum lipid reducing agents
- Level 3: C10A – Cholesterol and triglyceride reducers
- Level 4: C10AA – HMG CoA reductase inhibitors
- Level 5: C10AA01 – Simvastatin (the generic drug).

Use of the pharmaceutical classifications in reporting

For pharmaceutical data, there is the choice of reporting in terms of the CAPS coding scheme or the ATC. They each have advantages in different circumstances.

In the CAPS system, a new drug enters at the product and generic level, and is immediately allocated a generic code. Therefore, the CAPS classification uses a bottom-up approach.

In the ATC, a new generic may initially enter the classification at any level (1 to 5), not necessarily always at the generic level. Reclassification to lower ATC levels may occur later. Therefore, the ATC uses a top-down approach.

When analysing medications across time, a generic medication that is initially classified to a higher ATC level will not be identifiable in that data period and may result in under-enumeration of that drug during earlier data collection periods.

- When reporting the 2007–08 annual results for pharmaceutical data, the CAPS database is used in tables of the ‘most frequent medications’ (Table 9.4).
- When reporting the annual results for pharmaceuticals in terms of the ATC hierarchy, ATC Levels 1, 3, and 5 are used. The reader should be aware that the results reported at the generic level (Level 5) may differ slightly from those reported in the ‘most frequent medication’ tables for the reasons described above.

Quality assurance

All morbidity and therapeutic data elements were secondarily coded by staff entering key words or word fragments and selecting the required term or label from a pick list. This was then automatically coded and classified by the computer. A quality assurance program to ensure reliability of data entry includes ongoing development of computer-aided error checks (‘locks’) at the data entry stage and a physical check of samples of data entered versus

those on the original recording form. Further logical data checks are conducted through SAS on a regular basis.

Validity and reliability

A discussion of the reliability and validity of the BEACH program has been published elsewhere.¹² In this section we touch on some aspects of reliability and validity of active data collection from general practice that should be considered by the reader.

In the development of a database such as BEACH, data gathering moves through specific stages: GP sample selection, cluster sampling around each GP, GP data recording, secondary coding and data entry. At each stage the data can be invalidated by the application of inappropriate methods. The methods adopted to ensure maximum reliability of coding and data entry have been described above. The statistical techniques adopted to ensure valid analysis and reporting of recorded data are described above. Previous work has demonstrated the extent to which a random sample of GPs recording information about a cluster of patients represents all GPs and all patients attending GPs.¹³ Other studies have reported the degree to which GP-reported patient RFEs and problems managed accurately reflect those recalled by the patient¹⁴ and the reliability of secondary coding of RFEs¹⁵ and problems managed.⁹ The validity of ICPC as a tool with which to classify the data has also been investigated in earlier work.¹⁶

However, the question of the extent to which the GP-recorded data are a reliable and valid reflection of the content of the encounter must also be considered. In many primary care consultations, a clear pathophysiological diagnosis is not reached. Bentsen¹⁷ and Barsky¹⁸ suggest that a firm and clear diagnosis is not apparent in about half of GPs' consultations, and others suggest the proportion may be even greater.¹⁹ Further, studies of general ambulatory medical practice have shown that a large number of patients presenting to a primary care practitioner are without a serious physical disorder.^{20,21} As a result, it is often necessary for a practitioner to record a problem in terms of symptoms, signs, patient concerns, or the service that is requested, such as immunisation. For this reason, this report refers to patient 'problems' rather than 'diagnoses'.

A number of studies have demonstrated wide variance in the way a GP perceives the patient's RFE and the manner in which the GP describes the problem under management. In a direct observational study of consultations via a one-way mirror, Bentsen demonstrated differences in the way practitioners labelled problems, and suggested that clinical experience may be an important influence on the identification of problems within the consultation.¹⁷ Two other factors that might affect GPs' descriptions of patient RFEs have been identified: while individuals may select the same stimuli, some label each stimulus separately whereas others cluster them under one label; individuals differ in the number of stimuli they select (selective perception).²²

The extent to which therapeutic decisions may influence the diagnostic label selected has also been discussed. Howie²³ and Anderson²⁰ argue that, while it is assumed that the diagnostic process used in general practice is one of symptom → diagnosis → management, the therapeutic method may well be selected on the basis of the symptom, and the diagnostic label chosen last. They suggest that the selection of the diagnostic label is therefore influenced by the management decision already made.

Anderson has also pointed out that the therapeutic decision may be influenced by fashion, and, in turn, this affects the selection of the problem label. He gives the example of a rise in the occurrence of neurotic depression in parallel with a decrease in the use of menopause as a

diagnosis in the United Kingdom, and suggests this may be the result of a change in the preferred treatment from oestrogen therapy to antidepressants.²⁰ This should be remembered when considering the changes in general practice described in this report.

Alderson contends that to many practitioners 'diagnostic accuracy is only important to the extent that it will assist them in helping the patient'. He further suggests that if major symptoms are readily treatable, some practitioners may feel no need to define the problem in diagnostic terms.²⁴ Crombie stated that in the second and third national morbidity surveys in the United Kingdom there was 'enormous variability in the rates at which doctors perceive and record illnesses'. He concluded that the probable cause arose from the different ways in which GPs gave priority in their perceptions and recording of certain morbidities while discounting or ignoring others. He was unable to account statistically for this variation by the effect of geography, age, sex or class differences in the practice populations.²⁵ Differences in the way male and female GPs label problems also appear to be independent of such influences.²⁶

These problems are inherent in the nature of general practice. Knottnerus argues that the GP is confronted with a fundamentally different pattern of problems from the specialist, the GP often having to draw up general diagnostic hypotheses related to probability, severity and consequences.²⁷ Anderson suggests that morbidity statistics from family practice should therefore be seen as 'a reflection of the physician's diagnostic opinions about the problems that patients bring to them rather than an unarguable statement of the problems managed'.²⁰ In any case, doctors base their actions on problems as they perceive them.

While these findings regarding limitations in the reliability and validity of practitioner-recorded morbidity should be kept in mind, they apply equally to data drawn from medical records, whether paper or electronic, as they do to active data collection methods.^{28,29} There is as yet no more reliable method of gaining detailed data about morbidity and its management in general practice. Further, irrespective of the differences between individual GPs in their labelling of the problems, morbidity data collected by GPs in active data collection methods have been shown to provide a reliable overview of the morbidity managed in general practice.³⁰

Other BEACH applications

The BEACH method can be applied in various health settings. In the past the AGPSCC has used the method to conduct a variety of studies in collaboration with other organisations. Examples of past studies are described below.

In 2004, a study was conducted in collaboration with Monash University and the Victorian Metropolitan Alliance. The BEACH methods were used to measure the experience gained by GP registrars during each stage of their training. The results will help to better define the areas in which registrars should receive training, and identify areas in which they are not gaining experience.

Another registrar study was conducted in 2003 as a consultancy for North Coast GP Training Ltd and the Institute of General Practice Education. This study looked at the clinical activities of registrars compared with those of their supervisors, to assess their education program in terms of actual practice.

A study in the Victoria Community Health Centres was done in 2004 in collaboration with the Victorian Department of Human Services. The project aimed to provide information about the clinical role of Community Health Service GPs and the characteristics of the

patients they see, and how these may differ from the 'average' GP in Australia. The department will use the results to help them plan future health services.

From 2002–04, the BEACH methods were used in the Alternative Pathway Program to assess the educational needs of each GP enrolled in the program. The Alternative Pathway Program was conducted by the National Consortium for Education in Primary Medical Care. The results for each GP were used in identifying specific educational needs and in planning an educational program for the individual practitioner.

In 2002–03, the Australian General Practice Statistics and Classification Centre conducted a longitudinal, matched, controlled trial of active computerised data collection compared with paper-based data collection in the western, north-western and south-western areas of Sydney. Software was developed that reflected the data elements collected in BEACH; the software did not interact with any clinical system being used by GPs. This study demonstrated that active GP computerised data collection in structured, stand-alone software does not provide a reliable and valid measure of GP activity and could not be adopted at this stage as an acceptable alternative to the paper-based data collection methods currently being used.³¹

As BEACH collects data nationally it is possible to analyse data at a level specific to local areas. For example, reports have been published comparing general practice in the different states and territories of Australia and investigating the differences between metropolitan and rural general practice. The research team has also developed Statistical Evaluation Areas (referred to as SEAs) that allow the provision of localised data for divisions of general practice.

References: Appendix 1

1. Britt H, Miller GC, Henderson J, Bayram C 2007. Patient-based substudies from BEACH: abstracts and research tools 1999–2006. AIHW General practice series no. 20. Cat. no. GEP 20 Canberra: AIHW.
2. Britt H, Miller G, Charles J, Bayram C, Pan Y, Henderson J et al. 2008. General practice activity in Australia 2006–07. AIHW General practice series no. 21. Cat. no. GEP 21 Canberra: AIHW.
3. Britt H, Miller GC, Charles J, Henderson J, Bayram C, Harrison C et al. 2008. General practice activity in Australia 2007–08. AIHW General practice series no. 22. Cat. no. GEP 22 Canberra: AIHW.
4. SAS Proprietary Software Release 9.1, 2003. Cary: SAS Institute Inc.
5. Classification Committee of the World Organization of Family Doctors (WICC) 1998. ICPC-2: International Classification of Primary Care. 2nd ed. Oxford: Oxford University Press.
6. World Health Organization (WHO) 2004. Family of international classifications. Viewed 4 September 2008, < www.who.int/classifications/en/WHOFICFamily.pdf>
7. Australian Institute of Health and Welfare 2005. Australian family of health and related classifications matrix. Viewed 14 August 2008, <www.aihw.gov.au/datadevelopment/matrix/index.cfm>
8. Britt H 1997. A new coding tool for computerised clinical systems in primary care – ICPC plus. Aust Fam Physician 26(Suppl 2):S79–S82.

9. Bridges-Webb C, Britt H, Miles DA, Neary S, Charles J, Traynor V 1992. Morbidity and treatment in general practice in Australia 1990–1991. *Med J Aust* 157(19 Oct Spec Sup):S1–S56.
10. O’Halloran J, Miller GC, Britt H 2004. Defining chronic conditions for primary care with ICPC-2. *Fam Pract* 21(4):381–6.
11. World Health Organization Collaborating Centre for Drug Statistics Methodology (WHO) 1997. Anatomical Therapeutic Chemical (ATC) classification index with Defined Daily Doses (DDDs). January 1998 ed. Oslo: WHO.
12. Britt H, Miller G, Bayram C 2007. The quality of data on general practice: a discussion of BEACH reliability and validity. *Aust Fam Physician* 36(1–2):36–40.
13. Driver B, Britt H, O’Toole B, Harris M, Bridges-Webb C, Neary S 1991. How representative are patients in general practice morbidity surveys? *Fam Pract* 8:261–8.
14. Britt H, Harris M, Driver B, Bridges-Webb C, O’Toole B, Neary S 1992. Reasons for encounter and diagnosed health problems: convergence between doctors and patients. *Fam Pract* 9:191–4.
15. Britt H 1998. Reliability of central coding of patient reasons for encounter in general practice, using the International Classification of Primary Care. *Informatics* (May):3–7.
16. Britt H 1997. A measure of the validity of the ICPC in the classification of reasons for encounter. *Informatics* (November):8–12.
17. Bentsen BG 1976. The accuracy of recording patient problems in family practice. *J Med Educ* 51:311–6.
18. Barsky AJ 1981. Hidden reasons why some patients visit doctors. *Ann Intern Med* 94(1):492–8.
19. Morrell D, Gage HG, Robinson NA 1971. Symptoms in general practice. *J R Coll Gen Pract* 21:32–43.
20. Anderson JE 1980. Reliability of morbidity data in family practice. *J Fam Pract* 10: 677–683.
21. Marsland DW, Wood M, Mayo F 1980. *Content of family practice*. New York: Appleton-Century-Crofts.
22. Bensing J 1983. The use of the RFE classification system in observation studies: some preliminary results. Presented at the 10th WONCA Conference on Family Medicine.
23. Howie JGR 1972. Diagnosis: the achilles heel? *J R Coll Gen Pract* 22:310–5.
24. Alderson M 1988. *Morbidity and health statistics*. 1st ed. Southampton: Stickton Press.
25. Crombie DL 1990. The problem of variability in general practitioner activities. In: *Yearbook of research and development*. London: Her Majesty’s Stationary Office: 21–4
26. Britt H, Bhasale A, Miles DA, Meza A, Sayer GP, Angelis M 1996. The sex of the general practitioner. A comparison of characteristics, patients, and medical conditions managed. *Med Care* 34(5):403–415.
27. Knottnerus JA 1991. Medical decision making by general practitioners and specialists. *Fam Pract* 8:305.

28. Britt H, Meza RA, Del Mar C 1996. Methodology of morbidity and treatment data collection in general practice in Australia: a comparison of two methods. *Fam Pract* 13(5):462-7.
29. Gehlbach SH 1979. Comparing methods of data collection in an academic ambulatory practice. *J Med Educ* 54:730-2.
30. Britt H, Angelis M, Harris E 1998. The reliability and validity of doctor-recorded morbidity data in active data collection systems. *Scand J Prim Health Care* 16:50-5.
31. Britt H, Miller, G C, Valenti L, Charles J 2003. Computer BEACH: a general practice computerised active data collection validation study. Viewed 4 September 2008, <www.fmrc.org.au/research_comp.htm>

Appendix 2: Patient risk factor substudy methods

Body mass index

Patient BMI was investigated for a subsample of 40 of the 100 patient encounters. Each GP was instructed to ask the patient (or their carer in the case of children):

- What is your height in centimetres (without shoes)?
- What is your weight in kilograms (unclothed)?

Metric conversion tables (feet and inches; stones and pounds) were provided to the GP.

The BMI for an individual was calculated by dividing weight (kilograms) by height (metres) squared. The recent WHO recommendations¹ for BMI groups were used, which specify that an adult (18 years and over) with a BMI:

- less than 18.5 is underweight
- greater than or equal to 18.5 and less than 25 is normal
- greater than or equal to 25 and less than 30 is overweight
- of 30 or more is obese.

The reported height for adult patients was checked against sex-appropriate upper and lower height limits from the Australian Bureau of Statistics (ABS).² Encounters with adults whose reported heights were outside the sex-appropriate limits were excluded from the analysis.

The division between underweight and normal was, in reports published before 2006, set at a BMI of 20. In tables 14.1 to 14.3 patient BMI have been recalculated for all years and are reported according to the current WHO criteria.

The standard BMI cut-offs described above are not appropriate in the case of children. Cole et al. developed a method which calculates the age-sex-specific BMI cut-off levels for overweight and obesity specific to children aged 2–17 years.³ There are three categories defined for childhood BMI: underweight/normal, overweight and obese. This method, based on international data from developed Western cultures, is applicable in the Australian setting.

The reported height of children was checked against age-sex-appropriate upper and lower height limits from the ABS.² In reports published before 2007, encounters with children whose reported heights were outside either of the age-sex-appropriate limits were not excluded from the analysis. In Table 14.1 the BMI of children have been recalculated and reported for all years excluding data from children whose reported heights were outside either of the age-sex-appropriate limits.

The BEACH data on BMI are presented separately for adults (aged 18 years and over) and children (aged 2–17 years). The standard BMI cut-offs have been applied for the adult sample, and the method described by Cole et al. has been used for defining overweight and obesity in children (aged 2–17 years).³

Smoking

GPs were instructed to ask adult patients (18 years and over):

- What best describes your smoking status?
 - Smoke daily
 - Smoker occasionally
 - Previous smoker
 - Never smoked

Respondents were limited to adults aged 18 years and over because there are ethical concerns about approaching the younger patient group to ask for information about smoking for survey purposes. In addition, the reliability of this information from patients aged less than 18 years may be compromised if a parent or carer is present at the consultation.

Alcohol consumption

To measure alcohol consumption, BEACH uses three items from the WHO Alcohol Use Disorders Identification Test (AUDIT)⁴, with scoring for an Australian setting.⁵ Together, these three questions assess 'at-risk' alcohol consumption. The scores for each question range from zero to four. A total (sum of all three questions) score of five or more for males or four or more for females suggests that the person's drinking level is placing him or her at risk.⁵

GPs were instructed to ask adult patients (18 years and over):

- How often do you have a drink containing alcohol?
 - Never
 - Monthly or less
 - Once a week/fortnight
 - 2-3 times a week
 - 4+ times a week
- How many standard drinks do you have on a typical day when you are drinking?

- How often do you have six or more standard drinks on one occasion?
 - Never
 - Less than monthly
 - Monthly
 - Weekly
 - Daily or almost daily

A standard drinks chart was provided to each GP to help the patient identify the number of standard drinks consumed.

Respondents were limited to adults aged 18 years and over because there are ethical concerns about approaching the younger patient group to ask for information about alcohol consumption for survey purposes. In addition, the reliability of this information from patients aged less than 18 years may be compromised if a parent or carer is present at the consultation.

The wording of the responses to the first and third questions was changed from 2001-02 onwards to reflect exactly the AUDIT instrument from which the responses are derived. This update, along with a data entry change enabling more specific entry for the second question, slightly increased the rates of at-risk drinking. The data collected from 2001-02 onwards are a more accurate reflection of the alcohol consumption of general practice patients and these are the years compared in this report.

References: Appendix 2

1. World Health Organization 2006. Global database on body mass index. Viewed 4 September 2008, <www.who.int/bmi/index.jsp?introPage=intro_3.html>
2. Australian Bureau of Statistics 1998. National Nutrition Survey: nutrient intakes and physical measurements, Australia 1995. Canberra: ABS.
3. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH 2000. Establishing a standard definition for child overweight and obesity worldwide: international survey. *BMJ* 320(7244):1240-3.
4. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M 1993. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption – II. *Addiction* 88(6):791-804.
5. Centre for Drug and Alcohol Studies 1993. The alcohol use disorders identification test. Sydney: Royal Prince Alfred Hospital and the University of Sydney.

Appendix 3: Example of a 2007–08 recording form

BEACH (Bettering the Evaluation And Care of Health) - Morbidity and Treatment Survey - National © BEACH General Practice & Statistics Classification Unit University of Sydney 1996 **DOC ID**

Encounter Number	Date of encounter ____/____/____	Date of Birth ____/____/____	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Patient Postcode _____	Yes / No	PATIENT SEEN BY GP <input type="checkbox"/> PATIENT NOT SEEN BY GP <input type="checkbox"/> Medicare Item Nos: (if applicable) Workers comp paid <input type="checkbox"/> 1. _____ State Govt/Other paid ... <input type="checkbox"/> 2. _____ 3. _____ No charge <input type="checkbox"/>
START Time ____ : ____ AM / PM (please circle)	Patient Reasons for Encounter		1. _____ 2. _____ 3. _____		New Patient <input type="checkbox"/> <input type="checkbox"/> Health Care/Benefits Card... <input type="checkbox"/> <input type="checkbox"/> Veterans Affairs Card..... <input type="checkbox"/> <input type="checkbox"/> NESB..... <input type="checkbox"/> <input type="checkbox"/> Aboriginal..... <input type="checkbox"/> <input type="checkbox"/> Torres Strait Islander <input type="checkbox"/> <input type="checkbox"/>	

Diagnosis/ Problem ① : Problem Status New <input type="checkbox"/> Old <input type="checkbox"/> Work related <input type="checkbox"/> <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th>Drug Name AND Form for this problem</th> <th>Strength of product</th> <th>Dose</th> <th>Frequency</th> <th>No. of Rpts</th> <th>OTC</th> <th>GP Supply</th> <th colspan="2">Drug status</th> </tr> <tr> <th colspan="7"></th> <th>New</th> <th>Cont.</th> </tr> </thead> <tbody> <tr><td>1.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>2.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>3.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>4.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> </tbody> </table>	Drug Name AND Form for this problem	Strength of product	Dose	Frequency	No. of Rpts	OTC	GP Supply	Drug status									New	Cont.	1.									2.									3.									4.									Diagnosis/ Problem ② : Problem Status New <input type="checkbox"/> Old <input type="checkbox"/> Work related <input type="checkbox"/> <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th>Drug Name AND Form for this problem</th> <th>Strength of product</th> <th>Dose</th> <th>Frequency</th> <th>No. of Rpts</th> <th>OTC</th> <th>GP Supply</th> <th colspan="2">Drug status</th> </tr> <tr> <th colspan="7"></th> <th>New</th> <th>Cont.</th> </tr> </thead> <tbody> <tr><td>1.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>2.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>3.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>4.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> </tbody> </table>	Drug Name AND Form for this problem	Strength of product	Dose	Frequency	No. of Rpts	OTC	GP Supply	Drug status									New	Cont.	1.									2.									3.									4.								
Drug Name AND Form for this problem	Strength of product	Dose	Frequency	No. of Rpts	OTC	GP Supply	Drug status																																																																																																						
							New	Cont.																																																																																																					
1.																																																																																																													
2.																																																																																																													
3.																																																																																																													
4.																																																																																																													
Drug Name AND Form for this problem	Strength of product	Dose	Frequency	No. of Rpts	OTC	GP Supply	Drug status																																																																																																						
							New	Cont.																																																																																																					
1.																																																																																																													
2.																																																																																																													
3.																																																																																																													
4.																																																																																																													

Procedures, other treatments, counselling this consult for this problem 1. _____ Prac Nurse? <input type="checkbox"/> 2. _____ Prac Nurse? <input type="checkbox"/>	Procedures, other treatments, counselling this consult for this problem 1. _____ Prac Nurse? <input type="checkbox"/> 2. _____ Prac Nurse? <input type="checkbox"/>
---	---

Diagnosis/ Problem ③ : Problem Status New <input type="checkbox"/> Old <input type="checkbox"/> Work related <input type="checkbox"/> <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th>Drug Name AND Form for this problem</th> <th>Strength of product</th> <th>Dose</th> <th>Frequency</th> <th>No. of Rpts</th> <th>OTC</th> <th>GP Supply</th> <th colspan="2">Drug status</th> </tr> <tr> <th colspan="7"></th> <th>New</th> <th>Cont.</th> </tr> </thead> <tbody> <tr><td>1.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>2.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>3.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>4.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> </tbody> </table>	Drug Name AND Form for this problem	Strength of product	Dose	Frequency	No. of Rpts	OTC	GP Supply	Drug status									New	Cont.	1.									2.									3.									4.									Diagnosis/ Problem ④ : Problem Status New <input type="checkbox"/> Old <input type="checkbox"/> Work related <input type="checkbox"/> <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th>Drug Name AND Form for this problem</th> <th>Strength of product</th> <th>Dose</th> <th>Frequency</th> <th>No. of Rpts</th> <th>OTC</th> <th>GP Supply</th> <th colspan="2">Drug status</th> </tr> <tr> <th colspan="7"></th> <th>New</th> <th>Cont.</th> </tr> </thead> <tbody> <tr><td>1.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>2.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>3.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>4.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> </tbody> </table>	Drug Name AND Form for this problem	Strength of product	Dose	Frequency	No. of Rpts	OTC	GP Supply	Drug status									New	Cont.	1.									2.									3.									4.								
Drug Name AND Form for this problem	Strength of product	Dose	Frequency	No. of Rpts	OTC	GP Supply	Drug status																																																																																																						
							New	Cont.																																																																																																					
1.																																																																																																													
2.																																																																																																													
3.																																																																																																													
4.																																																																																																													
Drug Name AND Form for this problem	Strength of product	Dose	Frequency	No. of Rpts	OTC	GP Supply	Drug status																																																																																																						
							New	Cont.																																																																																																					
1.																																																																																																													
2.																																																																																																													
3.																																																																																																													
4.																																																																																																													

Procedures, other treatments, counselling this consult for this problem 1. _____ Prac Nurse? <input type="checkbox"/> 2. _____ Prac Nurse? <input type="checkbox"/>	Procedures, other treatments, counselling this consult for this problem 1. _____ Prac Nurse? <input type="checkbox"/> 2. _____ Prac Nurse? <input type="checkbox"/>
---	---

NEW REFERRALS, ADMISSIONS Problem(s) 1. _____ 1 2 3 4 2. _____ 1 2 3 4	IMAGING/Other tests Body site Problem(s) 1. _____ - _____ 1 2 3 4 2. _____ - _____ 1 2 3 4	PATHOLOGY Problem(s) PATHOLOGY (cont) Problem(s) 1. _____ 1 2 3 4 4. _____ 1 2 3 4 2. _____ 1 2 3 4 5. _____ 1 2 3 4 3. _____ 1 2 3 4
--	--	--

Patient reported Height: _____ cm Weight: _____ kg	To the patient if 18+: Which best describes your smoking status? Smoke daily <input type="checkbox"/> Smoke occasionally <input type="checkbox"/> Previous smoker <input type="checkbox"/> Never smoked <input type="checkbox"/>	To the patient if 18+: How often do you have a drink containing alcohol? Never <input type="checkbox"/> Monthly or less <input type="checkbox"/> Once a week/fortnight..... <input type="checkbox"/> 2-3 times a week <input type="checkbox"/> 4+ times a week <input type="checkbox"/>	How many 'standard' drinks do you have on a typical day when you are drinking? _____	How often do you have 6 or more standard drinks on one occasion? Never <input type="checkbox"/> Less than monthly <input type="checkbox"/> Monthly <input type="checkbox"/> Weekly <input type="checkbox"/> Daily or almost daily <input type="checkbox"/>	FINISH Time _____ : _____ AM / PM (please circle) BA10
---	--	--	---	---	---

Appendix 4: GP characteristics questionnaire, 2007–08



The University of Sydney
at Westmead Hospital

Australian General Practice
Statistics and
Classification Centre



a collaborating unit of the

Australian Institute of Health and Welfare

Doctor Identification Number

--	--	--	--	--

Please fill in boxes or circle answers

1. Sex Male / Female (please circle)
2. Age.....
3. How many years have you spent in general practice?.....
4. How many GPs (full time equivalents) work at this practice (including yourself)?
(Practice = shared medical records)
5. Postcode of major practice address ..
6. In which GP Division is this practice
.....
7. Year of graduation
8. Place of graduation (primary medical degree):
 - Aust 1
 - NZ 2
 - Asia 3
 - UK / Ireland..... 4
 - Other: (specify) 5
9. Do you conduct any of your consultations in a language other than English?
 - No..... 1
 - Yes - <25%..... 2
 - Yes - 25 to 50%..... 3
 - Yes - >50%..... 4
10. Are you a GP registrar (i.e. in training)?... Yes / No
11. Do you hold FRACGP ?..... Yes / No
12. Is your major practice accredited ?..... Yes / No
13. Is there a practice nurse at your major practice address ?..... Yes / No
If yes, how many full time equivalents?
14. Number of general practice sessions you usually work per week?
(1 session = ~4 hrs eg a morning session)
15. Direct patient care hours worked per week?
(Include hours of direct patient care, instructions, counselling etc and other services such as referrals, prescriptions, phone calls etc.)

16. Over the past four weeks have you provided any patient care(Circle all that apply)
 - As a locum 1
 - In a deputising service 2
 - In a residential aged care facility 3
 - As a salaried/sessional hospital medical officer..... 4
 - None of the above 5
17. What are the normal after-hours arrangements for your practice? (Circle all that apply)
 - Practice does its own.....1
 - Co-operative with other practices2
 - Deputising service.....3
 - Referral to other service (eg A&E)4
 - Other5
 - None6
18. Do you bulk bill ALL patients?..... Yes / No
If No, which groups are bulk billed?
(Tick those that apply)

	All	Some
Pensioner/Healthcare Card holders ...	<input type="checkbox"/>	<input type="checkbox"/>
Children <16 years.....	<input type="checkbox"/>	<input type="checkbox"/>
Selected other patients	<input type="checkbox"/>	<input type="checkbox"/>
19. To what extent are computers used -
 - (i) at your major practice? (ii) by you (at work)?
 - Not at all 1 Not at all 1
 - Billing.....2 Test ordering 2
 - Prescribing.....3 Prescribing3
 - Medical Records.....4 Medical Records 4
 - Other Admin.....5 Internet 5
 - Internet / Email.....6 Email6
 - (iii) Prescribing / Health record software used is —
.....
20. Is your major practice site a teaching practice?
(Circle all that apply)
 - for undergraduates..... 1
 - for GP registrars 2
 - No..... 3
21. Did any of your BEACH consultations take place in an Aboriginal Community Controlled Health Service (ACCHS)?
 - No..... 1
 - Yes - all..... 2
 - Yes - some (which dates?) 3

© BEACH General Practice & Statistics Classification Unit, University of Sydney 1996

Thank you for participating in the BEACH PROGRAM.

Appendix 5: Code groups from ICPC-2 and ICPC-2 PLUS

Table A5.1: Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label
Reasons for encounter and problems managed			
Abdominal pain	D01		Pain/cramps; abdominal general
	D06		Pain; abdominal localised; other
Abnormal test results	A91		Abnormal result investigations NOS
	B84		Unexplained abnormal white cells
	U98		Abnormal urine test NOS
	X86		Abnormal cervix smear
Anaemia		B78002	Anaemia; sickle cell
		B78003	Anaemia; hereditary haemolytic
		B79001	Anaemia; congenital
		B79004	Anaemia; hereditary
	B80		Iron deficiency anaemia
	B81		Anaemia; vitamin B12/folate deficiency
	B82		Anaemia; other/unspecified
Anxiety	P01		Feeling anxious/nervous/tense
	P74		Anxiety disorder/anxiety state
Arthritis—all	L88		Rheumatoid/seropositive arthritis
	L89		Osteoarthritis of hip
	L90		Osteoarthritis of knee
	L91		Osteoarthritis, other
		L70009	Arthritis; pyogenic
		L70010	Arthritis; viral
		L70021	Arthritis; septic
		L81003	Arthritis; traumatic
		L81015	Haemarthrosis
		L83010	Arthritis; spine cervical
		L83011	Osteoarthritis; spine; cervical
		L84003	Arthritis; spine
		L84004	Osteoarthritis; spine
		L84009	Osteoarthritis; spine; thoracic
		L84010	Osteoarthritis; spine; lumbar
		L84011	Osteoarthritis; lumbosacral
		L84012	Osteoarthritis; sacroiliac
		L92006	Arthritis; shoulder

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label
Reasons for encounter and problems managed (continued)			
Arthritis—all (continued)		L92007	Osteoarthritis; shoulder
		L92011	Humeroscapular periarthritis
		S91002	Arthritis; psoriatic
		T99063	Arthritis; crystal (excluding gout)
Back complaint	L02		Back symptom/complaint
	L03		Low back symptom/complaint
	L86		Back syndrome with radiating pain
Cardiac check-up			See Check-up—ICPC chapter, Cardiovascular
Check-up—all	–30		Medical examination/health evaluation, complete
	–31		Medical examination/health evaluation, partial
	X37		Pap smear
Check-up—ICPC chapter	A30; A31		General
	B30; B31		Blood
	D30; D31		Digestive
	F30; F31		Eye
	H30; H31		Ear
	K30; K31		Cardiovascular
	L30; L31		Musculoskeletal
	N30; N31		Neurological
	P30; P31		Psychological
	R30; R31		Respiratory
	S30; S31		Skin
	T30; T31		Endocrine
	U30; U31		Urology
	W30; W31		Prenatal/postnatal
	X30; X31; X37		Female genital
Y30; Y31		Male genital	
Z30; Z31		Social	
Depression	P03		Feeling depressed
	P76		Depressive disorder
Diabetes—non-gestational	T89		Diabetes; insulin-dependent
	T90		Diabetes; non-insulin-dependent
Diabetes—all	T89		Diabetes; insulin-dependent
	T90		Diabetes; non-insulin-dependent
	W85		Gestational diabetes
Female genital check-up			See Check-up—ICPC chapter, Female genital

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label
Reasons for encounter and problems managed (continued)			
Fracture	L72		Fracture; radius/ulna
	L73		Fracture; tibia/fibula
	L74		Fracture; hand/foot bone
	L75		Fracture; femur
	L76		Fracture; other
		L84019	Fracture; compression; spine
		L99017	Fracture; non-union
		L99018	Fracture; pathological
		L99019	Fracture; malunion
		L99095	Fracture; stress
		N54005	Decompression; fracture; skull
		N80012	Fracture; skull (base)
		N80013	Fracture; skull
		N80014	Injury; head; fracture
Gastroenteritis	D70		Gastrointestinal infection
	D73		Gastroenteritis, presumed infectious
General check-up			See Check-up—ICPC chapter, General
Hypertension/high BP (RFEs)	K85		Elevated blood pressure (without hypertension)
	K86		Hypertension; uncomplicated
	K87		Hypertension; complicated
		W81002	Hypertension; pre-eclamptic
		W81003	Hypertension in pregnancy
Hypertension (problems)	K86		Hypertension; uncomplicated
	K87		Hypertension; complicated
		W81002	Hypertension; pre-eclamptic
		W81003	Hypertension in pregnancy
Immunisation/vaccination—all	A44		Preventive immunisation/medication; general/unspecified
	D44		Preventive immunisation/medication; digestive
	N44		Preventive immunisation/medication; neurological
	R44		Preventive immunisation/medication; respiratory
Ischaemic heart disease	K74		Ischaemic heart disease with angina
	K76		Ischaemic heart disease without angina
Menstrual problems	X02		Pain; menstrual
	X03		Pain; intermenstrual
	X05		Menstruation; absent/scanty
	X06		Menstruation; excessive
	X07		Menstruation; irregular/frequent

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label
Reasons for encounter and problems managed (continued)			
Menstrual problems (continued)	X08		Intermenstrual bleeding
	X09		Premenstrual symptom/complaint
	X10		Postponement of menstruation
Oral contraception	W10		Contraception; postcoital
	W11		Contraception; oral
	W50		Medication; reproductive system
Osteoarthritis		L83011	Osteoarthritis; spine; cervical
		L84004	Osteoarthritis; spine
		L84009	Osteoarthritis; spine; thoracic
		L84010	Osteoarthritis; spine; lumbar
Osteoarthritis		L84011	Osteoarthritis; lumbosacral
		L84012	Osteoarthritis; sacroiliac
		L89001	Osteoarthritis; hip
		L90001	Osteoarthritis; knee
		L91001	Osteoarthritis; degenerative
		L91003	Osteoarthritis
		L91008	Heberdens nodes
		L91015	Osteoarthritis; wrist
	L92007	Osteoarthritis; shoulder	
Pregnancy	W01		Question of pregnancy
	W78		Pregnancy
	W79		Unwanted pregnancy
Pre/postnatal check-up			See Check-up—ICPC chapter, Prenatal/postnatal
Prescription—all	–50		Medication prescription/request/renewal/injection
Rash	S06		Rash; localised
	S07		Rash generalised
Rheumatoid arthritis	L88		Rheumatoid/seropositive arthritis
Sprain/strain		L19014	Strain; muscle(s)
		L77	Sprain/strain; ankle
		L78	Sprain/strain; knee
		L79	Sprain/strain; joint NOS
		L83023	Sprain; neck
		L83024	Strain; neck
		L84020	Sprain; back
		L84021	Strain; back

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label
Reasons for encounter and problems managed (continued)			
Swelling (skin)	S04		Lump/swelling; localised
	S05		Lump/swelling; generalised
Test results	-60		Results tests/procedures
	-61		Results examination/test/record/letter other provider
Tonsillitis	R76		Tonsillitis; acute
	R90		Hypertrophy; tonsils/adenoids
Urinary tract infection	U70		Pyelonephritis/pyelitis
	U71		Cystitis/urinary infection other
Clinical treatments			
Advice/education		A45002	Advice/education
		B45002	Advice/education; blood
		D45002	Advice/education; digestive
		F45002	Advice/education; eye
		H45002	Advice/education; ear
		K45002	Advice/education; cardiovascular
		L45002	Advice/education; musculoskeletal
		N45002	Advice/education; neurological
		P45001	Advice/education; psychological
		R45002	Advice/education; respiratory
		S45002	Advice/education; skin
		T45002	Advice/education; endocrine/metabolic
		U45002	Advice/education; urology
		W45004	Advice/education; reproductive
		X45002	Advice/education; genital; female
		Y45002	Advice/education; genital; male
		Z45002	Advice/education; social
Advice/education—medication		A45015	Advice/education; medication
		A45032	Advice/education; Dosette box
		A45033	Advice/education; Webster pack
		A48003	Review; medication
		A48005	Increased; drug dosage
		A48006	Decreased; drug dosage
		A48007	Change (in); drug dosage
		A48008	Stop medication
		A48009	Recommend medication (not new)
	A48010	Change (in); medication	

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label	
Clinical treatments (continued)				
Advice/education—medication (continued)		A48011	Medication; request; refusal	
		A48012	Review; immunisation	
		A50010	Medication; given	
Advice/education—treatment		A45016	Advice/education; treatment	
		A45019	Advice; time off work	
		A45020	Advice; rest/fluids	
		A45021	Advice; naturopathic treatment	
		A45030	Advice/education; first aid	
		A48004	Review; treatment	
		L45004	Advice/education; RICE	
		R45004	Advice/education; asthma	
		T45004	Advice/education; diabetes	
		T45009	Advice; home glucose monitoring	
Counselling/advice—alcohol		P45005	Advice/education; alcohol	
		P58009	Counselling; alcohol	
Counselling/advice—drug abuse		P45006	Advice/education; illicit drugs	
		P58010	Counselling; drug abuse	
		P58020	Rehabilitation; drug	
		P58021	Rehabilitation; alcohol	
Counselling/advice—exercise		A45004	Advice/education; exercise	
		A58005	Counselling; exercise	
Counselling/advice—health/body		A45005	Advice/education; health	
		A45009	Health promotion	
		A45010	Information; health	
		A45011	Health promotion; injury	
		A45018	Advice/education; body	
		A45026	Advice/education; hygiene	
		A58006	Counselling; health	
		A98001	Health maintenance	
	Counselling/advice—lifestyle		P45008	Advice/education; lifestyle
			P58012	Counselling; lifestyle
Counselling/advice—nutrition/weight		A45006	Advice/education; diet	
		T45005	Advice/education; nutritional	
		T45007	Advice/education; weight management	
		T58002	Counselling; weight management	

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label
Clinical treatments (continued)			
Counselling/advice—pregnancy		W45009	Advice/education; pregnancy
		W58004	Counselling; prenatal
		W58006	Counselling; pregnancy
Counselling/advice—prevention		A45025	Advice/education; immunisation
		A58007	Counselling; prevention
		X45004	Advice/education; breast self-exam
		X45007	Advice/education; Pap smear
		X45008	Advice/education; mammography
		Z45005	Advice/education; environment
Counselling/advice—relationship		Z45006	Advice/education; parenting
		Z45007	Advice/education; mothering
		Z45008	Advice/education; fathering
		Z58001	Counselling; conjugal (partner)
		Z58003	Counselling; marriage/relationship
		Z58006	Counselling; parenting
		Z58007	Counselling; mothering
		Z58008	Counselling; fathering
		Z58009	Counselling; family
		Z58011	Counselling; conflict resolution
	Counselling/advice—relaxation		P45007
		P58011	Counselling; relaxation
		P58017	Counselling; stress management
Counselling/advice—smoking		P45004	Advice/education; smoking
		P58008	Counselling; smoking
Counselling/advice—STDs		A45012	Advice/education; STD
		A58008	Counselling; STDs
		X58004	Counselling; STDs; female
		Y58004	Counselling; STDs; male
Counselling—problem		A58002	Counselling; problem
		A58003	Counselling; individual
		B58001	Counselling; problem; blood
		D58001	Counselling; problem; digestive
		F58001	Counselling; problem; eye
		H58001	Counselling; problem; ear
		K58001	Counselling; problem; cardiovascular
		L58001	Counselling; problem; musculoskeletal
		N58001	Counselling; problem; neurological

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label	
Clinical treatments (continued)				
Counselling—problem (continued)		R58001	Counselling; problem; respiratory	
		S58001	Counselling; problem; skin	
		T58001	Counselling; problem; endocrine/metabolic	
		U58001	Counselling; problem; urology	
		W58003	Counselling; problem; reproductive	
		X58001	Counselling; problem; genital; female	
		X58003	Counselling; sexual; physical; female	
		Y58001	Counselling; problem; genital; male	
		Y58003	Counselling; sexual; physical; male	
		Z58002	Counselling; problem; social	
	Counselling—psychological		P45013	Anger management
			P58001	Counselling; psychiatric
			P58002	Psychotherapy
			P58004	Counselling; psychological
			P58005	Counselling; sexual; psychological
		P58006	Counselling; individual; psychological	
		P58007	Counselling; bereavement	
		P58013	Counselling; anger	
		P58014	Counselling; self-esteem	
		P58015	Counselling; assertiveness	
		P58018	Therapy; group	
		P58019	Cognitive behavioural therapy	
		P58022	Counselling; body image	
Family planning			A98002	Counselling; genetic female
			A98003	Counselling; genetic male
		W14002	Family planning; female	
		W45006	Advice/education; preconceptual	
		W45007	Advice/education; contraception; female	
		W45008	Advice/education; family planning; female	
		W58001	Counselling; abortion	
		W58005	Counselling; terminate pregnancy	
		W58007	Counselling; preconceptual	
		W58012	Counselling; sterilisation; female	
		W58013	Counselling; family planning; female	
		Y14001	Family planning; male	
		Y45006	Advice/education; family planning; male	
		Y45007	Advice/education; contraception; female	
		Y58005	Counselling; sterilisation; male	
	Y58006	Counselling; family planning; male		

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2/ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label
Clinical treatments (continued)		
Observe/wait	A45001	Observe/wait
	B45001	Observe/wait; blood
	D45001	Observe/wait; digestive
	F45001	Observe/wait; eye
	H45001	Observe/wait; ear
	K45001	Observe/wait; cardiovascular
	L45001	Observe/wait; musculoskeletal
	N45001	Observe/wait; neurological
	P45002	Observe/wait; psychological
	R45001	Observe/wait; respiratory
	S45001	Observe/wait; skin
	T45001	Observe/wait; endocrine/metabolic
	U45001	Observe/wait; urology
	W45003	Observe/wait; reproductive
	X45001	Observe/wait; genital; female
	Y45001	Observe/wait; genital; male
	Z45001	Observe/wait; social
Other admin/document	-62 (excluding A62008 and A62014)	
Reassurance, support	A58010	Reassurance/support
Sickness certificate	A62008	Admin; certificate; sickness
	A62014	Admin; certificate; workers' compensation
Procedures		
Incision/drainage/flushing/aspiration/ removal body fluid	-51	
Excision/removal tissue/biopsy/ destruction/debridement/cauterisation	-52	
Repair/fixation-suture/cast/prosthetic device (apply/remove)	-54	
Local injection/infiltration	-55	
	A50007	Injection; allergy
	A50008	Injection; desensitisation
	B50001	Injection; iron
	B50007	Injection; blood
	D50006	Injection; digestive
	F50006	Injection; eye
	H50006	Injection; ear
	K50006	Injection; cardiovascular
	L50007	Injection; musculoskeletal

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2/ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label
Procedures (continued)		
Local injection/infiltration (continued)	N50005	Injection; neurological
	P50006	Injection; psychological
	R50005	Injection; respiratory
	S50006	Injection; skin
	T50006	Injection; endocrine/metabolic
	T50007	Injection; vitamin; B12
	T50008	Injection; hormone
	T50009	Injection; vitamin
	U50006	Injection; urological
	X50006	Injection; genital; F
Y50005	Injection; genital; M	
Dressing/pressure/compression/tamponade	-56	
Physical medicine/rehabilitation	-57	
Other procedures/minor surgery NEC	-59	
	A50009	Chemotherapy
	A50011	Refill; Dosette box
	A50012	Refill; Webster pack
Check-up—practice nurse	-31 (excluding A31015)	Medical examination/health evaluation, partial
Clinical measurements		
Diagnostic endoscopy	-40	
Electrical tracings	-42	
Glucose test	T34005	Test; glucose
INR test	B34025	Test; INR
Other diagnostic procedures	-43	
	A31015	Assessment; ADL
Other preventive procedures/high-risk medication	-49	
	A31027	Assessment; physical fitness
	X31001	Exam; breast
	X31005	Check-up; breast
	Y31003	Check-up; prostate
Pap smear	X37001	Pap smear
	X37003	Test; cytology; genital; female
	X37004	Vault smear
	X37005	Pap smear; thin prep
Physical function test	-39	

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2/ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label
Clinical measurements (continued)		
Urine test	A35001	Test; urine
	A35002	Urinalysis
	B35001	Test; urine; blood
	D35001	Test; urine; digestive
	P35001	Test; urine; psychological
	T35001	Test; urine; endocrine/metabolic
	U35002	Test; urine; urology
	W35001	Test; urine; reproductive
	X35001	Test; urine; genital; female
Y35001	Test; urine; genital; male	
Referrals		
Allied health services	-66	Referral to other provider/nurse/therapist/ social worker
	-68 (excluding A68011; Z68003; Z68004; Z68007 and Z68008)	Other referrals NEC
	Z67002	Referral; respite care
Specialist	-67 (excluding A67010; A67011; A67022; A67015; P67005 and Z67002)	Referral to physician/specialist/clinic/hospital
	A68009	Referral; oncologist
Emergency department	A67011	Referral; accident and emergency
Hospital	A67010	Referral; hospital
	A67015	Referral; hospice
	A67022	Admission; hospital
	P67005	Referral; hospital; psychiatrist
	P67005	Referral; hospital; psychiatrist
Other referrals	A68011	Referral
	Z68003	Referral; financial/legal services
	Z68004	Referral; police
	Z68007	Referral; women's shelter
	Z68008	Referral; Centrelink
Pathology test orders (MBS groups)		
Chemistry		
Amylase	D34004	Test; amylase
B12	B34015	Test; B12
	D34009	Test; Schillings
C reactive protein	A34005	Test; C reactive protein
Calcium/phosphate	A34006	Test; calcium
	A34013	Test; phosphate
	A34024	Test; calcium phosphate

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Cardiac enzymes	D34005	Test; aspartate aminotransferase
	K34003	Test; cardiac enzymes
	K34004	Test; creatine kinase
Chemistry; other	A33023	Test; alpha fetoprotein
	A33026	Test; cancer antigen 125
	A33027	Test; cancer antigen 15.3
	A33028	Test; cancer antigen 19.9
	A33029	Test; carcinoembryonic antigen
	A33041	Test; cancer antigen
	A34015	Test; protein
	A34018	Vitamin assay
	A34019	Test; lead
	A34020	Test; blood gas analysis
	A34022	Test; mineral
	A34023	Test; zinc
	A34025	Test; DHEAS
	A34030	Test; biochemistry
	A34031	Test; blood alcohol
	A34032	Test; prolactin
	A34033	Test; testosterone
	A34037	Test; Glutathione S-transferase
	A34038	Test; magnesium
	A34040	Test; renin
	A35004	Test; urine sodium
	A35007	Test; urine; albumin
	A35008	Test; albumin creatine ratio
	B34023	Test; transferrin
	D34002	Test; alanine aminotransferase
	D35002	Test; 5-HIAA
	K34001	Test; blood; digitalis
	K34006	Test; amino acids
	K34007	Test; troponin
	N34001	Test; blood; phenylhydantoin
P34003	Test; methadone	
T34018	Test; androgens	
T34019	Test; insulin	
T34021	Test; C peptide	
T34029	Test; aldosterone	

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Chemistry; other (continued)	T34030	Test; parathyroid hormone
	T34035	Test; lipase
	T35002	Test; catecholamines
	W34008	Test; PAPP A
	W38002	Amniocentesis
Drug screen	A34002	Drug assay
	A34026	Blood drug screen
	A34027	Blood screen
	A35003	Drug screen
	A35005	Urine drug screen
	K34005	Test; digoxin
	N34003	Test; phenytoin
	N34004	Test; valproate
	N34005	Test; carbamazepine
	P34002	Test; lithium
EUC	A34007	Test; chloride
	A34008	Test; electrolytes
	A34010	Test; EUC
	A34014	Test; potassium
	A34017	Test; sodium
	A34029	Test; U&E
	A34034	Test; E&C
	U34002	Test; creatinine
	U34003	Test; urea
	HbA1c	T34010
T34017		Test; fructosamine
T34022		Test; HBA1
Ferritin	B34016	Test; ferritin
	B34019	Test; iron studies
Folic acid	B34017	Test; folic acid
	B34024	Test; folate
Glucose/tolerance	T34005	Test; glucose
	T34009	Test; glucose tolerance
	T34023	Test; glucose (fasting/random)
	T34025	Test; glucose; fasting
	T34026	Test; glucose; random

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Hormone assay	A34003	Hormone assay
	D33015	Test; anti gliadin antibody
	T34007	Test; cortisol
	T34034	Test; ACTH
	W34005	Test; HCG
	W34006	Test; B HCG level (titre/quant)
	X34002	Test; LH
	X34003	Test; progesterone
	X34004	Test; oestradiol
	X34005	Test; FSH
	X34006	Test; SHBG; female
	X34007	Test; free androgen index; female
	Y34004	Test; SHBG; male
	Y34005	Test; free androgen index; male
	Lactose intolerance	D38002
Lipids	T34001	Check-up; cholesterol
	T34004	Test; lipids profile
	T34006	Test; cholesterol
	T34011	Test; cholesterol HDL
	T34013	Test; cholesterol LDL
	T34016	Test; triglycerides
	T34020	Test; free fatty acids
	T34024	Test; cholesterol/triglycerides
Liver function	A34004	Test; albumin
	D34003	Test; alkaline phosphatase
	D34006	Test; bilirubin
	D34007	Test; gGT
	D34008	Test; liver function
	T34012	Test; LDH
Multi-biochemical analysis	A34012	Test; multi-biochemical analysis
	A34021	Test; E & LFT
Prostate specific antigen	Y34002	Test; acid phosphatase
	Y34003	Test; prostate specific antigen
Thyroid function	T34015	Test; thyroid function
	T34027	Test; thyroxine
	T34028	Test; TSH
Urate/uric acid	U34004	Test; urate/uric acid

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Cytopathology		
Cytology	A37002	Test; cytology
	B37003	Test; cytology; blood
	D37002	Test; cytology; digestive
	F37002	Test; cytology; eye
	H37002	Test; cytology; ear
	K37002	Test; cytology; cardiovascular
	L37002	Test; cytology; musculoskeletal
	N37002	Test; cytology; neurological
	R37002	Test; cytology; respiratory
	R37003	Test; sputum cytology
	S37002	Test; cytology; skin
	T37002	Test; cytology; endocrine/metabolic
	U37002	Test; cytology; urology
	W37002	Test; cytology; reproduction
	Y37002	Test; cytology; genital; male
	Pap smear	X37001
X37003		Test; cytology; genital; female
X37004		Vault smear
X37005		Pap smear; thin prep
Haematology		
Blood grouping & typing	B33001	Test; Coombs
	B33002	Test; blood grouping & typing
	B33009	Test; blood group
	B33013	Test; blood; cross match
Blood; other	A33042	Test; lymphocyte type & count
	A34035	Test; blood film
	A34036	Test; blood thick film
	B33003	RH; antibody titre
	B34005	Test; blood; platelets
	B34007	Test; blood; sickle cell
	B34021	Test; reticulocyte count
	B34031	Test; haemoglobin epg
	B34032	Test; packed cell volume
	B34033	Test; blood; blood
	B37001	Exam; bone marrow

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label	
Pathology test orders (continued)			
Coagulation	B34003	Test; coagulation time	
	B34006	Test; part thromboplastin time	
	B34009	Test; prothrombin time	
	B34014	Test; APTT	
	B34022	Test; thrombin time	
	B34025	Test; INR	
	B34026	Test; fibrinogen	
	B34028	Test; bleeding time	
	B34029	Test; coagulation screen	
	K34008	Test; D-Dimer	
ESR	A34009	Test; ESR	
Full blood count	A34011	Test; full blood count	
Haemoglobin	B34018	Test; haemoglobin	
Tissue pathology (Histopathology)			
Histology; skin	S37001	Test; histopathology; skin	
Histology; other	A37001	Test; histopathology	
	B37002	Test; histopathology; blood	
	D37001	Test; histopathology; digestive	
	F37001	Test; histopathology; eye	
	H37001	Test; histopathology; ear	
	K37001	Test; histopathology; cardiovascular	
	L37001	Test; histopathology; musculoskeletal	
	N37001	Test; histopathology; neurological	
	R37001	Test; histopathology; respiratory	
	T37001	Test; histopathology; endocrine/metabolic	
	U37001	Test; histopathology; urology	
	W37001	Test; histopathology; reproductive	
	X37002	Test; histopathology; genital; female	
	Y37001	Test; histopathology; genital; male	
	Immunology		
	Anti-nuclear antibodies	L33004	Test; anti-nuclear antibodies
Immunology; other	A32001	Test; sensitivity	
	A33005	Test; immunology	
	A33011	Test; HLA	
	A33024	Test; bone marrow surface mark	
	A33025	Test; serum electrophoresis	
	A33051	Test; immune status	
	A33052	Test; skin patch	

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Immunology; other (continued)	A38004	Test; DNA
	B33005	Test; immunology; blood
	B33007	Test; immunoglobulins
	B33011	Test; IgE
	B34027	Test; FBC for surface markers
	B34030	Test; intrinsic factor
	D32001	Test; sensitivity; digestive
	D33004	Test; immunology; digestive
	D33014	Test; endomysial antibody
	D33028	Test; mitochondrial antibodies
	D33031	Test; anti-tissue transglutaminase
	D34010	Test; transglutamase
	F33002	Test; immunology; eye
	H33002	Test; immunology; ear
	K33002	Test; immunology; cardiovascular
	K33003	Test; ANCA
	L33003	Test; immunology; musculoskeletal
	L34001	Test; lupus erythematosus; cell prep
	N33002	Test; immunology; neurological
	R32004	Test; sensitivity; respiratory
	R33004	Test; immunology; respiratory
	S32001	Test; sensitivity; skin
	S33002	Test; immunology; skin
	T33002	Test; immunology; endocrine/metabolic
	U33003	Test; immunology; urology
	W33007	Test; immunology; reproductive
	X33002	Test; immunology; genital; female
	Y33002	Test; immunology; genital; male
RAST	A34016	Test; RAST
Rheumatoid factor	L33001	Test; rheumatoid factor
Infertility/pregnancy	W33002	Test; pregnancy
	W34002	Test; blood; pregnancy
	W34003	Test; antenatal
	W34007	Test; pregnancy screen
	Y38002	Test; sperm count
	Y38003	Test; semen examination

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Microbiology		
Antibody	A33003	Test; antibody
Cervical swab	X33004	Test; cervical swab M,C&S
Chlamydia	A33006	Test; chlamydia
	A33034	Test; chlamydia direct immunofl
	X33006	Test; viral culture; genital; female
Ear swab and C&S	H33003	Test; ear swab M,C&S
Faeces M,C&S	D33002	Stool(s); culture
	D33008	Test; faeces M,C&S
	D36001	Test; faeces; cyst/ova/parasite
Fungal ID/sensitivity	A33008	Test; fungal ID/sensitivity
	A33030	Test; skin scraping fungal M,C&S
Hepatitis serology	D33005	Test; hepatitis A serology
	D33006	Test; hepatitis B serology
	D33007	Test; hepatitis C serology
	D33013	Test; hepatitis serology
	D33018	Test; hepatitis A antibody
	D33019	Test; hepatitis B antibody
	D33020	Test; hepatitis D antibody
	D33021	Test; hepatitis E antibody
	D33022	Test; hepatitis A antigen
	D33023	Test; hepatitis C antigen
	D33024	Test; hepatitis D antigen
	D33025	Test; hepatitis E antigen
	D33026	Test; hepatitis antibody
	D33027	Test; hepatitis antigen
HIV	A33021	Test; cytomegalovirus serology
	B33006	Test; HIV
	B33008	Test; AIDS screen
	B33012	Test; HIV viral load
H pylori	D33009	Test; H Pylori
Microbiology; other	A33004	Test; microbiology
	A33007	Test; culture and sensitivity
	A33012	Test; mycoplasma serology
	A33013	Test; parvovirus serology
	A33015	Test; Barmah forest virus
	A33016	Test; Antistreptolysin O Titre
	A33017	Test; herpes simplex culture

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Microbiology; other (continued)	A33019	Test; herpes simplex serology
	A33020	Test; toxoplasmosis serology
	A33033	Test; swab M,C&S
	A33035	Test; serology
	A33036	Antibodies screen
	A33038	Test; rapid plasma regain
	A33039	Test; viral swab M,C&S
	A33040	Test; viral serology
	A33043	Test; HPV
	A33044	Test; Brucella
	A33045	Test; fungal M,C&S
	A33046	Test; measles virus antibodies
	A33047	Test; Rickettsial serology
	A33053	Test; Bartonella
	A33054	Test; MC&S
	A34028	Test; blood culture
	A34039	Test; Q fever
	B33004	Test; microbiology; blood
	B33010	Test; serum immunoglobulins
	D33003	Test; microbiology; digestive
	D33010	Test; hepatitis D serology
	D33011	Test; hepatitis E serology
	D33012	Test; rotavirus
	D33016	Test; hepatitis C antibody
	D33017	Test; hepatitis B antigen
	F33001	Test; microbiology; eye
	F33003	Test; eye swab M,C&S
	H33001	Test; microbiology; ear
	K33001	Test; microbiology; cardiovascular
	L33002	Test; microbiology; musculoskeletal
	N33001	Test; microbiology; neurological
	R33001	Culture; tuberculosis
	R33002	Culture; throat
	R33003	Test; microbiology; respiratory
	R33009	Test; influenza serology
	R33010	Test; Legionnaires antibodies
	R33011	Test; RSV
	S33001	Test; microbiology; skin

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label	
Pathology test orders (continued)			
Microbiology; other (continued)	S33005	Test; varicella zoster serology	
	S33006	Test; varicella zoster culture	
	S33007	Test; nail M,C&S	
	T33001	Test; microbiology; endocrine/metabolic	
	U33002	Test; microbiology; urology	
	W34004	Test; antenatal serology	
	W33006	Test; microbiology; reproductive	
	X33001	Test; microbiology; genital; female	
	X33003	Culture; gonococcal; female	
	Y33001	Test; microbiology; genital; male	
	Y33003	Culture; gonococcal; male	
	Y33004	Test; viral culture; genital; male	
	Y33005	Test; urethral/penile swab	
	Monospot	A33002	Test; monospot
		A33014	Test; Paul Bunnell
A33031		Test; Epstein Barr virus serology	
A33032		Test; Epstein Barr virus	
Nose swab C&S	R33008	Test; nose swab M,C&S	
Pertussis	R33007	Test; pertussis	
Ross River fever	A33009	Test; Ross River Fever	
Rubella	A33001	Test; rubella	
Skin swab C&S	S33003	Test; skin swab M,C&S	
Sputum C&S	R33005	Test; sputum M,C&S	
Throat swab C&S	R33006	Test; throat swab M,C&S	
Urine M,C&S	U33001	Test; culture; urine	
	U33004	Test; urine M,C&S	
Vaginal swab and M,C&S	X33005	Test; vaginal swab M,C&S	
Venereal disease	A33010	Test; venereal disease	
	A33022	Test; syphilis serology	
	A33057	STI screen	
Simple basic tests	B35001	Test; urine; blood	
	D36003	Test; occult blood	
	R32001	Test; Mantoux	
	R32002	Test; tuberculin	
	W33001	Test; urine; pregnancy	
	W35003	Test; urine; HCG	

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Other NEC		
Blood test	A34001	Test; blood
Urine test	A35001	Test; urine
Urinalysis	A35002	Urinalysis
Faeces test	A36001	Test; faeces
Other pathology test NEC	A35006	Test; urine; FWT
	A38001	Test; other lab
	A38002	Pathology
	A38003	Test; genetic
	A38005	Test; disease screen
	B38001	Test; other lab; blood
	D34001	Test; blood; digestive
	D35001	Test; urine; digestive
	D36002	Test; faeces; digestive
	D38001	Test; other lab; digestive
	F34001	Test; blood; eye
	F38001	Test; other lab; eye
	H34001	Test; blood; ear
	H38001	Test; other lab; ear
	K34002	Test; blood; cardiovascular
	K38001	Test; other lab; cardiovascular
	L34003	Test; blood; musculoskeletal
	L38001	Test; other lab; musculoskeletal
	N34002	Test; blood; neurological
	N38001	Test; other lab; neurological
	P34001	Test; blood; psychological
	P35001	Test; urine; psychological
	P38001	Test; other lab; psychological
	R34001	Test; blood; respiratory
	R38001	Test; other lab; respiratory
	S34001	Test; blood; skin
	S38001	Test; other lab; skin
T34002	Test; blood; endocrine/metabolic	
T35001	Test; urine; endocrine/metabolic	
T38001	Test; other lab; endocrine/metabolic	
U34001	Test; blood; urology	
U35002	Test; urine; urology	
U38001	Test; other lab; urology	
W34001	Test; blood; reproductive	

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Other pathology test NEC (continued)	W35001	Test; urine; reproductive
	W38001	Test; other lab; reproductive
	X34001	Test; blood; genital; female
	X35001	Test; urine; genital; female
	X38001	Test; other lab; genital; female
	Y34001	Test; blood; genital; male
	Y35001	Test; urine; genital; male
	Y38001	Test; other lab; genital; male
	Z38001	Test; other lab; social
Imaging test orders (MBS groups)		
Diagnostic radiology	A41001	Radiology; diagnostic
	A41002	X-ray; chest
	A41006	X-ray; abdomen
	A41007	Imaging other
	A41010	Radiology
	A41014	Test; imaging; contrast/special
	B41001	Radiology; diagnostic; blood
	D41001	GI series
	D41003	Radiology; diagnostic; digestive
	D41006	X-ray; oesophagus
	D41007	X-ray; biliary ducts
	D41008	X-ray; digestive tract
	D41009	X-ray; mouth
	D41012	X-ray; dental
	D41015	Barium enema
	D41016	Barium meal
	D41017	Barium swallow
	F41001	Radiology; diagnostic; eye
	F41002	X-ray; eye
	H41001	Radiology; diagnostic; ear
	H41002	X-ray; ear
	K41002	Radiology; diagnostic; cardiovascular
	K41003	Cardiogram
	K41005	Angiography; coronary
	K41006	Angiography; femoral
	K41007	Angiography; cerebral
K41011	Angiogram	

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Imaging test orders (continued)		
Diagnostic radiology (continued)	K41012	Angiogram; coronary
	K41013	Angiogram; cerebral
	K41014	Angiogram; femoral
	L41001	Arthrogram
	L41003	X-ray; bone(s)
	L41004	Plain x-ray; bone(s)
	L41005	Radiology; diagnostic; musculoskeletal
	L41013	X-ray; elbow
	L41014	X-ray; hand
	L41015	X-ray; wrist
	L41016	X-ray; knee
	L41017	X-ray; hip
	L41018	X-ray; neck
	L41019	X-ray; pelvis
	L41020	X-ray; shoulder
	L41021	X-ray; lumbosacral
	L41022	X-ray; cervical
	L41023	X-ray; thoracic
	L41024	X-ray; spinal
	L41025	X-ray; joint(s)
	L41026	X-ray; foot/feet
	L41027	X-ray; ankle
	L41028	X-ray; leg
	L41029	X-ray; ribs
	L41030	X-ray; face
	L41032	X-ray; arm
	L41033	X-ray; spine; lumbar
	L41034	X-ray; spine; sacrum
	L41035	X-ray; spine; coccyx
	L41036	X-ray; finger(s)/thumb
	L41037	X-ray; toe(s)
	L41038	X-ray; heel
	L41039	X-ray; tibia/fibula
	L41040	X-ray; femur
	L41041	X-ray; radius/ulna
	L41042	X-ray; clavicle
	L41043	X-ray; humerus
	L41044	X-ray; jaw

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Imaging test orders (continued)		
Diagnostic radiology (continued)	L41045	X-ray; temporomandibular joint
	L41060	X-ray; spine; cervicothoracic
	L41061	X-ray; spine; sacrococcygeal
	L41062	X-ray; spine; thoracolumbar
	L41063	X-ray; back
	L41064	X-ray; back lower
	L41065	X-ray; forearm
	L41066	X-ray; leg lower
	L41067	X-ray; metacarpal
	L41068	X-ray; metatarsal
	L43003	Test; densitometry
	N41001	Radiology; diagnostic neurological
	N41004	X-ray; skull
	P41001	Radiology; diagnostic; psychological
	R41001	Radiology; diagnostic; respiratory
	R41002	X-ray; sinus
	R41003	X-ray; nose
	S41001	Radiology; diagnostic; skin
	T41001	Radiology; diagnostic; endocrine/metabolic
	T41003	X-ray; endocrine/metabolic
	U41001	Pyelogram; intravenous
	U41002	Pyelogram; retrograde
	U41005	Radiology; diagnostic; urology
	U41007	X-ray; urinary tract
	U41008	X-ray; kidney/ureter/bladder
	W41002	Radiology; diagnostic; reproductive
	W41003	X-ray; uterus
	X41001	Mammography; female
	X41002	Mammography; request; female
	X41003	Thermography; breast
	X41005	Radiology; diagnostic; genital; female
	X41007	X-ray; breast; female
	Y41001	Radiology; diagnostic; genital; male
Ultrasound	A41012	Ultrasound
	A41015	Ultrasound; abdomen
	A41017	Ultrasound; chest
	A41021	Ultrasound; inguinal
	A41022	Ultrasound; abdomen; upper
	A41023	Ultrasound; abdomen; lower

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 PLUS code	ICPC-2 PLUS label
Imaging test orders (continued)		
Ultrasound (continued)	B41002	Ultrasound; spleen
	D41013	Ultrasound; gallbladder
	D41014	Ultrasound; liver
	K41001	Echocardiography
	K41016	Ultrasound; cardiac
	K43003	Test; Doppler
	K43004	Test; Doppler carotid
	K43005	Scan; duplex
	L41046	Ultrasound; neck
	L41047	Ultrasound; pelvis
	L41048	Ultrasound; shoulder
	L41049	Ultrasound; spine
	L41050	Ultrasound; knee
	L41051	Ultrasound; elbow
	L41070	Ultrasound; wrist
	L41071	Ultrasound; ankle
	L41072	Ultrasound; groin
	L41073	Ultrasound; back
	L41074	Ultrasound; back lower
	L41075	Ultrasound; hand/finger(s)
	L41076	Ultrasound; foot/toe(s)
	L41078	Ultrasound; arm
	L41079	Ultrasound; leg
	N41005	Ultrasound; brain
	N41007	Ultrasound; head
	T41004	Ultrasound; thyroid
	U41009	Ultrasound; renal tract
	U41010	Ultrasound; kidney
	W41004	Ultrasound; obstetric
	W41005	Ultrasound; nuchal translucency
	X41009	Ultrasound; breast; female
	X41011	Ultrasound; uterus (not pregnant)
	Y41005	Ultrasound; prostate
	Y41006	Ultrasound; scrotum
Y41008	Ultrasound; breast; male	

(continued)

Table A5.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 PLUS code	ICPC-2 PLUS label
Imaging test orders (continued)		
Computerised tomography	A41013	CT scan
	A41016	CT scan; abdomen
	A41018	CT scan; chest
	A41019	CT scan; abdomen; upper
	A41020	CT scan; abdomen; lower
	D41018	CT scan; liver
	K41017	CT scan; cardiac
	L41052	CT scan; neck
	L41053	CT scan; pelvis
	L41054	CT scan; spine
	L41055	CT scan; spine; cervical
	L41056	CT scan; spine; thoracic
	L41057	CT scan; spine; lumbar
	L41058	CT scan; spine; lumbosacral
	L41059	CT scan; spine; sacrum
	L41069	CT scan; spine; thoracolumbar
	L41077	CT scan; spine; cervicothoracic
	L41080	CT scan; leg
	N41006	CT scan; brain
	N41008	CT scan; head
	R41004	CT scan; sinus
	X41010	CT scan; breast; female
	Y41007	CT scan; breast; male
Nuclear medicine	A41009	Nuclear medicine
	A41011	Isotope scan
	K41015	Scan; thallium heart
	L41002	Scan; bone(s)
	R41005	Scan; VQ (lung)
Magnetic resonance imaging	A41008	MRI

Notes

1. NOS—not otherwise specified; STD—sexually-transmitted disease; NEC—not elsewhere classified; MBS—Medicare Benefits Schedule; EUC—electrolytes, urea and creatinine; LDL—low-density lipoprotein; HDL—high-density lipoprotein; ESR—erythrocyte sedimentation rate; M,C&S—microscopy, culture and sensitivity; HIV—human immunodeficiency virus.
2. ‘-code’—signifies that the concept includes all of the specified code across all chapters of ICPC-2 (excluding the Z social chapter). Codes listed in this appendix are only those currently active within ICPC-2 PLUS.

Appendix 6: Chronic code groups from ICPC-2 and ICPC-2 PLUS

Table A6.1: Chronic code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC/ICPC-2 PLUS label
Chronic problems managed			
Acne (chronic)		S96007	Acne
		S96003	Acne; conglobulate
		S96002	Acne; vulgaris
Anaemia (chronic)	B81		Anaemia, vitamin B12/folate deficiency
	B82		Anaemia, other/unspecified
Arthritis (excl osteoarthritis and rheumatoid arthritis)		L83010	Arthritis; spine cervical
		L84003	Arthritis; spine
		L84023	Arthritis; spine thoracic
		L84024	Arthritis; spine lumbar
		L84025	Arthritis; lumbosacral
		L84026	Arthritis; sacroiliac
		L89004	Arthritis; hip
		L90004	Arthritis; knee
		L91007	Arthritis; degenerative
		L91009	Arthritis
		L91010	Arthritis; acute
		L91011	Arthritis; allergic
		L91012	Polyarthritis
		L91013	Arthritis; hands/fingers
		L91014	Arthritis; wrist
	L92006	Arthritis; shoulder	
	S91002	Arthritis; psoriatic	
Diabetes (non-gestational)	T89		Diabetes, insulin dependent
	T90		Diabetes, non-insulin dependent
Hypertension (non-gestational)	K86		Hypertension, uncomplicated
	K87		Hypertension, complicated

Note: Excl—excluding. The code groups listed in Appendix 6 are those which differ from other code groups used in the report (see Appendix 5), limiting analysis to only chronic conditions (see Glossary).

Appendix 7: Dissemination of results from the BEACH program

A full list of BEACH publications is also available from the Family Medicine Research Centre website: <<http://www.fmrc.org.au/publications/>>.

BOOKS—GENERAL PRACTICE SERIES (BEACH) ISSN 1442-3022

Britt H, Miller GC, Charles J, Bayram C, Pan Y, Henderson J, Valenti L, O'Halloran J, Harrison C, Fahridin S 2008. General practice activity in Australia 2006–07. Cat. no. GEP 21. Canberra: AIHW.

Britt H, Miller GC, Henderson J, Bayram C 2007. Patient-based substudies from BEACH: abstracts and research tools 1999–2006. Cat. no. GEP 20. Canberra: AIHW.

Britt H, Miller GC, Charles J, Pan Y, Valenti L, Henderson J, Bayram C, O'Halloran J, Knox S 2007. General practice activity in Australia 2005–06. Cat. no. GEP 19. Canberra: AIHW.

Britt H, Miller GC, Knox S, Charles J, Pan Y, Henderson J, Bayram C, Valenti L, Ng A, O'Halloran J 2005. General practice activity in Australia 2004–05. Cat. no. GEP 18. Canberra: AIHW.

Knox S, Britt H, Pan Y, Miller GC, Bayram C, Valenti L, Charles J, Henderson J, Ng A, O'Halloran J 2005. Locality matters: the influence of geography on general practice activity in Australia 1998–2004. Cat. no. GEP 17. Canberra: AIHW.

Britt H, Miller GC, Knox S, Charles J, Valenti L, Pan Y, Henderson J, Bayram C, O'Halloran J, Ng A 2004. General practice activity in Australia 2003–04. Cat. no. GEP 16. Canberra: AIHW.

Britt H, Miller GC, Knox S, Charles J, Valenti L, Bayram C, O'Halloran J, Henderson J, Pan Y, Harrison C 2004. General practice activity in the states and territories of Australia 1998–2003. Cat. no. GEP 15. Canberra: AIHW.

Britt H, Miller GC, Knox S, Charles J, Valenti L, Henderson J, Pan Y, Bayram C, Harrison C 2003. General practice activity in Australia 2002–03. Cat. no. GEP 14. Canberra: AIHW.

Britt H, Knox S, Miller GC 2003. Changes in pathology ordering by GPs in Australia 1998–2001. Cat. no. GEP 13. Canberra: AIHW.

O'Halloran J, Britt H, Valenti L, Harrison C, Pan Y, Knox S 2003. Older patients attending general practice in Australia 2000–02. Cat. no. GEP 12. Canberra: AIHW.

Bayram C, Britt H, Kelly Z, Valenti L 2003. Male consultations in general practice in Australia 1999–00. Cat. no. GEP 11. Canberra: AIHW.

Britt H, Miller GC, Knox S, Charles J, Valenti L, Henderson J, Pan Y, Sutton C, Harrison C 2002. General practice activity in Australia 2001–02. Cat. no. GEP 10. Canberra: AIHW.

Henderson J, Pan Y, Britt H, Charles J, Miller GC, Knox S 2002. Cardiovascular problems and risk behaviours among patients at general practitioner encounters in Australia 1998–00. Cat. no. GEP 9. Canberra: AIHW.

Britt H, Miller GC, Knox S, Charles J, Valenti L, Henderson J, Kelly Z, Pan Y 2001. General practice activity in Australia 2000–01. Cat. no. GEP 8. Canberra: AIHW.

Britt H, Miller GC, Valenti L 2001. 'It's different in the bush': a comparison of general practice activity in metropolitan and rural areas of Australia 1998–2000. Cat. no. GEP 6. Canberra: AIHW.

Britt H, Miller GC, Knox S 2001. Imaging orders by general practitioners in Australia 1999–00. Cat. no. GEP 7. Canberra: AIHW.

Britt H, Miller GC, Charles J, Knox S, Sayer GP, Valenti L, Henderson J, Kelly Z 2000. General practice activity in Australia 1999–2000. Cat. no. GEP 5. Canberra: AIHW.

Sayer GP, Britt H, Horn F, Bhasale A, McGeechan K, Charles J, Miller GC, Hull B, Scahill S 2000. Measures of health and health care delivery in general practice in Australia. Cat. no. GEP 3. Canberra: AIHW.

Britt H, Miller GC, McGeechan K, Sayer GP 1999. Pathology ordering by general practitioners in Australia 1998. Cat. no. GEP 4. Canberra: Department of Health and Aged Care.

Britt H, Sayer GP, Miller GC, Charles J, Scahill S, Horn F, Bhasale A, McGeechan K 1999. General practice activity in Australia 1998–99. Cat. no. GEP 2. Canberra: AIHW.

Britt H, Sayer GP, Miller GC, Charles J, Scahill S, Horn F, Bhasale A 1999. BEACH Bettering the Evaluation and Care of Health: a study of general practice activity, six-month interim report. Cat. no. GEP 1. Canberra: AIHW.

OTHER BOOKS

Senes S, Britt H 2001. A general practice view of cardiovascular disease and diabetes in Australia. Cardiovascular disease series no. 18. Cat. no. CVD 17. Canberra: Australian Institute of Health and Welfare.

CONTRIBUTIONS TO BOOKS

Australian Institute of Health and Welfare. 2008 Australia's health 2008: the eleventh biennial health report of the Australian Institute of Health and Welfare. Britt H, Harrison C, contributors. Canberra: AIHW.

Australian Institute of Health and Welfare 2006. Australia's health 2006: the tenth biennial health report of the Australian Institute of Health and Welfare. Britt H, contributor. Canberra: AIHW.

Australian Government Department of Health and Ageing 2005. General practice in Australia: 2004. Britt H, contributor. Canberra: DoHA.

Australian Institute of Health and Welfare 2004. Australia's health 2004: the ninth biennial health report of the Australian Institute of Health and Welfare. Britt H, contributor. Canberra: AIHW.

Australian Institute of Health and Welfare 2002. Australia's health 2002: the eighth biennial health report of the Australian Institute of Health and Welfare. Britt H, contributor. Canberra: AIHW.

Australian Institute of Health and Welfare 2000. Australia's health 2000: the seventh biennial health report of the Australian Institute of Health and Welfare. Britt H, contributor. Canberra: AIHW.

Commonwealth Department of Health and Aged Care 2000. General practice in Australia: 2000. Britt H, contributor. Canberra: DHAC.

Australian Institute of Health and Welfare 1998. Australia's health 1998: the sixth biennial health report of the Australian Institute of Health and Welfare. Britt H, contributor. Canberra: AIHW.

REFEREED ARTICLES IN RECOGNISED JOURNALS

Britt HC, Harrison CM, Miller GC, Knox SA 2008. Prevalence and patterns of multimorbidity in Australia. *Med J Aust* 189(2):72

Knox SA, Harrison CM, Britt HC, Henderson JV 2008. Estimating prevalence of common chronic morbidities in Australia. *Med J Aust* 189(2):66-70.

Henderson J, Miller G, Pan Y, Britt H 2008. The effect of advertising in clinical software on general practitioners' prescribing behaviour. *Med J Aust* 188(1):15-20.

Bayram C, Knox S, Miller G, Ng A, Britt H 2007. Clinical activity of overseas-trained doctors practising in general practice in Australia. *Aust Health Rev* 31(3):440-8.

Stark RJ, Valenti L, Miller GC 2007. Management of migraine in Australian general practice. *Med J Aust* 187(3):142-6.

O'Halloran J, Britt H, Valenti L 2007. General practitioner consultations at residential aged-care facilities. *Med J Aust* 187(2):88-91.

Bindman AB, Forrest CB, Britt H, Crampton P, Majeed A 2007. Diagnostic scope of and exposure to primary care physicians in Australia, New Zealand, and the United States: cross sectional analysis of results from three national surveys. *BMJ* 334(7606):1261-6.

Gunasekera H, Knox S, Morris P, Britt H, McIntyre PB, Craig JC 2007. The spectrum and management of otitis media in Australian Indigenous and non-Indigenous children: a national study. *Pediatr Infect Dis J* 26:689-92.

Britt H, Miller G, Bayram C 2007. The quality of data on general practice – A discussion of BEACH reliability and validity. *Aust Fam Physician* 36(1-2):36-40.

Charles J, Britt H, Knox S 2006. Patient perception of their weight, attempts to lose weight and their diabetes status. *Aust Fam Physician* 35(11):925-8.

Henderson J, Britt H, Miller G 2006. Extent and utilisation of computerisation in Australian general practice. *Med J Aust* 185(2):84-87.

Charles J, Britt H, Valenti L 2006. The independent effect of age of general practitioner on clinical practice. *Med J Aust* 185(2):105-9.

Miller GC, Britt HC, Valenti L, Knox S 2006. Adverse drug events: counting is not enough, action is needed [letter]. *Med J Aust* 184(12):646.

Miller GC, Britt HC, Valenti L 2006. Adverse drug events in general practice patients in Australia. *Med J Aust* 184(7):321.

Proude EM, Britt H, Valenti L, Conigrave KM 2006. The relationship between self-reported alcohol intake and the morbidities managed by GPs in Australia. *BMC Fam Pract* 7(1):17.

Pan Y, Henderson J, Britt H 2006. Antibiotic prescribing in Australian general practice: How has it changed from 1990-91 to 2002-03? *Respir Med* 100(11):2004-11.

Chen MY, Pan Y, Britt H, Donovan B 2006. Trends in clinical encounters for pelvic inflammatory disease and epididymitis in a national sample of Australian general practices. *Int J STD AIDS* 17(6):384.

Doran CM, Valenti L, Robinson M, Britt H, Mattick RP 2006. Smoking status of Australian general practice patients and their attempts to quit. *Addict Behav* 31(5):758.

Freedman E, Britt H, Harrison CM, Mindel A 2006. Sexual health problems managed in Australian general practice: a national, cross sectional survey. *Sex Transm Infect* 82(1):61-6.

- Rae K, Britt H, Orchard J, Finch C 2005. Classifying sports medicine diagnoses: a comparison of the International classification of diseases 10 – Australian modification (ICD-10-AM) and the Orchard sports injury classification system (OSICS-8). *Br J Sports Med* 39(12):907–11.
- Degenhardt L, Knox S, Barker B, Britt H, Shakeshaft A 2005. The management of alcohol, tobacco and illicit drug use problems by general practitioners in Australia. *Drug Alcohol Rev* 24(6):499–506.
- Britt HC, Valenti L, Miller GC 2005. Determinants of consultation length in Australian general practice. *Med J Aust* 183(2):68–71.
- Valenti L, Charles J, Britt H 2005. Passive smoke in Australian homes: 1999 to 2004 [letter]. *Aust N Z J Public Health* 29(4):387–8.
- Harrison CM, Britt HC 2005. Antidepressant use in children: a less depressing story [letter]. *Med J Aust* 182(2):92.
- Harris MF, Furler J, Valenti L, Harris E, Britt H 2004. Matching care to need in general practice: A secondary analysis of Bettering the Evaluation and Care of Health (BEACH) data. *Australian Journal of Primary Health* 10(3):151–5.
- Knox SA, Chondros P 2004. Observed intra-cluster correlation coefficients in a cluster survey sample of patient encounters in general practice in Australia. *BMC Med Res Methodol* 4(1):30.
- O'Halloran J, Britt H, Valenti L, Harrison C, Pan Y, Knox S et al. 2004. Encounters with older patients in Australian general practice. *Aust Fam Physician* 33(10):776.
- Gruen RL, Knox S, Carson P, O'Rourke IC, Britt H, Bailie RS 2004. The demand for surgery: an analysis of referrals from Australian general practitioners. *ANZ J Surg* 74(10):863–8.
- Harrison CM, Britt H 2004. The rates and management of psychological problems in Australian general practice. *Aust N Z J Psychiatry* 38(10):781–8
- Caldwell TM, Jorm AF, Knox S, Braddock D, Dear KB, Britt H 2004. General practice encounters for psychological problems in rural, remote and metropolitan areas in Australia. *Aust N Z J Psychiatry* 38(10):774–80.
- Miller G, Britt H, Pan Y, Knox S 2004. Relationship between general practitioner certification and characteristics of care. *Med Care* (Aug)42(8):770–8.
- O'Halloran J, Britt H 2004. General practice encounters with older Australians. *Australas J Ageing* 23(1):7–12.
- Pegram RW, Valenti L 2004. Factors influencing billing status in general practice (letter). *Med J Aust* 181(2):115.
- Johnston VJ, Britt H, Pan Y, Mindel A 2004. The management of sexually transmitted infections by Australian general practitioners. *Sex Transm Infect* (Jun)80(3):212–15.
- Gruen RL, Knox S, Britt H, Bailie RS 2004. The Surgical Nosology In Primary-care Settings (SNIPS): a simple bridging classification for the interface between primary and specialist care. *BMC Health Serv Res* (May)4(1):8.
- O'Halloran J, Miller GC, Britt H 2004. Defining chronic conditions for primary care with ICD-10. *Fam Pract* (Aug)21(4):381–6.
- Britt H, Valenti L, Miller GC, Farmer J 2004. Determinants of GP billing in Australia: content and time. *Med J Aust* (Jul)181(2):100–4.

- Charles J, Britt H, Valenti L 2004. The evolution of the general practice workforce in Australia, 1991–2003. *Med J Aust* (Jul)181(2):85–90.
- Charles J, Pan Y, Britt H 2004. Trends in childhood illness and treatment in Australian general practice, 1971–2001. *Med J Aust* (Mar)180(5):216–19.
- Henderson J, Knox S, Pan Y, Britt H 2004. Changes in asthma management in Australian general practice. *Primary Care Respiratory Journal* (Sep)13(3):138–43.
- Knox SA, Britt H 2004. The contribution of demographic and morbidity factors to self-reported visit frequency of patients: a cross-sectional study of general practice patients in Australia. *BMC Fam Pract* (Aug)5(1):17.
- Charles J, Valenti L, Britt H 2003. GP visits by health care card holders. A secondary analysis of data from Bettering the Evaluation and Care of Health (BEACH), a national study of general practice activity in Australia. *Aust Fam Physician* 32(1–2):85–8, 94.
- Bridges-Webb C, Wolk J, Britt H, Pond D 2003. The management of dementia in general practice. A field test of guidelines. *Aust Fam Physician* 32(4):283–5.
- Harrison CM, Britt HC 2003. Prescriptions for antipsychotics in general practice (letter). *Med J Aust* 178(9):468–9.
- McManus P, Mant A, Mitchell P, Britt H, Dudley J 2003. Use of antidepressants by general practitioners and psychiatrists in Australia. *Aust N Z J Psychiatry* 37(2):184–9.
- Britt H, Valenti L, Miller G 2002. Time for care. Length of general practice consultations in Australia. *Aust Fam Physician* 31(9):876–80.
- Gruen RL, Knox S, Britt H 2002. Where there is no surgeon: the effect of specialist proximity on general practitioners' referral rates. *Med J Aust* 177(2):111–15.
- Knox SA, Britt H 2002. A comparison of general practice encounters with patients from English-speaking and non-English-speaking backgrounds. *Med J Aust* 177(2):98–101.
- Britt HC, Miller GC 2000. The BEACH study of general practice. *Med J Aust* 173(2):63–4.

OTHER PUBLICATIONS IN REFEREED JOURNALS

- Charles J, Fahridin S, Britt H 2008. Referrals to A&E. *Aust Fam Physician* 37(7):505.
- Harrison C, Charles J, Britt H 2008. AD(H)D. *Aust Fam Physician* 37(6):393.
- Charles J, Fahridin S, Britt H 2008. Vertiginous syndrome. *Aust Fam Physician* 37(5):299.
- Fahridin S, Britt H 2008. Allergic rhinitis. *Aust Fam Physician* 37(4):203.
- Charles J, Britt H, Fahridin S 2008. Urinary incontinence in the older patient. *Aust Fam Physician* 37(3):105.
- Charles J, Britt H, Valenti L 2008. Lifestyle matters. *Aust Fam Physician* 37(1–2):9.
- Fahridin S, Harrison C, Britt H, Charles J 2007. Skin malignancies in general practice. *Aust Fam Physician* 36(12):984–5.
- Charles J, Miller G, Fahridin S 2007. Management of stroke in general practice. *Aust Fam Physician* 36(11):890–1.
- Charles J, Miller G, Harrison C 2007. Management of haemachromatosis in general practice. *Aust Fam Physician* 36(10):792–3.
- Britt H, Fahridin S 2007. Presentations of nausea and vomiting. *Aust Fam Physician* 36(9):682–3.

Bayram C, Britt H, Fahridin S 2007. Adolescent attendances in general practice. *Aust Fam Physician* 36(8):586-7.

Fahridin S, Charles J, Miller G 2007. Atrial fibrillation in Australian general practice. *Aust Fam Physician* 36(7):490-1.

Charles J, Britt H, Fahridin S 2007. Chronic musculoskeletal problems managed in general practice. *Aust Fam Physician* 36(6):392-3.

Bayram C, Pan Y, Miller G 2007. Management of travel related problems in general practice. *Aust Fam Physician* 36(5):298-9.

Charles J, Britt H, Fahridin S, Miller G 2007. Mental health in general practice. *Aust Fam Physician* 36(4):200-1.

Bayram C, Pan Y, Miller G 2007. Gynaecological cancer in Australian general practice. *Aust Fam Physician* 36(3):104-5.

Charles J, Pan Y, Britt H 2006. Work related encounters in general practice. *Aust Fam Physician* 35(12):938-9.

Charles J, Harrison C 2006. Irritable bowel syndrome in Australian general practice. *Aust Fam Physician* 35(11):840-1.

Charles J, Harrison C, Britt H 2006. Malignant neoplasms – management in Australian general practice. *Aust Fam Physician* 35(10):760-1.

Charles J, Knox S, Britt H 2006. Postnatal depression in Australian general practice. *Aust Fam Physician* 35(9):668-9.

Valenti L, Charles J, Britt H 2006. BMI of Australian general practice patients. *Aust Fam Physician* 35(8):570-1.

Charles J, Knox S, Britt H 2006. Skin excisions in Australian general practice. *Aust Fam Physician* 35(7):474.

Charles J, Ng A, Miller G 2006. Management of type 2 diabetes in Australian general practice. *Aust Fam Physician* 35(6):378.

Miller G, Valenti L, Charles J 2006. Use of diagnostic imaging in Australian general practice. *Aust Fam Physician* 35(5):280.

Charles J, Miller G, Ng A 2006. GI malignancies in Australian general practice. *Aust Fam Physician* 35(4):186.

Charles J, Miller G, Ng A 2006. Management of psychosis in Australian general practice. *Aust Fam Physician* 35(3):88.

AIHW Australian GP Statistics and Classification Centre BEACH overview 2006. *Aust Fam Physician* 35(3):153-4.

O'Halloran J, Ng A, Britt H, Charles J 2006. EPC encounters in Australian general practice. *Aust Fam Physician* 35(1-2):8-10.

Charles J, Ng A, Britt H 2005. Management of epilepsy in general practice patients. *Aust Fam Physician* 34(12):1000.

Charles J, Miller G, Ng A 2005. Management of renal problems in Australian general practice. *Aust Fam Physician* 34(11):904.

Charles J, Britt H, Knox S 2005. Encounters with Indigenous patients in Australian general practice. *Aust Fam Physician* 34(10):810.

- Charles J, Britt H, Ng A 2005. Management of growth delay in patients aged less than 6 years. *Aust Fam Physician* 34(9):714-15.
- Charles J, Ng A, Britt H 2005. Presentations of headache in Australian general practice. *Aust Fam Physician* 34(8):618-19.
- Charles J, Ng A, Britt H 2005. Presentations of shortness of breath in Australian general practice. *Aust Fam Physician* 34(7):520-1.
- Charles J, Britt H, Ng A 2005. Management of cardiovascular conditions in Australian general practice. *Aust Fam Physician* 34(6):410-11.
- Charles J, Britt H, Ng A 2005. Management of inflammatory skin conditions in Australian general practice. *Aust Fam Physician* 34(5):316-17.
- Britt H 2005. Adolescent mental health: Reply [letter]. *Aust Fam Physician* 34(4):215-16.
- Britt H, Valenti L, Miller G, Charles J 2005. Presentations of diarrhoea in Australian general practice. *Aust Fam Physician* 34(4):218-19.
- Charles J, Pan Y, Britt H 2005. Management of infertility in Australian general practice. *Aust Fam Physician* 34(3):104-5.
- Charles J, Ng A, Britt H, Pan Y, Miller GC, Valenti L et al. 2005. The treatment of adolescents in Australian general practice. *Aust Fam Physician* 34(1/2):8-9.
- Bayram C, Pan Y, Valenti L, Britt H, Charles J, Miller GC et al. 2004. Current status of hormone therapy in general practice in Australia. *Aust Fam Physician* 33(11):872-3.
- Britt H, Valenti L, Miller G, Bayram C, Charles J, Knox S et al. 2004. Presentations of abdominal pain in Australian general practice. *Aust Fam Physician* 33(12):968-9.
- Britt H, Pan Y, Miller GC, Valenti L, Charles J, Knox S et al. 2004. Presentations of 'itch' in Australian general practice. *Aust Fam Physician* 33(7):488.
- Charles J, Harrison C, Britt H, Pan Y, Miller GC, Valenti L et al. 2004. General practitioners in teaching practices. *Aust Fam Physician* 33(9):682.
- Britt H 2003. BEACH – Bettering the Evaluation And Care of Health: a continuous national study of general practice activity. *Commun Dis Intell* 27(3):391-3.
- Britt H, Miller G 2003. General practice medical records (correspondence in reply). *Aust Fam Physician* 24:2250.
- Britt H, Miller GC, Knox S, Charles J, Valenti L, Henderson J et al. 2003. Bettering the Evaluation And Care of Health 2001-2002 (summary of results). *Aust Fam Physician* 32(1/2):59-63.
- Britt H 1998. BEACH Bettering the Evaluation And Care of Health. *Fam Pract Wonca News* 24(4):vii-viii.

RELATED PUBLICATIONS IN REFEREED JOURNALS

- Wang Y, Patrick J, Miller G, O'Halloran J 2006. Linguistic Mapping of Terminologies to SNOMED CT. Presented at the SMCS 2006 – Semantic Mining Conference on SNOMED CT; 10 September 2006, Copenhagen.
- Britt H, Angelis M, Harris E 1998. The reliability and validity of doctor-recorded morbidity data in active data collection systems. *Scand J Prim Health Care* 16:50-5.

Britt H 1998. Reliability of central coding of patient reasons for encounter in general practice, using the International Classification of Primary Care. *Informatics* (May)3-7.

Britt H 1997. A measure of the validity of the ICPC in the classification of reasons for encounter. *Informatics* (November)8-12.

Britt H, Meza RA, Del Mar C 1996. Methodology of morbidity and treatment data collection in general practice in Australia: a comparison of two methods. *Fam Pract* 13(5):462-7.

Meza RA, Angelis M, Britt H, Miles DA, Seneta E, Bridges-Webb C 1995. Development of sample size models for national general practice surveys. *Aust J Pub Health* 19(1):34-40.

Britt H, Harris M, Driver B, Bridges-Webb C, O'Toole B, Neary S 1992. Reasons for encounter and diagnosed health problems: convergence between doctors and patients. *Fam Pract* 9:191-4.

Bridges-Webb C, Britt H, Miles DA, Neary S, Charles J, Traynor V 1992. Morbidity and treatment in general practice in Australia 1990-1991. *Med J Aust* 157(19 Oct Spec Sup):S1-S56.

Driver B, Britt H, O'Toole B, Harris M, Bridges-Webb C, Neary S 1991. How representative are patients in general practice morbidity surveys? *Fam Pract* 8:261-8.

PUBLISHED FULL-LENGTH CONFERENCE PAPERS

Britt H, Pan Y, Henderson J, Miller GC 2002. The prevalence of cardiovascular disease in general practice in Australia. Presented at Health Outcomes 2002: Current Challenges and Future Frontiers; 17 Jul 2002, Canberra.

Henderson J, Pan Y, Britt H 2002. Asthma management in general practice. Presented at Health Outcomes 2002: Current Challenges and Future Frontiers; 17 Jul 2002, Canberra.

Britt H, Miller GC, Valenti L 2001. 'It's different in the bush': a comparison of general practice activity in metropolitan and rural areas of Australia 1998-2000. Presented at the 6th National Rural Health Conference; 7 Apr 2001, Canberra.

THESES AND TREATISES

Henderson J 2007. The effect of computerisation on the quality of care in Australian general practice. PhD, University of Sydney.

O'Halloran J 2002. Aged patient encounters in the general practice setting. Bachelor of Applied Science, Health Information Management (Honours) thesis. Sydney: University of Sydney.

Sutton C 2001. Male encounters with general practitioners in Australia 1999-00. Bachelor of Applied Science, Health Information Management (Honours) thesis. Sydney: University of Sydney.

Charles J 1999. Changes in morbidity and its management between 1991 and 1997 in general practice in Victoria. Master of Science in Medicine thesis. Sydney: University of Sydney.

Henderson J 1999. Influencing prescribing behaviour in general practice: a five year follow-up study. Bachelor of Applied Science, Health Information Management (Honours) thesis. Sydney: University of Sydney.

Kelly Z 1999. Management of upper gastrointestinal problems for patients presenting to general practice in Australia 1998-99. Bachelor of Applied Science, Health Information Management (Honours) thesis. Sydney: University of Sydney.

Sedgwick D 1998. The prescribing of antibiotics for upper respiratory infections in general practice and its relationship to socio-economic status. Master of Public Health thesis. Sydney: University of Sydney.

SAND ABSTRACTS (ISSN 1444-9072), available from <<http://pandora.nla.gov.au/tep/14007>>

AIHW (Australian Institute of Health and Welfare) Australian GP Statistics and Classification Centre. 2007. Erectile dysfunction. Fahridin S (ed). SAND abstracts from the BEACH program no. 110.

AIHW Australian GP Statistics and Classification Centre. 2007. Secondary prevention of heart attack and stroke. Charles J (ed). SAND abstracts from the BEACH program no. 109.

AIHW Australian GP Statistics and Classification Centre. 2007. Type 2 diabetes among patients attending general practice. Harrison C (ed). SAND abstracts from the BEACH program no. 108.

AIHW Australian GP Statistics and Classification Centre. 2007. Type 2 diabetes and dyslipidaemia. Charles J (ed). SAND abstracts from the BEACH program no. 107.

AIHW Australian GP Statistics and Classification Centre. 2007. Weight loss attempts and methods. Charles J (ed). SAND abstracts from the BEACH program no. 106.

AIHW Australian GP Statistics and Classification Centre. 2007. Measurement of severity of illness in general practice. Miller G (ed). SAND abstracts from the BEACH program no. 105.

AIHW Australian GP Statistics and Classification Centre 2007. Asthma management and medication use among patients attending general practice. Henderson J (ed). SAND abstracts from the BEACH program no. 104.

AIHW Australian GP Statistics and Classification Centre 2007. Cardiovascular risk in patients attending general practice. Fahridin S (ed). SAND abstracts from the BEACH program no. 103.

AIHW Australian GP Statistics and Classification Centre 2007. Alzheimer's disease or dementia in patients attending general practice. O'Halloran J (ed). SAND abstracts from the BEACH program no. 102.

AIHW Australian GP Statistics and Classification Centre 2007. Types of medicine use and patient use of medicines list. Britt H (ed). SAND abstracts from the BEACH program no. 101.

AIHW Australian GP Statistics and Classification Centre 2007. Gastrointestinal symptoms in patients attending general practice. Miller G (ed). SAND abstracts from the BEACH program no. 100.

AIHW Australian GP Statistics and Classification Centre 2007. Lipid management in patients with high risk conditions. Bayram C (ed). SAND abstracts from the BEACH program no. 99.

AIHW Australian GP Statistics and Classification Centre 2007. Management of hypertension and angina in general practice patients. Fahridin S (ed). SAND abstracts from the BEACH program no. 98.

AIHW Australian GP Statistics and Classification Centre 2007. Statin medication use among high CHD risk patients attending general practice. Charles J (ed). SAND abstracts from the BEACH program no. 97.

AIHW Australian GP Statistics and Classification Centre 2007. Inhaled corticosteroid use for asthma management. Britt H (ed). SAND abstracts from the BEACH program no. 96.

AIHW Australian GP Statistics and Classification Centre 2007. Cultural background of patients attending general practice. Britt H (ed). SAND abstracts from the BEACH program no. 95.

AIHW Australian GP Statistics and Classification Centre 2006. Type 2 diabetes – investigations and related conditions. O’Halloran J (ed). SAND abstracts from the BEACH program no. 94.

AIHW Australian GP Statistics and Classification Centre 2006. Sexual dysfunction – premature ejaculation. Henderson J (ed). SAND abstracts from the BEACH program no. 93.

AIHW Australian GP Statistics and Classification Centre 2006. Prevalence of metabolic syndrome. Bayram C (ed). SAND abstracts from the BEACH program no. 92.

AIHW Australian GP Statistics and Classification Centre 2006. Prevalence and management of gastrointestinal symptoms. Bayram C (ed). SAND abstracts from the BEACH program no. 91.

AIHW Australian GP Statistics and Classification Centre 2006. Prevalence, management and investigations for chronic heart failure in general practice patients. Miller G (ed). SAND abstracts from the BEACH program no. 90.

AIHW Australian GP Statistics and Classification Centre 2006. Estimates of the prevalence of chronic illnesses identified as Health Priority Areas among patients attending general practice. Britt H (ed). SAND abstracts from the BEACH program no. 89.

AIHW Australian GP Statistics and Classification Centre 2006. Arthritis rates and NSAID use in general practice patients. Miller G (ed). SAND abstracts from the BEACH program no. 88.

AIHW Australian GP Statistics and Classification Centre 2006. Management of cardiovascular or diabetes related conditions. O’Halloran J (ed). SAND abstracts from the BEACH program no. 87.

AIHW Australian GP Statistics and Classification Centre 2006. Diabetes Types 1 and 2 and coronary heart disease. Henderson J (ed). SAND abstracts from the BEACH program no. 86.

AIHW Australian GP Statistics and Classification Centre 2006. Management of osteoporotic fractures in general practice patients. Charles J (ed). SAND abstracts from the BEACH program no. 85.

AIHW Australian GP Statistics and Classification Centre 2006. Menopausal status, symptoms and treatment of women aged 18 and over. Charles J (ed). SAND abstracts from the BEACH program no. 84.

AIHW Australian GP Statistics and Classification Centre 2006. Prevalence and management of migraine. Valenti L (ed). SAND abstracts from the BEACH program no. 83.

AIHW Australian GP Statistics and Classification Centre 2006. Prevalence and management of chronic pain. Henderson J (ed). SAND abstracts from the BEACH program no. 82.

AIHW Australian GP Statistics and Classification Centre 2005. Prevalence and indications for gabapentin use by patients attending general practice. Valenti L (ed). SAND abstracts from the BEACH program no. 81.

AIHW Australian GP Statistics and Classification Centre 2005. Employment status and workers compensation claims in general practice patients. Charles J (ed). SAND abstracts from the BEACH program no. 80.

AIHW Australian GP Statistics and Classification Centre 2005. Hypertension and dyslipidaemia – comorbidity and management in general practice patients. O'Halloran J (ed). SAND abstracts from the BEACH program no. 79.

AIHW Australian GP Statistics and Classification Centre 2005. NSAID & acid suppressant use in general practice patients. Miller G (ed). SAND abstracts from the BEACH program no. 78.

AIHW Australian GP Statistics and Classification Centre 2005. Heart failure – underlying causes and medication management. Bayram C (ed). SAND abstracts from the BEACH program no. 77.

AIHW Australian GP Statistics and Classification Centre 2005. Patients with risk factors for metabolic syndrome. Britt H (ed). SAND abstracts from the BEACH program no. 76

AIHW Australian GP Statistics and Classification Centre 2005. Prevalence, management and investigations for chronic heart failure. Pan Y (ed). SAND abstracts from the BEACH program no. 75.

AIHW Australian GP Statistics and Classification Centre 2005. Smoking and passive smoking in the home. Valenti L (ed). SAND abstracts from the BEACH program no. 74.

AIHW Australian GP Statistics and Classification Centre 2005. Warfarin use in patients with qualifying morbidity. Pan Y (ed). SAND abstracts from the BEACH program no. 73.

AIHW Australian GP Statistics and Classification Centre 2005. Contraceptive use among female general practice patients aged 16–44 years. Bayram C (ed). SAND abstracts from the BEACH program no. 72.

AIHW Australian GP Statistics and Classification Centre 2005. Patient BMI, morbidity and medication use in adults. Ng A (ed). SAND abstracts from the BEACH program no. 71.

AIHW Australian GP Statistics and Classification Centre 2005. Inhaled corticosteroid use for asthma management. Miller G (ed). SAND abstracts from the BEACH program no. 70.

AIHW Australian GP Statistics and Classification Centre 2005. Patient weight, methods and medications tried for weight loss in adults. Henderson J (ed). SAND abstracts from the BEACH program no. 69.

AIHW Australian GP Statistics and Classification Centre 2005. Patient weight, perception of weight and weight loss in adults. Charles J (ed). SAND abstracts from the BEACH program no. 68.

AIHW Australian GP Statistics and Classification Centre 2005. Risk factors of patients on lipid-lowering medications. Knox S (ed). SAND abstracts from the BEACH program no. 67.

AIHW GP Statistics and Classification Unit 2004. Anti-psychotic medication use by general practice patients. Britt H (ed). SAND abstracts from the BEACH program no. 66.

AIHW GP Statistics and Classification Unit 2004. Language and cultural background of general practice patients. Knox S (ed). SAND abstracts from the BEACH program no. 65.

AIHW GP Statistics and Classification Unit 2004. Current use of statins by general practice patients. Pan Y (ed). SAND abstracts from the BEACH program no. 64.

AIHW GP Statistics and Classification Unit 2004. Asthma-prevalence, management and medication side-effects. Henderson J (ed). SAND abstracts from the BEACH program no. 63.

AIHW GP Statistics and Classification Unit 2004. Use of proton pump inhibitors by general practice patients. Ng A (ed). SAND abstracts from the BEACH program no. 62.

AIHW GP Statistics and Classification Unit 2004. Prevalence of chronic illnesses identified as National Health Priority Areas among general practice patients. Knox S (ed). SAND abstracts from the BEACH program no. 61.

AIHW GP Statistics and Classification Unit 2004. Prevalence of GORD and associated proton pump inhibitor use. O'Halloran J (ed). SAND abstracts from the BEACH program no. 60.

AIHW GP Statistics and Classification Unit 2004. Hypertension management and control in general practice patients. Pan Y (ed). SAND abstracts from the BEACH program no. 59.

AIHW GP Statistics and Classification Unit 2004. Lipid lowering medications: patient eligibility under PBS. Miller G (ed). SAND abstracts from the BEACH program no. 58.

AIHW GP Statistics and Classification Unit 2004. Prevalence and management of chronic heart failure in general practice patients. Bayram C (ed). SAND abstracts from the BEACH program no. 57.

AIHW GP Statistics and Classification Unit 2004. Prevalence, cause and severity of adverse pharmacological events. Valenti L (ed). SAND abstracts from the BEACH program no. 56.

AIHW GP Statistics and Classification Unit 2004. Patient weight, perception of weight and weight loss. Charles J (ed). SAND abstracts from the BEACH program no. 55.

AIHW GP Statistics and Classification Unit 2003. Secondary prevention of heart attack or stroke. Harrison C (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 54.

AIHW GP Statistics and Classification Unit 2003. Smoking status of adults and their attempts to quit. Valenti L (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 53.

AIHW GP Statistics and Classification Unit 2003. Language and cultural background of patients. Knox S (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 52.

AIHW GP Statistics and Classification Unit 2003. Use of proton pump inhibitors for gastrointestinal problems. Miller G (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 51.

AIHW GP Statistics and Classification Unit 2003. Risk factors of patients on lipid lowering medications. Britt H (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 50.

AIHW GP Statistics and Classification Unit 2003. Health status and management of patients on non-steroidal anti-inflammatory drugs. Knox S (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 49.

AIHW GP Statistics and Classification Unit 2003. Asthma prevalence and management. Bayram C (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 48.

AIHW GP Statistics and Classification Unit 2003. Management of depression and anxiety. Harrison C (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 47.

AIHW GP Statistics and Classification Unit 2003. Coronary heart disease, risk factors and lipid lowering medication. Charles J (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 46.

AIHW GP Statistics and Classification Unit 2003. Diabetes mellitus prevalence, management and risk factors. Charles J (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 45.

AIHW GP Statistics and Classification Unit 2003. Severity of illness. Miller G (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 44.

AIHW GP Statistics and Classification Unit 2003. Initiation and purpose of pathology orders. Pan Y (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 43.

AIHW GP Statistics and Classification Unit 2003. Prevalence and management of chronic pain. Henderson J (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 42.

AIHW GP Statistics and Classification Unit 2003. Time of visit and billing status. Valenti L (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 41.

AIHW GP Statistics and Classification Unit 2003. Type 2 diabetes mellitus, prevalence and management. Henderson J (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 40.

AIHW GP Statistics and Classification Unit 2003. Severity of asthma, medications and management. Bayram C (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 39.

AIHW GP Statistics and Classification Unit 2003. Prevalence of chronic heart failure, its management and control. Pan Y (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 38.

AIHW GP Statistics and Classification Unit 2002. Prevalence of common morbidities in patients encountered in general practice. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 37.

AIHW GP Statistics and Classification Unit 2002. Patient use of complimentary therapies. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 36.

AIHW GP Statistics and Classification Unit 2002. Smoking status of adults and their attempts to quit. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 35.

AIHW GP Statistics and Classification Unit 2002. Gastro-oesophageal reflux disease (GORD). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 34.

AIHW GP Statistics and Classification Unit 2002. Prevalence and management of cardiovascular risk factors. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 33.

AIHW GP Statistics and Classification Unit 2002. Patient use of after-hours medical services. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 32.

AIHW GP Statistics and Classification Unit 2002. Prevalence and severity of chronic heart failure. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 31.

AIHW GP Statistics and Classification Unit 2002. Lipid lowering medications and coronary heart disease. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 30.

AIHW GP Statistics and Classification Unit 2002. Non-steroidal anti-inflammatory drugs (NSAIDs) and acid suppressant use. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 29.

AIHW GP Statistics and Classification Unit 2002. Prevalence of Alzheimer's disease and dementia. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 28.

AIHW GP Statistics and Classification Unit 2002. Prevalence and management of influenza. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 27.

AIHW GP Statistics and Classification Unit 2002. Prevalence of diagnosed hypertension and difficulties in treatment. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 26.

AIHW GP Statistics and Classification Unit 2002. Prevalence of diabetes, medications and control. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 25.

AIHW GP Statistics and Classification Unit 2001. Gastro-oesophageal reflux disease (GORD) in general practice patients. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 24.

AIHW GP Statistics and Classification Unit 2001. Depression. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 23.

AIHW GP Statistics and Classification Unit 2001. Asthma – prevalence, severity and management. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 22.

AIHW GP Statistics and Classification Unit 2001. Diabetes – prevalence, management and screening. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 21.

AIHW GP Statistics and Classification Unit 2001. Screening and management of blood cholesterol. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 20.

AIHW GP Statistics and Classification Unit 2001. Osteoporosis. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 19.

AIHW GP Statistics and Classification Unit 2001. Drugs for the treatment of peptic ulcer and reflux. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 18.

AIHW GP Statistics and Classification Unit 2001. Private prescription products. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 17.

AIHW GP Statistics and Classification Unit 2001. Effect of day and time of GP visit on billing method. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 16.

AIHW GP Statistics and Classification Unit 2001. Lipid lowering medication. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 15.

AIHW GP Statistics and Classification Unit 2001. Co-medications. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 14.

AIHW GP Statistics and Classification Unit 2000. Perceived stress. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 13.

AIHW GP Statistics and Classification Unit 2000. Smoking and passive smoking in general practice patients. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 12.

AIHW GP Statistics and Classification Unit 2000. Patient employment status and occupation. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 11.

AIHW GP Statistics and Classification Unit 2000. Length of consultation; after-hours arrangements; co-morbidity. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 10.

AIHW GP Statistics and Classification Unit 2000. Influenza and absenteeism. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 9.

AIHW GP Statistics and Classification Unit 2000. Hormone replacement therapy (HRT). Sydney: University of Sydney, SAND abstracts from the BEACH program no. 8.

AIHW GP Statistics and Classification Unit 2000. Health services utilisation, lifestyle status and chronicity. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 7.

AIHW GP Statistics and Classification Unit 2000. Employment status and workers' compensation claims. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 6.

AIHW GP Statistics and Classification Unit 2000. Depression. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 5.

AIHW GP Statistics and Classification Unit 2000. Cardiovascular disease. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 4.

AIHW GP Statistics and Classification Unit 2000. Asthma. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 3.

AIHW GP Statistics and Classification Unit 2000. Anxiety/stress, consultation time, level of education. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 2.

AIHW GP Statistics and Classification Unit 2000. Allergic rhinitis. Sydney: University of Sydney, SAND abstracts from the BEACH program no. 1.

ARTICLES IN NON-REFEREED JOURNALS AND OTHER PUBLICATIONS

Charles J, Harrison C, Britt H 2008. Diabetes policy and general practice activity. GP Review 12(3):18.

Charles J, Britt H 2008. Practice Nurses working with GPs. GP Review 12(2):15.

Charles J, Harrison C, Britt H 2008. Osteoporosis: not just a problem for women. GP Review 12(1):15.

O'Halloran J, Miller GC, Britt H 2007. SNOMED CT: is it valid for use by Australian GPs? GP Review 11(5):22.

Charles J, Britt H 2007. 50 years of national general practice surveys. GP Review 11(4):17.

Harrison C, Charles J, Britt H 2007. Posttraumatic stress disorder among Australian veterans. GP Review 11(3):17.

Britt H 2007. Preventive activities in general practice. GP Review 11(2):16.

Charles J, Britt H 2007. Different from the rest. GP Review 11(1):15.

AIHW Australian GP Statistics and Classification Centre 2006. Generation X visits to the GP. GP Review 10(5):17.

AIHW Australian GP Statistics and Classification Centre 2006. Lipid disorders in Australian general practice. GP Review 10(4):11.

AIHW Australian GP Statistics and Classification Centre 2006. Over the counter medications advised by GPs. Charles J (ed). GP Review 10(3):10.

Miller G, Britt H, Knox S, Charles J 2006. Inhaled corticosteroids and management of asthma. GP Review 10(2):10.

AIHW Australian GP Statistics and Classification Centre 2006. Injury management in general practice. Charles J (ed). GP Review 10(1):13.

AIHW Australian GP Statistics and Classification Centre 2005. Locality matters: the influence of geography on general practice in Australia 1998–2004. GP Review 9(5):8.

AIHW Australian GP Statistics and Classification Centre 2005. Alcohol consumption among general practice patients. Charles J (ed). GP Review 9(4).

AIHW Australian GP Statistics and Classification Centre 2005. Changing face of the general practice workforce. Charles J (ed). GP Review 9(3).

AIHW Australian GP Statistics and Classification Centre 2005. Non-pharmacological treatments provided by GPs. GP Review 9(2).

AIHW GP Statistics and Classification Unit 2005. General practice activity in Australia's states and territories. Charles J (ed). GP Review 9(1).

AIHW GP Statistics and Classification Unit 2004. Childhood illness and treatment over three decades. Charles J (ed). GP Review 8(Sept).

AIHW GP Statistics and Classification Unit 2004. Indigenous Australians at general practice encounters. Charles J (ed). GP Review 8(July).

AIHW GP Statistics and Classification Unit 2004. Decrease in prescribing rates—5 years of BEACH. Charles J (ed). GP Review 8(May).

AIHW GP Statistics and Classification Unit 2004. Changes over time: management of depression in general practice. Charles J (ed). GP Review 8(Mar).

AIHW GP Statistics and Classification Unit 2003. Changes over time—patient health risk factors. Charles J (ed). GP Review 7(Nov).

AIHW GP Statistics and Classification Unit 2003. Changes over time—NSAID use in general practice. Charles J (ed). GP Review 7(Aug).

AIHW GP Statistics and Classification Unit 2002. Gender of the general practitioner. Charles J (ed). GP Review 6(Nov).

Britt H 2002. The BEACH Program. Gpinfonet 6(6):8.

Britt H 2002. BEACH—Bettering the Evaluation And Care of Health. National Networks (32).

Britt H 2002. The International Classification of Primary Care (ICPC-2 and ICPC-2 Plus). Coding Matters 9(June):3.

AIHW GP Statistics and Classification Unit 2002. Measurement of body mass in children attending general practice. Charles J (ed). GP Review 6(June).

AIHW GP Statistics and Classification Unit 2002. Counselling general practice patients. Charles J (ed). GP Review 6(May).

AIHW GP Statistics and Classification Unit 2002. Referrals. Charles J (ed). GP Review 6(April).

AIHW GP Statistics and Classification Unit 2001. Smoking and passive smoking in general practice patients. Charles J (ed). GP Review 5(Dec).

AIHW GP Statistics and Classification Unit 2001. Severity of illness in general practice patients. Charles J (ed). GP Review 5(Oct).

AIHW GP Statistics and Classification Unit 2001. Weighty matters: body mass in general practice patients. Henderson J (ed). GP Review 5(Sept).

AIHW GP Statistics and Classification Unit 2001. Influenza vaccination in general practice patients. Charles J (ed). GP Review 5(Aug).

GP Statistics and Classification Unit 2001. Measures of health and health care delivery in Australia. AIHW Access (July).

AIHW GP Statistics and Classification Unit 2001. Employment status and occupation of general practice patients. Charles J (ed). GP Review 5(July).

AIHW GP Statistics and Classification Unit 2001. Weakness and tiredness as a reason for encounter in general practice. Miller GC (ed). GP Review 5(May).

AIHW GP Statistics and Classification Unit 2001. Anxiety and stress in patients presenting to GPs in Australia. Britt H (ed). GP Review 5(April).

Britt H 1999. General practice activity in Australia 1998-1999. NSW Public Health Bulletin 10(12):167-9.

List of tables

Table 1.1: Number of general practice professional services claimed from Medicare Australia each financial year, 1998–99 to 2007–08 ('000)	6
Table 3.1: Annual summary of data sets, 1998–99 to 2007–08 (final weighted data)	11
Table 4.1: GP characteristics, summary of annual results, BEACH, 1998–99 to 2007–08	15
Table 5.1: Summary of morbidity and management, summary of annual results, BEACH, 1998–99 to 2007–08	21
Table 5.2: Type of encounter, summary of annual results (most frequent events), BEACH, 1998–99 to 2007–08	23
Table 5.3: Consultation length (minutes), summary of annual results, BEACH, 2000–01 to 2007–08.....	24
Table 6.1: Characteristics of patients at encounters, summary of annual results, BEACH, 1998–99 to 2007–08	28
Table 6.2: Number of patient reasons for encounter, summary of annual results, BEACH, 1998–99 to 2007–08	30
Table 6.3: Rate of patient reasons for encounter by ICPC-2 chapter, summary of annual results, BEACH, 1998–99 to 2007–08	30
Table 6.4: Rate of patient reasons for encounter by ICPC-2 component, summary of annual results, BEACH, 1998–99 to 2007–08	32
Table 6.5: Most frequent patient reasons for encounter, summary of annual results, BEACH, 1998–99 to 2007–08	33
Table 7.1: Number of problems managed at an encounter, summary of annual results, BEACH, 1998–99 to 2007–08	40
Table 7.2: Distribution of problems managed, by ICPC-2 component, summary of annual results, BEACH, 1998–99 to 2007–08	41
Table 7.3: Distribution of problems managed, by ICPC-2 chapter, summary of annual results, BEACH, 1998–99 to 2007–08	42
Table 7.4: Most frequently managed problems, summary of annual results, BEACH, 1998–99 to 2007–08.....	44
Table 7.5: Most frequently managed new problems, summary of annual results, BEACH, 1998–99 to 2007–08	47
Table 7.6: Most frequently managed chronic problems, summary of annual results, BEACH, 1998–99 to 2007–08	49
Table 8.1: Summary of management, summary of annual results, BEACH, 1998–99 to 2007–08.....	53
Table 8.2: Encounters and problems for which at least one management was recorded, BEACH, 1998–99 to 2007–08	55
Table 9.1: Rates of medications prescribed, advised for over-the-counter purchase, supplied, summary of annual results, BEACH, 1998–99 to 2007–08	60
Table 9.2: Number of repeats for prescribed medications, summary of annual results, BEACH, 1998–99 to 2007–08	60
Table 9.3: Distribution of prescribed medications, by ATC Level 2, summary of annual results, BEACH, 1998–99 to 2007–08	61
Table 9.4: Most frequently prescribed medications (CAPS generic), summary of annual results, BEACH, 1998–99 to 2007–08	63

Table 9.5: Medications most frequently supplied by GPs, summary of annual results, BEACH, 1998-99 to 2007-08	68
Table 9.6: Most frequently advised over-the-counter medications, summary of annual results, BEACH, 1998-99 to 2007-08	69
Table 10.1: The most frequent clinical treatments, summary of annual results, BEACH, 1998-99 to 2007-08.....	72
Table 10.2: The most common problems managed with a clinical treatment, summary of annual results, BEACH, 1998-99 to 2007-08.....	74
Table 10.3: The most frequent procedural treatments, summary of annual results, BEACH, 1998-99 to 2007-08	76
Table 10.4: The most common problems managed with a procedural treatment, summary of annual results, BEACH, 1998-99 to 2007-08.....	77
Table 11.1: The most frequent referrals, summary of annual results, BEACH, 1998-99 to 2007-08.....	80
Table 12.1: Number of encounters for which pathology or imaging was ordered, summary of annual results, BEACH, 1998-99 to 2007-08.....	85
Table 12.2: Distribution of pathology orders across pathology groups, summary of annual results, BEACH, 2000-01 to 2007-08	86
Table 12.3: Most frequent imaging tests ordered, summary of annual results, BEACH, 1998-99 to 2007-08.....	87
Table 13.1: Summary of practice nurse involvement at encounter, and claims made, BEACH, 2005-06 to 2007-08	89
Table 13.2: Distribution of practice nurse item numbers recorded at encounter	90
Table 13.3: Summary of treatments provided by practice nurse	91
Table 13.4: Most frequent treatments provided by practice nurses	92
Table 13.5: The most common problems managed with the involvement of practice nurse	93
Table 14.1: Comparative results for all patient risk factors, summary of annual results, BEACH, 1998-99 to 2007-08	99
Table 14.2: Comparative results for male patient risk factors, summary of annual results, BEACH, 1998-99 to 2007-08	101
Table 14.3: Comparative results for female patient risk factors, summary of annual results, BEACH, 1998-99 to 2007-08	102
Table A5.1: Code groups from ICPC-2 and ICPC-2 PLUS	127
Table A6.1: Chronic code groups from ICPC-2 and ICPC-2 PLUS	153

List of figures

Figure 4.1:	Summary of changes in GP characteristics, 1998–99 to 2007–08	13
Figure 6.1:	Age distribution of patients, 1998–99 to 2007–08 (95% CI)	25
Figure 7.1:	Changes in management rate of selected chronic problems, 1998–99 to 2007–08 (95% CI).....	38
Figure 7.2:	Changes in management rate of selected acute problems, 1998–99 to 2007–08 (95% CI).....	39
Figure 9.1:	Medication rates per 100 encounters, 1998–99 to 2007–08	57
Figure 9.2:	Prescribed medication rates per 100 encounters, 1998–99 to 2007–08 (95% CI).....	58
Figure 9.3:	Prescribed medications recorded as brand or generic, 1998–99 to 2007–08	58
Figure 9.4:	Per cent of prescriptions with five repeats for total problems and for chronic problems managed, 1998–99 to 2007–08	59
Figure 9.5:	Influenza vaccine prescribed and supplied per 100 encounters, 1998–99 to 2007–08	67
Figure 12.1:	Encounters where pathology was ordered and pathology test order rates per 100 encounters, 1998–99 to 2007–08 (95% CI)	84
Figure 14.1	Rates of overweight and obesity among adults (aged 18 years and over), 1998–99 to 2007–08	95
Figure 14.2:	Rates of overweight and obesity among male adults (aged 18 years and over), 1998–99 to 2007–08	95
Figure 14.3:	Rates of overweight and obesity among female adults (aged 18 years and over), 1998–99 to 2007–08	96
Figure 14.4:	Rates of daily smoking among adults (aged 18 years and over), 1998–99 to 2007–08	97
Figure 14.5:	Rates of at-risk alcohol consumption among adults (aged 18 years and over), 2000–01 to 2007–08	98
Figure A1.1:	The BEACH relational database.....	111
Figure A1.2:	The structure of the International Classification of Primary Care – Version 2 (ICPC-2).....	113